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Abstract 
Over the past decades, the transition-metal catalyzed C-H bond functionalization has emerged 
as a powerful tool for the straightforward access to molecular complexity, while respecting 
the principles of atom- and step-economy. 
The research at the Baudoin group mainly focuses on the activation and the functionalization 
of C-H bonds with palladium. The investigation led to the development of new methodologies 
including intramolecular Csp3-H bond activation, and the arylation of remote Csp3-H bond via 
migrative cross-couplings. These methodologies were applied in the synthesis of biologically 
active complex molecules. 
The ligand-controlled regioselective arylation of cyclic and acyclic N-Boc-amines via Pd(0)-
catalyzed migrative Negishi cross-coupling was recently developed within our group. In light 
of this work, the enantioselective -arylation of O-carbamates was achieved by combining 
Hoppe’s sparteine-mediated enantioselective lithiation-deprotonation and Pd(0)-catalyzed 
Negishi cross-coupling. 
We then focused on the ligand-controlled migrative arylation of O-carbamates. The attempts 
toward the selective -arylation were unsuccessful but led us to the discovery of a ligand-
controlled -arylation of ,-unsatured O-carbamates. The reaction proceeds via a non-
canonical haptotropic rearrangement of the palladium intermediate. 
As a follow-up, we examined the feasibility of an intermolecular Pd(0)-catalyzed 
atroposelective Csp2-H arylation. Our investigation led us to the discovery of a catalytic 
system involving newly introduced bifunctionnal ligands. 
Key words: C-H functionalization, C-H activation, organometalic catalysis, palladium, 
Negishi coupling, migrative arylation, enantioselectivity, haptrotropic rearrangement, 
atroposelectivity 
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Abbreviations 
()- or ()-sp. ()- or ()-sparteine 
Ad adamantyl 
API active pharmaceutical ingredient 
Boc tert-butyloxycarbonyl 
C-H bond carbon-hydrogen bond 
CPME cyclopentyl methyl ether 
dba dibenzilideneacetone 
d.e. diastereomeric ratio 
DFT density functional theory 
DMAc dimethylacetamide 
DME 1,2-dimethoxyethane 
DMF dimethylformamide 
e.e. enantiomeric excess 
eq. equivalent 
e.r. enantiomeric ratio 
e.s. enantiospecificity 
F-TOTP tris(5-fluoro-2-methylphenyl)phosphine 
GCMS gas-chromatography/mass-spectrometry 
HPLC high-performance liquid chromatography 
i-Bu iso-butyl 
i-Pr iso-propyl 
MS XÅ molecular sieves XÅ 
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NASA National Aeronautics and Space Administration 
n-Bu n-butyl 
NHC N-heterocyclic carbene 
NMR nuclear magnetic resonance 
n-Pr n-propyl 
s-Bu sec-butyl 
TBS tert-butyldimethylsilyl 
t-Bu tert-butyl 
THF tetrahydrofuran 
TEMPO 2,2,6,6-tetramethylpiperidinyloxyl 
TMEDA tetramethylethylenediamine 
TMP-Zn base 2,2,6,6-tetramethylpiperidinyl 
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1. General bibliography 
In the early 21st century, major technological developments led to the manufacture of 
reusable space rockets, the discovery of Earth-like planets, and the detection of water on 
Mars. The NASA launched a wide space programm with the aim of sending human to the 
Red Planet in 2030. While all of this is happening, Voyager I and II probes are travelling 
out of our solar system. 
In contrast, climate variations, inequal growth of wealthiness and population, as well as 
massive production are proposed as linked to the harmful pollution and the unstoppable 
impoverishment of ressources. 
In this context, scientists put many efforts in finding solutions to stemthe potential 
worldwide lack of ressources. 
In organic chemistry, this evolution is reflected in the development of more concise 
syntheses, involving less protecting groups and minimal changes of oxidation states as 
well as atom economical transformations.1 The traditional approach consists in an iterative 
change of functional group to obtain the desired chemical function. This strategy requires 
a prefunctionalized starting material, and often uses a stoichiometric amount of reactants. 
Despite the wide variety of known chemical transformations, and their application to solve 
chemo- and regioselectiviy issues, the synthetic routes remain very long and laborious.2 
This led chemists to investigate on less atom and step demanding alternatives (Scheme 
1a.). 
 
Scheme 1. An overview for the functionalization of organic compounds 
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In the early 80’s, the comprehension and the development of transition metal catalysis 
revolutionized organic synthesis by providingnew tools for the construction of carbon-carbon 
bonds.This synthetic approach allowed new disconnections to access molecular complexity in 
a reduced number of steps with high selectivity thus enabling convenient and straightforward 
syntheses (Scheme 1b.).3 In particular, palladium-catalysis cross-couplings witnessed an 
exponential growth of interest in academia and industry, as shown by the positive evolution of 
literature in the field (Figure 1). Moreover, Heck, Negishi and Suzuki received the Nobel 
Prize in Chemistry in 2010 for their contribution to these developments.4 
 
Figure 1.Growth in the number of publications and patents on metal-catalyzed cross-
coupling 
The catalytic cycle of this type of transition metal-catalyzed cross-coupling, as depicted in 
Scheme 2 with palladium, generally involves the oxidative addition of a catalytically active 
Pd0complexto a carbon-halide or pseudohalide bond. The resulting electrophilic PdII 
organometallic species undergoes transmetalation with a nucleophilic organometallic 
compound, thus generating a PdII intermediate bearing the two organic coupling partner 
fragments. Subsequent reductive elimination produces the desired cross-coupling compound 
via the formation of a carbon-carbon bond, while regenerating the Pd0 species that enters a 
new catalytic cycle. This catalytic system offers various advantages, notably step-economy in 
synthesis, enabling versatile retrosynthetic analyses5and alsonovel industrial applications.6 
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The system still encounters limitations, such as the use of pre-functionalized coupling 
partners, but also the production of a stoichiometric amount of toxic metal wastes. 
 
Scheme 2. General catalytic cycle for palladium-catalyzed cross-coupling reaction 
Despite the universality of these cross-couplings, their drawbacks pushed chemists to turn 
their attention to the C-H bond functionalization. Indeed, the ubiquity of the C-H bond in 
organic compounds makes them perfect candidates for selective functionalization, while 
respecting the atom and step economy principlesto the benefit of more flexible and versatile 
retrosynthetic analyses.The C-H bond functionalization has longly been occulted because of 
the relative inertness of these bonds, as reflected by the high bond dissociation energy (BDE) 
of 104 kcal/mol in methane,7even if very reactive species such as radicals, carbenes and 
highly acidic compounds can react with aliphatic C-H bonds.8 
During the development of transition-metal catalyzed cross-couplings, Kumada,9Negishi10 
and Hayashi11 observed the ability of these metals to migrate along an aliphatic chain via a 
chain walking process, thus opening an access to the functionalization of aliphatic C-H bonds 
from a pre-functionalized substrate(Scheme 1b’.). A typical mechanism for this 
transformation, as illustrated in Scheme 3with palladium, involvesthe oxidative addition of 
the catalytic Pd0 in the (pseudo)halide electrophile. The newly formed PdII complex 
undergoes transmetalation with the organometallic nucleophile. Once installed, the direct 
reductive elimination event leads to the classical cross-coupling product, while the -hydride 
elimination provides the olefin -complex which can undergo rotation and hydropalladation 
to give rise to an isomerized Pd-alkyl complex.The latter, after reductive elimination, yields 
the C-H functionalized productof the migrative cross-coupling. Noteworthy the 
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decomplexation of the olefin -complex releases the unsaturated product along with the 
palladium-hydride complex. 
 
Scheme 3. Typical mechanism for C-H functionalization via migrative cross-coupling 
Even if the migrative cross-couplings offer new synthetic disconnections, this approach 
suffers the same drawbacks as the direct cross-couplings due to the need of pre-functionalized 
starting materials.The direct C-H functionalization of non-acidic C-H bonds has emerged as 
the ideal path toward the rapid and efficient construction of molecular complexity (Scheme 
1c.). The discoveries of Shul’pin and Shilov, Fujiwara, and Felkin and Crabtree in the 
70’sdemonstrated the feasibility of transition-metal catalyzedfunctionalization of aromatic, as 
well as aliphatic C-H bonds via C-H bond activation.12The contemporary developments led 
chemists to overcome the challenging chemoselectivity and site selectivity in “first 
functionalization” and in late stage functionalization, making directed and non-directed C-H 
bond functionalizationspowerful tools for organic synthesis.13 
The transition metal C-H bond functionalization can proceed via an outer sphere mechanism 
or an inner sphere mechanism, the latter being commonly called “authentic” C-H activation.14 
In the outer sphere process, the activable C-H bond interacts first with a highly-activated 
ligand of a metal complex, such as a carbene,15 a nitrene16 or an oxene,17 before the C-H bond 
cleavage/functionalization event. Two different pathways can be considered: the first involves 
the C-H insertion of the activated ligand, whereas the second proceeds via H abstraction and 
radical rebound of the coupling partner. In both cases, the metal doesn’t interact directly with 
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the carbon bearing the activated proton (Scheme 4). Due to the involvement of a radical 
and/or cationic character at the carbon center, the transformation is more likely to be selective 
of weak C-H bonds (benzylic, allylic, tertiary or in  to heteroatoms). 
 
Scheme 4. C-H functionalization by outer sphere mechanism 
In the inner sphere mechanism, an organometallic intermediate is formed by C-H bond 
cleavage. This intermediate then reacts with an external reagent or at the metal center to 
obtain the C-H functionalized product. The C-H bond cleavage involves an agostic interaction 
between the metal center and the C-H bond prior to the proper C-H activation, via oxidative 
addition or CMD (Scheme 5).18 The regio- and the stereoselectivity are mainly governed by 
the structural and electronic requirements of the organometallic intermediate, and other 
factors such as the ligand environment at the metal center can also influence these 
selectivities. In contrast to the outer sphere mechanisms, this C-H activation proceeds in 
principle with high selectivity for less sterically hindered C-H bonds, but this approach 
generally favors Csp2-H activation over Csp3-H activation, which is in agreement with the 
relative acidity of these bonds. Moreover, the Csp3-H bonds in alkanes do not contain -
electrons, thus not allowing any -metal pre-coordination, making the Csp3-H bond activation 
more challenging.19 
 
Scheme 5. C-H functionalization by inner sphere mechanism (C-H activation) 
The metalation event in the C-H activation can be facilitated by the installation of a directing 
group that pre-coordinates the metal complex to the substrate. This complexation can 
modulate the reactivity of the substrate, but particularly enhances the selectivity and the 
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reactivity of the targeted C-H bond, thus triggering the intramolecular C-H activation. The 
oxidative addition of a C-(pseudo)halide bond followed by intramolecular C-H activation is 
another reliable approach. An example of the principle is depicted for C-H activation of 
aliphatic bonds in Scheme 6. The intermolecular C-H activation/functionalization constitutes 
an elegant but more challenging approach since no proximity between the metal center and 
the targeted C-H bond are induced.20 
 
Scheme 6. Pre-coordination of the metal to trigger C-H activation 
The Baudoin group research is mainly focused on the palladium oxidative-addition-initiated 
Csp3-H activation for the control of selectivity in the Csp3-H bond functionalization, in 
addition to the palladium catalyzed migrative cross-coupling of organometallics (Scheme 7), 
for the construction of APIs and in application to the total synthesis of natural compounds. 
The control of stereoselectivity is of major interest to enhance the power of these novel and 
step economical synthetic approaches. 
 
Scheme 7. Current research topics at the Baudoin group 
Before the description of the projects developed during the course of this PhD, a summary of 
the development and the recents advances in the Negishi cross-coupling will be presented, 
followed by an overview of the use of palladium in migrative cross-coupling, to introduce the 
first research topic of this thesis. A third part will present the achievements of the Baudoin 
group in the field of C-H activation and the current investigation which led to the second 
subject of this thesis. 
19 
 
1.1. Negishi cross-couplings : development and recent advances 
In 1976, Negishi first reported on the cross-coupling reaction of organoaluminum 
partners, employing nickel catalysts (Scheme 8a.).21 However, a significant deterioration of 
stereospecificity was observed when organoaluminum reagents were involved in the synthesis 
of conjugated dienes. This drawback was overcome by replacing nickel with palladium. The 
following year, Negishi22 and Fauvarque and Jutand23 reported the use of organozinc reagents 
as coupling partners (Scheme 8b and c). The former authors highlighted the remarkable 
chemoselectivity of organozincs thanks to their tolerance toward sensitive functionalities such 
as esters, nitriles or nitros. Moreover, a screen of organometallic reagents showed that the 
palladium-catalyzed cross-coupling of an aryl iodide with zinc-, boron-, and tin-based 
partners was efficient.24 
 
Scheme 8. Development of the Negishi cross-coupling reaction 
Since then, the palladium-catalyzed Negishi cross-coupling found a myriad of applications in 
academia and industry, which were the topic of numerous publications and discussions, thus 
completing the scope of the transition metals catalyzed cross-couplings. It is noteworthy that 
the Negishi cross-coupling has also been studied with other transition-metals such as nickel or 
cobalt, and iron or copper catalysts were reported as being efficient for this type of coupling.25 
1.1.1. General considerations 
The general catalytic cycle for the palladium-catalyzed Negishi cross-coupling of zinc 
organometallics with aryl halides involves the oxidative addition of the catalytically active 
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Pd0 to the carbon-halide bond. The intermediate PdIIcomplex1.Atransmetallates the 
organozinc, releasing zinc salt as a waste. The newly formed PdIIcomplex1.Bbearing the two 
organic coupling partners fragment undergoes reductive elimination to produce the arylated 
product 1.C and thus regenerate the Pd0 catalyst (Scheme 9). This coupling finds its 
advantage in the fast transmetalation of the organozinc to palladium, compared to boronic 
acids used in Suzuki coupling.4a Nevertheless, organozinc are mostly air and moisture 
sensitive, where boronic acids and esters are stable in these conditions, but also broadly 
available.26 
 
Scheme 9. General mechanism for palladium-catalyzed Negishi cross-coupling 
Common ligands used for the palladium-catalyzed Negishi cross-coupling are 
aryl(alkyl)phosphines and NHCs (Figure 2). The use of more hindered aryl(alkyl)phosphine 
generally suppresses the undesired isomerization by -hydride elimination/migratory insertion 
in the coupling of secondary alkylzinc reagent. Thus, Buchwald and coworkers developed a 
panel of biphenyl-based hindered phosphinesand integrated them to aminobiphenyl-based 
palladacycle precatalysts, giving the advantage to be air and moisture stable but also to easily 
release the catalytically active Pd0 species under basic conditions and at room temperature, 
then allowing Negishi couplings under milder conditions.27Organ and coworkers developed a 
series of hindered NHC-based Pd-complexes, which proved to be efficient for Negishi cross-
couplings of secondary alkylzinc reagent with good selectivities.28 The use of a very bulky 
imidazole-based phosphine developed by Baudoin and coworkers also allowed the direct 
coupling of functionalized secondary alkylzinc with high selectivities.29 
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Figure 2.Common ligands and palladium complexes for Negishi coupling 
The organozinc partner can be prepared by oxidative addition of zinc powder to various 
aromatic, heterocyclic, benzylic, andalkyl bromides or iodides.30 The highly activated Rieke-
zinc is prepared by reduction of zinc chloride using lithium naphtalenide in THF,31 and the 
commercial zinc powder insert more easily in presence of LiCl. The reaction scope of this 
insertion was increased by replacing zinc with bimetallic reagents couples such as Mg, 
ZnCl2,32or Mg, Zn(OPiv)2.33Gosmini showed that cobalt halides catalyze the preparation of 
various zinc reagents.34 Yoshikai demonstrated that the latters undergo efficient palladium 
catalyzed Negishi cross-coupling.35 The transmetalation of lithium, magnesium and aluminum 
organometallics generated from halogen/metal exchange36, directed metalation,37 or 
carbometalation38also provided zinc organometallics which were shown to be suitable for 
cross-coupling reactions. Alternatively, the directed zincation using TMP-zinc bases proved 
to be efficient for the cross-coupling of sensitive heterocycles (Scheme 10).39 
 
Scheme 10.  Formation of zinc organometallics for Negishi cross-coupling 
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1.1.2. Stereo-induction in palladium-catalyzed Negishi coupling 
A highly diastereoselective version of the Negishi cross-coupling was developed by 
Knochel and coworkers (Scheme 11). The treatment of cyclic organozinc reagents1.6-1.8 with 
various arylhalides in presence of a palladium catalyst at low temperatures gave cis- or trans-
disubstituted product with high d.r.. In this case, the substrates govern the selectivity. Indeed, 
1,2- and 1,4-disubstituted organozincs1.6 and 1.8 lead to the correspondingtrans-arylated 
products1.6a and 1.8a ; whereas the 1,3-disubstituted organozinc reagent 1.7 leads to the cis-
arylated product 1.7a. In all cases, the C-Pd bond in the Pd-complex intermediate is in 
equatorial position, thus explaining the induction.40 
 
Scheme 11.  Highly diastereoselective arylation of cyclohexane derivatives 
Campos and O’Brien described the stereospecific Negishi coupling of enantioenriched 
pyrrolidylzinc with arylbromides leading to a precursor of (S)-nicotine.41 The enantioselective 
lithiation of N-Boc-pyrrolidine in presence of catalytic (+)-sparteine surrogate and bispidine 
followed by the transmetalation to zinc and cross-coupling with 3-bromopyridine in presence 
of palladium acetate and PtBu3 afforded the Boc-protected arylated intermediate1.9 in 46% 
yield. Its subsequent deprotection and methylation provided (S)-nicotine in 44% yield and 
98:2 e.r. over the 3 steps, thus illustrating the application of this formal enantioselective 
Negishi coupling in natural and active product synthesis. 
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Scheme 12. Enantioselective arylation of N-Boc-pyrrolidine 
In the scope of this arylation reaction, the authors also observed relevant amounts (up to 8%) 
of products resulting from the -elimination pathway (olefin or isomerized arylated product) 
despite the use of a hindered ligand. 
While many scientists were investing their efforts in the improvement of the direct Negishi 
cross-coupling, other groups took benefit of the lack of selectivity observed with certain 
transition metals to develop novel approaches for the functionalization of surrounding C-H 
bonds. 
1.2. Csp3-H bond functionalization via migrative cross-coupling 
The “chain walking, chain running, or metal walk” is defined as a process in which 
discrete alkyl metal species undergo an iterative sequence of 1,2 or 1,3-hydride shifts along a 
single hydrocarbon chain. This constitutes a remote Csp3-H bond functionalization relying on 
the ability of transition-metal complexes to undergo rapid olefin isomerization. The first 
catalytic examples were observed with titanium and zirconium in the early 60’s, and the 
development of industrial processes notably with ruthenium, rhodium and iridium led to a 
deeper interest in the migrative processes in the 70’s. In the last decades have also been taken 
into account iron and cobalt, while nickel has been the subject of major innovations.Those 
advances in the field were recently summarized by Martin and Marek.42 Only migrative 
coupling with palladium will be discussed in this section, after the presentation of historical 
examples. 
1.2.1. Heck-type migrative cross-couplings 
In 1976, Heck43 as well as Magennis44 observed isomerized products in the palladium 
catalyzed arylation of unsaturated aliphatic alcohols with aryl halides. The corresponding 
arylated aldehydes1.10-1.13were obtained in low yield and selectivities under harsh 
conditions. Nevertheless, these examples gave rise to the development of Larock’s remote 
functionalization of longer olefinic alcohols using Heck cross-coupling to install the 
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palladium on the olefin. The corresponding carbonyl compounds1.14 and 1.15 were obtained 
in good yields at only 50°C (Figure 3).45 
 
Figure 3: Historical examples of migratory Heck cross-coupling reactions 
This work established the basis of the leading improvements, such as Marek’s remote 
functionalization of olefinic alcohols that include a cyclopropane in the chain, which 
undergoes selective ring cleavage;46 Mazet’s long range redox isomerization of olefinic 
alcohols, initiated by hydropalladation;47or Sigman’s enantioselective construction of remote 
quaternary stereocenters via redox-relay Heck reaction.48 
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Figure 4. Recent advances in the migrative Heck-type reactions 
The common path in the reactions proceeds with the coordination of the PdII species to the 
unsaturation of 1.D-type olefinic alcohols, followed by the corresponding carbo- or 
hydropalladation giving rise to 1.E1-type intermediates. The regio- and stereoselectivity is 
determined during this step.  Once the PdII is installed on the chain, the metal undergoes -
hydride elimination and migratory insertion to give complex 1.E3 through Pd-hydride 
complex 1.E2. The process is repeated toward the alcohol via the chain walking process, in 
which the elementary steps are reversible and potentially bidirectional. The ultimate -
oxopalladium species 1.E4 furnishes the corresponding enol by -hydride elimination 
(palladium assisted tautomerization)47or the corresponding carbonyl product by concomitant 
oxidative deprotonation of the substrate and reduction of the PdII to Pd0 (Scheme 13).49 The 
initial Csp2 center in 1.D is transformed to a functionalized Csp3 center in the migration 
product 1.F. 
 
Scheme 13. Common palladium chain walking in migrative Heck-type reactions 
Another strategy relies on the stability of allylpalladium species. After migration of complex 
1.24a, the terminating event is not anymore the carbonyl formation, but the formation of a 
stabilized allylpalladium in the insaturation distal to the introduction site of the palladium, as 
in 1.24b. This intermediate complex is trapped by a nucleophile, thus releasing Pd0 catalyst 
(Scheme 14). This approach was used by Larock for the synthesis of naturally occurring 
pyridine alkaloids.50 
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Scheme 14. Larock’s remote difunctionalization via migrative Heck coupling 
Kochi and coworkers recently proposed a sequence of chain-walking/cyclisation. A substrate 
containing a strategically placed olefin such as 1.26 has undergone cyclisation after 
hydropalladation on a terminal unsaturation and migration (respectively 1.26a and 1.26b). 
The insertion of the olefin provides a five membered ring organopalladium intermediate of 
type 1.26c. The subsequent-hydride eliminations/isomerizations furnish a mixture of olefin 
isomers of type 1.27 which after hydrogenation provides valuable (hetero)cyclic compounds 
of type 1.28 (Scheme 15).51 
 
Scheme 15. Kochi’s chain walking cycloisomerization/hydrogenation of remote dienes. 
All those examples are based on palladium catalyzed Heck-type couplings, requiring an 
unsaturation to install the PdII catalytic intermediate on the olefinic chain, and a remote 
functionality such as an alcohol or another unsaturation to terminate the migration. The 
methods provide the product of a formal remote Csp3-H functionalization. We have seen in 
the previous section that researchers put many efforts in the direct cross-coupling of 
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secondary alkyl organometallics, such as in the Negishi coupling, to avoid the migration of 
the palladium intermediates notably by using hindered ligands. But those organometallics are 
also the starting materials of choice for a proper remote Csp3-H functionalization via 
migrative cross-coupling. 
1.2.2. Transmetalation-induced migrative cross-couplings 
In 1980, Negishi and coworkers observed the formation of the migration product in the 
coupling of an elaborated iodoalkene1.30 with sec-butyl organometallics1.31 (Scheme 16). 
The use of a zinc or a magnesium based sec-butyl metal under palladium catalysis provided 
the coupling products1.32 in 68% and 40% yield respectively. The low selectivity of 60:40 
was in favor of the direct couplingproduct1.32bin the case where the organozinc was used, 
and a reversed selectivity in favor of 1.32l was observed with the organomagnesium.52 
 
Scheme 16. Historical example of palladium catalyzed Negishi cross-coupling 
While exploring the scope of the Suzuki coupling of secondary alkyltrifluoroborates with 
arylchlorides and bromides, Molander also observed the formation of non desired linear 
migratory coupling products1.34l (Scheme 17).53 
 
Scheme 17. Migrative coupling in the palladium catalyzed Suzuki cross-coupling 
In this study, the use of the hindered ligand PtBu3 conducted to the major formation of the 
branched product (iPr) via direct coupling, but surprisingly the use of PAd2nBu led to a higher 
rate of the linear product (nPr) via migrative coupling. The substitution effect of the aryl 
chloride is remarkable. Ortho-substituted aryls tend to undergo migrative coupling more than 
the para-substituted aryls. Moreover, the electronic effect is notable. Indeed, the use of rich 
28 
 
(methoxy) or poor (methylbenzoate) aryl nucleophiles leads to higher ratios of branched to 
linear product, in contrast to neutral aryls (methyl) (Figure 5). 
 
Figure 5. Ligand and aryl effects in the branched to linear product ratio 
Next, the coupling of the diastereomerically pure potassium trans-2-methylcyclohexyl-
trifluoroborate1.35 with 4-chlorobiphenyl in presence of PAd2nBu, PtBu3, andPtBu2Ph 
always led to a mixture of 4 products, comprising 3 products of migration. In every case, the 
productof direct coupling 1.36awas mainly obtained (Table 1). Interestingly, the biphenyl 
moiety can be coupled to the methyl substituent via two successive -H 
eliminations/migratory insertions, to obtain substrate 1.36d. The migration occurs through a 
tertiary carbon center. 
 
Entry Ligand Conditionsa a b c d Yield (%) of 1.36 
1 PAd2nBu A 4.4 1.0 2.0 1.4 80 
2 PtBu3 B 16.0 1.0 1.0 6.0 48 
3 PtBu2Ph B 27.7 1.6 1.0 8.1 72 
a Conditions : A) Pd(OAc)2 2 %mol, Ligand 3% mol, RBF3K 1.1 eq, Cs2CO3 3 eq,  
toluene/H2O (10:1), 100°C, 24h. B)  Pd(OAc)2 5 %mol, Ligand 3% mol, RBF3K 
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 1.3 eq, toluene/H2O (10:1), 100°C, 72h. 
Table 1. Selectivity in the cross-coupling of potassium trans-2-methylcyclohexyl-
trifluoroborate 
Buchwald and coworkers observed a similar trend in the palladium catalyzed Negishi 
coupling of isopropylzinc bromide with ortho-substituted aryl bromides.54 The important 
ligand effect is highlighted by the reversal of selectivity between 1.37 and 1.38when XPhos 
(1.L3) is used in place of CPhos (1.L6) with arylbromides bearing either an electroattracting 
group (nitrile) or an electrodonating group (methoxy) (Figure 6). 
 
 
Figure 6. Ligand effect on the selectivity of branched to linear Negishi coupling product 
1.2.3. Mechanistic insights and ligand design 
The common mechanism of these palladium catalyzed cross-couplings involves the 
oxidative addition of the Pd0 into the aryl (pseudohalide) bond to form the catalytically active 
PdII species1.G bearing the aryl moiety. This complex undergoes transmetalationwith the 
secondary alkyl organometallic nucleophile to give intermediate 1.H. Once installed, the 
direct reductive elimination event leads to the classical cross-coupling product 1.I (i.e. the 
branched product). The -hydride elimination event triggers the migration process and 
provides the olefin -complex1.J which undergoes rotation and hydropalladation to give rise 
to the isomerized Pd-alkyl complex1.K. The subsequent reductive elimination gives rise to 
the arylated product 1.L via migrative cross-coupling (i.e. the linear product) (Scheme 18). In 
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the reaction, a non activated Csp3-H bond is transformed to a Csp3-C bond, thus constituting a 
proper remote Csp3-H bond functionalization. 
 
Scheme 18. Csp3-H bond arylation via palladium catalyzed cross-coupling 
As shown by Molander and Buchwald in the previous examples, the substitution of the aryl 
halide as well as the ligand play an important role in the migration of the palladium complex. 
Both studies show that the ortho substitution of the aryl electrophile tends to favor the 
migration in spite of the direct coupling. The design and choice of the ligand is essential for 
the regioselectivity of the arylation. Surprisingly, in said examples, hindered ligands 
originally designed to favor the direct coupling are allowing the migrative coupling with high 
selectivities. 
Based on a report from Hartwig and coworkers,55 Baudoin and coworkers studied the 
selectivity control in the palladium-catalyzed arylation of the lithium enolates of isobutyric 
esters 1.39 with aryl halides (Scheme 19).56 The combination of ortho substituted (hetero)aryl 
halides with DavePhos 1.L4 as the ligand afforded the -arylated products 1.41 in good yields 
and excellent selectivities. In contrast, the use of PtBu3 favored the formation of the -
arylated product 1.40, via direct cross-coupling. The installation of the PdII proceeds via 
lithium-palladium transmetalation of the lithium enolate,57 followed by migration and 
reductive elimination. 
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Scheme 19. Palladium-catalyzed -arylation of carboxylic esters 
The pathway leading to the direct or migrative coupling products, i. e.- or -arylation, of the 
methyl isobutyrates were computed by DFT, enlightening the role of the aryl substitution and 
of the ligand.58 The electronegative ortho substitution disfavors the -reductive elimination, 
whereas a very bulky ligand favors this event. Moreover, the use of a more flexible ligand 
such as the DavePhos1.L4 decreases the energy barrier of the 180° rotation of the intermediate 
-complex arising from -hydride elimination, thus the palladium complex undergoes more 
easily migratory insertion (Figure 7).59 
 
Figure 7. Analysis of selectivity factors using DFT calculations (B3PW91/6-31G**), SDD, 
PCM). Values refer to Gibbs free energies in kcal mol-1 
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The method was extended in the long range arylation of -aminoesters enolates1.42.60 The 
use of a more flexibleimidazole-based ligand611.L8 provides complete selectivity for the -
arylated products 1.43,after deprotection of the amine, independent of the aryl bromide 
substitution. The terminal alkylation occurs on longer side-chains, but requires an 
electronegative ortho substitution. Nevertheless, - to -arylation could be achieved in modest 
yields but excellent selectivities (1.43b and 1.43c), via a chain walking process. The amine 
was deprotected in a subsequent hydrogenation to obtain the free arylalanine homologues 
(Scheme 20). 
 
Scheme 20. Long range arylation of -aminoesters lithium enolates 
A similar methodology was developed using silyl ketene acetals1.44 as an alternative to 
lithium enolates.62 This novel approach was applied in the synthesis of benzo-fused -
lactones1.46a-b (Scheme 21). 
 
33 
 
Scheme 21.Migrative arylation of silyl ketene acetals and application to the synthesis of 
valuable compounds 
Coldham described in 2008 the Negishi coupling of -piperidinylzinc1.48obtained by 
directed lithiation and transmetalation to zinc, in presence of PtBu3.63Following this study, 
Knochel described the diastereoselective arylations of substituted N-Boc-piperidines.64 In this 
report, the -organozinc, formed by directed lithiation/deprotonation, undergoes Negishi 
coupling in presence of SPhos1.L1orRuPhos 1.L2. Surprisingly, when a 2-methyl-N-Boc-
piperidine was submitted to the -arylation condition, the -arylated product1.49 was formed 
exclusively. The regioselectivity, obtained by migration of the intermediate palladium 
complex, was shown to be induced by the hindrance of the 2-methyl substitution. Thus the 
selectivity in this case is controlled by the substrate (Scheme 22). 
 
Scheme 22.Selectivity in the Negishi coupling of piperidinylzinc chloride 
Following their work on the controlled migrative arylation for remote C-sp3-H bond 
functionalization, Baudoin and coworkers developed the ligand-controlled -arylation of N-
Boc-piperidines1.47 (Scheme 23).65 A new flexible N-phenyl-pyrrole-based phosphine 
ligand1.L9 allows the selective -arylation in good yields and excellent selectivities, 
contrasting with the opposite -arylation obtained in presence of RuPhos1.L4. The mild basic 
and nucleophilic character of the intermediate organozinc allows the use of sensitive 
functional groups on the arylbromide partner. 
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Scheme 23. Ligand controlled -selective Csp3-H arylation of N-Boc-piperidines 
The methodology was extended to the selective - and -arylations of acyclic N-Boc-amines 
via Negishi coupling (Scheme 24).66 The coupling in presence of PtBu3 provides the -
products 1.52, whereas the flexible ligands such asL9 afford the migration products1.53.A 
similar mechanism as for the arylation of isobutyric esters was determined by DFT 
calculation, thus questioning the generalization of this methodology to other organometallic 
starting materials. 
 
Scheme 24. Ligand controlled - and -arylation of acyclic N-Boc-amines 
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Nevertheless, this methodology did not give access to a longer range arylation. Indeed, the 
efficiency of the lithiation got dramatically affected by the bulkiness of the amine 
substituents, and suitable substrates for longer migration, such as the di-n-propyl-N-Boc-
amine, only gave a poor conversion along with poor selectivities. The -arylated N-Boc-
amines were accessed via the Negishi coupling of zincated N-Boc-allylamines.67 
An alternative approach to the long range arylation was found in the Negishi coupling of 
secondary alkylzinc chloridesformedby in-situtransmetalation of the corresponding Barbier 
reagents. The linear products were selectively obtained by the fine tuning of the ligand. This 
powerful strategy was notably exemplified by the terminal Csp3-H arylation of regioisomeric 
mixture of brominated alkanes1.54 in presence of 1.L11 (Scheme 25).68 
 
Scheme 25. Terminal selective functionalization of alkyl chains via regioconvergent cross-
coupling 
This last example illustrates the most recent advances in the field of palladium-catalyzed 
migrative cross-coupling, which is still actively under investigation within the Baudoin group. 
1.2.4. Task 1 : ligand-controlled migrative coupling of aliphatic alcohols 
Motivated by the successful ligand-controlled regioselectivity in the arylation of cylic 
and acyclic N-Boc-amines, and by the study and the understanding of the migration 
mechanism, the ligand controlled -, - and longer range arylation of protected aliphatic 
alcohols has been proposed as a novel access to various arylated alcohols, which the 
derivatives are widely represented in bioactive molecules of interest (Figure 8). 
 
Figure 8. Examples of arylated alcohols derivatives in bioactive molecules 
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The formation of an (chiral) organozinc reagent in -position of a nitrogen atom has proven 
to be feasible by transmetalation of an organolithium obtained by deprotonation/lithiation. 
Moreover, this type of organozinc reagent undergoes efficient direct and migrative Negishi 
cross-couplings. 
In the same way, the preparation of -oxo-alkylzinc reagent has been envisioned. The direct 
-lithiation of hindered carbamates derived from aliphatic alcohols is a well established 
method for the introduction of functionality at the -position of the oxygen upon electrophilic 
quenching. The methods developed by Hoppe allow the deprotonation/lithiation of secondary 
and activated tertiary carbons, also in asymmetric manner thanks to the use of sparteine as the 
ligand.69 With the introduction of the hindered TIB ester, Aggarwal could allow the 
stereoretentive deprotonation of stereogenic tertiary carbons.70In addition, it has been shown 
that the lithiation of -stereogenic carbamates and the transmetalation with a zinc halide are 
both stereoretentive, and the electrophilic quenching afforded enantioenriched secondary 
alcohols derivatives.71Thus, non-racemic -oxo-alkylzinc reagent could be prepared (Scheme 
26). 
 
Scheme 26. Preparation of the non racemic -oxo-alkylzinc 
The investigation would focus in a first time on thepreparation of the intermediate -oxo-
organozinc species and its evaluation in both the direct and migrative Negishi cross-
couplings. The variation of the ligand would allow the regio-selectivity in the arylation 
reaction, and hence new ligands could be designed and synthesized to improve the selectivity 
in the coupling.The use of hindered, non-flexible ligands would favor the direct coupling, 
whereas (in-house) flexible ligands would trigger the migration (Scheme 27). The 
enantioselective version of the reaction must be explored. 
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Scheme 27. Envisioned ligand-controlled direct and migrative Negishi cross-couplings 
The deprotection of the arylated targets would give rise to a variety of benzylic, homobenzylic 
and longer homologues of arylated alcohols, thus demonstrating the synthetic utility of the 
methodology (Scheme 28). 
 
Scheme 28. Obtention of various arylated alcohols after deprotection 
1.3. Palladium-catalyzed C-H bond activation/functionalization 
1.3.1. Baudoin’s approach to C-H activation/functionalization 
Over the last 15 years, Baudoin and coworkers developed many methodologies for the 
construction of four and five members (hetero)cyclic rings through Pd0/PdII catalyzed Csp3H 
functionalization (Scheme 29).72 A first report in 2003 described the formation of 
benzocyclobutenes 1.56 via the C-H activation of benzylic gem-dialkyl groups.73 The 
development of the catalytic system, and notably the ligand, allowed the synthesis of 
functionalized indanes1.57.74From the experience acquired, the synthesis of 
benzocyclobutene1.56 was improved and made general, including a full mechanistic study.75 
A further work in collaboration with Fagnou established the first example of an efficient and 
general palladium-catalyzed intramolecular Csp3-H arylation of (hetero)aryl chlorides for the 
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synthesis of cyclobutarenes1.56, indanes1.57, indolines, dihydrobenzofurans1.58, and 
indanones.76 An extension of this work to indanols1.59 and indanamines1.60 was reported in 
2014.77 
 
Scheme 29. Examples of intramolecular Csp3-H activation/arylation of unactivated C-H bond 
These methodologies were nevertheless restricted to the synthesis of fused 
benzo(hetero)cycles, even if the latter are important scaffolds included in natural products and 
active pharmaceutical ingredients. In 2012, it was demonstrated that the Csp3-H alkenylation 
allows the access to more Csp3-rich compounds, which are also important in the synthesis of 
bioactive compounds of interests. The synthesis of the Choi core1.63 (2-carboxy-6-
hydroxyoctaindole core) has been made possible by a novel intramolecular Csp3H 
alkenylation of substrate 1.61 (Scheme 30). This Csp3-H activation strategy has proven its 
efficiency in the synthesis of congeners of the aeruginosin, a family of natural products.78 
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Scheme 30. Divergent synthesis of aeruginosins based on Csp3-H activation strategy 
Various cyclic alkaloid precursors were obtained via the synthesis of strained -lactamssuch 
as1.64 by Csp3-H alkenylation. The methodology was applied in the synthesis of -
coniceine.79 The synthesis of -lactamssuch as1.65 by Csp3-H carbamoylation allowed the 
synthesis of enantiopure non-natural -aminoacid (Scheme 31).80 
 
Scheme 31. Csp3-H activation strategy for the synthesis of bioactive compounds 
1.3.2. General mechanism and enantiocontrol 
On the mechanistic level, the experimental and computational studies of Davies and 
McGregor81 as well as Echavarren and Maseras82 on the palladium catalyzed Csp2-H 
activation/arylation discarded the outdated mechanisms for the C-H activation step 
(carbopalladation, electrophilic aromatic substitution, -bond methatesis)83 in favor of the 
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concerted metalation deprotonation (CMD) mechanism.84 Thanks to their mechanistic studies 
on Csp2-H and Csp3-H functionalization, Baudoin and Fagnou proposed the CMD to be 
involved in the activationof these C-H bonds.85 A general mechanism for the above 
mentioned reaction starts with the oxidative addition of a monoligated Pd0 complex into the 
carbon-(pseudo)halide bond of the substrate to form complex 1.M (Scheme 32). A ligand 
exchange with a base such as a carboxylate or a carbonate forms the following PdII 
intermediate complex 1.N. This complex undergoes C-H activation with the assistance of the 
base to form the intermediate palladacycle 1.P (favored 5-membered > 6-membered >7-
membered ring) via the transition state 1.O. After reductive elimination of 1.P, the cyclized 
product 1.Q is formed and the Pd0 catalyst is regenerated. The formation of the olefinic 
product from -hydride elimination has been previously investigated.86 
 
Scheme 32.General mechanism for the intramolecular Csp3-H activation/arylation 
Because of the importance of chirality in chemistry, the control of selectivity is of major 
interest, especially for the synthesis of biologically relevant compounds. The involment of the 
base and the ligand in the the CMD of the intramolecular Csp3-H arylation opens two 
strategies for the enantiocontrol of the functionalized product. Indeed, their respective 
stereochemical information could be transferred during the CMD to discriminate two 
enantiotopic activable alkyl groups, thus the CMD would be the enantiodetermining step 
leading to enantioenriched products (Scheme 33). 
41 
 
 
Scheme 33. Two strategies for the enantioselective Csp3-H activation/arylation 
The enantioselective C-H bond activation/functionalization has been mostly investigated in 
the last decade.87 Baudoin and coworkers utilized binepine ligand1.L12 for the enantio- and 
diastereo-selective synthesis of fused cyclopentanes such as 1.66. The methodology have 
shown to be applicable for the activation of methylene C-H bond, but no general method in 
this case could be elaborated.88 More recently, the same group reported the first highly 
enantioselective Pd0 catalyzed Csp3-H activation with a BINOL derived phosphoric base1.67 
in presence of an achiral ligand for the synthesis of chiral indolines 1.68(Scheme 34).89This 
catalytic system was competitive with the previously described methodologies involving 
chiral phosphines or chiral NHCs.87b 
 
Scheme 34. Application of the ligand and the base stereocontrol in Csp3-H activation 
The presence of the ancillary ligand and the base at the CMD opens also the opportunity to 
combine them in a unique bifunctional molecule. The use of bifunctional ligands in PdII-
catalyzed C-H activation has been previously described.90 In 2018, Baudoin developed the 
first example of Pd0-catalyzed enantioselective C-H activation with a chiral binaphtyl-based 
bifunctional ligandsuch as 1.L13 including a phosphine moiety and a carboxylic acid (Scheme 
35).91 The ligands showed high efficiency and enantioselectivity for a desymmetrizing Csp2-H 
arylation providing 5,6-dihydrophenantridines such as 1.69. The corresponding 
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monofunctionnal ligand such as the MOP1.L15, lacking the carboxylic acid function, only 
induced low enantioselectivities, thus demonstrating the necessity of the bifunctionality in this 
case. The proposed enantiodetermining step involves a more organized structure at the CMD 
transition step. 
 
Scheme 35. First example of Pd0 C-H activation with a chiral bifunctional ligand 
1.3.3. Early syntheses of  bioactive biaryl compounds 
The construction of biaryl scaffolds has been an early topic of interest for Baudoin and 
coworkers. The investigation was focused on the synthesis and the biological evaluation of 
()-rhazinilam analogues (Scheme 36).92 This natural tetracyclic alkaloid was isolated from 
various Apocynaceae. The molecule posseses an axially chiral phenyl-pyrrole subunit, and a 
9-membered median lactam-ring. It was found to have antimitotic properties, with inhibition 
of tubulin assembly. In addition, the molecule presents activity against various cancer cell 
lines. As part of a program directed toward the synthesis of (-)-rhazinilam, the authors showed 
that the biphenyl analogue1.70 exhibited enhanced properties against tubulin assembly and 
similar activities against cancer cell lines. Various approaches, including a palladium-
catalyzed borylation/Suzuki-coupling, allowed the synthesis of racemic (hetero)biaryl 
analogues of type 1.71.92a,e An atroposelective Suzuki-coupling was proposed for the 
synthesis of enantiopure analogues. A large screen of ligand only led to moderate yields and 
low level of selectivity for the chiral biaryl 1.72 when KenPhos 1.L16was used.92b 
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Scheme 36. An early approach for the construction of enantiopure rhazinilam analogues. 
Allocolchicine and steganacin are two naturally occurring chiral biaryls that were found to 
inhibit the tubulin assembly in a similar way to colchicine. A prodrug of N-actetyl colchinol 
caused the selective destruction of tumor vasculature, thus having potential anticancer 
properties. The stereogenic biaryl axis in steganacin bears a stable aR configuration, thanks to 
the height membered bridging ring conformation that prevents from racemization. On the 
other hand, the seven-membered ring of allocochicine and N-acetylcolchinol allows 
atropisomerization, and these molecules occur as mixture of equilibrating isomers (Figure 9). 
The absolute configuration of their biaryl axis has been found to be crucial for their targeted 
bioactivity. Indeed, the activity is often restricted to the aR atropisomers.Baudoin and 
coworkers proposed enantioselective syntheses of hybrid analogues1.73, as well as amino 
analogues of N-acetylcolchinol1.74, in order to evaluate their biological properties.93 
 
Figure 9. Bioactive chiral biaryls 
A developed approach consisted in the atropo-diastereoselective construction of the biaryl 
axis of by Suzuki coupling of a chiral aryl iodide1.75 with of an achiral pinacol arylborane 
1.76. The selectivity arises from the transfer of chirality from the chiral stereocenter to the 
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axial bond. Then, the biaryl axis in the intermediate 1.77 relays its stereochemical information 
to the temporarly destroyed stereocenter in a SN1-type dehydrative cyclization. N-
acetylcolchinol hybrid analogues such as 1.78 could be accessed in good yield and high 
enantiopurity(Scheme 37).93b 
 
Scheme 37. Access to a N-acetylcholinol hybrid analogue via diasereoselective Suzuki cross-
coupling 
Another approach involved the construction of the biaryl axis of 1.81 by racemic Suzuki 
coupling followed by a subsequent Grignard addition to obtain a diastereoenriched 
intermediate1.82 in the synthesis ofthe target racemic amino analogues (Scheme 38).93d 
 
Scheme 38. Suzuki coupling and diastereoselective Grignard addition toward a N-
acetylcholinol amino analogue intermediate 
1.3.4. Modern syntheses of axially chiral biaryls 
The importance of biaryl-based compounds exhibiting an axis of chirality is no longer 
to demonstrate. Various natural and synthetic biologically active substances bear at least one 
chiral axis, such as steganacin (vide supra) or gossypol.94 Stereogenic ligands such as BINOL 
or BINAP are non-negligible inductors for enantioselective synthesis. Moreover, new 
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materials such as liquid crystals95 and dyes96, found their properties based on atropisomeric 
architecture (Figure 10). 
 
Figure 10. Examples of stereo-enriched atropisomeric compounds 
The historical access to atropisomerically enriched backbones was the resolution of racemic 
mixtures. The advances and development in organic and organometallic chemistry over the 
21st century gave new accesses to these scaffolds. To date, numerous methodologies allow the 
construction of stereoenriched biaryls.97 The modern approaches generally involve the 
stereoselective functionalization of racemic or prochiral biaryls, the construction of aromatic 
ring(s), the stereoselective rearomatization via “central to axial” chirality transfer, but notably 
the direct construction of the biaryl axis (Scheme 39).98 These approaches often lie on the use 
of the appropriate organo- or organometallic catalyst.99 The use of transition metal catalyzed 
asymmetric synthesis of axially chiral biaryl compounds has been extensively investigated 
and recently reviewed;100 and the discussion will focus on the palladium-catalyzed Csp2-H 
activation/arylation for the synthesis of biaryl scaffolds. 
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Scheme 39. Modern approaches toward atropisomeric biaryls 
1.3.5. Challenges in palladium catalyzed Csp2-H functionalization 
The first occurrences of the Pd0 catalyzed intramolecular Csp2-H arylation appeared in 
the early 80’s, notably with the work of Ames and Bull,101 for the synthesis of valuable 
heterocycles.102 Tajima independently reported the direct arylation of isoxazoles with aryl 
iodide in presence of a heterogeneous palladium catalyst.103 These early works interrogated 
the o,m,p-regioselectivity in the direct Csp2-H arylation of (hetero)arenes; and this 
challenging point was mainly overcome by intramolecular and/or directed C-H 
activation/arylation (Scheme 40).104 
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Scheme 40. Challenges in the selectivity of the Pd-catalyzed C-H arylation 
The very challenging intermolecular undirected Csp2-H activation/functionalization105 has 
been firstly discussed by Fujiwara in the late 60’s.106 In recent reports by Jacobs107 and Yu,108 
the authors developed a palladium-catalyzed oxidative olefination of arenes, and observed 
that the functionalized arenes lacking directing groups undergo Csp2-H activation 
preferentially at the most electron-rich C-H bond. Nevertheless, no clear regioselectivity was 
obtained, as depicted for Jacobs’s system (Scheme 41). 
 
Scheme 41. Lack of selectivity in Jacobs’s PdII Csp2-H olefination 
In contrast, the regioselectivity in the Csp2-H activation of heteroarenes can be high and is 
mainly influenced by the electronic properties of the C-H bond, as well as its steric 
accessibility. Fagnou reported a systematic study of the regioselectivity in the direct arylation 
of heteroarenes under Pd0 catalysis (Scheme 42). The reaction occurs at the most acidic or 
nucleophilic C-H bond of the heteroarene, to give various heterobiaryls 1.85.109 DFT 
calculations of the energy barriers for the C-H bond cleavage by CMD correlated well with 
the experimental observations.110 
 
Scheme 42. Selected examples of Fagnou’s directed Csp2-H arylation 
The preferential site selectivity in the non-directed intermolecular arylation of (hetero)arenes 
had already been taken in account by several research groups for the synthesis of bioactive 
compounds111 and new materials.112 The researchers at Merck demonstrated in 2005 the first 
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application of transition-metal catalyzed intermolecular Csp2-H arylation of arenes to the 
synthesis of GABA agonists such as 1.88 (Scheme 43).113 
 
Scheme 43. First application of intermolecular Pd0 catalyzed Csp2-H activation/arylation to 
the synthesis of bioactive compound 
The developed methodologies generally suffer from the hindrance around the newly formed 
axis. Indeed, the addition of ortho groups commonly shuts the reaction off; and harsher 
conditions are required, such as the increaseof palladium loading or of the temperature; as 
well as reaction times. In his ligand-free Pd0 catalyzed direct arylation of thiazoles, Doucet 
described the formation of the mono-ortho-methylated product1.89a in 90% yield, whereas no 
product 1.89b could be obtained when using the di-ortho-methylbromobenzene, even with 
higher catalyst loading (Scheme 44).114 
 
Scheme 44. Steric hindrance blocking the formation of biaryl axis 
The new NHC based catalyst 1.90 used by Liu in 2017 proved to be efficient in the direct 
coupling of several heteroarenes.115 The arylation of dimethyl isoxazole with 3-
bromoquinoline gave 1.91a in 77% in presence of 0.1 %mol of catalyst at 130°C. In the same 
condition, the reaction with 4-bromoquinoline only afforded 46% yield of 1.91b, in 
consequence of the increased steric hindrance at the ortho position. An excellent yield of 97% 
could be achieved by increasing the catalyst loading to 0.5 %mol (Scheme 45). 
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Scheme 45. Harscher conditions for the formation of congested biaryl axis 
The syntheses of restricted (hetero)biaryl bearing a potential axis of chirality by palladium-
catalyzed Csp2-H arylation are commonly concealed due to the poor reactivity encountered in 
the construction of the biaryl axis. 
1.3.6. Enantiocontrol in palladium-catalyzed Csp2-H arylation 
The construction of chiral elements by Pd0-catalyzed Csp2-H arylation was scarcely 
reported and only central or planar chirality could be accessed via intramolecular reaction.116 
Cramer and coworkers disclosed in 2009 the first Pd0-catalyzed enantioselective Csp2-H 
desymmetrizing arylation involving the intramolecular arylation of vinyl triflates 1.92 
providing chiral indanes 1.93 bearing an all-carbon quaternary stereocenter.117 The authors 
discovered that monophosphine ligands displayed high reactivity, and the TADDOL-derived 
phosphoramidites such as 1.L17 provided excellent enantiocontrol. Based on the mechanistic 
studies of Maseras, Echavarren, Fagnou and Baudoin,118 the enantiodetermining step was 
proposed to be the carboxylate-assisted CMD. The methodology was extended to the 
synthesis of dibenzazepinones 1.95 in 2013 (Scheme 46).119 
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Scheme 46. First example of Pd0 catalyzed enantioselective Csp2-H activation/arylation, and 
an extension of methodology 
Very high levels of enantioselectivity were obtained in the synthesis of fluoreno- and 
pyridylferrocenes (planar chirality), notably by employing simple and general reaction 
conditions comprised of catalytic Pd(OAc)2 and BINAP in presence of Cs2CO3 as an 
inorganic base.120 Selected examples of the scope of Gu and You in 2015 are depicted in 
Scheme 47. 
 
Scheme 47. Construction of planar chirality by Pd0 catalyzed  Csp2-H arylation 
During the writing of this manuscript, Cramer and coworker established the first 
atroposelective Pd0-catalyzed Csp2-H arylation for the synthesis of axially chiral 
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dibenzazepinones1.99 in an intramolecular fashion.121 The direct arylation proceeds in mild 
conditions and tolerates both electron rich and poor aryls. The hindrance in the ortho-position 
was found necessary to obtain configurationally stable products (Scheme 48). 
 
Scheme 48. Cramer’s first atroposelective Pd0-catalyzed Csp2-H activation/arylation 
To date, only Itami and Studer have provided an access to the intermolecular Pd-catalyzed 
atroposelective C-H arylation.122 In 2012, the authors developed a PdII-catalyzed direct 
arylation of thiophenes with hindered arylboronic acid. The reaction proceeds at 80°C in 
presence of a chiral bisoxazoline1.L20 as the ligand. Good yields of 1.100 were obtained along 
with excellent C4 regioselectivities (Scheme 49). The reaction is applicable to other 
heteroaryls such as benzofurans or indoles. 
 
52 
 
Scheme 49. Itami and Studer’s synthesis of hindered biaryl 
Since the optimal ligands for this reaction are chiral, the selective construction of the biaryl 
axis was investigated. In first place, the stability of the substituted thiophenes1.100toward 
racemization was evaluated. The rotational barrier of 3-methyl-4-(2-methylnaphtalen-1-
yl)thiophene1.100a was calculated. The activation energies for the two modes of 
racemization, comprised between 33.2 kcal/mol and 33.5 kcal/mol, were found to be high 
enough for the two isomers to exist as stable atropisomers at room temperature. After an 
extensive screening of conditions, an asymmetric induction was observed. After 12h at 70°C, 
the enantioenriched 1.100a was obtained in 41% e.e. and in 63% yield. When the steric 
encumbrance in ortho-position was increased by addition of an iPr group, the enantiomeric 
excess rose up to 72% e.e., to the detriment of the yield. Indeed, the biaryl 1.100c was 
obtained in only 27% yield (Scheme 50).122a 
 
Scheme 50. First intermolecular Pd-catalyzed atroposelective Csp2-H arylation 
Despite the clear reactivity-selectivity dilemma, this example established the first step into 
intermolecular enantioselective biaryl coupling via C-H activation. The following year, Itami 
improved his catalytic system by using a catalytic iron-based oxidant instead of a 
stoichiometric TEMPO (Scheme 51).122b The reactivity for hindered coupling partner was 
enhanced and the reaction was also applicable to the oxidative coupling of alkenes. Various 
heterobiaryls 1.101 were isolated in good yield. 
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Scheme 51. Itami’s improved Pd-catalyzed C-H arylation 
With this catalytic system, the enantioenriched product1.100cwas obtained in 61 % e.e. and in 
61% yield under the optimal conditions (70°C, 24h), thus the enantioselectivity was not 
increased but the yield was greater than in the previous methodology (Scheme 52). Further 
mechanistic studies indicated that, contrary to the Pd0 catalyzed atroposelective C-H arylation, 
no enantiodetermining CMD step occurs.123 
 
Scheme 52. Itami’s modification for the intermolecular atroposelective Csp2-H arylation 
1.3.7. Task 2 : atroposelective Pd0-catalyzed Csp2-H activation/arylation 
Axially chiral (hetero)biaryls became more importants and investigated molecular 
scaffolds, especially for the development of new active pharmaceutical ingredients. With the 
experience of the Baudoin group in both atroposelective cross-couplings and catalytic 
enantioselective C-H activation/ functionalization, the objective is to develop an efficient, 
general and scalable atropo-enantioselective method based on Pd0-catalyzed Csp2-H 
activation. The aim is to access new (hetero)biaryl scaffolds which could find their 
application in the synthesis of drugs or drug candidates. 
Both intra- and intermolecular C-H arylation has been originally considered, with 1,2,3-
triazoles as a starting point. The induction of chirality would arise from 1. the use of a chiral 
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monodentate ligand in combination with an achiral base, 2. the combination of an achiral 
ligand with a chiral base, 3. ideally, the use of a chiral bifunctionnal ligand including the 
ligand and the base (Scheme 53). 
 
Scheme 53. Proposed model system and inductions 
The model substrates for the C-H activation would be substituted 1,2,3-triazoles in 
combination with encoumbered aryl bromides. Indeed, close examples of palladium catalyzed 
arylation in racemic fashion have been reported, and the starting materials are easily 
accessible through copper-catalyzed azide-alkyne cycloaddition (CuAAC ; “Click” 
chemistry). The intermolecular reaction would give rise to 5-aryltriazoles, whereas  
intramolecular reactions would furnish various bridged triazoles (Scheme 54). 
 
Scheme 54. Model substrates for the atroposelective Csp2-H arylation 
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It will be important to evaluate the configurational stability of our products toward 
racemization under the reaction conditions. The usually high temperatures (>100°C) required 
for C-H activation could lower down the selectivity by gradual erosion of the enantiomeric 
excess over time, and the choice of the substitution around the biaryl axis must be judicious. 
A screening of the different types of ligands and/or bases would allow us to identify the most 
promising catalyst, and the optimization of the reaction conditions as well as a ligand 
design/synthesis (if necessary) would furnish high levels of enantiocontrol (e.r.>95:5). 
  
56 
 
2. Arylation of O-carbamates via Negishi cross-coupling 
2.1. Enantioselective -arylation of O-carbamates 
2.1.1. Introduction 
All along this chapter, the following notation will be used for the protecting/directing 
groups borne by the alcohols (Figure 11): 
O O
N
O
O N
O
ON
-TIB -Cb -Cby -Cbx  
Figure 11. The protecting/directing groups and their names 
2.1.2. Preliminary study 
We started our investigation on the arylation of protected aliphatic alcohols using the 
deprotonation/lithiation conditions developed within the Aggarwal research group (Table 
2).124 The TIB-protected secondary alcohol 2.1 was deprotonated with s-BuLi/TMEDA (2/6 
eq.) for 1h at -50°C in CPME, and subsequently quenched with MeOD to obtain the -
deuterated alcohol D-2.1 in 85% D-integration (entry 1). A lower loading of TMEDA in 
CPME resulted in a decrease of D-integration (entry 2), as well as in other solvents (entries 3-
5). The transmetalation of the organolithium to the organozinc was also attempted by addition 
of ZnCl2 (2 eq. in THF) to the organolithium at -78°C, and then the warm up to 20°C, but the 
following quench with MeOD only led to variable proportions of the deuterated alcohol (entry 
6). This deuteration was furthermore not reflecting whether or not the transmetalation to zinc 
occurred and if this complex was stable toward the variation of temperature. 
 
Entry Conditions TMEDA eq. Solvent Yield D-2.1%a (D-int.%)a 
1 i), then MeOD 6 CPME 90  90 
2 i), then MeOD 2 CPME 90 52 
3 i), then MeOD 2 Et2O 75 40 
4 i), then MeOD 2 THF 100 0 
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5 i), then MeOD 2 Toluene 50 20 
6 i), then ii) then MeOD 6 CPME <50 n.d. 
aYields and D-integration determined by 1H NMR. 
Table 2. Variation of conditions for the metalation of 2.1 
The Negishi cross-croupling was nevertheless attempted. After evaporation of the volatiles 
under high-vacuum, the assumed -zincated ester was reacted with 4-bromoanisole (1.3 eq.) 
in presence of Pd2(dba)3 (5 %mol) and the ligand (10 %mol), at 60°C for 18h in toluene 
(Table 3). In presence of the hindered Pt-Bu3, the expected -arylated product 2.1a was not 
observed (entry 1). Instead, the side-product 2.1sp resulting from transmetalation and 
subsequent coupling of s-BuLi, was mainly observed. Likewise, with the more flexible ligand 
1.L9, no terminal -arylation product 2.1b was formed (entry 2). The direct coupling of the 
organolithium125 was attempted, but only led to the homocoupling product 2.1homo (entry 3). 
 
Entry Conditions Ligand Product 
1 i), ii), then iii) Pt-Bu3.HBF4 only 2.1sp 
2 i), ii) then iii) 1.L9 no 2.1b 
3 i), then iii) Pt-Bu3.HBF4 only 2.1homo 
Table 3. Arylation attempts on 2.1 
The TIB-protected ethanol 2.2 and cyclohexanol 2.3 were engaged in the same conditions, 
with Pt-Bu3 as the ligand, without success. The reaction with the Cb-protected ethanol 2.4 did 
not show any efficiency as well (Scheme 55). 
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Scheme 55. Arylation attempts on other protected alcohols 
We then turned our attention to the reaction system involving the deprotonation/lithiation step 
developed by Beak and Hoppe (Table 4).126 The protected alcohols 2.2 and 2.4 were lithiated 
with s-BuLi/TMEDA (1.3 equivalents) for 5h at -78°C, and then quenched with MeOD. The 
compound D-2.2 was obtained in 82% yield and 100% D-integration (entry 1), and D-2.4 was 
obtained with a similar yield and D-integration (entry 2), showing the efficiency of the 
lithiation conditions. The corresponding organozinc intermediates were formed by addition of 
ZnCl2 (1.4 eq. in THF) at -78°C, before being allowed to warm up to 20°C. After evaporation 
of the volatiles, the organozinc was subsequently coupled with 4-bromoanisole in presence of 
Pd2(dba)3 (5 %mol) and Pt-Bu3 (10 %mol) at 60°C for 18h in toluene. The coupling product 
2.2a was not observed (entry 3), but to our delight, the -zincated carbamate 2.4 underwent 
Negishi cross-coupling to give 2.4a in 72% yield (entry 4). This discovery established the 
feasibility of the -arylation of protected alcohols. 
 
Entry Substrate Conditions Product Yield% (D-int.%)a 
1 2.2 i), then MeOD D-2.2 82 (100) 
2 2.2 i), then MeOD D-2.4 86 (100) 
3 2.4 i), ii), then iii) 2.2a not observed 
4 2.4 i),ii), then iii) 2.4a 72% 
aYields and D-integration determined by 1H NMR 
Table 4. Arylation attempts using Beak’s deprotonation/lithiation sequence. 
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To finish the preliminary study, the substrate 2.4 was deprotonated in presence of ()-
sparteine over 5h at -78°C in Et2O and the enantioenriched organolithium intermediate was 
transmetalated to zinc and subjected to Negishi cross-coupling in presence of preformed 
Pd(Pt-Bu3)2. We were pleased to obtain the enantioenriched -arylated carbamate 2.4a in 
60% yield and with 97:3 e.r. (Scheme 56). 
 
Scheme 56.Enantioselective -Arylation attempt with XX4 
This preliminary study established the feasibility of the -arylation of protected alcohols and 
its enantioselective version, via a sequential deprotonation/lithiation, transmetalation to zinc 
and palladium-catalyzed Negishi cross-coupling. The reaction conditions were optimized. 
2.1.3. Optimization of the reaction conditions 
Optimization of the ligand 
The ligand plays an essential role in the reactivity and the (regio)selectivity of the 
arylation under Negishi cross-coupling conditions. To evaluate the impact of the different 
ligands on this coupling, the racemic -zincated carbamate formed from 2.4 was arylated with 
4-bromoanisole (1.3 eq) in presence of Pd0 (from Pd2dba3, 5 %mol) and the ligand (10 %mol) 
(Table 5). Other hindered trialkyl phosphines such as P(Cy)3 and CataCXium A gave lower 
yields than Pt-Bu3 (entries 1-3). Nevertheless, the latter suffered a lack of constancy in the 
yield of arylated product, using either its HBF4 adduct or the preformed Pd(Pt-Bu3)2 from 
different provider, in the same stoichiometry (entries 3-5). Buchwald-type ligands, which are 
known for their efficiency in numerous direct and migrative arylation reactions, were 
screened. JohnPhos 2.L23 and CPhos 1.L6, bearing respectively a –Pt-Bu2 and a –PCy2 
moiety, gave yields below 3% (Table 5, entries 6-7). PhDavePhos 2.L24 gave a lower yield 
than its more electron-rich analog DavePhos 1.L4 and comparable yield to XPhos 1.L3 and 
BrettPhos 2.L25, in a range of 20% to 29% (entries 8-11). The arylation in presence of RuPhos 
1.L2 showed a higher reactivity (43% yield). A comparable yield was obtained when the 
preformed RuPhos Pd G3 [1.L2-PdG3] was used (Entries 12-13).  
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Entry Ligand Yield%b 
1 P(Cy)3 <5 
2 CataCXiumA 19 
3 Pt-Bu3.HBF4 (72) 
4a Pd(Pt-Bu3)2 (Sigma-Aldrich) 22 
5a Pd(Pt-Bu3)2 (Strem) (50) 
6 JohnPhos 2.L23 <3 
7 CPhos 1.L6 <3 
8 PhDavePhos 2.L24 20 
9 DavePhos 1.L4 29 
10 XPhos 1.L3 25 
11 BrettPhos  2.L25 20 
12 RuPhos 1.L2 43 (39) 
13a RuPhos PdG3 [1.L2-PdG3] 46 
aThe Pd complex (10 %mol) was used. bGCMS yield with dodecane 
 as an internal standard, isolated yield in brackets. 
Table 5.Effect of the ligand on the -arylation reaction 
The free RuPhos 1.L2was selected as the ligand of choice for this reaction, in combination 
with Pd2dba3. Indeed, this ligand was also more readily available than its preformed catalytic 
precursor [1.L2-PdG3]. 
Optimization of the zinc source 
ZnCl2 in THF was used in the first place as it has been the zinc source for 
transmetalation in, for example, the direct and migrative arylations of N-Boc-amines. The 
racemic organolithium was formed with s-BuLi/TMEDA (1.3 eq.) as in the above 
optimizations, but only for 1h at -78°C in Et2O. Indeed, a control experiment on the 
deuteration step showed that 1h only was necessary for the complete deprotonation/lithiation 
of the carbamate 2.4. The organolithium was then transmetalated with the corresponding zinc 
source (1.4 eq. in THF) at -78°C for 30 min and then warmed-up to 20°C over 30 min. After 
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evaporation of the volatiles, the organozinc was submitted to a Negishi cross-coupling under 
the previously defined conditions (Table 6). ZnBr2 and ZnI2gave lower yields than ZnCl2 
(entries 2-3), where ZnF2 did not provide any arylated product (entry 4). Surprisingly, the 
carboxylates provided higher yields than the halides. Commercially available Zn(OAc)2 
increased the yield to 63%, whereas Zn(OPiv)2 and Zn(OTFA)2 afforded the arylated product 
in average yields (entries 5-7). 
 
Entry Zinc Source Yield%a 
1 ZnCl2 43 (39) 
2 ZnBr2 29 
3 ZnI2 16 
4 ZnF2 0 
5 Zn(OAc)2 63 (55) 
6 Zn(OPiv)2 55 (51) 
7 Zn(OTFA)2 51 
aGCMS yield with dodecane as an internal standard, isolated  
yield in brackets. 
Table 6.Variation of the zinc source for the transmetalation step 
A critical effect of the zinc salt on the outcome of the reaction was observed. Zn(OAc)2 
proved to be superior to ZnCl2, and was selected as the ideal zinc source for the 
transmetalation step in our standard procedure. 
Variation of the catalyst and the electrophile loadings 
The catalyst loading was decreased to evaluate the possibility of using less palladium 
and less ligand in this arylation reaction (Table 7). This also reflects the robustness of the 
catalytic system for this Negishi cross-coupling. The loading was divided by two to reach 5 
%mol of Pd/L, and afforded a similar yield than with 10 %mol of Pd/L(entries 1-2). A 
significantly decreased yield was observed with only 2.5 %mol of the catalytic system (entry 
3). When the latter was decreased to 1 %mol, the yield decreased to only 25% (entry 4). A 
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loading of 5 %mol of the catalytic system, with respect to the carbamate, was chosen to 
continue the optimization. The stoichiometry of the electrophile was also decreased to 0.7 eq. 
with respect to the carbamate, and we were pleased to observe a crucial increase to 77% yield 
of the arylated product (entry 5). With this lower load of 4-bromoanisole, the stoichiometry of 
the catalytic system was also tested. The decrease of Pd/L loading to 10 %mol with respect to 
the arylbromide (equivalent to 7 %mol with respect to the carbamate) afforded a slightly 
lower yield, as well as with 5 %mol with respect to the arylbromide (entries 6-7). Further 
lowering of the catalyst loading resulted in a poor yield (entry 8). 
OCb
OCb
s-BuLi/TMEDA 1.3eq,
-78°C, 1h, Et2O
then Zn(OAc)2 1.4 eq in THF,
-78 to 20°C
then Pd2dba3 x %mol,
RuPhos y %mol in toluene,
4-bromoanisole z eq, 80°C, 18h
O
2.4a
2.4
 
Entry x %mol y %mol z eq. Yield% a 
1 5 10 1.3 63 (55) 
2 2.5 5 1.3 58 
3 1.25 2.5 1.3 51 
4 0.5 1 1.3 25 
5 5 10 0.7 77 (70) 
6 3.5 7 0.7 (73) 
7 1.75 3.5 0.7 (71) 
8 0.88 1.75 0.7 (39) 
aGCMS yield with dodecane as an internal standard, isolated yield in brackets. 
Table 7. Variation of the catalyst and the electrophile equivalents 
With the variation of the catalyst and the electrophile loading, 2.4a was afforded with 71% 
yield in presence of a minimized amount of catalyst (Pd2dba3 1.75 %mol / RuPhos 3.5 %mol) 
and of the electrophile (0.7 eq.) ; thus defining the new standard catalyst loading for this 
Negishi cross-coupling. 
Alternative directing group 
 In parallel, the Cby-protected alcohol 2.5 has been submitted to the same reaction 
conditions, in order to estimate the potential of another directing group (Table 8). The 
intermediate racemic organozinc was formed, and engaged with 10 %mol of the catalytic 
63 
 
system in presence of 1.3 eq of 4-bromoanisole, to afford an average yield (entry 1). 
Furthermore, the -zincated 2.5 was prepared in an enantioselective fashion and engaged in 
the Negishi cross-coupling. We were very satisfied to obtain a similar yield, but with an 
excellent e.r. of 99:1 when using ()-sparteine as the diamine (entry 2). The equivalents of 
catalyst and electrophile were switched to those defined in the previous section. We were then 
enchanted to obtain more than 80% yield of 2.5a with both protocols, and an excellent e.r. of 
99.5:0.5 (entry 3-4), showing the efficiency of the protocols and a full transfer of chirality 
along all the steps of the arylation sequence. 
 
Entry x %mol y %mol z eq diamine Yield %a e.r.b 
1 5 10 1.3 TMEDA 44 rac 
2 5 10 1.3 ()-sp 44 99:1 
3 1.75 3.5 0.7 TMEDA 81 rac 
4 1.75 3.5 0.7 ()-sp 86% 99.5:0.5 
aIsolated yields.be.r. valuedetermined by HPLC analysis on a chiral 
 stationnary phase. 
Table 8. -arylation on an alternative carbamate 
This study sealed our standard conditions and brought us to the last step of optimization, 
which was the evaluation of the most suitable electrophile. 
Evaluation of the ideal electrophile 
The coupling partner is of critical importance in cross-coupling reactions (Table 9). 
The electrophiles propose different reactivities toward the insertion of palladium in the 
(pseudo)halide bond, thus changing the outcome of the reaction. The optimization was carried 
out with 4-bromoanisole (entry 1) and other (pseudo)halides were engaged in the Negishi 
cross-coupling with the -zincated 2.5 as the coupling partner. The yield decreased to 70% 
when 4-iodoanisole was used (entry 2), and the reaction was dramatically shut down when 
using 4-chloroanisole to afford only 7% of the 2.5a (entry 3). The corresponding triflate only 
generated 40% yield (entry 4). 
64 
 
 
Entry 4-X-anisole Yield%a 
1 4-Br-anisole 81 
2 4-I-anisole 70 
3 4-Cl-anisole 7 
4 4-OTf-anisole 41 
aIsolated yields. 
Table 9. Effect of the electrophile 
Bromo-electrophiles were selected as the coupling-partner of choice. With these conditions in 
hand, two additional directing groups were evaluated in this coupling as the first part of the 
reaction scope. 
2.1.4. Study of the directing group 
The known directing groups allowing the deprotonation/lithiation in -position of 
protected alcohols were screened under the previously optimized conditions, in both racemic 
and enantioselective fashion, with 4-bromoanisole as the coupling partner (Table 10). The 
racemic protocol involves the deprotonation/lithiation step in presence of TMEDA for 1h, 
while the enantioselective protocol involves the initial deprotonation/lithiation in presence of 
()-sparteine for 5h, under otherwise identical conditions. The Cb carbamate 2.4 afforded 
2.4a in 71% for the racemic protocol, and furnished the enantioenriched 2.4a  in 51% yield 
and 98:2 e.r. (entry 1). The aminal derived Cby 2.5 and Cbx 2.6 gave improved yields and e.r. 
for both protocols (entry 2-3). In addition, the TIB ester 2.2 proved to be a competent reaction 
partner in this coupling, despite reduced yield and e.r. (entry 4). 
 
   Yieldsa  
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Entry Product DG TMEDA ()-sparteine e.r.b 
1 2.4a Cb 71 50 98:2 
2 2.5a Cby 81 86 99.5:0.5 
3 2.6a Cbx 87 70 99.5:0.5 
4 2.2a TIB 47 62 92.5:7.5 
aIsolated yields.be.r. valuedetermined by HPLC analysis on a  
chiral stationnary phase. 
Table 10. Study of the directing groups under the optimized conditions. 
The Cby carbamate was selected for the study of the reaction scope and limitations with 
respect to the bromo-electrophile. 
2.1.5. Scope and limitations of the electrophile 
The reaction proved to be compatible with a variety of aryl bromides, in both racemic (with 
TMEDA,for 1h, A) and enantioselective (with ()-sparteine, for 5h, B) protocols (Scheme 
57), including unsubstituted (2.5b), para- (2.5a,c-h), meta- (2.5i), ortho- (2.5j-k),  as well as 
polysusbtituted arenes (2.5l-n). The mild conditions of the Negishi coupling step also 
tolerated sensitive functional groups such as a ketone (2.5e), nitrile (2.5f), nitro (2.5g) and 
methyl ester (2.5h). In all cases, excellent enantioselectivities were obtained, when ()-
sparteine was used as the diamine. 3-bromopyridine was also reacted successfully in both 
protocols (2.5o), whereas the 2-bromo isomer only reacted in the racemic reaction (2.5p). 
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Scheme 57.Scope with respect to the aryl electrophile 
The absolute configuration of the compound 2.5f was determined to be (R) by X-Ray 
diffraction analysis and the configurations of the other products were therefore assigned as (R) 
by analogy (Figure 12). 
 
Figure 12. X-Ray diffraction analysis of 2.5f 
The scope of the electrophile was nevertheless limited (Figure 13). Methyl 2-bromobenzoate 
did not undergo Negishi coupling, presumably because of the steric hindrance at the ortho-
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position. The other heteroarylhalides gave only low coupling yields (below 15%), as well as 
the alkenyl and the alkynyl electrophiles. Thus, there use was not further explored. 
 
Figure 13. Unsuccessfull electrophiles in the -arylation conditions 
Next, the scope with respect to the carbamate was investigated. 
2.1.6. Scope with respect to the carbamate reactant 
Both protocols allowed the arylation in moderate-to-very good yields with p-bromotoluene as 
the coupling partner (Scheme 58). The reaction time for the lithiation in the racemic version 
was nevertheless increased to allow a complete deprotonation. Excellent e.r. were achieved 
using ()-sparteine for the carbamates bearing a secondary carbon at the -position (2.5q, t-u, 
w-z). Lower yields and e.r. were obtained for carbamates containing a more hindered tertiary 
carbon (2.5r-s). Several usefull functional groups were tolerated, such as a benzene ring 
(2.5t, w), an olefin (2.5u-v), a TBS-protected alcohol (2.5x) and a dibenzyl-amine (2.5z). The 
bis-carbamate 2.5y underwent an efficient and exclusive monoarylation. The reaction could 
also be scaled-up to 3 mmol (5-folds scale) with ()-sparteine and phenylbromide to offer 
equally good performance (74% yield, e.r. 99:1), as shown with compound 2.5v. 
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Scheme 58. Scope of the a-arylation in carbamate 
A variety of other carbamates were not successful with these protocols (Figure 14). The N-
substituted aminoethanols 2.8a-b only provided low yields. The Cby-protected benzylic 
alcohol underwent Negishi coupling in 39% yield of 2.9, after tuning of the lithiation time, 
but was not further considered. Surprisingly, benzyl protected propanediol was arylated 
exclusively at the benzylic position to give 2.10 in a rather low yield of 36%. N-Boc-N-methyl 
propanolamine was found to react selectively in -position to the nitrogen to afford 2.11 in 
33% yield. 
 
Figure 14.Unsuccessfull carbamates under the -arylation conditions 
In our aim to synthesize valuable building blocks and to demonstrate the versatility of this 
methodology, the deprotection of the scalemic -arylated carbamates was performed. 
2.1.7. Deprotection of the carbamates 
The Cby group was also chosen for its relative easy removal. Where the Cb group is 
nearly impossible to cleave, even under really harsh conditions, typically 10 equivalents of 
LiAlH4 in refluxing THF for several days; the N,O-acetonide of the Cby is opened with 
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MeSO3H in refluxing methanol, and thereafter the hydroxyl group plays a role in presence of 
Ba(OH)2.8H2O to release the free alcohol (Scheme 59).  
 
Scheme 59.Standard deprotection of the Cby group. 
On the one hand, the cleavage of the directing group was attempted on the 
enantioenriched (R)-2.5a(e.r. 99:1) by reduction with LiAlH4. The benzylic alcohol (R)-2.12a 
was obtained in 50% yield, but with a reduced e.r. of 86:14. On the other hand, the acido-
basic conditions were applied and the free alcohol was obtained in average to good yields. 
Unfortunately, the e.r. was completely eroded during the deprotection to give only the 
racemic alcohol. We assumed that the benzylic carbocation 2.12int formed under these 
conditions, leading to the racemic 2.12a (Scheme 60). 
 
Scheme 60. Deprotection attempt on the -arylated carbamate 2.5a. 
The protocols reported by Aggarwal and co-workers127 for the Cb group were adapted as a 
formal deprotection of these benzylic carbamates. The lithiation/borylation/oxydation 
sequence was performed with HB(pin) from carbamate (R)-2.5ato give the desired alcohol in 
78% yield and an e.r. of 96:4, thus exhibiting a very good enantiospecificity (e.s. 94%, 
Scheme 61). 
 
Scheme 61. Deprotection of (R)-2.5a via Aggarwal’s lithiation/borylation sequence. 
70 
 
Likewise, the (S)-enantiomer of 2.5a was obtained using ()-sparteine in a 3 mmol scale 
asymmetric arylation, and its lithiation/borylation/oxidation afforded (S)-2.12a with a similar 
yield and enantiospecificity. The (R)-configured tertiary alcohols 2.12b and 2.12c were 
obtained similarly using the organoboronates EtB(pin) and PhB(pin), respectively, in place of 
the pinacolborane. Both showed an excellent preservation of the optical purity (e.s. 96%, 
Scheme 62). 
 
Scheme 62. Access to 2° and 3° alcohols using Aggarwal’s methods. 
The deprotection of the carbamates demonstrated the versatility of the -arylation 
methodology, which coupled to Aggarwal’s lithiation/borylation methodology provides a 
divergent access to very enantioenriched secondary and tertiary alcohols as valuable building 
blocks, with an excellent enantiospecifity all along the transmetalation steps. 
2.1.8. Mechanistic insights 
As shown earlier, the methodology provides highly enantioenriched -arylated O-
carbamates. The chiral diamine controls the selectivity during the deprotonation/lithiation 
step. The use of ()-sparteine induces the deprotonation of the pro-S proton in -position to 
give intermediate 2.A-Li, which undergoes transmetalation to zinc in a stereoretentive manner 
to give 2.A-Zn. The stereospecific course of the transmetalation has been studied by Nakai 
and co-workers128 and exemplified in the methodology of Taylor and co-workers.129 The 
reductive elimination takes place without inversion of configuration and the products were 
assigned as being (R) thanks to the crystal structure of 2.5f, thus demonstrating the 
enantioretention of the transmetalation to the organopalladium 2.A-Pd during the Negishi 
coupling (Scheme 63). 
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Scheme 63. Stereoretentive course of the -arylation. 
Carbamates 2.5r and 2.5s bearing a more hindered tertiary carbon at the -position were 
obtained in lower e.r., but the ()-sparteine mediated lithiation of the carbamate precursor of 
2.5r was reported to occur with an e.r.>97.5:2.5.130 This erosion of e.r. arises thus more likely 
from the partial racemization of the corresponding organozinc or organopalladium 
intermediate, due to the neighboring steric hindrance (Scheme 64). 
 
Scheme 64. Partial racemization in the arylation of 2.7b 
It is remarkable to observe that the configuration of secondary and tertiary alcohols 2.12a-c is 
controlled by the initial sparteine-mediated lithiation of the primary carbamate2.5, followed 
by a sequence of 5 discrete stereospecific steps, including : 
 Li-Zn transmetalation 
 Zn-Pd transmetalation and reductive elimination affording 2.5a 
 Stereoretentive lithiation 
 Borylation followed by the 1,2-rearrangement 
 Oxidation of the boronic ester 
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2.1.9. Application in total synthesis 
With the collaboration of Yann Baumgartner,131 we attempted to apply the 
enantioselective arylation methodology in total synthesis. The first target was Erinceolactone 
C, a natural lactone isolated from the culture broth of Hericium Erinaceus, and known as a 
plant growth inhibitor. No synthesis of this compound has yet been described. The synthetic 
approach involves the enantioselective arylation of bis-carbamate 2.7h using our new 
methodology, a substrate-directed asymmetric carboxylation, and a deprotection/lactonisation 
sequence (Scheme 65).132 
 
Scheme 65. Proposed synthetic approach of Erinaceolactone C 
A synthetic pathway for the synthesis of the required trisubstituted aryl bromide 2.16 involves 
a directed ortho-lithiation/chlorination step  to access 2.15 followed by an iridium-catalyzed 
meta-selective borylation/copper mediated bromination sequence (Scheme 66).133 
 
Scheme 66. Proposed pathway for the synthesis of the trisubstituted aryl bromide 
In a first time, a deuteration experiment was run on product rac-2.5yto determine the 
regioselectivity of the deprotonation/lithiation sequence in view of the carboxylation step. 
Indeed, the directed deprotonation with s-BuLi in presence of TMEDA could occur either on 
the activated but hindered benzylic -position, or at the desired ’-position. Unfortunately, 
only benzylic deuteration was observed and the synthesis was not further explored (Scheme 
67). 
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Scheme 67. Regioselectivity of the deprotonation/lithiation of rac-7y 
We then turned our attention to the synthesis of fluoxetine (Prozac), a blockbuster 
antidepressant. Two routes were envisaged from the arylation product product 2.5v (Scheme 
68). The first approach involves the ozonolysis of the terminal insaturation, followed by the 
reductive amination with MeNH2 to obtain the key O--arylated 1,3-aminopropanol (Route 
A). The latter would subsequently be deprotected and arylated to obtain the desired target. 
The second route involves the deprotection of 2.5v, the ozonolysis of the insaturation and the 
subsequent carbonyl reduction to obtain the enantiopure O--arylated 1,3-propanediol 2.20, a 
key intermediate in a synthetic approach of (R)-fluoxetine by Genêt and coworkers (Route 
B).134 
Scheme 68. Synthetic approaches to (R)-fluoxetine from 2.5v 
The ozonolysis followed by the addition of zinc dust (10 eq) and acetic acid (10 eq) in Route 
A afforded the aldehyde 2.17 in quantitative yield. Unfortunetly, the following reductive 
amination was low yielding, and after a screen of numerous reducing agents, only 45% of the 
1,3-aminopropanol was observed in the crude mixture. The desired compound 2.18 was 
isolated in only 10% yield (Scheme 69), which was not sufficient for a further application. 
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Scheme 69. Development of Route Atoward Fluoxetine 
The second route also proved to be challenging. Indeed, Aggarwal’s 
deprotonation/lithiation/borylation sequence with pinacolborane, followed by oxidation, did 
not lead to the deprotected product 2.19. Only starting material or degraded product could be 
observed under classical conditions. It is proposed that the coordination of the unsaturation to 
the lithium in the intermediate boronate complex blocks the 1,2-migration of the hydride, as 
discussed by Aggarwal and coworkers in a previous report (Scheme 70).135 The addition of 
12-crown-4, water and TMSCl, as disclosed in the latter report, did not trigger the reaction. 
OCby
rac-2.5v
OH
s-BuLi/TMEDA
then HB(pin)
then aq. NaOH, H2O2
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Scheme 70. Unsuccessful deprotection of 2.5v 
In the same time, the scope of the reaction was completed and the training period of Yann 
Baumgartner ended. No further development for the method application was investigated. 
2.1.10. Conclusion 
In this chapter, a general methodology for the enantioselective -arylation of O-
carbamates was described. The high enantioenrichment of the benzylic carbamates relies on 
the stereoselective deprotonation/lithiation with sparteine. The mild conditions of the Negishi 
cross-coupling allow the use of various useful and sensitive functional groups. This method, 
combined with Aggarwal’s lithiation/borylation/oxidation sequence, provides a concise and 
divergent access to enantioenriched secondary and tertiary benzylic alcohols that 
complements other enantioselective methods (Scheme 71).136 
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Scheme 71. Enantioselective -arylation of O-carbamates 
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2.2. Attempts toward the -Arylation of O-carbamates 
Greatly motivated by our results, and in view of the previous successful projects on 
the migrative arylation of N-Boc amines, we aimed the ligand-controlled migrative arylation 
of O-carbamates. The initial proposition involved the formation of the -zincated carbamate 
of type 2.B with the protocol developed for the -arylation. The organozinc would be 
submitted to Negishi cross-coupling in presence of the adapted ligand. After installation of the 
palladium in the -position such as in 2.C1, the favored -hydride elimination, followed by 
rotation and reinsertion, would give rise, after reductive elimination, to the corresponding -
arylated carbamate of type 2.D (Scheme 72, A). The methodology could ideally be adapted to 
longer chains such as 2.E and the migration to the terminal position as in 2.F would afford an 
array of terminal arylated alcohols of type 2.G after deprotection (Scheme 72, B). In addition, 
the migration could occur toward a non-terminal position, thus forming a stereogenic center. 
The application of Hoppe’s technology to install enantioselectively the palladium at the -
position (2.I) would potentially result in the enantiospecific migrative arylation (2.J) to obtain 
highly valuable building blocks of type 2.K after deprotection (Scheme 72, C). 
 
Scheme 72.-arylation and longer range arylation of the O-carbamates 
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2.2.1. Ligand controlled -arylation of O-carbamates 
 In a first time, carbamate 2.5 was lithiated and transmetalated to zinc. The organozinc 
was engaged in the Negishi cross-coupling under the -arylation conditions, in presence of 1-
bromo-2-fluorobenzene, but with different ligands (Table 11). Not surprisingly, only the -
arylated product was observed when RuPhos 1.L2 was used (entry 1). The use of more 
flexible pyrrole-based ligands (1.L9-10, 2.L26) which proved to be effective in previous 
migrative couplings in the Baudoin group, led exclusively to the -arylated carbamate (entries 
2-4). The imidazole-based cataCXium PICy underwent the same pathway (entry 5). The steric 
bulk of the more hindered Cbx group of 2.6, in combination with bulky Buchwald-type 
ligands, did not bring the desired push effect to force the migration (entries 7-8). The use of 
more flexible pyrrole- or imidazole- based ligands was unsuccessful as well (entries 9-13). In 
all cases, no -arylated product was observed. 
 
Entry S.M. DG Ligand / ratioa 
1 2.5 Cby RuPhos 1.L2 100/0 
2 2.5 Cby 1.L10 n.r. 
3 2.5 Cby 1.L9 100/0 
4 2.5 Cby 2.L26 100/0 
5 2.5 Cby CataCXium PICy 2.L27 100/0 
6 2.6 Cbx RuPhos 1.L1 100/0 
7 2.6 Cbx BrettPhos 2.L25 100/0 
8 2.6 Cbx DavePhos 1.L4 100/0 
9 2.6 Cbx 1.L11 n.r. 
10 2.6 Cbx 1.L9 100/0 
11 2.6 Cbx 2.L26 100/0 
12 2.6 Cbx 1.L8 100/0 
13 2.6 Cbx CataCXium PICy 2.L27 100/0 
aThe ratios were determined by GCMS 
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Table 11. First attempts toward the ligand controlled -arylation 
With the catalytic system being inefficient for the observation of the -arylated products, we 
envisaged to design the substrate in order to stabilize the potential palladated intermediate. 
2.2.2. Design of the substrate for -arylation 
As a first step, the substrates were designed to bear a functional group in the -position 
of the carbamate, or a ,-insaturation (2.L). In this way, after installation of the palladium in 
the -position of the carbamate (2.M), the interaction with these functional groups would lead 
to an enhanced reactivity toward the -hydride elimination, thus triggering the migration of 
the palladium complex to intermediate 2.N (Scheme 73). 
 
Scheme 73. First design of substrate for the -arylation of O-carbamates 
The designed carbamates were submitted to the -arylation protocol with 1-bromo-2-
fluorobenzene as the electrophile. The cross-couplings were conducted at 60°C with RuPhos 
1.L2 as the ligand to establish our reference -products, and then with CataCXium PICy 2.L27 
(selected ligands among others for -arylation attemps) to induce the migration (Scheme 74). 
The carbamates 2.7g and 2.7i, bearing a silyl-ether and a dibenzyl-amine respectively, 
underwent exclusive -arylation in both protocols. The ,-unsaturated carbamate 2.7d 
bearing a phenyl ring did not lead to any arylation at the benzylic position. The alkyne 2.7j 
and the pyridine 2.7k only afforded poor conversion and no migrative arylation product was 
observed. But to our delight, the alkene 2.7e gave the expected -arylated product with 
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RuPhos as the ligand, and a distribution of regioisomers when arylated in presence of 
CataCXium PICy. 
 
Scheme 74.-arylation attempts on designed susbtrates I 
The different isomers included 16% of the -arylated product and 24% of the -arylated 
product, as well as 60% of other isomers, constituting the first discovery toward a new type of 
migration, which will be developed in the next section.  
At the same time, the substrates were also designed in order to catch the palladium at the -
position, in the course of its migration (Scheme 75, 2.O). After the first -H eliminitation 
(2.P), rotation and reinsertion, the palladium complex would be stabilized thanks to a 
functional group located at the -position or a ,-unsaturation (2.Q). The subsequent 
reductive elimination would lead to the -arylated product. 
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Scheme 75. Second design of substrates for the -arylation of O-carbamates 
In the same way, carbamates 2.7f and 2.7l-n were engaged following the -arylation protocol, 
at 60°C with 1–bromo-2-fluorobenzene as the coupling partner (Scheme 76). With RuPhos as 
the ligand, only the -arylation products were obtained, for both -substituted and ,-
unsaturated substrates. These latter reacted equally when CataCXium PICy was used for the 
arylation, to deliver exclusively the corresponding -arylated products. Of note, the 
carbamate 2.7m bearing a pyridine moiety only gave poor conversion and an unexploitable 
mixture of products, probably due to a non-effective lithiation in this case. Surprisingly, the 
,-unsaturated carbamate 2.7n did not provide any migrationproduct, enlightening the critical 
effect of the ,-unsaturation in 2.7e (above in Scheme 74). 
 
Scheme 76. -arylation attempts on designed susbtrates II 
This study led us to the discovery of a potent substrate for the migrative arylation of O-
carbamates (Scheme 77). In this regard, the arylation products of 2.7e were analysed and their 
structures were determined. Surprisingly, the expected - and -arylated carbamates 2.20a 
and 2.20b were obtained in 11% and 15% 19F-NMR yield respectively, along with a mixture 
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of the Z and E isomers of the -arylated product 2.20c in 33% 19F-NMR yield. The -arylation 
product was not detected. 
 
Scheme 77.Observation of migrative arylation products 
The different screens of ligands and designed substrates for the -arylation of O-carbamates 
were unsuccessful. Nevertheless, the carbamate 2.7e afforded a mixture of -, -, and -
arylated products, the latter being the major one. With this result in hand, we turned our 
attention to the synthesis of the -arylated product, as well as the study of the mechanism 
leading to this regioselectivity in the coupling step. 
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2.3. Ligand-controlled -arylation of O-carbamates 
2.3.1. Ligand screen 
In a first place, a large screening of ligand was operated on substrate 2.7e (>25 ligands 
were tested). Selected results are compiled in Scheme 78. The -organozinc was formed 
under standard conditions, and then coupled with 2-F-bromobenzene in presence of  Pd2dba3 
and the ligand. The phenylpyrrole based ligands 1.L11and 1.L9, known for their good 
selectivity control in previous migrative arylations, were in this case inefficient. Switching the 
alkyl groups to cyclohexyl moieties in 2.L28 allowed the observation of migration products in 
reasonable amounts. The phosphine bearing cyclohexyl chains was kept and the o-NMe2 
substitution of the lower ring in 2.L26led to 49% yield of arylated products, but including only 
12% of 2.20g. The substitutions with an o-OMe in 2.L29 or the 2,6-diOi-Pr in 2.L30 
completely shut down the reactivity. When the upper ring was changed to a more flexible 
imidazole such as 1.L8, a larger ratio of -product was obtained. The pyrazole congenere 2.L32 
provided a better global yield of arylated product, but with a higher selectivity for the -
product. The more hindered 2,6-diNMe2 substituted 2.L31underwent exclusive -arylation in 
good yield, likewise the biphenyl ligands RuPhos 1.L2 and DavePhos 1.L4. The CataCXium 
PICy 2.L27 was found to give a better global yield of isomers in this series, with 59% 19F-
NMR yield. Moreover, an interesting proportion of -product (33%) was obtained, thus this 
ligand was selected for further optimization steps. 
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Scheme 78. Selected ligands for the -arylation of ,-unsaturated O-carbamates 
Despite this result, the regioselectivity in this reaction was not yet satisfying. The substrate 
was furthermore modified to bear a simple methyl substitution on the terminal double bond, in 
order to observe its effect on the outcome of the reaction (Scheme 79). Thus, the substrate 
(E)-2.21 was arylated in presence of 2.L27, which delightfully gave rise to 61% yield of the -
products 2.21g. The pyrrole-based 2.L26 afforded a way lower yield of 18%, and the –Pi-Pr2 
imidazole analogue 2.L33slightly improved this result (22% yield). The series of imidazole-
based ligand 2.L34-39 bearing an o-subtitution on the lower ring only gave yield in a range of 
11%-34%. The methyl substitution on the imidazole in 2.L40 did not bring a notable 
modification of the yield; and the disubstituted 2.L41 was not favorable for this reaction, 
despite a higher yield than the said series. 
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Scheme 79. Effect of the ligand on the methyl substituted ,-unsaturated O-carbamate 
Strong of our result with 2.L27, the reaction was tested in an enantioselective fashion. 
2.3.2. Enantioselective migrative cross-coupling 
The substrate (E)-2.21 was lithiated enantioselectively in presence of (+)-sparteine, 
and transmetalated to zinc. The enantioenriched -organozinc was then engaged in the 
migrative Negishi cross-coupling with 2.L27as the ligand (Scheme 80). The reaction outcome 
was comparable to that of the racemic version and 2.21g was obtained in 45% yield, with a 
ratio Z/E of 75:25. Both cis- and trans-products exhibited an excellent e.r. of 98:2, but were 
not separable by a standard silica gel column chromatography or by preparative HPLC. 
 
Scheme 80.Enantioselective -arylation 
The enantioenriched Z/E mixture of -products 2.21g was hydrogenated to determine the 
relative configuration of the stereocenter at the -position. The reaction proceeded in 93% 
yield with 1% of palladium under 50 bar of H2 at 50°C for 20h. Unfortunately, the 
hydrogenated product was obtain with 75:25 e.r.. 
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Scheme 81.Hydrogenation of the scalemic mixture 
The ratio of this scalemic mixture reflects the opposite configuration at the stereocenter in -
position (Figure 15). In consequence, any post-arylation modification of the enantioenriched 
substrate would lead to a dramatic loss of enantioenrichment. Nevertheless, this reversed 
selectivity at the -position also informed us about the mechanism of this arylation, that will 
be developed later. 
 
Figure 15. Opposite configurations at the -position 
An amelioration of the Z/E ratio of the -product was thus necessary and new ligands were 
thereby synthesized and tested in this coupling. 
2.3.3. Ligand design for selectivity 
A series of imidazole-based ligands bearing a 2,6-substitution on the lower ring was 
synthesized and tested in the racemic -arylation of (E)-2.21 (Table 12). The change from Cy 
to i-Pr on the 2.L27 core in 2.L42resulted in a critical loss of reactivity, despite comparable Z/E 
selectivities (entries 1-2). In contrast, the same change from ligand 2.L43 to ligand 2.L44, 
bearing a N-(2,6-dimethoxyphenyl), resulted in an enhanced reactivity, along with a lower 
selectivity for the (Z)-2.21g isomer (entries 3-4). Of note, ligand 2.L43 provided a suitable 
selectivity but a lower yield. At the exception of the t-Bu, providing only the -product with a 
rather good conversion, any other P-substitution shut down drastically the reactivity (entries 
5-9, 2.L45-50). When the imidazole was changed to the pyrazole in 2.L51, the -product 2.21g 
was afforded in 50% 19F-NMR yield, with a lower selectivity than for 2.L44 (entries 11 and 4). 
The effect of the substitution on the lower ring was also investigated. When bulkier 2,6-
alkyloxy groups were used in 2.L52and 2.L53, the reactivity slightly increased but the 
selectivity remained at 88:12 Z/E (entries 12-13 and 4). The 2,6-diethyl substitution in L54 
86 
 
gave a lower selectivity than 2.L27 (entry 14). To finish, the ligand 2.L55 bearing a 2,6-
difluorophenyl moiety proposed a good reactivity, but the Z/E selectivity was importantly 
lowered to 68:32. 
 
Entry Structure Ligand X Y R yield a % 2.21g ratio Z:E a 
1 
 
2.L27 - - Cy 61 75:25 
2 2.L42 - - iPr 8 75:25 
3 
 
2.L43 CH N Cy 23 91:9 
4 2.L44 CH N i-Pr 44 88:12 
5 2.L45 CH N t-Bu 0, only  n.d. 
6 2.L46 CH N Ph n.r. n.d. 
7 2.L47 CH N n-Bu n.r. n.d. 
8 2.L48 CH N Et n.r. n.d. 
9 2.L49 CH N i-Bu n.r. n.d. 
10 2.L50 CH N Np n.r. n.d. 
11 2.L51 N CH i-Pr 50 80:20 
12 
 
2.L52 - - OEt 51 88:12 
13 2.L53 - - OiPr 48 88:12 
14 2.L54 - - Et 50 82:18 
15 2.L55 - - F 53 68:32 
aThe yield and the ratios were determined by 19F-NMR with trifluorotoluene as the reference. 
Table 12. Effect of the designed ligand on the -arylation of (E)-2.21 
With this last screen, the ligand bearing a N-(2,6-alkyloxyphenyl)imidazole, in combination 
with a diisopropylphosphine gave the best compromise in terms of yield of -product 2.21g 
and Z/E selectivity, but the latter was not suitable for the development of an enantioselective 
version of the reaction. Moreover, the syntheses of the precursors of the ligands 2.L52 and 
2.L53 were lacking efficiency. The other parameters of the reaction were then optimized with 
2.L27, simply due to its availability within our chemical library. 
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2.3.4. Variation of the directing group 
The selectivity of the arylation was studied with respect to the directing group, with 
either 1.L2or 2.L27 as the ligand, for - and -arylation respectively (Table 13). The use of the 
more hindered Cbx group in (E)-2.23 led to a similar outcome than with Cby, under the 
conditions for both - and -conditions (entries 3-4). A fraction of the product was isolated 
via preparative HPLC, containing only the Z product in 3% yield. Of note, the conversion was 
low, leading to a complex separation even by preparative HPLC. The less elaborated Cb-
protected substrate (E)-2.24 underwent arylation in both cases, but with rather low yield, and 
showed a lower selectivity for the majorcis-product (Z)-2.25g (entries 5-6). The -product was 
isolated in 18% yield with a ratio Z/Eof 70:30. The TIB ester (E)-2.25 was also engaged, but 
provided the -arylated product as the major isomer in both protocols, despite the observation 
of only one migration product by GCMS (entries 7-8). 
 
Entry S.M. DG Ligand ratioa//Z/E -productb 
1 (E)-2.21 Cby RuPhos 70/0/22/7 n.d. 
2 (E)-2.21 Cby CataCXium PICy 9/6/64/21 2.21g, 48%, 75:25 Z/E 
3 (E)-2.23 Cbx RuPhos 76/0/24/0 n.d. 
4 (E)-2.23 Cbx CataCXium PICy 6/6/69/18 2.23g, 3%, 100:0 Z/E 
5 (E)-2.24 Cb RuPhos 69/3/20/7 n.d. 
6 (E)-2.24 Cb  CataCXium PICy 4/10/59/28 2.24g, 18%, 70:30 Z/E 
7 (E)-2.25 TIB RuPhos 96/0/4/0 n.d. 
8 (E)-2.25 TIB CataCXium PICy 57/0/43/0 n.d.  
aRatio determined by GCMS. bIsolated yield, Z/E ratio determined by 1H-NMR. 
Table 13.Effect of the directing group on the -arylation 
This study indicated that the Cby group was the most adapted for this reaction, in terms of 
reactivity and selectivity, as well as for purification purpose. Indeed, the corresponding -
products 2.21g were more likely separable from the other isomers by preparative HPLC. 
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2.3.5. Variation of conditions 
Different conditions for the arylation of (E)-2.21 were tested, varying from the 
standard conditions (Table 14). The use of ZnCl2 instead of Zn(OAc)2 lowered the yield of 
2.21g to 35%, as well as the Z/E ratio to 71:29, following the same trend as for the -arylation 
(entry 2). The lowering or the increase of the electrophile loading decreased the yield, with a 
more pronounced impact when 1 eq was engaged in the reaction (entries 3,4). The increase of 
the catalytic loading proved to be beneficial to the reaction and a yield of 54% of 2.21g was 
obtained with 7 %mol of the catalytic system (entry 5). Also, 14 %mol of catalytic system 
brought a similar result, with no further amelioration of the yield (entry 6). A run over 40 h 
led to the same 19F-NMR yield and was not considered more efficient despite a higher isolated 
yield (entry 7). The other sources of palladium impacted the reaction outcome and 
surprisingly the desired product was obtained in an average yield when 3.5 %mol of 
[PdCl2(MeCN)2] was used (entries 8-10). The solvent for the arylation step was changed 
(entries 11-15). The reactivity in benzene was comparable, but decreased in n-hexane (entries 
11-12). The use of polar solvents dramatically lowered the yield and no conversion was 
observed in DMAc or 1,4-dioxane (entries 14-15). To finish, the temperature of the coupling 
step was changed, and also resulted in a loss of reactivity in any case (entries 16-17). It is 
important to observe that, for every variation of the conditions, no significant variation of the 
Z/E ratio of 2.21g was observed, exposing the essential role of the ligand in this selectivity. 
 
Entry Deviation NMR yield%a yield, Z/E ratio 
1 - 49/12 48%, 75:25 
2 ii) ZnCl2 i/o Zn(OAc)2 n.d. 35%, 71:29 
3 iii) 0.5 eq ArBr 38/9 44%, 75:25 
4 iii) 1 eq ArBr 32/9.5 35%, 75:25 
5 iii) 3.5 %mol Pd2dba3, 7 %mol 2.L27 46/14 54%, 75:25 
6 iii) 7 %mol Pd2dba3, 14 %mol 2.L27 44/13 n.d. 
7 iii) reaction 40h 44/14 55%, 75:25 
8 iii) 3.5 %mol Pd(dba)2, 3.5 %mol 2.L27 14/4 n.d. 
9 iii) 3.5 %mol Pd(OAc)2, 7 %mol 2.L27 20/6 n.d. 
10 iii ) 3.5 %mol [PdCl2MeCN2], 7 %mol 2.L27 45/14 50%, 75:25 
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11 iii) in benzene 39/11 47%, 76:24 
12 iii) in n-hexane 26/4 29%, 73:27 
13 iii) in THF 31/2 19%, 71/29 
14 iii) in DMAc n.r. n.d. 
15 iii) in 1,4-dioxane n.r. n.d. 
16 iii) at 80°C 44/16 33%, 71/29 
17 iii) at 40°C 40/11 31%, 77/23 
aYield determined by 19F-NMR with trifluorotoluene as the reference bIsolated yield, Z/E ratio determined by 1H-
NMR. 
Table 14. Variations of the standard conditions for the g-arylation of (E)-2.21. 
Only slight ameliorations were brought by this screening of conditions, and the initial ones 
were kept as the standard conditions, mainly for practical reasons, and also because of the 
availability of the palladium sources. Indeed, the slight increase of yield observed when the 
catalyst loading is two folds higher doesn’t justify the use of 7 %mol of this Pd/L 
combination. Furthermore, [PdCl2MeCN2] is more expensive than Pd2dba3 (Sigma-Aldrich 
catalog, June 2018). 
2.3.6. Evaluation of the ,-unsaturation effect 
The essential role of the ,-unsaturation could be observed earlier, during the attemps 
for -arylation (see part 2.2) and the screen of ligands on 2.7e and (E)-2.21 (part 2.3.1). In 
addition, the carbamates (Z)-2.21, 2.7n and 2.26-2.30 were engaged in the - and the -
arylation reactions to verify the necessity of this insaturation and to evaluate the scope of this 
reaction with respect to the carbamate (Table 15). The allylcarbamate 2.26 was poorly 
converted in both protocols (entries 5-6). Interestingly, the GCMS ratios of isomers were 
similar to the one observed with (E)-2.21 and different stereoisomers of the starting material 
were observed. The saturated carbamate 2.27 underwent exclusively -arylation in both 
protocols, as well as the ,-unsaturated carbamate 2.7n (entries 7-10).The Z isomer (Z)-2.21  
reacted in a similar manner as (E)-2.21, providing an average yield with a lower selectivity 
for (Z)-2.21g (entries 11-12). Of note, (Z)-2.21 is also less prompt to migrative coupling than 
its E-isomer, in the -arylation reaction, as observed by GCMS (entries 11 and 3). 
Unfortunately, when the ,-unsaturation was more substituted, as in 2.28, the reactivity was 
dramatically shut down to observe only a poor conversion and traces of the desired products 
(entries 13-14). Nevertheless, the GCMS ratios clearly showed a similar selectivity induced 
by the ligand, as for the less hindered carbamates. The carbamate 2.29, bearing a trans-
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cyclopropyl instead of the double bond, did not undergo any opening or activation of the 3-
membered ring and only the corresponding -arylation product was observed, with poor 
conversion (entries 15-16). This result also suggested that no radical pathway was involved in 
this migrative arylation. Traces of migration products were detected on GCMS when 2.30 was 
engaged in the -arylation protocol (entry 18). 
OCby OCby
2.26 2.27
OCby
2.7n
OCby
(Z)-2.21
OCby
2.28
OCby
2.29
OCby
2.30
OCby
(E)-2.21
OCby
2.7e
OCby
OCby
i) s-BuLi/TMEDA 1.4 eq, Et2O, -78°C, 4 h
ii) Zn(OAc)2 1.5 eq, -78°C to 20°C, 1 h
iii) Pd2dba3 1.75 %mol, L 3.5 %mol,
2-F-PhBr 0.7 eq, toluene, 60°C, 18 h -product
F
OCby
-product
+
R
F
OCby
-product
R'
F
+R R
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Entry Susbtrate Ligand ratio a//Z/E -productb 
1 2.7e 1.L2 100/0/0/0 only 2.20a 
2 2.7e 1.L27 18/25/40/18 2.20g, 33%, Z/E 64:36 
3 (E)-2.21 1.L2 70/0/22/7 n.d. (42% 2.21a) 
4 (E)-2.21 1.L27 9/6/64/21 2.21g, 48%, 75:25 Z/E 
5 2.26 1.L2 10/5/63/22 traces 
6 2.26 1.L27 12/6/60/22 traces 
7 2.27 1.L2 100/0/0/0 only  
8 2.27 1.L27 100/0/0/0 only  
9 2.7n 1.L2 100/0/0/0 only  
10 2.7n 1.L27 100/0/0/0 only  
11 (Z)-2.21 1.L2 85/3/8/3 n.d. 
12 (Z)-2.21 1.L27 13/9/56/22 2.21g, 51%, 73:27 Z/E 
13 2.28 1.L2 80/0/10/10 traces 
14 2.28 1.L27 12/7/58/12 traces  
15 2.29 1.L2 100/0/0/0 only  
16 2.29 1.L27 100/0/0/0 only  
17 2.30 1.L2 100/0/0/0 traces 
18 2.30 1.L27  traces 
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Table 15. Evalutation of the ,-unsaturation effect 
The arylation of substrate 2.31 was attempted under the conditions favoring the migration 
(Scheme 82). The -arylation would provide a quaternary carbon center, which has, to date, 
not been accessed by palladium-catalyzed migrative cross-coupling. Unfortunately, only the 
direct coupling was observed. 
 
Scheme 82. -Arylation attempt on 2.31 
The ,-unsaturation is vital to observe this -arylation. When this insaturation is more 
substituted, as in 2.28, the reaction is shut down. With a conjugated double-bond, as in 2.30, 
only traces of a long range coupling are observed. When the unsaturation is located in the ,-
position, i.e. when the allylic O-carbamate 2.26 is engaged, only traces of the desired product 
are obtained;  in contrast to the outcome observed when allylic N-Boc-amines are engaged. It 
is assumed that the lithiation and/or the transmetalation steps are not efficient in this case. 
Hence, the study was continued uniquely with the substrate 2.21 and the substrate scope 
became narrower. Then, the potential of other aryl halides was rapidly evaluated. 
2.3.7. Determination of the ideal aryl halide 
The 1-iodo- and the 1-chloro-2-fluorobenzene were engaged as coupling partners in 
the -arylation reaction (Table 16). The same trend as for the -arylation was observed. The 
iodo- partner is less efficient than the bromo- (entry 2 and 1) and the reaction is shut down 
when the chloro- is used (entry 3).  No effect on the Z/E ratio was observed. 
 
Entry X  ratio a//Z/E NMR yield % b yield, Z/E ratio c 
1 Br 8/7/65/20 49/12 48%, 75:25 Z/E 
2 I 7/7/64/22 33/8 37%, 75:25 Z/E 
aRatio determined by GCMS. bIsolated yield, Z/E ratio determined by 1H-NMR. 
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3 Cl 7/7/63/24 10/2 < 5%, 75:25 Z/E 
aRatio determined by GCMS. b Yield determined by 19F-NMR with trifluorotoluene 
 as the reference cIsolated yield, Z/E ratio determined by 1H-NMR. 
Table 16. Evaluation of the ideal aryl halide for the -arylation 
The final conditions for the -arylation were fixed, and the scope of the reaction was 
processed. 
2.3.8. Scope and limitations of the electrophile 
The scope of the reaction with respect to the arylbromide was examinated, to exhibit 
the synthetic potential of the methodology, and to dismiss the possibility that this reactivity 
would be limited to a unique substrate (Figure 16). After improvement of the quality of s-
BuLi (filtration on celite before titration and use), 2.21g was obtained in 60% isolated yield, 
with a Z/E ratio of 75:25. The variation of the o-substitution to o-OCF3 provided a clear 
selectivity for the -product, and 2.32a was isolated in 64% yield, nevertheless the Z/E ratio 
was lowered to 61:39. The effect of the o-CF3 was more pronounced, indeed 2.32b was 
obtained in 42% yield and with no selectivity for one of the two Z/E stereoisomers. The 
arylation proved to be efficient in the cases where the p-position was substituted. Products 
2.32c and 2.32d bearing a p-Me and a p-OMe, respectively, were obtained with a good 
selectivity for the -product. Sensitive functionalities were compatible with the mild 
conditions of the Negishi coupling, such as a methyl ester or a nitrile, providing 2.32e and 
2.32f in average yields. The p-NO2-arene underwent Negishi coupling to afford 2.32g in 31% 
yield, showing a similar reactivity as in the -arylation. The reaction also took place with a 
heteroaryl to afford the fluoropyridine derivative 2.32h with an exclusive selectivity toward 
the -product. 
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Figure 16. Scope of the -arylation with respect to the (hetero)aryl bromide 
Nevertheless, the scope of this reaction was very limited, and many arylbromides did not 
undergo a successful migrative coupling (Figure 17). With a less electronegative substituent 
on the o-position, such as an OMe, the migration occurs less likely (only 49:51 iso/, and 25% 
isolated yield of 2.32i). This effect is enhanced with an o-Me, for which the -arylated 
product is largely predominant, even when a fluorine is added on the p-position (2A). The o-
effect is also obvious when the -CF3 is moved to the m- or p- position. In this case the 
formation of the -arylated product is favored with very good conversion (2B). Other halides 
on the o-position led only to poor conversion, but with similar selectivities toward the -
products. The double o-F-substitution was not more efficient and no reaction occurred with 
the bromo-2,4,6-trifluorobenzene (2C), suggesting also that the electronic balance of the aryl 
halide must be finely tuned. 3-bromopyridine afforded traces of coupling with a 1:1 
selectivity for the desired migration product to the other isomers. The other 
heteroarylbromides, even containing an o-fluoro substitution, were not efficient (2D). 
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Figure 17. Unsuccessful -arylation of some (hetero)aryl bromides  
2.3.9. Scope with respect to the carbamate reactant 
Others ,-unsaturated carbamates were consecutively synthesized and engaged in the 
-arylation reaction (Figure 18). As seen in part 2.3.6, 2.20g was obtained in 33% yield with a 
moderate selectivity. The -arylated product (E)-2.21g was also obtained from (Z)-2.21, with 
a lower yield and selectivity. Nevertheless, this example shows a type of convergence to 
2.21gfrom the E or Z starting material 2.21, suggesting a common mechanistic pathway. 
Thus, the starting material could be a mixture of E and Z isomers, but the synthesis of the 
starting -carbamates remained challenging. The carbamates 2.33 and 2.34 bearing a longer 
side chain underwent -arylation to provide 2.38a and 2.38b in average yield, with no relevant 
modification of the Z/E ratio. The product 2.38c bearing a TBS protected alcohol was isolated 
in the pure Z isomeric form, despite a low yield of 17%. The hindrance of the -position 
induced a slight effect on the selectivity, which could also be attributed to the difficulties 
faced during the purification of the corresponding products. Indeed the arylation of 2.36 gave 
a mixture of four defined regioisomers (as seen in 2D 1H NMR spectroscopy), containing a 
total yield of 44% of the desired -product 2.38d with a Z/E ratio of 87:13, bearing a 
cyclohexyl chain at the -position. In the same way, the arylation of 2.37, bearing a t-Bu 
group at the -position, afforded a mixture of four regioisomers, which contained 25% of the 
desired compound 2.38e in 80:20 Z/E ratio. 
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Figure 18. Scope of the -arylation with respect to the carbamate 
In addition to the unfruitful carbamates presented in 2.3.6, Table 15, biscarbamate 2.39 only 
underwent poor conversion under the-arylation conditions. Carbamates 2.40a-b suffered a 
challenging synthetic approach and were not synthesized (Figure 19). 
OCby
CbyO X
OCby
2.39 2.40a : R=OMe
2.40b : R=NMe2  
Figure 19. Other ,-unsaturated carbamates 
The study of the scope of the -arylation reaction led us to examine more closely the 
mechanism of this transformation. Indeed, the migration path is not obvious and the ,-
unsaturation is vital for the selective arylation to occur in presence of the appropriated ligand. 
In order to gain more insights on the mechanism, the suitable deuterated substrate was 
synthesized. 
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2.3.10. Deuterium labeling 
The -deuterated carbamate 2.41 was synthesized and then engaged in the -arylation reaction 
in presence of 2.L27 with Pd2dba3 as the palladium source (Scheme 83). The GCMS trace 
showed similar signals as for the arylation product 2.38b, suggesting no dramatic isotopic 
effect on the arylation. The - and - products 2.41a, (Z)-2.41g and (E)-2.41g were isolated, 
and only traces of -product were observed. Moreover, no scrambling and no longer range 
arylation occurred on the side chain of the ,-insaturation, providing us more information 
about the probable reaction intermediates. 
 
Scheme 83. -Arylation of the deuterium-labelled substrate 
Thus, all the elements discovered during the study of this -arylation led us to postulate a non-
canonical mechanism for this migrative coupling. 
2.3.11. Mechanistic insights 
The first step of the proposed mechanism is the installation of the palladium in the -
position of the carbamate by transmetalation of the non-racemic organozinc intermediate 
arising from the enantioselective deprotonation/lithiation with (+)-sparteine. The newly 
formed PdII species could then undergo two different -hydride eliminations. Indeed, the 
rotation of the C-C bond can place each of the two diastereotopic -hydrogen in the 
required syn-coplanar position to the metal center. After the subsequent elimination the (Z)-
enol-carbamate (from AZ) or the (E)-enol-carbamate (from AE) can be formed (Scheme 84, 
A). Since the major product of the reaction is the (Z)-enol-carbamate, the elimination of HZin 
AZ is favored and the formation of BZ is predominant. Ligand optimization could not improve 
the elimination ratio of HZ:HE 88:12 leading to the corresponding (E)- or (Z)-products and no 
rational relashionship between the ligand structure and the selectivity could be established. 
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The newly formed conjugated (E),(Z)-dienolcarbamate BZ and (E),(E)-dienolcarbamate 
BEcouldallow the palladium to undergo haptotropic rearrangement137 along the conjugated -
system in trans-conformation (Scheme 84, B). A cross-over experiment indicates that the 
palladium complex doesn’t de-coordinate from the elongated -system. Indeed, when the 
installation of the metal is carried out in asymmetric fashion, the two diastereomeric products 
are obtained separately with very high enantiomeric excesses. Nevertheless, the absolute 
configuration of the chiral Ccenter hasn’t been determined yet. Thus the trans- or cis-
conformation of the intermediate dienes has not been determined yet.  
Only small amounts of -product could be observed, suggesting that the haptotropic 
rearrangement is kinetically and/or thermodynamically favored over the rotation and the 
subsequent insertion of the metal center leading to the -arylation. Moreover, no -arylated 
product could be observed, confirming that only the haptotropic rearrangement takes place 
before the insertion of the palladium hydride complexe into the C-C unsaturation, and no 
rotation of the complex occurs.  
It is not excluded that the fluxional behavior of the palladium along the conjugated -system 
is caused by a steric effect of the carbamate moiety, “pushing” the palladium complex toward 
the less hindered part of the chain. On similar but less hindered homoallylic systems, only 
allylic arylation is obtained after exclusive migration to the -position.138 However this effect 
must be added to the electronic and the steric effects of the ligand and the aryl substitution on 
the metal center. 
After coordination of the palladium to the - unsaturation via the above mentioned 
haptrotropic rearrangement, possible complexes BZc and BEcundergo stereospecific insertion 
on the predetermined face of the diene to give complexes CZ and CE, respectively (Scheme 
84, C). Their stereospecific reductive elimination gives rise to the Z- and the E-products, 
respectively, which bear an opposite configuration at the Cstereocenter. 
However the palladium might also undergo haptotropic rearrangement along the conjugated 
-system in cis-conformation. In this case, the other enantiomers of both (Z) and (E) products 
would be obtained (Scheme 84, B’). It is to note that the migration occurs on the face of the 
,-unsaturation which was defined during the -H elimination step, and on the face of the 
,-unsaturation wich is defined by the trans- or cis- conformation of the diene. Importantly, 
the migration occurs exclusively in trans- or in cis- configuration. Equilibrium between those 
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configurations on one of the (Z) or (E) precursors would lead to lower level of 
enantioselectivity. Moreover if a product precursor would be in trans while the other’s 
product precursor would be in cis, then no opposite configuration would be observed at the 
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Scheme 84. Proposed mechanism for the -arylation of O-carbamates 
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This mechanism also brings to the fore the selectivity issues which would be associated to an 
enantioselective migrative coupling along an acyclic saturated aliphatic chain. In our case, the 
first -hydride elimination leading to the (Z) or (E) alkene intermediate is critical for the 
stereochemical outcome of the reaction. The metal center is installed on the chain in -
position with a very high selectivity (99:1 e.e., as seen in the corresponding -arylation), and 
the selectivity is eroded during the -hydride elimination step, because of the unselective 
abstraction of the HZ or HE. Thus the metal center is installed on one of the diastereoisomeric 
faces of the rising alkene. In this study, the palladium undergoes only one -hydride 
elimination/migration event, and the selectivity HZ:HE could not be increased to 87:13, giving 
rise to two diastereoisomeric compounds (Scheme 85, A). Moreover, a study involving 
deuterium labeling has been provided by Sigman and coworkers.139 A poor selectivity of 
43:57 HZ:HE could be obtain on the -deuteride elimination/migrative insertion of a 
stereochemically well defined palladium complex intermediate (Scheme 85, B). 
 
Scheme 85. Lack of selectivity in the -hydride elimination 
Considering an acyclic saturated chain where the metal center migrates in one direction in a 
nondissociative process, the erosion could be repeated for each -hydride 
elimination/migrative insertion step (I and then II), thus leading to a complete loss of 
stereochemical information (Scheme 86, A). In a cyclic system, no complete rotation is 
allowed on the C-C bond, hence the -hydride elimination/migrative insertion would 
conserve the stereochemical information by exclusive abstraction of the hydride syn to the 
palladium (Scheme 86, B).140 Since the steric and electronic effects of the ligand, the aryl and 
the substrate are not fully understood, the enantioselective migrative cross-coupling along an 
acyclic saturated aliphatic chain seems a priori challenging. 
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Scheme 86. Stereospecific migration in linear vs cyclic alkanes 
A derivatization of the products has been attempted in order to determine the absolute 
configuration of the products. Because the configuration of the asymmetric 
deprotonation/lithiation and transmetalation is known, the absolute configuration of the 
products would give us the key to determine the trans- or cis- conformation of the diene 
intermediate, which is required to validate our proposed mechanism. 
2.3.12. Product derivatization 
First, a mixture of Z and E-isomer was hydrogenated with Pd/C and 50 bars of 
hydrogen (see Scheme 81). The hydrogenation of a 87:13 mixture of enantiopure Z/E 
products (e.e.>98:2, respectively) obtained from the enantioselective arylation with ligand 
2.L44, provided the hydrogenated carbamate 2.22 in 84% yield and 86.5:13.5 e.e. (Scheme 
87), thus confirming the opposite configuration at the Cin the two isomers . 
 
Scheme 87. Hydrogenation of a 87:13 mixture of -products 
A subsequent deprotection of a recemic mixture of 2.22 took place in quantitative yield by 
using MeSO3H in refluxing methanol to open the acetonide, and then Ba(OH)2 to remove the 
opened carbamate. The racemic alcohol 2.42 was obtained in 96% yield (Scheme 88). 
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Scheme 88. Deprotection of the -arylated saturated carbamate 
In our aim to obtain a crystal to determine the absolute configuration, we envisaged to esterify 
the alcohol with a bulky and heavy acid to obtain a solid ester (Scheme 89). The ester of 
ferrocene carboxylic acid 2.43a was accessed, but was oily at ambient temperature, even in its 
enantiopure form. The ester of p-nitrobenzoic acid 2.43b was obtained as an oil which 
crystallized in solution at -30°C, but the obtained crystals were not suitable for analysis. 
Based on this observation, the biphenyl congener was synthesized and its ester 2.43c was 
synthesized in a racemic fashion. To our delight, the product was a solid. The separation by 
semi-preparative HPLC provided a sample with >97:3 e.e.. Again, the crystals were not 
suitable for structure determination. The crystallization of this compound is still currently 
under investigation. 
 
Scheme 89. Attempts for the formation of a crystalline ester 
2.3.13. Conclusion 
Our attempts toward the - and longer range arylation of protected aliphatic alcohol via 
migrative Negishi cross-coupling remained unfruitful. In this study, a non-classical migration 
process was discovered. When using the adequate ligand, the ,-unsaturated -oxoalkylzinc 
reagents formed by directed lithiation and transmetalation undergo migrative Negishi 
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coupling to obtain -arylated O-carbamates. The reaction tolerates only a tight range of aryl 
bromides and homoallyl alcohol carbamates. Mechanistic studies, such as a deuterium 
labeling and a cross-over experiment, allowed us to propose a non-canonical mechanism 
which involves a haptotropic rearrangement of the intermediate palladium complex along an 
extended -system. This type of rearrangement has, to date, not been reported for synthetic 
methodologies with palladium, nor for cross-coupling reactions. Only rare occurrences of 
palladium haptotropic rearrangements appear in the literature.141 The determination of the 
absolute configuration of the product would be the key to validate the trans- or cis- pathway 
involved in the postulated mechanism. 
The control of stereoselectivity in this arylation has been a major issue and our efforts to 
design and synthesize new ligands did not lead to an ideal selectivity. No proper 
rationalization could be obtained. Nevertheless, this study also enlightened us about the 
possible challenges for the control of regio- and stereo-selectivity in palladium-catalyzed 
migrative cross-couplings, which are currently under investigation in the Baudoin group. 
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3. Intermolecular atroposelective Csp2-H arylation 
3.1. Early development 
We started our investigation by attempting the racemic Csp2-H arylation of the 1,2,3-
triazole 3.1 with 1-bromonaphtalene (Table 17). The use of the conditions described by 
Gevorgyan142 led us to 9% of 3.2a (entry 1), where the arylation gave 66% yield in the 
original report. More classical conditions for C-H activation allowed us to obtain the desired 
product in 39% yield (entry 2). The reactivity dramatically decreased when the temperature 
was lowered to 70°C (entry 3). The reaction in DME provided a reactivity which is 
comparable as the one in mesitylene (entry 4). In the more polar DMF, in the absence of 
pivalic acid, the product was afforded in a modest yield of 23% (entry 5). 
 
Entry Conditions Yield 3.2a (%) 
1 Pd(OAc)2 5 %mol, Bu4NOAc 2 eq, 
NMP, 100°C, 18h 
9 
2 Pd(OAc)2 5 %mol, P(Cy)3 10 %mol, 
PivOH 30 %mol, Cs2CO3 1.5 eq, 
Mesitylene, 100°C, 18h 
39 
3a Entry 2 at 70°C < 3% 
4a Entry 2 in DME 42% 
5a Entry 2 in DMF, no PivOH 23% 
a1H NMR yield with trichloroethylene as the reference. 
Table 17. Determination of conditions for the Csp2-H arylation of 3.1 
The racemic mixture was separated by semi-preparative HPLC on chiral phase, and the 
enantiopurity of the scalemic sample was determined with respect to time (Table 18). The 
assumed enantiopure sample was always observed with an erosion of e.e. when being 
analyzed within an hour after the purification. When the sample was aged at 23°C in heptane, 
a fast racemization occurred. Starting from a 86:14 e.r. sample, the enantioenrichment 
tumbled down to 55:45 e.r. after 6h, and a total racemization was observed after 18h. 
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Entry Time (h) e.r.a 
1 1 86:14 
2 6 55:45 
3 18 50:50 
4 36 50:50 
ae.r. valuedetermined by HPLC analysis on a chiral stationary phase. 
Table 18. Evolution of the e.r. of 3.2a with respect to time at 23°C 
This first substrate was not adapted for Csp2-H arylation at high temperature (>100°C) and 
long reaction times (>15h). This study encouraged us to use a more hindered coupling partner, 
in order to increase the rotational barrier of the system, thus allowing us to study the 
enantioselective version of this arylation. 
The racemic arylation of 3.1 was then studied with 1-bromo-2-methylnaphtalene as the 
coupling partner (Table 19). The reaction in classical conditions with P(Cy)3 as the ligand at 
120°C provided 12% of the isolated product 3.2b for racemization tests (entry 1). The NMR 
yield increased to 35% when the reaction was conducted at 150°C (entry 2). The use of P(n-
Bu)3 was not efficient, and the product could be afford in only 11% with P(Ph)3 (entries 3-4). 
Interestingly, with PAd2n-Bu (CataXCium A), the product was afforded in 42% yield (entry 
5). Moreover, an amelioration of the yield was observed at higher temperature and with a 
longer reaction time (entries 6-7). In contrast, RuPhos and the classical NHCs IPr and IBiOx 
did not provide any product in these conditions (entries 8-10). The reaction in more polar 
solvents such as NMP or DMAc showed to be inefficient a 120°C (entries 11-12). 
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Entry Conditions deviation Ligand Yielda 2.a (%) 
1 120°C P(Cy)3 12b 
2 / P(Cy)3 35 
3 72h P(n-Bu)3 no prod. 
4 / P(Ph)3 11 
5 / PAd2n-Bu 42 
6 72h PAd2n-Bu 50 
7 170°C, 72h PAd2n-Bu 50 
8 / 1.L2 no prod. 
9 / 3.L56 no prod. 
10 / 3.L57 no prod. 
11 Pd(OAc)2 2.5 %mol, NMP PAd2n-Bu no prod. 
12 K2CO3 1.5 eq, DMAc PAd2n-Bu no prod. 
a 1H NMR yield with trichloroethylene as the reference. b Isolated yield.  
 
Table 19. Study of the Csp2-H arylation of A1 
The enantiomers of 3.2b were separated by semi-preparative HPLC on chiral phase, and the 
enantiopurity of the scalemic sample was determined with respect to time at different 
temperatures in mesitylene (Table 20). No erosion of the enantiopurity of a 98:2 e.r. sample 
was observed at 23°C over 20h (entry 1). Gratifyingly, no decline was observed also at 120°C 
over 2.5h (entry 2). Furthermore, the enantiomeric ratio stayed intact a 150°C over 2.5h (entry 
3). 
 
Entry Temperature (°C) Time (h) e.r.a 
1 23 20 98:2 
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2 120 2.5 98:2 
3 150 2.5 98:2 
ae.r. valuedetermined by HPLC analysis on a chiral stationary phase. 
Table 20. Evolution of the e.r. of enantiopure 3.2b with respect to time and temperature 
Since a scalemic mixture of 3.2b would not suffer an erosion of e.e. at high temperatures, we 
envisioned to develop the enantioselective version of this Csp2-H arylation reaction with 3.1 
in presence of 1-bromo-2-methylnaphtalene. 
3.2. System optimization with 1-bromo-2-methylnaphtalene 
3.2.1. Ligand screen 
As a first step, different families of ligand were screened in combination with Pd2dba3 
as the metal catalyst (Table 21). In these conditions, the reactivity with CataXCium A got 
lower than with Pd(OAc)2 (entry 1). The achiral NHCs 3.L56 nd 3.L57 were also inefficient 
(entries 2-3). We were satisfied to observe that the bifunctional ligand 3.L58 in absence of 
PivOHprovided 13% NMR yield, and a 70:30 e.r. of the isolated product (entry 4). Other 
classes of ligand, such as binepines, phosphoramidite, and taddol-derived phosphonites did 
not show any reactivity (entries 5-9). The use of the chiral phosphoric 3.L64 acid in presence 
of P(Cy)3 did not lead to the product (entries 10). A quick screen of conditions did not bring 
any major amelioration of the result obtained with the 3.L58 (entries 11-15). 
 
Entry Condition deviations Ligand Yielda A1b (%) e.r.b 
1 / PAd2n-Bu 16 rac 
2 / 3.L56 no prod. n.d. 
3 / 3.L57 no prod. n.d. 
4 No PivOH 3.L58 13 (10)c 70:30 
5 / 3.L59 no prod. n.d. 
6 / 3.L60 no prod. n.d. 
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7 / 3.L61 no prod. n.d. 
8 / 3.L62 no prod. n.d. 
9 / 3.L63 no prod. n.d. 
10 Pd(PCy3)2 3.L64 no prop. n.d. 
11 PdCl2MeCN2 3.L58 14 70:30 
12 [Pd(-cin)Cl]2 3.L58 14 70:30 
13 PdMe2TMEDA 3.L58 18.5 70:30 
14 DME 3.L58 13.5 66:33 
15 Rb2CO3 3.L58 14.5 70:30 
a 1H NMR yield with trichloroethylene as the reference. be.r. valuedetermined 
 by HPLC analysis on a chiral stationary phase. c Isolated yield in brackets. 
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3.L62 : Ar= 3,5-diCF3Ph ; R = Ph
3.L63 : Ar= 3,5-diCF3Ph ; R = Cy  
Table 21. First screen of ligand 
The effect of the catalyst loading was evaluated in both the racemic and enantioselective 
fashion, with respect to the base equivalents (Table 22). The yield increased to 22% with a 
double loading of the catalyst, from 5 %mol to 10 %mol, in presence of 1.5 eq of base for the 
racemic procedure (entries 1-2). The increase of base stoichiometry was not more effective 
(entries 3-4). A stoichiometry of 1:2 Pd/L also provided a similar yield (entry 5). This 
stoichiometry proved to be much for efficient when used for the enantioselective protocol, 
with Pd(OAc)2 as the metal source and 3.L58 as the ligand (entries 6-7). Nevertheless, the 
reaction afforded 30% yield of the desired product when Pd2dba3 was the catalyst (entry 8). 
As a side note, the e.r. of 70/30 remained unaffected in this screen. 
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Entry Pd source %mol Ligand %
mol 
Cs2CO3 
eq 
Yielda A1b 
(%) 
e.r.b 
1 Pd2dba3 2.5 PdAd2n-Bu 5 1.5 14 rac 
2 Pd2dba3 5 PdAd2n-Bu 10 1.5 22 rac 
3 Pd2dba3 2.5 PdAd2n-Bu 5 3 14 rac 
4 Pd2dba3 5 PdAd2n-Bu 10 3 20 rac 
5 Pd2dba3 2.5 PdAd2n-Bu 10 1.5 20 rac 
6 Pd(OAc)2, no 
PivOH 
2.5 3.L58 5 1.5 16 70:30 
7 Pd(OAc)2, no 
PivOH 
2.5 3.L58 10 1.5 28 70:30 
8 Pd2dba3, no PivOH 2.5 3.L58 10 1.5 30 (20)c 70:30 
a 1H NMR yield with trichloroethylene as the reference. be.r. valuedetermined by HPLC analysis on a 
 chiral stationary phase. c Isolated yield in brackets. 
Table 22. Evalutation of the catalyst loading for both protocols 
With these last conditions in hands, we varied the parameters of the bifunctional ligand, such 
as the chain length to the acid, the aryl substitution and the hindrance of the chain (Table 23). 
The change in the 3,5-disubstition caused a decrease of reactivity. Yields between 10% and 
18% were obtained (entries 2-4), and interestingly the opposite configuration of the product 
was induced with the fluorinated ligand 3.L66 (entry 3). Nevertheless, the selectivity was not 
ameliorated. When the 3,5-disubstitution was suppressed in 3.L68, the reactivity got 
recovered, and the selectivity rose up (entry 5) ; suggesting an negative effect of the close 
congestion at the reactive site. The ethyl ester 3.L68E and the MOP were engaged in the same 
conditions (entries 6-7). Surprisingly, the product was obtained with a higher selectivity, but 
in low yield. In this case, it is assumed that the carbonate could perform the deprotonation. 
When the same experiments were run in presence of PivOH (entries 8-10), similar results 
were obtained, thus showing that the acid inductor in the bifunctional ligand is not crucial; 
and may not play an essential role in this reaction. The selectivity may be predominantly 
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induced by the phosphine moiety. Despite these ambiguous observations, the chain length to 
the acid was screened (entries 11-15); an enhanced reactivity and selectivity were found when 
the chain was 5 carbon-long in 3.L73. The hindrance at the -position of the acid dramatically 
decreased the reactivity and the selectivity when 3.L75 was used (entry 16). Furthermore, no 
more reaction occurred with 3.L77 as the ligand (entry 17).  
 
Entry Additive Bifunct. Ligand Ar n Yielda A1b (%) e.r.b 
1 / 3.L58 3,5-diMePh 1 30 (20) 70:30 
2 / 3.L65 3,5-diOMePh 1 15 67.5:32.5 
3 / 3.L66 3,5-diCF3Ph 1 18 40:60 
4 / 3.L67 3,5-dit-BuPh 1 10 68:32 
5 / 3.L68 Ph 1 26 73:27 
6 / 3.L68E - - 20 77:23 
7 / 3.L69 - - 11 80:20 
8 PivOH 30 %mol 3.L68 Ph 1 26 75:25 
9 PivOH 30 %mol 3.L68E - - 25 75:25 
10 PivOH 30 %mol 3.L69 - - 17 78:22 
11 / 3.L70 Ph 2 14 76:24 
12 / 3.L71 Ph 3 12 77:23 
13 / 3.L72 Ph 4 13 78:22 
14 / 3.L73 Ph 5 24 78:22 
15 / 3.L74 Ph 6 15 77:23 
16 / 3.L75 - - 7 58.5:41.5 
17 / 3.L76 - - no prod. n.d. 
a 1H NMR yield with trichloroethylene as the reference. be.r. valuedetermined by HPLC 
 analysis on a chiral stationary phase. 
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Table 23. Variation of the bifunctional ligand 
The variation of the parameters of the bifunctional ligand showed us that the reaction is very 
sensitive to congestion at the reaction site. The role of the acid moiety of this bifunctional 
ligand is ambiguous, but its presence (in 3.L68) affects positively the outcome of the reaction 
when compared to the corresponding ester or to the MOP. The best result was obtained with 
3.L73, the bifunctional ligand bearing a –PPh2 moiety and a (CH2)5 spacing chain to the acid. 
A last screen of chiral ligand was operated in previously used conditions (Table 24). The 
NHC 3.L77 developed by Kunding did not provide any product (entry 1). The Cramer type 
ligand 3.L78, a chiral phosphine based on the Buchwald type ligand, afforded the desired 
product in 14% yield and a reverse selectivity (entry 2), comparable to the one obtained with 
the previously screened bifunctional ligands. The (S)-KenPhos3.L79 was ineffective in the 
coupling (entry 3), while the (S)-Quinap 3.L80 and the (R)-Binap 3.L81 afforded very low 
yields of 3.2b as near racemic mixtures (entries 4-5). 
 
Entry Ligand Yielda A1b (%)  e.r.b 
1 3.L77 no prod.  n.d. 
2 3.L78 14  30:70 
3 3.L79 no prod.  n.d. 
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4 3.L80 8  51:49 
5 3.L81 15  49:51 
a 1H NMR yield with trichloroethylene as the reference. be.r. 
valuedetermined by HPLC analysis on a chiral stationary 
 phase. 
 
Table 24. Additional ligand screen 
These other ligands did not provide any satisfactory results. Interestingly, the Cramer type 
ligand gave a comparable result as with the bifunctional ligand. Nevertheless, this class of 
ligand suffers a challenging synthesis and only a small sample was available in our chemical 
library for testing purpose. The reaction in presence of 3.L73 was then optimized. 
3.2.2. Optimization of the reaction conditions 
The different parameters of the reaction were optimized. The concentration of the 
reaction was varied (Table 25). The ligand optimization was run at a concentration in starting 
material of 0.25 M. The dilution of the reaction was negative in terms of yield but favorable 
for selectivity (entries 1-2). On the other hand, when the concentration was increased, the 
yield followed the trend while the selectivity slightly decreased (entries 5-6). Note that the 
reaction in neat 1-bromo-2-methylnaphtalene provided 36% yield with a near average 
e.e.(entry 7). The optimal concentration was 0.5 M (entry 4). 
 
Entry 3.1 Concentration (mol/L) Yield 3.2b (%) e.r. 
1 0.0625 23 80:20 
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2 0.125 26 79:21 
3 0.25 27 78:22 
4 0.5 36 78:22 
5 0.75 33 77:23 
6 2.5 32 76:24 
7 Neat in 10 eq BrAr 34 75.5:24.5 
a 1H NMR yield with trichloroethylene as the reference. be.r. value 
determined by HPLC analysis on a chiral stationary phase. 
Table 25. Concentration optimization 
The optimal solvent was also determined for the reaction in presence of 3.L73, and also the 
MOP 3.L73 with or without PivOH (Table 26). Polar solvents were not suitable for the 
reaction (entries 1-4). Heavy ethers provided the product in respectable yield with 3.L69 
(entries 5-6). Apolar aromatic solvents proved to be efficient (entries 7-13), and the optimal 
solvent for the reaction with 3.L73 was the mixture of xylenes, which provided 3..2b in 36% 
yield and 78:22 e.r. (entry 11). The optimal solvent for the reaction with 3.L69 in presence of 
PivOH was the 1,2,4-trimethylbenzene, which afforded the desired product in 23% yield and 
73:27 e.r. (entry 7). The reactivity was dramatically decreased when the 3.L69 was used 
without PivOH. It is important to notice that no relevant variation of selectivity is observed in 
this series. 
 
Entry Solvent 
3.L73 
yielda, e.r.b 
3.L69+PivOH 30 %mol 
yielda, e.r.b 
3.L69 
yielda, e.r.b 
1 NMP 5%, n.d. 6%, n.d. 4%, n.d. 
2 DMAc 3%, n.d. 4%, n.d. 3%, n.d. 
3 DMF 3%, n.d. 3%, n.d. 3%, n.d. 
4 Benzonitrile traces traces no prod. 
5 Diethoxyethane 5%, n.d. 15%, 74:26 8%, n.d. 
6 Dibutylether 17%, 75:25 16%, 71:29 6%, n.d. 
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7 1,2,4-Trimethylbenzene 27%, 78:22 23%, 73:27 8%, n.d. 
8 p-Cymene 32%, 78:22 12%, 76:24 11%, 74:26 
9 Cumene 30%, 78:22 20%, 75:25 7%, n.d. 
10 Anisole 26%, 76:24 14%, 73:27 4%, n.d. 
11 Xylenes 36%, 78:22 17%, 74:26 13%, 73:27 
12 p-Xylene 14%, 78:22 15%, 74:26 9%, n.d. 
13 m-Xylene 36%, 78:22 15%, 74:26 6%, n.d. 
a 1H NMR yield with trichloroethylene as the reference. be.r. valuedetermined by HPLC 
 analysis on a chiral stationary phase. 
Table 26. Solvent screen the the atroposelective arylation 
The stoichiometry of the bromide was surveyed and the addition of molecular sieves was 
examined, in presence of 3.L73 (Table 27). The yield increased when the proportion of the 
aryl increased (entries 1-5). In contrast, the selectivity was not influenced by this variation. A 
ratio of bromide/3.1 1.5:1 was found ideal (entry 3). In these conditions, the addition of 
molecular sieves proved to be very effective (entries 6-8). The 4Å MS was kept as the 
additive of choice, thanks to its availability. 
 
Entry X/3.1 eq, additive Yielda 3.2b (%) e.r.b 
1 0.75:1 23c 78:22 
2 1:1 26 78:22 
3 1.5:1 27 78:22 
4 3:1 27 78:22 
5 5:1 30 78:22 
6 1.5:1, MS 3Å 35 77.5:22.5 
7 1.5:1, MS 4Å 33 78:22 
8 1.5:1, MS 5Å 35 78.5:21.5 
a 1H NMR yield with trichloroethylene as the reference. be.r. valuedetermined by HPLC 
 analysis on a chiral stationary phase. cYield calculated with respect to the bromide. 
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Table 27. Survey of the stoichiometry of the bromide 
The optimal conditions for 3.L73 and the MOP were combined and evaluated on the bromide 
as well as the iodide (Table 28).  We were satisfied to obtain 3.2b in 48% isolated yield in 
77.5:22.5 e.r. with the bifunctional ligand (entry 1). The use of the 1-iodo-2-methylnaphtalene 
did not bring any amelioration (entry 2). When the MOP 3.L69 was used, the product was 
obtained in 34% yield in 75:25 e.r. (entry 3). The iodide did not affect the outcome of the 
reaction (entry 4). 
 
Entry Ligand Solvent X Yielda 3.2b (%) e.r.b 
1 3.L73 Xylenes Br 57 (48)c 77.5:22.5 
2 3.L73 Xylenes I 56 78:22 
3 3.L69+PivOH 0.3 eq 1,2,4-trimethylbenzene Br 34 75:25 
4 3.L69+PivOH 0.3 eq 1,2,4-trimethylbenzene I 34 75:25 
a 1H NMR yield with trichloroethylene as the reference. be.r. valuedetermined by HPLC 
 analysis on a chiral stationary phase. c Isolated yield in brackets. 
Table 28. Arylation in the optimized conditions. 
To ensure that we reached the maximum potential of this reaction, a kinetic study of the 
arylation was done at 150°C, and the reaction was run at lower temperatures over 15h (Table 
29). The yield rapidly increases over 2h and stabilizes over 55% after 4h at 150°C (entries 1-
5). The enantiomeric ratio slowly decreases over 15h to reach 77.5:22.5. The reactivity shut 
down quickly when the temperature is lowered in a range of 140-120°C, despite a slightly 
better selectivity (entries 6-8). 
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Entry T (°C) t (h) Yielda 3.2b (%) e.r.b 
1 150 1 39 79:21 
2 150 2 53 78.2:21.8 
3 150 4 55 78:22 
4 150 7 59 78:22 
5 150 15 57 77.5:22.5 
6 140 15 45 77:23 
7 130 15 36 80:20 
8 120 15 29 80:20 
a 1H NMR yield with trichloroethylene as the reference. be.r. value 
determined by HPLC analysis on a chiral stationary phase. 
Table 29. Kinetic study of the arylation reaction 
In the end, more elaborated bifunctional ligands 3.L82a-b and 3.L82aE-bE bearing a lactyl moiety 
were engaged in the arylation reaction and compared to the ligand 3.L68 (Table 30). A 
match/mismatch effect was observed for both the free acids and the corresponding methyl 
esters in presence of PivOH 0.3 eq, and a global decrease of reactivity was observed, showing 
again the negative effect of a steric congestion at the reaction site (entries 2-5). The (S) 
configuration of the lactyl moiety in 3.L82a and 3.L82aE provoked a mismatch effect, reflected 
by a clear drop of yield and selectivity (entries 2 and 4). The match effect with the (R) 
configuration of the lactyl in 3.L82b and 3.L82bE was also pronounced and only a reduction of 
yield was observed, along with a rise of the selectivity (entries 3 and 5). The reactivities of the 
esters were similar to their free acid counterparts, denoting again a non substancial effect of 
the acid. 
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Entry Additive Ligand Yielda A1b (%) e.r.b 
1 / 3.L68 43 71.5:28.5 
2 / 3.L82a 18 59:41 
3 / 3.L82b 25 78:22 
4 PivOH 30 %mol 3.L82aE 21 66:34 
5 PivOH 30 %mol 3.L82bE 28 77.5:23.5 
a 1H NMR yield with trichloroethylene as the reference. be.r. value determined 
 by HPLC analysis on a chiral stationary phase. 
 
Table 30. Evaluation of a match/mismatch effect with ligands 3.L77 
All those results led us to reconsider the substrate and/or the bromide. Indeed, the 2-Me 
substitution of the naphthalene brings an important hindrance blocking the axial rotation, 
making this system suitable for high temperature and reaction times; but this hindrance also 
limits the reactivity and the selectivity in this arylation reaction. This suggests that the high 
limit of our system was reached with this combination of substrate, in contrast to the initially 
proposed arylation with 1-bromonaphalene, proving to be reactive but not adapted to the 
harsh reaction conditions for enantioselective Csp2-H activation. 
We then decided to change the bromoelectrophile engaged in the reaction, while keeping the 
optimized conditions. 
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3.3. Development with 1-bromo-2-methoxynaphtalene 
The arylation with 1-bromo-2-methoxynaphtalene as the coupling partner was 
examined. The racemic coupling proceeded in 40% yield with PCy3 as the ligand in xylenes 
(Scheme 90). The product 3.2c was isolated for analytical purpose. 
 
Scheme 90. Racemic arylation with 1-bromo-2-methoxynaphtalene 
3.3.1. Optimization with the bifunctional ligands 
The enantioselective version of the reaction was directly studied with respect to time and 
temperature, with 3.L73 as the ligand, in the previously optimized conditions (Table 31). The 
observed yield rapidly reached more than 90% after only 1h at 150°C, with 76:24 e.r. (entry 
1). The enantiopurity got dramatically affected by time and a near racemic mixture was 
obtained after 15h of reaction (entries 2-5). The reaction at 140°C for 15h afforded 3.2c in 
90% yield, in a better enantiomeric ratio of 66.5:33.5 (entry 6). Under 130°C, the reactivity 
started to decrease (entry 7-8), despite a higher conservation of the enantioenrichment over 
15h. 
 
Entry T (°C) t (h) Yielda 3.2c (%) e.r.b 
1 150 1 > 90 76:24 
2 150 2 > 90 70:30 
3 150 4 > 90 66.5:33.5 
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4 150 7 > 90 59:41 
5 150 15 > 90 53:47 
6 140 15 > 90 66.5:33.5 
7 130 15 75 68:32 
8 120 15 65 74:26 
a 1H NMR yield with trichloroethylene as the reference. be.r. value 
determined by HPLC analysis on a chiral stationary phase. 
Table 31. Time and temperature variation for the arylation toward 3.2c 
The reaction time was optimized at 140°C (Table 32). The yield reached 70% after 1h of 
reaction (entries 1-5) and topped 90% after 2h of reaction, affording 75:25 e.r.(entries 6). A 
longer reaction time provoked a depletion of the selectivity (entries 7-8). The optimal time of 
2h was selected for the further study. 
Entry t (min) Yielda 3.2c (%) e.r.b 
1 10 26 77:23 
2 20 47 77:23 
3 30 57 77:23 
4 45 61 77:23 
5 60 70 77:23 
6 120 > 95 75:25 
7 240 > 95 70:30 
8 420 > 95 66:34 
a 1H NMR yield with trichloroethylene as the reference. be.r. value 
determined by HPLC analysis on a chiral stationary phase. 
Table 32. Optimization of the reaction time for the arylation toward 3.2c 
At this step, it was necessary to re-evaluate the bifunctional ligands in order to ensure that 
3.L73 was the most suitable ligand for this transformation. The reactions were run after being 
stirred for 1 min at 23°C, for the sake of reproducibility. Indeed, notable variations in the 
results were observe when the reaction were run directly after addition of the solvent to the 
reactants. The variation of the chain length (entries 1-6) followed the same trend as the 
arylation with 1-bromo-2-methylnaphtalene, and the 5 carbons spacer in 3.L73 prove to be the 
most efficient, providing 3.2c in more than 95% yield and 73:27 e.r. (entry 2). The variation 
of the 3,5-disubstitution on the aryl moiety only induced a drop of reactivity, as well as a drop 
of selectivity (entries 7-10). The fluorinated ligand also reversed the selectivity (entry 9). The 
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ester 3.L68E turned down the reactivity, despite a conservation of the selectivity (entry 11). No 
reaction was observed with the MOP 3.L69 in the absence of acid (entry 12). Interestingly, in 
presence of PivOH, 3.L68 provided a better yield and a slight amelioration of selectivity (entry 
13). The reactivity was recovered with the ester, and a similar enantiomeric ratio was obtained 
(entry 14). The MOP also proved to be efficient in presence of PivOH, and the product was 
obtained in 55% yield and 66:34 e.r. in this case, thus providing another optimizable system 
that will be discuss in the next part. The hindrance in 3.L75 and 3.L76 shut down the reactivity 
(entries 16-17). A near racemic mixture was obtained with 3.L75 (entry 16), reinforcing the 
suggestion of a negative effect of the hindrance at the reactive site. The match effect with 
3.L82b was also observed with this coupling partner. The selectivity was increased and 3.2c 
was obtained in 20% yield but with 74:26 e.r. (entry 19). The switch to the –P(Cy)2 moiety in 
3.L68Cy was neither profitable for the reactivity nor for the selectivity (entry 18). 
 
Entry Additive Ligand Ar n Yielda A1c (%) e.r.b 
1 / 3.L74 Ph 6 80 73:27 
2 / 3.L73 Ph 5 > 95 73:27 
3 / 3.L72 Ph 4 61 73:27 
4 / 3.L71 Ph 3 18 71:28 
5 / 3.L70 Ph 2 27 70:30 
6 / 3.L68 Ph 1 42 66:34 
7 / 3.L58 3,5-diMePh 1 22 64:36 
8 / 3.L65 3,5-diOMePh 1 13 63:37 
9 / 3.L66 3,5-diCF3Ph 1 21 38:62 
10 / 3.L67 3,5-dit-BuPh 1 28 65:35 
11 / 3.L68E - - 9 72:27 
12 / 3.L69 - - no prod. n.d. 
13 PivOH 30 %mol 3.L68 Ph 1 55 70:30 
14 PivOH 30 %mol 3.L68E - - 26 70:30 
15 PivOH 30 %mol 3.L69 - - 55 66:34 
120 
 
16 / 3.L75 - - 13 53:47 
17 / 3.L76 - - traces n.d. 
18 / 3.L68Cy - - 10 61:39 
19 / 3.L82b - - 20 74:26 
a 1H NMR yield with trichloroethylene as the reference. be.r. valuedetermined by HPLC 
 analysis on a chiral stationary phase. 
3.L75 : R=Me
3.L82b : R=H
O
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CO2Hn
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Table 33. Ligand screen for the arylation toward 3.2c 
This ligand screen confirmed us the efficiency of the bifunctional ligand 3.L73for this Csp2-H 
arylation reaction. Nevertheless, the recovery of reactivity with the 1-bromo-2-
methoxynaphtalene did not compensate the lack of selectivity. The product 3.2c was observed 
in more than 95% yield but with an e.r. which stagnates at 73:27. Because the 3.L69 exhibited 
an interesting reactivity, it was chosen to optimize this system in parallel, since other 
combined parameters such as the acid could be varied under this arylation conditions. 
3.3.2. Optimization with the MOP3.L69 
The study suggested us that the combination of MOP as the ligand and an acid could 
be an alternative to bifunctional ligands in this atroposelective Csp2-H arylation reaction 
(Scheme 91). Moreover, different congeners of 3.L69and the acid could be rapidly screened. 
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Scheme 91. MOP as an alternative to bifunctional ligands 
A broad range of organic acids was examined in 10 %mol toward the starting material, 
equivalent to 1:1 of (R)-MOP:acid ratio, to compare to the use of 10 %mol of bifunctional 
ligand (Scheme 92). The yield of the reaction was increased to up to 95% when the hexanoic 
acid was used, reaching 71.5:28.5 e.r., in comparison to the use of PivOH. 
NN
N Ph
H
NN
N
Pd2dba3 2.5 %mol
3.L69 10 %mol
Acid 10 %mol
Cs2CO3 1.5 eq
MS 4Å
Xylenes, 2h, 140°C
Br
3.2c
1.5 eq
3.1
O
O
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Scheme 92. First screen of organic acid 
The aminoacids and protected derivatives proved to be non suitable for this reaction (Figure 
20). The use of the two enantiomers of the protected acid introduced by Cramer afforded 3.2c 
in around 20% yield, with no notable match/mistmach effect. Indeed, the product was 
obtained in both case with near 10% e.e.. 
 
Figure 20. Aminoacids screened in combination with MOP 
Additional acids were screened (Figure 21), and the racemic methoxy-lactic acid provided the 
desired product in 36% yield with 72:28 e.r., thus showing a reduced reactivity despite the 
conservation of the selectivity. On a side note, the pyridinone introduced as the acid in C-H 
activation by Yu and coworkers was not efficient in this coupling. 
 
Figure 21. Additional acids screened in combination with 3.L69 
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The hexanoic acid was kept as the ideal partner with 3.L69 as the ligand for this arylation. The 
reactivity in this case was increased, and 3.2c was obtained in 95% yield. Unfortunately, the 
enantiomeric ratio was only ameliorated to reach 70:30, which is comparable to the selectivity 
observed with the bifunctional ligand. No further amelioration of this ratio was observed for 
this arylation.  
Control experiments were run to address the necessity of each reactant, this time involving the 
acid in 30 %mol (Table 34). The removal of a component of the catalytic system (entries 3-6), 
or of the base (entry 2) totally shut the reaction down. Also, no reaction happened in the 
absence of the acid (entry 5-6), suggesting that the carbonate alone is not involved in the 
proton abstraction. 
NN
N Ph
H
NN
N
Pd2dba3 2.5 %mol
3.L69 10 %mol
Hexanoic acid 30 %mol
Cs2CO3 1.5 eq
MS 4Å
Xylenes, 2h, 140°C
Br
3.2c
1.5 eq
3.1
O
O
 
Entry Condition deviation Yielda 3.2c (%) e.r.b 
1 / > 95 (85)c 70:30 
2 no Cs2CO3 0 n.d. 
3 no 3.L69 0 n.d. 
4 no Pd2dba3 0 n.d. 
5 no hexanoic acid 0 n.d. 
6 no 3.L69, no hexanoic acid 0 n.d. 
a 1H NMR yield with trichloroethylene as the reference. be.r. value 
determined by HPLC analysis on a chiral stationary phase. cyield 
of the isolated product. 
Table 34. Control experiments with 3.L69 
Because no notable improvement of the selectivity was observed in the whole study, in spite 
of the discovery of two comparable system providing the arylated product in more than 90% 
yield and up to 73:27 e.r., we decided to design the substrate and to vary the substituent borne 
by the triazole moiety. 
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3.4. Variation of the starting materials 
3.4.1. Variation of the triazole 
 A variety of triazole was synthesized and engaged in the arylation reaction with 1-
bromo-2-methoxynaphtalene, in presence of the bifunctional ligand 3.L73 (Scheme 93). No 
product 3.3a was obtained when the phenyl moiety was replaced by a t-Bu group. The less 
hindered cyclohexyl or pentyl moieties afforded the corresponding products 3.3b and 3.3c in 
22% and 95% yield, respectively, but with a very low selectivity. The product 3.3d bearing an 
extended aromaticity on the biphenyl moiety was obtained in a similar fashion to 3.2c, with 
95% yield and 73:27 e.r.A slight amelioration of e.r. was observed when the benzyl was 
replaced by the corresponding saturated moiety, thus 3.3e was obtained in more than 70% 
yield and 75.5:24.5 e.r.. The totally conjugated product 3.3f was not detected in the crude 
mixture. 
 
Scheme 93. Variation of the triazole 
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To our delight, several tested triazole underwent Csp2-H arylation in acceptable to good yield. 
But in contrast, no remarkably positive amelioration of the selectivity was observed, and near 
racemic mixtures were obtained in some cases. 
3.4.2. Variation of the bromo-electrophile 
The arylation was attempted on A1with less hindered bromo-electrophiles (Scheme 94). The 
product 3.2d was obtained in a satisfying yield of 68%, but in less than 10% e.e.. The reaction 
with the -bromo-3-methylcyclohexenone did not lead to 3.2e, despite a total conversion of 
the bromide. 
 
Scheme 94. Variation of the bromo-electrophile 
After this quick evaluation of starting coupling partners, no further investigation was 
conducted, to leave space for the writing of this thesis. During this period, Cramer and 
coworkers reported a palladium-catalyzed intramolecular atroposelective Csp2-H arylation 
(see part1.3.6). To ensure of the uniqueness of our catalytic system, confirmation reaction 
were run. 
3.5. Comparison with Cramer’s report 
In order to confirm the our catalytic system was unique, we tested our optimized 
conditions for 3.L69 with Cramer’s phosphoramidite 3.L61 as the ligand (Table 35). Contrary 
to the efficiency observed in the intramolecular arylation, this monophosphine ligand only 
provided 11% yield of the desired biaryl, in 59:41 e.r. (entry 1). The 2,2-diphenylpropanoic 
acid was also tested in combination with the MOP (entry 2). But the effect of the steric bulk in 
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the acid completely shut down the reactivity and 19% yield of arylation was obtained. As in 
the screening of acids, the e.e. was not particularly affected and a ratio of 69.5:30.5 was 
observed. The reaction conditions of Cramer were tested and, not surprisingly, no reaction 
occurred at 60°C (entry 3-4). In addition, our system involves only 5% of palladium and 10 
%mol of ligand against 10% and 20%, respectively, in Cramer’s catalytic system. 
 
Entry Ligand Acid Yielda 3.2c (%) e.r.b 
1 Cramer Hexanoic 11 59:41 
2 MOP 2,2-diPh-propanoic 19 69.5:30.5 
3c Cramer 2,2-diPh-propanoic n.r. n.d. 
4d MOP Hexanoic n.r n.d. 
a 1H NMR yield with trichloroethylene as the reference. be.r. value determined by HPLC 
analysis on a chiral stationary phase. cPd(dba)2 10 %mol, ligand 20 %mol, K2CO3 1.5 eq, 
mesitylene, 60°C, 10h. dat 60°C. 
Table 35.Intermolecular arylation with Cramer’s conditions. 
3.6. Conclusion 
After the determination of suitable coupling partners for the palladium-catalyzed 
intermolecular Csp2-H arylation, the reaction conditions were optimized and two catalytic 
systems which, to date, proved to be efficient to date for the atroposelective arylation of 
triazoles. One catalytic system uses the recently developed bifunctional ligands bearing the 
phosphine and the acid on a chiral binaphtyl core. The selectivity obtained in these conditions 
is slightly higher than when the MOP is used in combination with the hexanoic acid. Both 
catalytic systems were efficient, in particular for the coupling of triazole 3.1 with 1-Br-2-
methylnaphtalene and with 1-Br-2-methoxynaphtalene. 
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Scheme 95. Two advanced catalytic systems for the intermolecular Pd(0)-catalyzed 
atroposelective Csp2-H arylation 
The screen of acids, ligands, and substrates brings to the fore the sensitivity of the reaction 
toward the steric hindrance nearby the metal center. The increase of bulk in the acid, as well 
as in the -position to the ether in the bifunctional ligands, resulted in lower reactivities. The 
stereochemical outcome of the reaction was affected by the temperature of the reaction 
(dynamic racemization of the biaryl), but also and mainly by the decoration of the ligands. 
Nevertheless, the products obtained from our chosen coupling partners only slowly racemize 
in our reaction conditions. 
According to Cramer’s study, the enantiodetermining step of the reaction is the CMD-step, 
thus the induction chirality would fully rise from the ligand. Considering this case, our 
binaphtyl-based ligands seem to be not fully adapted for the reaction we develop, and a screen 
of MOP-type ligand based on other backbones should be privileged. In another scenario, the 
palladium intermediate obtained after the CMD-step, bearing the two aryl fragments, could 
favor one isomer or also racemize before reductive elimination, thus leading to low levels of 
selectivity. In this case, the selectivity would be linked to the difference of stability between 
the two enantiomeric intermediates, and a ligand favouring the reaction at a lower temperature 
could be investigated to solve the selectivity issue. So far, our results do not allow us to 
conclude clearly on the stereocontrol in this reaction 
 A global observation is that for our system, a clear dilemma between reactivity and 
selectivity is present, as already reported by Itami. Nevertheless, and to our delight, the results 
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we obtained with our optimized catalytic systems show that our Pd0 system provides , to date, 
comparable yields and selectivities as Itami’s PdII catalytic system. 
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4. General conclusion 
Over the past decades, the transition-metal catalyzed C-H bond functionalization has emerged 
as a powerful tool for the straightforward access to molecular complexity, while respecting 
the principles of atom- and step-economy.  
Within our group, many advances have been made in the development of the functionalization 
of remote Csp3-H bonds via Pd(0)-catalyzed  migrative cross-couplings, and in the 
intramolecular Pd(0)-catalyzed Csp3-H bond activation. 
In this context and in light of the work on the ligand-controlled arylation of N-Boc-
piperidines, a versatile and highly enantioselective -arylation of O-carbamates derived from 
primary alcohols was developed by combining Hoppe’s sparteine-mediated enantioselective 
lithiation and Negishi coupling. This method, combined with Aggarwal’s 
lithiation/borylation/oxidation sequence, provides a concise and divergent access to 
enantioenriched secondary and tertiary benzylic alcohols (Scheme 96). 
 
Scheme 96.Enantioselective -arylation of O-carbamates and application 
The attempts toward the-arylation of O-carbamates remained unsuccessful, but led to the 
discovery of a new migration system. Indeed, the ,-unsaturated O-carbamates underwent 
selective -arylation with the appropriate ligand under Pd(0)-catalyzed Negishi cross-coupling 
conditions (Scheme 97). The scope of the reaction was limited, but the mechanistic study led 
to the discovery of an unconventional migration involving a haptotropic rearrangement of the 
palladium intermediate. The lack of selectivity in the reaction enlightened us about the 
potential challenges in the enantiospecific migrative cross-coupling, which is currently under 
investigation within our group. 
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Scheme 97. Ligand controlled -arylation of ,-unsaturated O-carbamates 
The investigation on the very challenging intermolecular atroposelective Pd(0)-catalyzed 
Csp2-H arylation led us to the discovery of two efficient catalytic systems. Despite the clear 
reactivity/selectivity dilemma, comparable yield and selectivities to the ones reported by Itami 
could be achieved (Scheme 98). The ligand still requires to be improved. The recent 
publication of Cramer on the intramolecular version of this reaction made us consider a 
potential collaboration with this research group on the intermolecular Csp2-H arylation 
developed in this thesis. 
NN
N Ph
H
NN
N
Pd2dba3 2.5 %mol
Ligand A or B 10 %mol
Cs2CO3 1.5 eq
MS 4Å
Xylenes, 2h, 140°C
Br
3.2b-c
1.5 eq
3.1
R
R
O
PPh2
A : 3.L73
B : 3.L69
+ 30 %mol Hexanoic acid
O
PPh2
CO2H5
NN
N Ph
3.2b
A : 63%, 77.5:22.5
B : 65%, 75:25
NN
N Ph
3.2c
A : >95%, 73:27
B : >95% (85% isol.), 70:30
O
 
Scheme 98. Advances in the intermolecular atroposelective Pd(0)-catalyzed Csp2-H arylation 
  
131 
 
  
132 
 
5. Supporting information 
5.1. Enantioselective -arylation of O-carbamates 
General information 
All reactions were performed under an argon atmosphere (unless otherwise noted) in Pyrex 
glassware equipped with a magnetic stir bar. GC/MS analyses were run on a Shimadzu 
QP2010 apparatus using aRTx®-5ms column lined with a mass (EI 0.86 kV) detection 
system.1H, 13C and 19F NMR spectra were recorded on a BrukerAvance III (400 MHz) 
spectrometer at 298 K in CDCl3 (residual peaks 1H δ 7.26 ppm, 13C δ 77.16 ppm). Chemical 
shifts (δ) are reported in ppm relative totetramethylsilane (0.00 ppm). Data are reported as 
follows: chemical shift in parts per million (ppm), multiplicity (s = singlet, d = doublet, t = 
triplet, q = quartet, m = multiplet, and br. for broad), integration value, coupling constant in 
Hz if applicable. Analytical Thin Layer Chromatography (TLC) was performed using pre-
coated Merck silica gel 60 F254 plates (0.25 mm). Visualization of the developed 
chromatogram was performed by UV absorbance (254 nm) or TLC stains (Phosphomolybdic 
acid or KMnO4) Flash chromatographies were performed using SilicycleSiliaFlash P60 (230-
400 mesh) with the indicated solvents. High resolution mass spectrometry recorded by Dr. H. 
Nadig of the University of Basel on a BrukermaXis 4G QTOF ESI mass spectrometer. 
Infrared spectra were measured on aATR Varian Scimitar 800 FT-IR spectrometer and 
reported in cm–1. HPLC analyses were done using a Shimadzu Prominence system with SIL-
20A auto sample, CTO-20AC column oven, LC-20AD pump system, DGU-20A3 degasser 
and SPD-M20A Diode Array or UV/Vis detector. Chiralcel OD-H, OJ, or OJ-H and 
Chiralpak AD-H, IA or IC columns from Daicel Corporation were used for separation. 
Optical rotationwere measured on a Perkin Elmer 341Polarimeter in a 1 mL cuvette (cell 
length 100 mm) with NaD-Line ( = 589 nm) at 20°C. The concentration (c) is given in g/dL. 
 Commercially available reagents were used without further purification unless otherwise 
stated. Anhydrous solvents (Diethyl ether, THF, Toluene) were purchased form Sigma 
Aldrich and used as received.Tetramethylethylenediamine (TMEDA) was freshly distilled 
over CaH2 under argon atmosphere. ()-Sparteine and (+)-sparteine were respectively 
purchased from Sigma Aldrich and Fluorochem, distillated over CaH2 under argon 
atmosphere, degassed under high vacuum via freeze-pumping process, and conserved at -
30°C. 2-Dicyclohexylphosphino-2’,6’-diisopropoxy-biphenyl (RuPhos) was purchased from 
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Strem. Tris(dibenzylideneacetone)dipalladium(0) (Pd2(dba)3) was purchased from Strem and 
ABCR. Zinc acetate (Zn(OAc)2)was purchased from Sigma Aldrich and thinly powdered. 
(RuPhos), (Pd2(dba)3), and (Zn(OAc)2) were conserved in a glove box. 
Optimization table 
 
N°  DG i) ii) iii) Yield 
(GCMS 
Yield%) 
1 
Prelimin
ary 
Studies 
Cb or 
TIB 
s-BuLi 2 eq, TMEDA 6 
eq,-50°C, 30 min, CPME 
ZnCl2 2 eq 
30 min at -50°C 
then 30 min at r.t. 
Pd2(dba)3 5%mol, 
PtBu3.HBF4 10%mol in Toluene, 
p-MeO-PhBr 1 eq, 60°C, 18h 
0% 
2 Cb s-BuLi 1.3 eq, TMEDA 
1.3 eq,-78°C, 5 h, Et2O 
ZnCl2 1.4 eq 
30 min at -78°C 
then 30 min at r.t. 
Pd2(dba)3 5%mol, 
PtBu3.HBF4 10%molin Toluene, 
p-MeO-PhBr 1 eq, 80°C, 18h 
~72% 
3 Cb s-BuLi 1.3 eq, TMEDA 
1.3 eq,-78°C, 3 h, Et2O 
ZnCl2 1.4 eq 
30 min at -78°C 
then 30 min at r.t. 
Pd2(dba)3 5%mol, 
PtBu3.HBF4 10%molin Toluene, 
p-MeO-PhBr 1.3 eq, 80°C, 18h 
50% 
4 Cb s-BuLi 1.3 eq, TMEDA 
1.3 eq,-78°C, 3 h, Et2O 
ZnCl2 1.4 eq 
30 min at -78°C 
then 30 min at r.t. 
[Pd(PtBu3)2] 10%mol in Toluene, 
p-MeO-PhBr 1.3 eq, 80°C, 18h 
50% 
5 Cb s-BuLi 1.3 eq, (-)-
Sparteine 1.3 eq, 
-78°C, 5 h, Et2O 
ZnCl2 1.4 eq 
30 min at -78°C 
then 30 min at r.t. 
[Pd(PtBu3)2] 10%molin Toluene, 
p-MeO-PhBr 1.3 eq, 80°C, 18h 
60%, e.r. 
97:3 
6 
Ligands 
Cb s-BuLi 1.3 eq, TMEDA 
1.3 eq,-78°C, 5 h, Et2O 
ZnCl2 1.4 eq 
30 min at -78°C 
then 30 min at r.t. 
[Pd(PtBu3)2] 10%mol (Sigma)  in 
Toluene,p-MeO-PhBr 1.3 eq, 80°C, 18h 
(22) 
7 Cb s-BuLi 1.3 eq, TMEDA 
1.3 eq,-78°C, 5 h, Et2O 
ZnCl2 1.4 eq 
30 min at -78°C 
then 30 min at r.t. 
[Pd(PtBu3)2] 10%mol (Strem)  in 
Toluene,p-MeO-PhBr 1.3 eq, 80°C, 18h 
50% 
8 Cb s-BuLi 1.3 eq, TMEDA 
1.3 eq,-78°C, 5 h, Et2O 
ZnCl2 1.4 eq 
30 min at -78°C 
then 30 min at r.t. 
Pd2(dba)3 5%mol, RuPhos 10%mol in 
Toluene,p-MeO-PhBr 1.3 eq, 80°C, 18h 
39% (43) 
9 Cb s-BuLi 1.3 eq, TMEDA ZnCl2 1.4 eq RuPhos Pd G3 10%mol in Toluene, (46) 
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1.3 eq,-78°C, 5 h, Et2O 30 min at -78°C 
then 30 min at r.t. 
p-MeO-PhBr 1.3 eq, 80°C, 18h 
10 Cb s-BuLi 1.3 eq, TMEDA 
1.3 eq,-78°C, 5 h, Et2O 
ZnCl2 1.4 eq 
30 min at -78°C 
then 30 min at r.t. 
Pd2(dba)3 5%mol, DavePhos 10%mol 
in Toluene,p-MeO-PhBr 1.3 eq, 80°C, 
18h 
(29) 
11 Cb s-BuLi 1.3 eq, TMEDA 
1.3 eq,-78°C, 5 h, Et2O 
ZnCl2 1.4 eq 
30 min at -78°C 
then 30 min at r.t. 
Pd2(dba)3 5%mol, CataCXium A 
10%mol in Toluene, 
p-MeO-PhBr 1.3 eq, 80°C, 18h 
(20) 
12 Cb s-BuLi 1.3 eq, TMEDA 
1.3 eq,-78°C, 5 h, Et2O 
ZnCl2 1.4 eq 
30 min at -78°C 
then 30 min at r.t. 
Pd2(dba)3 5%mol, P(Cy)3 10%mol in 
Toluene,p-MeO-PhBr 1.3 eq, 80°C, 18h 
(<5) 
13 ControlD
euteratio
n 
Cb s-BuLi 1.3 eq, TMEDA 
1.3 eq,-78°C, 1 h, Et2O 
MeOD  86% 
(100% D-
int) 
14 
Zinc 
Sources 
Cb s-BuLi 1.3 eq, TMEDA 
1.3 eq,-78°C, 1 h, Et2O 
ZnBr2 1.4 eq 
30 min at -78°C 
then 30 min at r.t. 
Pd2(dba)3 5%mol, RuPhos 10%mol in 
Toluene,p-MeO-PhBr 1.3 eq, 80°C, 18h 
(29) 
15 Cb s-BuLi 1.3 eq, TMEDA 
1.3 eq,-78°C, 1 h, Et2O 
Zn(OAc)2 1.4 eq 
30 min at -78°C 
then 30 min at r.t. 
Pd2(dba)3 5%mol, RuPhos 10%mol in 
Toluene,p-MeO-PhBr 1.3 eq, 80°C, 18h 
55% (63) 
16 Cb s-BuLi 1.3 eq, TMEDA 
1.3 eq,-78°C, 1 h, Et2O 
Zn(OPiv)2 1.4 eq 
30 min at -78°C 
then 30 min at r.t. 
Pd2(dba)3 5%mol, RuPhos 10%mol in 
Toluene,p-MeO-PhBr 1.3 eq, 80°C, 18h 
51% (55) 
17 Cb s-BuLi 1.3 eq, TMEDA 
1.3 eq,-78°C, 1 h, Et2O 
Zn(OTFA)21.4 eq 
30 min at -78°C 
then 30 min at r.t. 
Pd2(dba)3 5%mol, RuPhos 10%mol in 
Toluene,p-MeO-PhBr 1.3 eq, 80°C, 18h 
(51) 
18 
Catalyst 
Loading 
Cb s-BuLi 1.3 eq, TMEDA 
1.3 eq,-78°C, 1 h, Et2O 
Zn(OAc)2  1.4 eq 
30 min at -78°C 
then 30 min at r.t. 
Pd2(dba)3 2.5%mol, RuPhos 5%mol in 
Toluene,p-MeO-PhBr 1.3 eq, 80°C, 18h 
(58) 
19 Cb s-BuLi 1.3 eq, TMEDA 
1.3 eq,-78°C, 1 h, Et2O 
Zn(OAc)2  1.4 eq 
30 min at -78°C 
then 30 min at r.t. 
Pd2(dba)3 1.25%mol, RuPhos 
2.5%mol in Toluene, 
p-MeO-PhBr 1.3 eq, 80°C, 18h 
(51) 
20 Cb s-BuLi 1.3 eq, TMEDA 
1.3 eq,-78°C, 1 h, Et2O 
Zn(OAc)2  1.4 eq 
30 min at -78°C 
then 30 min at r.t. 
Pd2(dba)3 0.5%mol, RuPhos 1%mol in 
Toluene,p-MeO-PhBr 1.3 eq, 80°C, 18h 
(25) 
21 
Alternati
ve DG 
Cby s-BuLi 1.3 eq, TMEDA 
1.3 eq,-78°C, 1 h, Et2O 
Zn(OAc)2  1.4 eq 
30 min at -78°C 
then 30 min at r.t. 
Pd2(dba)3 5%mol, RuPhos 10%mol in 
Toluene,p-MeO-PhBr 1.3 eq, 80°C, 18h 
44% 
22 Cby s-BuLi 1.3 eq, (-)-
Sparteine 1.3 eq, 
Zn(OAc)2  1.4 eq 
30 min at -78°C 
Pd2(dba)3 5%mol, RuPhos 10%mol in 
Toluene,p-MeO-PhBr 1.3 eq, 80°C, 18h 
44%, e.r. 
99:1 
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-78°C, 1 h, Et2O then 30 min at r.t. 
23 
Lower 
Cat/ArBr 
Charge 
Cb s-BuLi 1.3 eq, TMEDA 
1.3 eq, 
-78°C, 1 h, Et2O 
Zn(OAc)2  1.4 eq 
30 min at -78°C 
then 30 min at r.t. 
Pd2(dba)3 3.5%mol, RuPhos 7%mol in 
Toluene,p-MeO-PhBr 0.7 eq, 80°C, 18h 
73% 
24 Cb s-BuLi 1.3 eq, TMEDA 
1.3 eq,-78°C, 1 h, Et2O 
Zn(OAc)2  1.4 eq 
30 min at -78°C 
then 30 min at r.t. 
Pd2(dba)3 1.75%mol, RuPhos 3.5%molin 
Toluene,p-MeO-PhBr 0.7 eq, 80°C, 18h 
71% 
25 Cb s-BuLi 1.3 eq, TMEDA 
1.3 eq,-78°C, 1 h, Et2O 
Zn(OAc)2  1.4 eq 
30 min at -78°C 
then 30 min at r.t. 
Pd2(dba)3 1.23%mol, RuPhos 1.75%mol 
in Toluene,p-MeO-PhBr 0.7 eq, 80°C, 
18h 
39% 
26 Cby s-BuLi 1.3 eq, TMEDA 
1.3 eq, 
-78°C, 1 h, Et2O 
Zn(OAc)2  1.4 eq 
30 min at -78°C 
then 30 min at r.t. 
Pd2(dba)3 1.75%mol, RuPhos 3.5%mol 
in Toluene, 
p-MeO-PhBr 0.7 eq, 80°C, 18h 
81% 
27 Cby s-BuLi 1.3 eq, (-)-
Sparteine 1.3 eq, 
-78°C, 1 h, Et2O 
Zn(OAc)2  1.4 eq 
30 min at -78°C 
then 30 min at r.t. 
Pd2(dba)3 1.75%mol, RuPhos 3.5%mol 
in Toluene,p-MeO-PhBr 0.7 eq, 80°C, 
18h 
86%, e.r. 
99.4:0.6 
28 
ArX 
Variation 
Cby s-BuLi 1.3 eq, TMEDA 
1.3 eq,-78°C, 1 h, Et2O 
Zn(OAc)2  1.4 eq 
30 min at -78°C 
then 30 min at r.t. 
Pd2(dba)3 1.75%mol, RuPhos 3.5%mol 
in Toluene,p-MeO-PhCl0.7 eq, 80°C, 
18h 
7% 
29 Cby s-BuLi 1.3 eq, TMEDA 
1.3 eq,-78°C, 1 h, Et2O 
Zn(OAc)2  1.4 eq 
30 min at -78°C 
then 30 min at r.t. 
Pd2(dba)3 1.75%mol, RuPhos 3.5%mol 
in Toluene,p-MeO-PhI0.7 eq, 80°C, 18h 
70% 
30 Cby s-BuLi 1.3 eq, TMEDA 
1.3 eq,-78°C, 1 h, Et2O 
Zn(OAc)2  1.4 eq 
30 min at -78°C 
then 30 min at r.t. 
Pd2(dba)3 1.75%mol, RuPhos 3.5%mol 
in Toluene,p-MeO-PhOTf0.7 eq, 80°C, 
18h 
41% 
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Synthesis of carbamates2.4-6a and 2.2a : 
2,2,4,4-Tetramethyl-1,3-oxazolidine-3-carbonyl chlorideS1 : 
 
The reaction must be carried out in a well-vented fumehood, in dry conditions ! A solution of 
2,2,4,4-tetramethyl-1,3-oxazolidine (26.4 g, 204 mmol, 1 eq) and triethylamine (34.4 mL, 245 
mmol, 1.2 eq) in benzene (100 mL) was added dropwise via a dropping funnel to a solution of 
bis(trichloromethyl) carbonate (triphosgene, 20.6 g, 69.4 mmol, 0.34 eq) in benzene (400 mL) 
at 0°C. After addition, the mixture was heated to reflux for 20 h. The orange slurry was 
cooled down, poured into a 2 M aq. HCl solution (150 mL), and the aqueous phase was 
extracted with Et2O (2 x 150 mL). The combined organic phases were washed with sat. 
NaHCO3 (150 mL), dried over MgSO4, and evaporated under vacuum. The residue was 
distillated (55°C, 0.1 mbar) to afford 30.5 g (78%) of the carbamoyl chloride as a colorless oil 
which slowly crystallized as a white solid. The analytical data were in accordance with the 
literature.143 
1H NMR (400 MHz, CDCl3, rotamers) :br. s, 2 br. s, 
6H), 1.53 (1.45) (2 br. s, 6H).13C-{1H} NMR (CDCl3, 100 MHz, rotamers) : 
143.8/142.6, 99.2/97.4, 76.9/75.3, 64.9/62.4, 26.8/25.5, 24.5/23.5 
Ethyl 2,4,6-triisopropylbenzoate2.2 : 
 
DIAD (2.1 mL, 10.5 mmol, 1.2 eq) was added dropwise over 10 min to a stirred solution of 
PPh3 (2.75 g, 10.5 mmol, 1.2 eq), 2,4,6-triisopropyl benzoic acid (2.5 g, 10.1 mmol, 1.1 eq), 
and ethanol (0.52 mL, 8.75 mmol, 1 eq) in THF (50 mL) at 0°C. The reaction mixture was 
stirred for 4 h at r.t., then the solvent was evaporated under vacuum, and the residue was 
dissolved in pentane (15mL) for 5 min. The white suspension was filtered and the cake was 
washed with pentane (100 mL). The solvent was removed under vacuum, to obtain a yellow 
oil.The crude mixture was purified by column chromatography (pentane/Et2O 99:1) to give 
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2.1 g (86 %) of the ester as a colorless oil. The analytical data were in accordance with the 
literature.144 
1H NMR (400 MHz, CDCl3) :s, 2H), 4.38 (q, J = 7.2), 2.93-2.82 (m, 3H), 1.37 (t, J 
= 7.2, 3H), 1.27-1.24 (m, 18H).13C-{1H} NMR (CDCl3, 100 MHz) : 171.0, 150.3, 144.9, 
130.8, 121.0, 61.0, 34.6, 31.6, 24.2, 24.1, 14.4. 
Ethyl N,N-diisopropylcarbamate2.4 : 
 
Ethyl chloroformate (7.2 mL, 75mmol, 1 eq) was added to a stirred mixture of diisopropyl 
amine (10.6 mL, 75 mmol, 1 eq) and K2CO3 (10.4 g, 75 mmol, 1 eq) in dichloromethane (80 
mL) at 0°C. After addition, the mixture was refluxed for 4h. After cooling, the mixture was 
filtrated and washed with a 10% KOH aq. solution (2 x 100 mL), and water (100 mL). The 
organic phase was dried over MgSO4, filtrated, and concentrated under vacuum. The residue 
was purified by column chromatography (pentane/Et2O 9:1) to give 9.8 g (75%) of the 
carbamate as an oil. The analytical data were in accordance with the literature.145 
1H NMR (400 MHz, CDCl3, rotamers) :4.11 (q, 2H, J = 7.1), 3.88 (br. s, 2H), 1.24 (t, 
3H, J = 7.1), 1.18 (d, 12H, J = 6.9).13C-{1H} NMR (CDCl3, 100 MHz, rotamers) : 156.0, 
60.5, 45.8 (br.), 21.1 (br.), 14.8 
Ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate2.5 : 
 
Ethyl chloroformate (11.1 mL, 116 mmol, 1.5 eq) was added to a stirred mixture of 2,2,4,4-
tetramethyl-1,3-oxazolidine (10 g, 77.4 mmol, 1 eq) and Na2CO3 (12.3 g, 116 mmol, 1.5 eq) 
in dichloromethane (100 mL) at 0°C. The mixture was stirred at r.t. for 5h and then filtrated. 
The solution was quenched with 1M aq. NaOH (100 mL) and washed with water (100 mL). 
The organic phase was dried over MgSO4, filtrated, and concentrated under vacuum. The 
residue was purified by column chromatography (pentane/Et2O 85:15) to give 12.5 g (80.2 %) 
of the carbamate as an oil. The analytical data were in accordance with the literature.146 
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1H NMR (400 MHz, CDCl3, rotamers) :m, 2H), 3.72 (s, 2H), 1.56 (1.52) (2 
br. s, 6H), (1.42) 1.36 (2 br. s, 6H), 1.30-1.25 (m, 3H).13C-{1H} NMR (CDCl3, 100 MHz, 
rotamers) : 153.0/152.3, 95.8/94.9, 76.5/76.2, 60.6/59.8, 60.4, 26.6/25.44, 25.38/25.3, 
14.6. 
Ethyl 3,3-dimethyl-1-oxa-4-azaspiro[4.5]decane-4-carboxylate2.6 : 
 
Ethyl chloroformate (2.4 mL, 24.6 mmol, 1 eq) was added to a stirred solution of 3,3-
dimethyl-1-oxa-4-azaspiro[4.5]decane (5 g, 29.5 mmol, 1.2 eq) in dry dichloromethane (15 
mL) at 0°C. The mixture was stirred at r.t. for 20h. The reaction mixture was quenched with 2 
M aq. HCl (20 mL), the organic layer was separated, and the aqueous layer was extracted with 
Et2O (2 x 50 mL). The combined organic phases were dried over MgSO4, and concentrated 
under vacuum. The residue was distillated (84°C, 0.6 mbar) to afford 2.8g (48 %) of the 
carbamate as a white solid. The analytical data were in accordance with the literature.147 
1H NMR (400 MHz, CDCl3) :4.11 (q, 2H, J = 7.1), 3.67 (s, 2H), 2.41-2.16 (m, 2H), 
1.58-1.34 (m, 14H), 1.26 (t, 3H, J = 7.1).13C-{1H} NMR (CDCl3, 100 MHz, rotamers) : 
153.1, 97.25/96.4, 76.4/76.0, 60.4/60.0, 60.3,
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Arylation of carbamates 2.2 and 2.4-6 
General procedure A : arylation with TMEDA 
In a tubular reactor (100 mm x 16 mm)capped with a rubber septum, a solution of the 
carbamate2.2 or 2.4-6(0.6 mmol, 1 eq) and TMEDA (118 µL, 0.78 mmol, 1.3 eq) in dry 
diethyl ether (2 mL) under argon was stirred and cooled down to -78°C (acetone bath, 
cryostat). s-Butyllithium (0.78 mmol, 1.3 eq, solution in hexane) was added dropwise, and the 
mixture was stirred for 1 h. A suspension of zinc acetate (154 mg, 0.84 mmol, 1.4 eq) in dry 
THF (2 mL) was sonicated for 30 min and added dropwise to the mixture. The resulting 
solution was stirred for 30 min at -78°C, and then allowed to heat to 20°C over 30 min. The 
solvents were evaporated over 30 min under high vacuum, and a solution of Pd2(dba)3 (9.62 
mg, 10.5 µmol, 1.75 %mol) and Ruphos (9.85 mg, 21 µmol, 3.5 %mol) in dry toluene (2 mL) 
was added, followed by the aryl bromide (0.42 mmol, 0.7 eq). The mixture was then 
vigorously stirred and heated to 80°C for 18h. After cooling down, the reaction was quenched 
with sat. aq. NH4Cl (2 mL), and the organic phase was diluted with EtOAc (5mL) and 
separated. The aqueous phase was extracted with EtOAc (2 x 5 mL). The combined organic 
layers were dried over MgSO4, filtrated over a pad of celite, and evaporated under vacuum. 
The residue was purified by column chromatography (pentane/Et2O) to afford the benzylic 
alcohols. 
General procedure B : enantioselective arylation with (-)-sparteine 
In a tubular reactor (100 mm x 16 mm) capped with a rubber septum, a solution of the 
protected alcohol2.2 or 2.4-6 (0.6 mmol, 1 eq) and (-)-sparteine (178 µL, 0.78 mmol, 1.3 eq) 
in dry diethyl ether (2 mL) under argon was stirred and cooled down to -78°C (acetone bath, 
cryostat). s-Butyllithium (0.78 mmol, 1.3 eq, solution in hexane) was added dropwise, and the 
mixture was stirred for 5 h. A suspension of zinc acetate (154 mg, 0.84 mmol, 1.4 eq) in dry 
THF (2 mL) was sonicated for 30 min and added dropwise to the mixture. The resulting 
solution was stirred for 30 min at -78°C, and then allowed to heat to 20°C over 30 min. The 
solvents where evaporated over 30 min under high vacuum, and a solution of Pd2(dba)3 (9.62 
mg, 10.5 µmol, 1.75 %mol) and Ruphos (9.85 mg, 21 µmol, 3.5 %mol) in dry toluene (2 mL) 
was added, followed by the arylbromide (0.42 mmol, 0.7 eq). The mixture was then 
vigorously stirred and heated to 80°C for 18h. After cooling down, the reaction was quenched 
with sat. aq. NH4Cl (2 mL), and the organic phase was diluted with EtOAc (5mL) and 
separated. The aqueous phase was extracted with EtOAc (2 x 5 mL). The combined organic 
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layers were dried over MgSO4, filtrated over a pad of celite, and evaporated under vacuum. 
The residue was purified by column chromatography (pentane/Et2O) to afford the protected 
benzylic alcohols. 
(R)-(+)-1-(4-Methoxyphenyl)ethyl 2,4,6-triisopropylbenzoate 2.2a: 
 
Following the general procedure A, ethyl 2,4,6-triisopropylbenzoate (166 mg) was arylated 
with 4-bromoanisole (52.7 µL). The crude residue was purified by column chromatography 
(pentane/Et2O 95:5 to 80:20) to give  75 mg (47%) of the racemic arylated product as an oil. 
Following the general procedure B, ethyl 2,4,6-triisopropylbenzoate (166 mg) was arylated 
with 4-bromoanisole (52.7 µL). The crude residue was purified by column chromatography 
(pentane/Et2O 95:5 to 80:20) to give 100 mg (62%) of the enantioenriched arylated product as 
an oil. 
1H NMR (CDCl3, 400MHz) :7.40-7.37(m, 2H), 6.99 (s, 2H), 6.91-6.88(m, 2H), 6.17 
(q,1H, J = 6.6Hz), 3.82 (s, 3H), 2.88 (sept, 1H, J = 6.9Hz), 2.76 (sept, 1H, J = 6.8Hz), 1.65 (d, 
3H,J = 6.6Hz), 1.24(d, 6H,J = 6.9Hz), 1.20 (d, 6H, J = 6.8Hz), 1.16(d, 6H, J = 6.8Hz).13C-
{1H} NMR (CDCl3,100 MHz) :170.2, 159.6, 150.2, 145.0, 133.5, 130.7, 128.2, 121.0, 
113.9, 72.9, 55.5, 34.6, 31.3, 24., 24.2, 24.1, 21.9.HPLC separation conditions : Chiralpak 
AD-H column, n-heptane/i-PrOH 99:1, flow rate 1 mL/min, 25°C, tR 6.1 min for (R)-
enantiomer (major) and tR 11.4 min for (S)-enantiomer (minor). e.r. = 92.5:7.5.[]D20 = +15.9° 
(c=1.1, CHCl3).HRMS (ESI) m/z: calcd. for C25H34O3Na ([M + Na]+): 405.2406; found: 
405.2398.IR (neat) v : 2961, 1721, 1247. 
(R)-(+)-1-(4-Methoxyphenyl)ethylN,N-diisopropylcarbamate2.4a : 
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Following the general procedure A, ethyl N,N-diisopropylcarbamate(104 mg) was arylated 
with 4-bromoanisole (52.7 µL). The crude residue was purified by column chromatography 
(pentane/Et2O 98:2 to 80:20) to give 83 mg (71%) of the racemic arylated product as an oil. 
Following the general procedure B, ethyl N,N-diisopropylcarbamate (104 mg) was arylated 
with 4-bromoanisole (52.7 µL). The crude residue was purified by column chromatography 
(pentane/Et2O 98:2 to 80:20) to give 60 mg (51%) of the enantioenriched arylated product as 
an oil. 
The analytical data were in accordance with the literature.148 
1H NMR (400 MHz, CDCl3) :m, 2H), 6.89-6.85 (m, 2H), 5.80 (q, 1H, J = 
6.6), 4.10-3.80 (br. m, 5H), 1.53 (d, 3H, J = 6.6), 1.19-1.17 (m, 12H).13C-{1H} NMR (100 
MHz, CDCl3) :159.1, 155.4, 135.1, 127.6, 113.9, 72.5, 55.4 (b.s.), 22.8, 21.3 
(b.s.).HPLC separation conditions : Chiralpak AD-H column,n-heptane/i-PrOH 99:1, flow 
rate 1 mL/min, 25°C, tR 10.0 min for (R)-enantiomer (major) and tR 16.2 min for (S)-
enantiomer (minor). e.r. = 98.2:1.8.[]D20 = +12.3° (c=1.1, CHCl3). 
(R)-(+)-1-(4-Methoxyphenyl)ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate2.5a : 
 
Following the general procedure A, ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate (121 
mg) was arylated with 4-bromoanisole (52.7 µL). The crude residue was purified by column 
chromatography (pentane/Et2O 95:5 to 80:20) to give 105 mg (81%) of the racemic arylated 
product as an oil. 
Following the general procedure B, ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate (121 
mg) was arylated with 4-bromoanisole (52.7 µL). The crude residue was purified by column 
chromatography (pentane/Et2O 95:5 to 80:20) to give 111 mg (86%) of the enantioenriched 
arylated product as an oil. 
1H NMR (400 MHz, CDCl3, rotamers) :m, 2H), 6.89-6.87 (m, 2H), 5.81 (q, 
1H, J = 6.6), 3.80 (s, 3H), 3.72-3.70 (m, 2H), 1.60-1.33 (m, 15H).13C-{1H} NMR (100 MHz, 
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CDCl3, rotamers) :159.2, 152.2/151.5, 134.5/134.4, 127.6, 113.9, 96.0/94.9, 76.5/76.2, 
72.5, 60.7/59.8, 55.3, 26.9/26.8, 25.6/25.6, 25.5, 24.3, 22.6/22.5. HPLC separation 
conditions : Chiralpak AD-H column, n-heptane/i-PrOH 99:1, flow rate 1 mL/min, 25°C, tR 
8.1 min for (R)-enantiomer (major) and tR 9.8 min for (S)-enantiomer (minor). e.r. = 
99.4:0.6.[]D20 = +11.5° (c=0.5, CHCl3). HRMS (ESI) m/z: calcd. for C17H25NO4Na ([M + 
Na]+): 330.1676; found: 330.1671. IR (neat) v : 2978, 1695, 1395, 1093, 1064. 
(R)-(+)-1-(4-Methoxyphenyl)ethyl 3,3-dimethyl-1-oxa-4-azaspiro[4.5]decane-4-
carboxylate2.6a : 
 
Following the general procedure A, ethyl 3,3-dimethyl-1-oxa-4-azaspiro[4.5]decane-4-
carboxylate (145 mg) was arylated with 4-bromoanisole (52.7 µL). The crude residue was 
purified by column chromatography (pentane/Et2O 95:5 to 80:20) to give 127 mg (87%) of 
the racemic arylated product as an oil. 
Following the general procedure B, ethyl 3,3-dimethyl-1-oxa-4-azaspiro[4.5]decane-4-
carboxylate (145 mg) was arylated with 4-bromoanisole (52.7 µL). The crude residue was 
purified by column chromatography (pentane/Et2O 95:5 to 80:20) to give 103 mg (70%) of 
the enantioenriched arylated product as an oil. 
1H NMR (400 MHz, CDCl3, rotamers) :m, 2H), 6.89-6.86 (m, 2H), 5.78 (q, 
1H, J = 6.6), 3.79 (s, 3H), 3.70-3.67 (m, 2H), 2.43-2.12 (m, 2H), 1.69-1.25 (m, 17H).13C-
{1H} NMR (100 MHz, CDCl3, rotamers) :159.2, 152.4/151.8, 134.6, 127.6/127.6, 113.9, 
97.4/96.5, 76.4/76.0, 72.7/72.5, 60.5/59.7, 55.4, 34.5/34.2, 32.9, 25.9/25.8, 25.2, 24.8, 24.5, 
23.7/23.6, 23.44/23.39, 22.9, 22.6.HPLC separation conditions : Chiralcel OJ-H column, n-
heptane/i-PrOH 99:1, flow rate 1 mL/min, 25°C, tR 12.0 min for (R)-enantiomer (major) and 
tR 17.5 min for (S)-enantiomer (minor). e.r. = 99.4:0.6.[]D20 = +18.7° (c=1.0, CHCl3).HRMS 
(ESI) m/z: calcd. for C20H29NO4Na ([M + Na]+): 370.1994; found: 370.1995.IR (neat) v : 
2931, 1692, 1394, 1247, 1065. 
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(R)-(+)-1-Phenylethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.5b: 
 
Following the general procedure A, ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate (121 
mg) was arylated with bromobenzene (44.3 µL). The crude residue was purified by column 
chromatography (pentane/Et2O 98:2 to 80:20) to give 104 mg (89%) of the racemic arylated 
product as an oil. 
Following the general procedure B, ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate (121 
mg) was arylated with bromobenzene (44.3 µL). The crude residue was purified by column 
chromatography (pentane/Et2O 98:2 to 80:20) to give 108 mg (92%) of the enantioenriched 
arylated product as an oil. 
The analytical data were in accordance with the literature.149 
1H NMR (CDCl3, 400MHz, rotamers) : m, 5H), 5.84 (q, 1H,J = 6.6 Hz), 
3.76-3.69 (m, 2H), 1.62-1.37 (m, 15H).13C-{1H} NMR (CDCl3,100 MHz, rotamers) 
:152.2/151.5, 142.5/142.4, 128.6, 127.8, 126.2, 96.1/95.0, 76.5/76.2, 72.9, 60.8/58.8, 
26.9/26.8, 25.7/25.6, 25.49/25.45, 24.32/24.30, 22.8/22.7.HPLC separation conditions : 
Chiralpak IC column, n-heptane/i-PrOH 99:1, flow rate 1 mL/min, 25°C, tR 6.0 min for (R)-
enantiomer (major) and tR 6.5 min for (S)-enantiomer (minor). e.r. = 99.6:0.4.[]D20= +11° 
(c=1.1, CHCl3).HRMS (ESI) m/z: calcd. for C16H23NO3Na ([M + Na]+): 300.1576; found: 
300.1573.IR (neat) v : 2979, 1696, 1394, 1376, 1064. 
(R)-(+)-1-(p-Tolyl)ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.5c: 
 
Following the general procedure A, ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate (121 
mg) was arylated with p-bromotoluene (51.8 µL). The crude residue was purified by column 
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chromatography (pentane/Et2O 98:2 to 80:20) to give 106 mg (86%) of the racemic arylated 
product as an oil. 
Following the general procedure B, ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate (121 
mg) was arylated with p-bromotoluene (51.8 µL). The crude residue was purified by column 
chromatography (pentane/Et2O 98:2 to 80:20) to give 116 mg (94%) of the enantioenriched 
arylated product as an oil. 
1H NMR (CDCl3, 400MHz, rotamers) : m, 2H), 7.16-7.14 (m, 2H), 5.81 (q, 
1H, J = 6.6 Hz), 3.75-3.68 (m, 2H), 2.34 (s, 3H), 1.61-1.35 (m, 15H).13C-{1H} NMR 
(CDCl3,100 MHz,rotamers) : 152.2/151.5, 139.5, 137.4, 129.3, 126.2, 96.0/94.5.0, 
76.5/76.2, 72.9, 60.8/59.8, 26.9/26.8, 25.7/25.6, 25.49/25.46, 24.3, 22.8/22.7, 21.3.HPLC 
separation conditions :Chiralpak AD-H column, n-heptane/i-PrOH 99:1, flow rate 1 
mL/min, 25°C, tR 6.0 min for (R)-enantiomer (major) and tR 7.1 min for (S)-enantiomer 
(minor). e.r. = 99.4:0.6.[]D20= +14.2° (c=1.5, CHCl3).HRMS (ESI) m/z: calcd. for 
C17H25NO3Na ([M + Na]+): 314.1727; found: 314.1723.IR (neat) v : 2981, 1697, 1394, 1376, 
1065. 
(R)-(-)-1-(4-(Trifluoromethyl)phenyl)ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.5d 
: 
 
Following the general procedure A, ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate (121 
mg) was arylated with 4-bromobenzotrifluoride (59.2 µL). The crude residue was purified by 
column chromatography (pentane/Et2O 98:2 to 80:20) to give 70 mg (48%) of the racemic 
arylated product as an oil. 
Following the general procedure B, ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate (121 
mg) was arylated with 4-bromobenzotrifluoride (59.2 µL). The crude residue was purified by 
column chromatography (pentane/Et2O 98:2 to 80:20) to give 102 mg (70%) of the 
enantioenriched arylated product as an oil. 
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1H NMR (CDCl3, 400 MHz, rotamers) : m, 2H), 7.47-7.43 (m, 2H), 5.86 (q, 
1H, J = 6.6), 3.77-3.70 (m, 2H), 1.61-1.35 (m, 15H). 13C-{1H} NMR (CDCl3, 100 MHz, 
rotamers) :152.0/151.2, 146.6/146.5, 130.1/129.8, 126.34/126.32, 125.7 (q, J = 3.6 Hz), 
122.9, 96.2/95.0, 76.5/76.2, 72.3, 61.0/60.0, 27.0/26.9, 25.7/25.6, 25.44/25.39, 24.26, 
22.72/22.66. F-{1H} NMR (CDCl3, 376 MHz, rotamers) : -62.54/-62.55.HPLC 
separation conditions : Chiralpak IA column, n-heptane/i-PrOH 99:1, flow rate 1 mL/min, 
25°C, tR 6.0 min for (R)-enantiomer (major) and tR 7.1 min for (S)-enantiomer (minor). e.r. = 
99.3:0.7. []D20 = -1.5° (c=1.0, CHCl3). HRMS (ESI) m/z: calcd. for C17H22F3NO3Na ([M + 
Na]+): 368.1449; found: 368.1444. IR (neat) v : 2982, 1697, 1325, 1067. 
(R)-1-(4-Acetylphenyl)ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.5e : 
 
Following the general procedure A, ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate (121 
mg) was arylated with 4-bromoacetophenone (83.7 mg in 1 mL of toluene). The crude residue 
was purified by column chromatography (pentane/Et2O 98:2 to 80:20) to give 73 mg (54%) of 
the racemic arylated product as an oil. 
Following the general procedure B, ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate (121 
mg) was arylated with 4-bromoacetophenone (83.7 mg in 1 mL of toluene). The crude residue 
was purified by column chromatography (pentane/Et2O 98:2 to 80:20) to give 64 mg (48%) of 
theenantioenriched arylated product as an oil. 
1H NMR (CDCl3, 400MHz, rotamers) : m, 2H), 7.44-7.40 (m, 2H), 5.84 (q, 
1H, J = 6.6 Hz), 3.75-3.68 (m, 2H), 2.58 (s, 3H), 1.60-1.34 (m, 15H).13C-{1H} NMR (CDCl3, 
100 MHz, rotamers) : 197.8, 151.4/151.2, 147.9/147.7, 136.6, 128.84, 126.2, 96.1/95.0, 
76.5/76.2, 72.4, 60.9/59.9, 26.9/26.8, 26.8, 25.7/25.6, 25.42/25.36, 24.3, 22.62/22.56.HPLC 
separation conditions: Chiralpak AD-H column, n-heptane/i-PrOH 99:1, flow rate 1 
mL/min, 25°C, tR 17.1 min for (R)-enantiomer (major) and tR 37.7 min for (S)-enantiomer 
(minor). e.r. = 99.6:0.4.[]D20= ±0° (c=1.5, CHCl3).HRMS (ESI) m/z: calcd. for 
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C18H25NO4Na ([M + Na]+): 342.1676; found: 342.1680.IR (neat) v : 2980, 1683, 1375, 1263, 
1064. 
 
(R)-(-)-1-(4-Cyanophenyl)ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.5f: 
 
Following the general procedure A, ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate (121 
mg) was arylated with 4-bromobenzonitrile (76.6 mg in 1 mL of toluene). The crude residue 
was purified by column chromatography (pentane/Et2O 95:5 to 80:20) to give 74 mg (58%) of 
the racemic arylated product as a white solid. 
Following the general procedure B, ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate (121 
mg) was arylated with 4-bromobenzonitrile (76.6 mg in 1 mL of toluene). The crude residue 
was purified by column chromatography (pentane/Et2O 95:5 to 80:20) to give 106 mg (83%) 
of the enantioenriched arylated product as a white solid. 
1H NMR (CDCl3, 400 MHz, rotamers) : m, 2H), 7.47-7.44 (m, 2H), 5.85 (q, 
1H, J = 6.7), 3.78-3.71 (m, 2H), 1.62-1.36 (m, 15H). 13C-{1H} NMR (CDCl3, 100 MHz, 
rotamers) :151.7/150.9, 147.9/147.8, 132.5, 126.6, 118.7, 111.5, 96.0/94.9, 76.3/76.0, 
72.0, 60.9/59.9, 26.8, 25.7/25.4, 25.3/25.2, 24.1, 22.44/22.38. HPLC separation conditions : 
Chiralpak AD-H column, n-heptane/i-PrOH 99:1, flow rate 1 mL/min, 25°C, tR 21.3 min for 
(R)-enantiomer (major) and tR 28.7 min for (S)-enantiomer (minor). e.r. = 99.3:0.7. []D20 = -
5.3° (c=1.25, CHCl3). HRMS (ESI) m/z: calcd. for C17H22N2O3Na ([M + Na]+): 325.1523; 
found: 325.1526. IR (neat) v : 2980, 2229, 1696, 1377, 1066.M.p.=91-93°C. 
(R)-(-)-1-(4-Nitrophenyl)ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.5g : 
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Following the general procedure A, ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate (121 
mg) was arylated with 1-bromo-4-nitrobenzene (85 mg in 1 mL of toluene). The crude residue 
was purified by column chromatography (pentane/Et2O 95:5 to 80:20) to give 45 mg (33%) of 
the racemic arylated product as a yellow solid. 
Following the general procedure B, ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate (121 
mg) was arylated with 1-bromo-4-nitrobenzene (85 mg in 1 mL of toluene). The crude residue 
was purified by column chromatography (pentane/Et2O 95:5 to 80:20) to give 64 mg (47%) of 
the enantioenriched arylated product as a yellow solid. 
1H NMR (CDCl3, 400 MHz, rotamers) :  8.22-8.18 (m, 2H), 7.50-7.47 (m, 2H), 5.87 (q, 
1H, J = 6.7 Hz), 3.76-3.69 (m, 2H), 1.60-1.33 (m, 15H). 13C-{1H} NMR (CDCl3, 100 MHz, 
rotamers) : 151.7/151.0, 150.0/149.9, 147.7, 126.76/126.73; 124.1, 96.2/95.0, 76.4/76.1, 
71.9, 61.0/50.0, 26.9, 25.8/25.5, 25.36/25.29, 24.2, 22.6/22.5.HPLC separation conditions : 
Chiralpak AD-H column, n-heptane/i-PrOH 99:1, flow rate 1 mL/min, 25°C, tR 16.1 min for 
(R)-enantiomer (major) and tR 32.7 min for (S)-enantiomer (minor). e.r. = 99.3:0.7. []D20 = -
6.2° (c=0.8, CHCl3). HRMS (ESI) m/z: calcd. for C16H22N2O5Na ([M + Na]+): 345.1421; 
found: 345.1421. IR (neat) v : 2981, 1693, 1341, 1092.M.p.=136-138°C. 
(R)-(+)-1-(4-(Methoxycarbonyl)phenyl)ethyl 2,2,4,4-tetramethyloxazolidine-3-
carboxylate2.5h: 
 
Following the general procedure A, ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate (121 
mg) was arylated with methyl-4-bromobenzoate (90.5 mg in 1 mL of toluene). The crude 
residue was purified by column chromatography (pentane/Et2O 95:5 to 80:20) to give 97 mg 
(69%) of the racemic arylated product as an oil. 
Following the general procedure B, ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate (121 
mg) was arylated with methyl-4-bromobenzoate (90.5 mg in 1 mL of toluene). The crude 
residue was purified by column chromatography (pentane/Et2O 95:5 to 80:20) to give 115 mg 
(81%) of the enantioenriched arylated product as an oil. 
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1H NMR (CDCl3, 400 MHz, rotamers) :  8.02-8.00 (m, 2H), 7.41-7.38 (m, 2H), 5.85 (q, 
1H, J = 6.6 Hz), 3.90-3.88 (m, 3H), 3.75-3.68 (m, 2H), 1.60-1.33 (m, 15H). 13C-{1H} NMR 
(CDCl3, 100 MHz, rotamers) : 166.9, 151.9/151.2, 147.6/147.5, 130.0, 129.6, 126.0, 
96.1/95.0, 76.5/76.1, 72.4, 60.9/59.89, 52.2, 26.9/26.8, 25.7/25.6, 25.41/25.37, 24.25, 
22.6/22.5. HPLC separation conditions : Chiralcel OJ column, n-heptane/i-PrOH 99:1, flow 
rate 1 mL/min, 25°C, tR 24.7 min for (R)-enantiomer (major) and tR 33.8 min for (S)-
enantiomer (minor). e.r. = 99.:0.5. []D20 = +0.7° (c=0.9, CHCl3). HRMS (ESI) m/z: calcd. 
for C18H25NO5Na ([M + Na]+): 358.1625; found: 358.1629. IR (neat) v : 2980, 1723, 1695, 
1376, 1275, 1065. 
(R)-(+)-1-(m-Tolyl)ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.5i : 
N
O
O O
 
Following the general procedure A, ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate (121 
mg) was arylated with m-bromotoluene (51 µL). The crude residue was purified by column 
chromatography (pentane/Et2O 98:2 to 80:20) to give 109 mg (89%) of the racemic arylated 
product as an oil. 
Following the general procedure B, ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate (121 
mg) was arylated with m-bromotoluene (51 µL). The crude residue was purified by column 
chromatography (pentane/Et2O 98:2 to 80:20) to give 110 mg (90%) of the enantioenriched 
arylated product as an oil. 
1H NMR (CDCl3, 400 MHz, rotamers) : 7.26-7.22 (m, 1H), 7.17-1.14 (m, 2H), 7.10-
7.08 (m, 1H), 5.81 (q, 1H, J = 6.6 Hz), 3.76-3.69 (m, 2H), 2.35 (s, 3H), 1.62-1.37 (m, 15H). 
13C-{1H} NMR (CDCl3, 100 MHz, rotamers) :152.2/151.5, 142.5/142.3, 138.1, 
128.53/128.47, 127.0, 123.1, 96.0/95.0, 76.5/76.2, 73.0, 60.8/59.8, 26.9/26.8, 25.7/25.6, 
25.5/25.4, 24.3, 22.9/22.8, 21.6. HPLC separation conditions : Chiralpak IC column, n-
heptane/i-PrOH 99:1, flow rate 1 mL/min, 25°C, tR 6.3 min for (R)-enantiomer (major) and tR 
7.1 min for (S)-enantiomer (minor). e.r. = 99.6:0.4. []D20 = +9,0° (c=1.75, CHCl3). HRMS 
(ESI) m/z: calcd. for C17H25NO3Na ([M + Na]+): 314.1727; found: 314.1728. IR (neat) v : 
2979, 1692, 1374, 1063. 
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(R)-(-)-1-(o-Tolyl)ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.5j : 
 
Following the general procedure A, ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate (121 
mg) was arylated with o-bromotoluene (50.7 µL). The crude residue was purified by column 
chromatography (pentane/Et2O 98:2 to 80:20) to give 102 mg (83%) of the racemic arylated 
product as an oil. 
Following the general procedure B, ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate (121 
mg) was arylated with o-bromotoluene (50.7 µL). The crude residue was purified by column 
chromatography (pentane/Et2O 98:2 to 80:20) to give 117 mg (95%) of the enantioenriched 
arylated product as an oil. 
1H NMR (CDCl3, 400 MHz, rotamers) : 7.42-7.36 (m, 1H), 7.25-7.12 (m, 3H), 6.07 (q, 
1H, J = 6.5 Hz), 3.76-3.69 (m, 2H), 2.39 (s, 3H), 1.64-1.36 (m, 15H). 13C-{1H} NMR 
(CDCl3, 100 MHz, rotamers) :152.2/151.5, 140.9/140.8, 134.5, 130.57, 127.5/126.3, 
125.2/125.1, 96.1/94.9, 76.5/76.2, 69.6, 60.8/59.8, 27.0/26.8, 25.7/25.6, 25.5/25.4, 
24.33/24.29, 22.0, 19.2. HPLC separation conditions : Chiralpak IC column, n-heptane/i-
PrOH 99:1, flow rate 1 mL/min, 25°C, tR 5.0 min for (R)-enantiomer (major) and tR 5.4 min 
for (S)-enantiomer (minor). e.r. = 99.7:0.3. []D20= -0.3° (c=1.1, CHCl3). HRMS (ESI) m/z: 
calcd. for C17H25NO3Na ([M + Na]+): 314.1727; found: 314.1728. IR (neat) v : 2979, 1694, 
1376, 1064. 
(R)-1-(2-Fluorophenyl)ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.5k : 
 
Following the general procedure A, ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate (121 
mg) was arylated with 1-bromo-2-fluorobenzene (46 µL). The crude residue was purified by 
column chromatography (pentane/Et2O 98:2 to 90:10) to give 98 mg (79%) of the racemic 
arylated product as an oil. 
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Following the general procedure B, ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate (121 
mg) was arylated with 1-bromo-2-fluorobenzene (46 µL). The crude residue was purified by 
column chromatography (pentane/Et2O 98:2 to 90:10) to give 103 mg (83%) of the 
enantioenriched arylated product as an oil. 
1H NMR (CDCl3, 400MHz, rotamers) : m, 1H), 7.27-7.24 (m, 1H), 7.15-
7.11 (m, 1H), 7.04-7.02 (m, 1H), 6.08 (q, 2H, J = 6.6 Hz), 3.77-3.70 (m, 2H), 1.62-1.37 (m, 
15H).13C-{1H} NMR (CDCl3, 100 MHz, rotamers) :159.9 (d, J = 247.4 Hz), 
151.9/151.2, 129.7/129.6, 129.4-129.2 (m), 127.5 (d, J = 4.3 Hz), 124.3 (d, J = 3.5 Hz), 115.8 
(d, J= 21.8 Hz), 96.1/95.0, 76.5/76.2, 67.8/67.7, 60.9/59.9, 26.9/26.7, 25.6/25.51, 25.46/25.4, 
24.29/24.26, 21.7/21.6.F-{1H} NMR (CDCl3, 376 MHz, rotamers) : -118.0/-118.04.HPLC 
separation conditions : Chiralpak IC column, n-heptane/i-PrOH 99:1, flow rate 0.5 mL/min, 
25°C, tR 14.7 min for (R)-enantiomer (major) and tR 15.4 min for (S)-enantiomer (minor). e.r. 
= 99.7:0.3.[]D20= ±0° (c=1.75, CHCl3).HRMS (ESI) m/z: calcd. for C16H22F1NO3Na ([M + 
Na]+): 318.1476; found: 318.1480.IR (neat) v : 2980, 1695, 1376, 1062, 756. 
(R)-(+)-1-(Benzo[1,3]dioxol-5-yl)ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.5l : 
 
Following the general procedure A, ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate (121 
mg) was arylated with 1-bromo-3,4-(methylenedioxy)benzene (50.6 µL). The crude residue 
was purified by column chromatography (pentane/Et2O 98:2 to 80:20) to give 103 mg (76%) 
of the racemic arylated product as an oil. 
Following the general procedure B, ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate (121 
mg) was arylated with 1-bromo-3,4-(methylenedioxy)benzene (50.6 µL). The crude residue 
was purified by column chromatography (pentane/Et2O 98:2 to 80:20) to give 105 mg (78%) 
of the enantioenriched arylated product as an oil. 
1H NMR (CDCl3, 400 MHz, rotamers) : 6.84-6.80 (m, 2H) , 6.76-6.74 (m, 2H), 5.93-
5.92 (m, 2H), 5.73 (q, 1H, J = 6.5 Hz), 3.73-3.67 (m, 2H),1.58-1.34 (m, 15H). 13C-{1H} NMR 
(CDCl3, 100 MHz, rotamers) :152.1/151.4, 147.8/147.1, 136.4/136.3, 119.8, 108.3, 
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106.7, 101.1, 96.0/94.9, 76.5/76.1, 72.7, 60.8/59.8, 26.9, 25.7/25.6, 25.4, 24.3, 22.8/22.7. 
HPLC separation conditions : Chiralpak AD-H column, n-heptane/i-PrOH 99:1, flow rate 1 
mL/min, 25°C, tR 9.9 min for (R)-enantiomer (major) and tR 11.6 min for (S)-enantiomer 
(minor). e.r. = 99.3:0.7. []D20 = +28.9° (c=1.5, CHCl3). HRMS (ESI) m/z: calcd. for 
C17H23NO5Na ([M + Na]+): 344.1468; found: 344.1472. IR (neat) v : 2979, 1693, 1367, 1246, 
1064. 
(R)-(+)-1-(3,4,5-Trimethoxyphenyl)ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.5m 
: 
 
Following the general procedure A, ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate (121 
mg) was arylated with 5-bromo-1,2,3-trimethoxybenzene (104 mg in 1 mL of toluene). The 
crude residue was purified by column chromatography (pentane/Et2O 98:2 to 60:40) to give 
98 mg (63%) of the racemic arylated product as an oil. 
Following the general procedure B, ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate (121 
mg) was arylated with 5-bromo-1,2,3-trimethoxybenzene (104 mg in 1 mL of toluene). The 
crude residue was purified by column chromatography (pentane/Et2O 98:2 to 60:40) to give 
82 mg (53%) of the enantioenriched arylated product as an oil. 
1H NMR (CDCl3, 400 MHz, rotamers) : 6.54-6.52 (m, 2H), 5.74 (q, 1H, J = 6.5), 3.82-
3.80 (m, 9H), 3.71-3.69 (m, 2H), 1.59-1.35 (m, 15 H). 13C-{1H} NMR (CDCl3, 100 MHz, 
rotamers) :153.3, 152.0/151.3, 138.3/138.2, 137.3, 102.8, 96.0/94.8, 76.4/76.1, 72.8, 
60.9, 60.8/59.8, 26.80/26.77, 25.6/25.5, 25.3, 24.3/24.2, 22.9/22.8. HPLC separation 
conditions : Chiralpak AD-H column, n-heptane/i-PrOH 99:1, flow rate 1 mL/min, 25°C, tR 
33.3 min for (R)-enantiomer (major) and tR 42.0 min for (S)-enantiomer (minor). e.r. = 
99.4:0.6. []D20 = +8.3° (c=1.4, CHCl3). HRMS (ESI) m/z: calcd. for C19H29NO6Na ([M + 
Na]+): 390.1887; found: 390.1889. IR (neat) v : 2978, 1691, 1375, 1236, 1127, 1092. 
(R)-(-)-1-(Naphthalen-1-yl)ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.5n : 
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Following the general procedure A, ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate (121 
mg) was arylated with 1-bromonaphtalene (58.9 µL). The crude residue was purified by 
column chromatography (pentane/Et2O 98:2 to 80:20) to give 98 mg (71%) of the racemic 
arylated product as an oil. 
Following the general procedure B, ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate (121 
mg) was arylated with 1-bromonaphtalene (58.9 µL). The crude residue was purified by 
column chromatography (pentane/Et2O 98:2 to 80:20) to give 91 mg (66%) of the 
enantioenriched arylated product as an oil. 
1H NMR (CDCl3, 400MHz, rotamers) : m, 1H), 7.89-7.80 (m, 2H), 7.63-
7.47 (m, 4H), 6.68 (q, 1H, J = 6.6), 3.78-3.73 (m, 2H), 1.75-1.35 (m, 15H).13C-{1H} NMR 
(CDCl3, 100 MHz, rotamers) : 152.3/151.6, 138.4, 134.0, 130.4, 129.0, 128.3, 126.4, 
125.8, 125.5, 123.4, 123.0, 96.2/95.0, 76.6/76.2, 69.7, 60.9/59.9, 27.0/26.7, 25.7/25.6, 
25.54/25.45, 24.37/24.31, 22.2.HPLC separation conditions : Chiralpak AD-H column, n-
heptane/i-PrOH 99:1, flow rate 1 mL/min, 25°C, tR 6.5 min for (R)-enantiomer (major) and tR 
7.8 min for (S)-enantiomer (minor). e.r. = 96.3:3.7.[]D20 = -38.0° (c=0.9, CHCl3).HRMS 
(ESI) m/z: calcd. for C20H25NO3Na ([M + Na]+): 350.1757; found: 350.1728.IR (neat) v : 
2979, 1689, 1372, 1059, 776. 
(S)-(-)-1-(Pyridin-3-yl)ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.5o : 
 
Following the general procedure A, ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate (121 
mg) was arylated with 3-bromopyridine (40.5 µL). The crude residue was purified by column 
chromatography (pentane/Et2O 90:10 to 50:50) to give 57 mg (49%) of the racemic arylated 
product as an oil. 
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Following the general procedure B, ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate (121 
mg) was arylated with 3-bromopyridine (40.5 µL) in presence of (+)-sparteine (178 µL, 0.78 
mmol, 1.3 eq). The crude residue was purified by column chromatography (pentane/Et2O 
20:80 to 0:100) to give 75 mg (64%) of the enantioenriched arylated product as an oil. 
1H NMR (CDCl3, 400 MHz, rotamers) : 8.66-8.64 (m, 1H), 8.56-8.55 (m, 1H), 7.69-
7.67(m, 1H), 7.31-7.28 (m, 1H), 5.88 (q, 1H, J = 6.6 Hz), 3.77-3.73 (m, 2H), 1.62-1.36 (m, 
15H). 13C-{1H} NMR (CDCl3, 100 MHz, rotamers) :151.8/151.1, 149.2, 148.0, 
137.8/137.7, 133.8/133.7, 123.5, 96.1/94.9, 76.4/76.1, 70.7, 60.9/59.9, 26.83/26.76, 25.7/25.5, 
25.3, 24.19/24.15, 22.4/.22.3.HPLC separation conditions : Chiralpak AD-H column, n-
heptane/i-PrOH 97:3, flow rate 1 mL/min, 25°C, tR13.0 min for (R)-enantiomer (minor) and tR 
15.7 min for (S)-enantiomer (major). e.r. = 0.7:99.3.[]D20 = -6.2° (c=0.92, CHCl3).HRMS 
(ESI) m/z: calcd. for C15H22N2O3Na ([M + Na]+): 301.1523; found: 301.1519. IR (neat) v : 
2979, 1693, 1392, 1063. 
1-(Pyridin-2-yl)ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.5p : 
 
Following the general procedure A, ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate (121 
mg) was arylated with 2-bromopyridine (40.3 µL) at 110°C. The crude residue was purified 
by column chromatography (pentane/Et2O 90:10 to 50:50) to give 56 mg (48%) of the 
racemic arylated product as an oil. 
1H NMR (CDCl3, 400MHz, rotamers) : 8.56 (m, 1H), 7.68-7.64 (m, 1H), 7.32-7.28 (m, 
1H), 7.18-7.15 (m, 1H), 5.88 (q, 1H, J = 6.6 Hz), 3.76-3.69 (m, 2H), 1.62-1.36 (m, 15H).13C-
{1H} NMR (CDCl3, 100 MHz, rotamers) :161.4/161.2, 152.1, 149.3, 136.8, 122.6, 
120.2, 96.1/95.1, 76.6/76.2, 73.7, 60.9/60.0, 26.9/26.8, 25.7/25.6, 25.5/25.3, 24.31/24.27, 
20.94/20.88. HRMS (ESI) m/z: calcd. for C15H22N2O3Na ([M + Na]+): 301.1523; found: 
301.1521.IR (neat) v : 2980, 1695, 1376, 1091, 1067.  
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Preparation of 2,2,4,4-tetramethyloxazolidine-3-carboxylates 2.7a-i 
The carbamates2.7a-b,d-f, were synthesized following the procedures of Sardina et al. and 
Hoppe et al..150 
 
General procedure : 
A solution of the corresponding alcohol (1.0 eq) in THF (10 mL) was addeddropwise to a 
suspension of sodium hydride (60% in mineral oil, 1.1 eq) in THF (30 mL) and the mixture 
was stirred for 30 min at room temperature. A solution of 2,2,4,4-tetramethyloxazolidine-3-
carbonyl chloride (1.05 eq.) in THF (10 mL) was then added dropwise and the mixture was 
stirred for 12 h. After quenching with water, the solvent was removed under reduced pressure 
and Et2O (50 mL) was added to the crude mixture. The organic phase was washed with sat. 
aq. NaHCO3 (30 mL), water (30 mL) and brine (30 mL) and dried over MgSO4. The solvent 
was removed under reduced pressure to obtain the corresponding carbamate. 
Cyclohexylmethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate2.7c : 
 
Following the general procedure, cyclohexanemethanol (0.71 mL, 5 mmol) gave 1.35 g 
(quant.) of the title carbamate as a colorless oil. 
1H NMR (CDCl3, 400 MHz, rotamers) :3.91-3.88 m, 2H), 3.73 (s, 2H), 1.76-1.67 (m, 
5H),1.56 (1.53) (2 br. s., 6H), (1.42) 1.37 (2 br. s., 6H), 1.31-1.15 (m, 4H), 1.06-0.96 (m, 
2H).13C-{1H} NMR (CDCl3, 100 MHz, rotamers) :153.1/152.4, 95.9/94.8, 76.4/76.2, 
70.09/70.05, 60.6/50.7, 37.5, 30.1, 26.7/26.5, 25.8, 25.45/25.41, 24.2.HRMS (ESI) m/z : 
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calcd. for C15H27NO3Na ([M + Na]+): 292.1883; found: 292.1886.IR neat (𝛖/cm-1) :2926, 
1694, 1340, 1065. 
Propane-1,3-diyl bis(2,2,4,4-tetramethyloxazolidine-3-carboxylate) 2.7h : 
 
Following the general procedure, 1,3-propanediol (0.73 mL, 10 mmol) was reacted with NaH 
(60% in mineral oil, 880 mg, 22 mmol, 2.2 eq) and 2,2,4,4-tetramethyl-1,3-oxazolidine-3-
carbonyl chloride (4.03 g, 21 mmol, 2.1 eq) to give 3.85 g (99%) of the title dicarbamate as a 
white solid (recryst. from <0°C cold pentane). 
1H NMR (CDCl3, 400 MHz, rotamers) :4.19-4.15 (m, 4H), 3.69 (s, 4H), 2.03-1.98 (m, 
4H), 1.52 (1.48) (2 br. s., 12H), (1.38) 1.33 (2 br. s., 12H).13C-{1H} NMR (CDCl3, 100 MHz, 
rotamers) :152.6/151.9, 95.9/94.7, 76.4/76.1, 61.4, 60.7/59.8, 28.7, 26.6, 25.4, 25.3, 
24.2.HRMS (ESI) m/z : calcd. for C19H34N2O6Na ([M + Na]+): 409.2309; found: 
409.2310.IR neat (𝛖/cm-1) :2936, 1683, 1363, 1066. 
3-((tert-Butyldimethylsilyl)oxy)propyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.7g: 
 
Following the general procedure, 3-(tert-butyldimethylsilyloxy)propan-1-ol151(761 mg, 4 
mmol) gave 1.1 g (80%) of the corresponding carbamate as a colorless oil. 
1H NMR (CDCl3, 400 MHz, rotamers) :4.17-4.11 (m, 2H), 3.71-3.65 (m, 4H), 1.85-1.81 
(m, 2H), 1.52 (1.48) (2 br. s., 6H), (1.38) 1.32 (2 br. s., 6H), 0.85 (s, 9H), 0.01 (s, 6H).13C-
{1H} NMR (CDCl3, 100 MHz, rotamers) :152.9/152.2, 95.9/94.9, 76.5/76.2, 61.6, 
60.7/59.7, 60.0, 32.3, 26.7, 26.0, 25.4, 24.3, 18.4, -5.3.HRMS (ESI) m/z : calcd. for 
C17H35NO4SiNa ([M + Na]+): 368.2228; found: 368.2226.IR neat (𝛖/cm-1) :2930, 1698, 
1068, 834. 
3-(Dibenzylamino)propyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.7i: 
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Following the general procedure, 3-(N,N-dibenzylamino)propanol152 (2.0 g, 7.83 mmol) gave 
1.85 g (58%)  of the title carbamate as a white solid. 
1H NMR (CDCl3, 400 MHz, rotamers) :7.38-7.22 (m, 10 H), 4.14-4-09 (m, 2H), 3.68-
3.65 (m, 2H), 3.57 (s, 4H), 2.57-2.51 (m, 2H), 1.90-1.84 (m, 2H), 1.54 (1.40) (2 br s, 6H), 
(1.30) 1.14 (2 br s, 6H).13C-{1H} NMR (CDCl3, 100 MHz, rotamers) :152.9/152.2, 
139.8, 128.8, 128.4, 127.0, 95.9/94.9, 76.4/76.2, 63.0, 60.6/59.7, 58.7, 50.6, 26.9, 26.5/25.4, 
25.3/24.3.HRMS (ESI) m/z : calcd. for C25H34N2O3H1 ([M + H]+): 411.2642; found: 
411.2645.IR neat (𝛖/cm-1) : 2973, 2800, 1683, 1337, 1095, 1067.Melting point : 65 °C. 
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Arylation of the carbamates 2.7a-i 
General procedure C : arylation with TMEDA 
In a tubular reactor (100 mm x 16 mm) set up with a rubber septum, a solution of the 
protected alcohol2.7a-i (0.6 mmol, 1 eq) and TMEDA (127 µL, 0.84 mmol, 1.4 eq) in dry 
diethyl ether (2 mL) under argon was stirred and cooled down to -78°C (acetone bath, 
cryostat). s-Butyllithium (0.84 mmol, 1.4 eq, solution in hexane) was added dropwise, and the 
mixture was stirred for 4 h. A suspension of zinc acetate (165 mg, 0.9 mmol, 1.5 eq) in dry 
THF (2 mL) was sonicated for 30 min and added dropwise to the mixture. The resulting 
solution was stirred for 30 min at -78°C, and then allowed to heat to 20°C over 30 min. The 
solvents where evaporated over 30 min under high vacuum, and a solution of Pd2(dba)3 (9.62 
mg, 10.5 µmol, 1.75 %mol) and Ruphos (9.85 mg, 21 µmol, 3.5 %mol) in dry toluene (2 mL) 
was added to solve the residue, followed by the bromoaryl (0.42 mmol, 0.7 eq). The mixture 
was then vigorously stirred and heated to 80°C for 18h. After cooling down, the reaction was 
quenched with sat. aq. NH4Cl (2 mL), and the organic phase was diluted with EtOAc (5mL) 
and separated. The aqueous phase was extracted with EtOAc (2 x 5 mL). The combined 
organic layers were dried over MgSO4, filtrated over a pad of celite, and evaporated under 
vacuum. The residue was purified by column chromatography (Et2O/pentane) to afford the 
benzylic alcohols. 
General procedure D : enantioselective arylation with (-)-sparteine 
In a tubular reactor (100 mm x 16 mm) set up with a rubber septum, a solution of the 
protected alcohol 2.7a-i (0.6 mmol, 1 eq) and (-)-sparteine (193 µL, 084 mmol, 1.4 eq) in dry 
diethyl ether (2 mL) under argon was stirred and cooled down to -78°C (acetone bath, 
cryostat). s-Butyllithium (0.84 mmol, 1.4 eq, solution in hexane) was added dropwise, and the 
mixture was stirred for 5 h. A suspension of zinc acetate (165 mg, 0.9 mmol, 1.5 eq) in dry 
THF (2 mL) was sonicated for 30 min and added dropwise to the mixture. The resulting 
solution was stirred for 30 min at -78°C, and then allowed to heat to 20°C over 30 min. The 
solvents where evaporated over 30 min under high vacuum, and a solution of Pd2(dba)3 (9.62 
mg, 10.5 µmol, 1.75 %mol) and Ruphos (9.85 mg, 21 µmol, 3.5 %mol) in dry toluene (2 mL) 
was added tosolve the residue, followed by the bromoaryl (0.42 mmol, 0.7 eq). The mixture 
was then vigorously stirred and heated to 80°C for 18h. After cooling down, the reaction was 
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quenched with sat. aq. NH4Cl (2 mL), and the organic phase was diluted with EtOAc (5mL) 
and separated. The aqueous phase was extracted with EtOAc (2 x 5 mL). The combined 
organic layers were dried over MgSO4, filtrated over a pad of celite, and evaporated under 
vacuum. The residue was purified by column chromatography (Et2O/pentane) to afford the 
protected benzylic alcohols. 
(R)-(+)-1-(p-Tolyl)propyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.5q: 
 
Following the general procedure C, propyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate (129 
mg) was arylated with p-bromotoluene (51.8 µL). The crude residue was purified by column 
chromatography (pentane/Et2O 98:2 to 80:20) to give 108 mg (84%) of the racemic arylated 
product as an oil. 
Following the general procedure D, propyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate (129 
mg) was arylated with p-bromotoluene (51.8 µL). The crude residue was purified by column 
chromatography (pentane/Et2O 98:2 to 80:20) to give 80 mg (62%) of the enantioenriched 
arylated product as an oil. 
1H NMR (CDCl3, 400 MHz, rotamers) :7.23-7.14 (m, 4H), 5.60 (t, 1H, J = 6.8 Hz), 
3.75-3.68 (m, 2H), 2.33 (s, 3H), 2.00-1.78 (m, 2H), 1.63-1.34 (m, 12H), 0.89 (q, 3H, J = 7.2 
Hz).13C-{1H} NMR (CDCl3, 100 MHz, rotamers) : 152.4/151.7, 138.2/138.1, 
137.4/137.2, 129.2, 126.7, 96.1/94.9, 78.0, 76.5/76.2, 60.8/59.8, 29.8/29.7, 27.0/26.9, 25.7, 
25.52/25.45, 21.3, 10.3/10.2.HPLC separation conditions: Chiralpak AD-H column, n-
heptane/i-PrOH 99:1, flow rate 1 mL/min, 25°C, tR 5.5 min for (R)-enantiomer (major) and tR 
7.1 min for (S)-enantiomer (minor). e.r. = 98.8:1.2.[]D20 = +18.2° (c=1.5, CHCl3).HRMS 
(ESI) m/z: calcd. for C18H27NO3Na ([M + Na]+): 328.1883; found: 328.1881.IR (neat) v : 
2975, 1697, 1377, 1094. 
 (R)-(+)-2-Methyl-1-(p-tolyl)propyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.5r: 
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Following the general procedure C, isobutyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 
(138 mg) was arylated with p-bromotoluene (51.8 µL). The crude residue was purified by 
column chromatography (pentane/Et2O 98:2 to 80:20) to give 112 mg (83%) of the racemic 
arylated product as an oil. 
Following the general procedure D, propyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate (138 
mg) was arylated with p-bromotoluene (51.8 µL). The crude residue was purified by column 
chromatography (pentane/Et2O 98:2 to 80:20) to give 74 mg (55%) of the enantioenriched 
arylated product as an oil. 
1H NMR (CDCl3, 400 MHz, rotamers) :7.18-7.12 (m, 4H), 5.46 (d, 1H, J = 7 Hz), 3.76-
3.69 (m, 2H), 2.33 (s, 3H), 2.17-2.10 (m, 1H), 1.66-1.32 (m, 12H), 1.01-0.98 (m, 3H), 0.84-
0.82 (m, 3H).13C-{1H} NMR (CDCl3, 100 MHz, rotamers) :152.9/151.7, 137.3, 137.2, 
128.9, 127.2, 96.2/94.9, 81.6, 76.6/76.3, 60.9/59.8, 34.0, 27.1, 25.9/25.8, 25.6/25.4, 
24.41/24.38, 21.3, 19.08/19.04,18.95. HPLC separation conditions : Chiralpak IC column, 
n-heptane/i-PrOH 99:1, flow rate 0.5 mL/min, 25°C, tR 10.1 min for (R)-enantiomer (major) 
and tR 12.4 min for (S)-enantiomer (minor). e.r. = 85.2:14.8.[]D20 = +4.8° (c=0.5, 
CHCl3).HRMS (ESI) m/z: calcd. for C19H29NO3Na ([M + Na]+): 342.2040; found: 
342.2039.IR (neat) v : 2967, 1694, 1375, 1091, 1060. 
(R)-(+)-Cyclohexyl(p-tolyl)methyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.5s: 
 
Following the general procedure C, cyclohexylmethyl 2,2,4,4-tetramethyloxazolidine-3-
carboxylate (162 mg) was arylated with p-bromotoluene (51.8 µL). The crude residue was 
purified by column chromatography (pentane/Et2O 98:2 to 80:20) to give 125 mg (83%) of 
the racemic arylated product as an oil. 
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Following the general procedure D cyclohexylmethyl 2,2,4,4-tetramethyloxazolidine-3-
carboxylate (162 mg) was arylated with p-bromotoluene (51.8 µL). The crude residue was 
purified by column chromatography (pentane/Et2O 98:2 to 80:20) to give 85 mg (56%) of the 
enantioenriched arylated product as an oil. 
1H NMR (CDCl3, 400 MHz, rotamers) :7.17-7.11 (m, 4H), 5.48 (d, 1H, J = 7.3 Hz), 
3.75-3.68 (m, 2H), 2.33 (s, 3H), 1.76-0.88 (m, 23H).13C-{1H} NMR (CDCl3, 100 MHz, 
rotamers) :152.5/151.8, 137.3, 137.2, 129.0, 127.2, 96.2/94.9, 81.1, 76.6/76.2, 60.9/59.8, 
43.6, 29.44/29.37, 27.2/27.1, 26.5, 26.2, 26.0/25.8, 25.7/25.5, 24.4, 21.3.HPLC separation 
conditions : Chiralpak IC column, n-heptane/i-PrOH 99:1, flow rate 0.5 mL/min, 25°C, tR 
10.2 min for (R)-enantiomer (major) and tR 11.8 min for (S)-enantiomer (minor). e.r. = 
90.8:9.2.[]D20= +5.4° (c=0.5, CHCl3).HRMS (ESI) m/z: calcd. for C22H33NO3Na ([M + 
Na]+): 382.2353; found: 382.2353.IR (neat) v : 2927, 1693, 1374, 1058. 
(R)-(-)-2-Phenyl-1-(p-tolyl)ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.5t: 
 
Following the general procedure C, phenethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 
(167 mg) was arylated with p-bromotoluene (51.8 µL). The crude residue was purified by 
column chromatography (pentane/Et2O 98:2 to 80:20) to give 125 mg (81%) of the racemic 
arylated product as an oil. 
Following the general procedure D, phenethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 
(167 mg) was arylated with p-bromotoluene (51.8 µL). The crude residue was purified by 
column chromatography (pentane/Et2O 98:2 to 80:20) to give 114mg (74%) of the 
enantioenriched arylated product as an oil. 
1H NMR (CDCl3, 400 MHz, rotamers) : 7.23-7.09 (m, 9H), 5.94 (t, 1H, J = 7.1 Hz), 
3.26-3.08 (m, 2H), 2.31 (s, 3H), 1.50-1.30 (m, 12H).13C-{1H} NMR (CDCl3, 100 MHz, 
rotamers) : 152.0/151.3, 137.7/137.6, 137.4, 137.21/137.15, 129.6, 129.1, 128.3, 
126.67/126.64, 126.5, 96.1/94.9, 77.2, 76.5/76.1, 60.8/59.8, 43.51/43.46, 27.0/26.6, 25.6/25.5, 
25.3, 24.3/24.2, 21.3. HPLC separation conditions : Chiralpak IC column, n-heptane/i-
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PrOH 99:1, flow rate 0.5 mL/min, 25°C, tR 11.7 min for (R)-enantiomer (major) and tR 13.7 
min for (S)-enantiomer (minor). e.r. = 99.2:0.8. []D20= -17.3° (c=1.0, CHCl3). HRMS (ESI) 
m/z: calcd. for C23H29NO3Na ([M + Na]+): 390.2040; found: 390.2045. IR (neat) v : 2979, 
1692, 1376, 1091, 1059. 
(R)-(+)-1-(p-Tolyl)but-3-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.5u: 
 
Following the general procedure C, but-3-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-
carboxylate (137 mg) was arylated with p-bromotoluene (51.8 µL). The crude residue was 
purified by column chromatography (pentane/Et2O 98:2 to 80:20) to give 90 mg (67%) of the 
racemic arylated product as an oil. 
Following the general procedure D, but-3-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-
carboxylate (137 mg) was arylated with p-bromotoluene (51.8 µL). The crude residue was 
purified by column chromatography (pentane/Et2O 98:2 to 80:20) to give 102 mg (76%) of 
the enantioenriched arylated product as an oil. 
1H NMR (CDCl3, 400 MHz, rotamers) :7.24-7.20 (m, 2H), 7.16-7.14 (m, 2H), 5.77-5.68 
(m, 1H), 5.10-5.03 (m, 1H), 3.75-3.68 (m, 2H), 2.71-2.55 (m, 2H), 2.33 (s, 3H), 1.61-1.34 (m, 
12H). 13C-{1H} NMR (CDCl3, 100 MHz, rotamers) :151.1/151.4, 137.9/137.7, 137.5, 
133.93/133.86, 129.2, 126.6, 117.9, 96.1/95.0, 76.5/76.2, 75.9, 60.8/59.9, 41.4/41.3, 26.9, 
25.71/25.67, 25.5/25.4, 24.33/24.27, 21.3. HPLC separation conditions : Chiralpak IC 
column, n-heptane/i-PrOH 99:1, flow rate 1 mL/min, 25°C, tR 10.8 min for (R)-enantiomer 
(major) and tR 13.0 min for (S)-enantiomer (minor). e.r. = 99.7:0.3. []D20 = +19.3° (c=1.25, 
CHCl3). HRMS (ESI) m/z: calcd. for C19H27NO3Na ([M + Na]+): 340.1883; found: 
340.1886. IR (neat) v : 2979, 1694, 1375, 1060. 
(R)-(+)-3-Phenyl-1-(p-tolyl)propyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.5w: 
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Following the general procedure C, 3-phenylpropyl 2,2,4,4-tetramethyloxazolidine-3-
carboxylate (175 mg) was arylated with p-bromotoluene (51.8 µL). The crude residue was 
purified by column chromatography (pentane/Et2O 98:2 to 80:20) to give 75 mg (47%) of the 
racemic arylated product as an oil. 
Following the general procedure D, 3-phenylpropyl 2,2,4,4-tetramethyloxazolidine-3-
carboxylate (175 mg, 0.375 mmol) was arylated with p-bromotoluene (51.8 µL). The crude 
residue was purified by column chromatography (pentane/Et2O 98:2 to 80:20) to give 127 mg 
(79%) of the enantioenriched arylated product as an oil. 
1H NMR (CDCl3, 400 MHz, rotamers) :7.28-7.23 (m, 4H), 7.19-7.13 (m, 5H), 5.73 (t, 
1H, J = 6.8 Hz), 3.76-3.68 (m, 2H), 2.71-2.50 (m, 2H), 2.34-2.28 (m, 4H), 2.13-2.07 (m, 1H), 
1.65-1.35 (m, 12H). 13C-{1H} NMR (CDCl3, 100 MHz, rotamers) :152.2/151.5, 141.6, 
138.0/137.9, 137.60/137.56, 129.3, 128.6, 128.4, 126.7, 126.1, 96.1/94.9, 76.9/76.2, 76.3, 
38.7/38.6, 32.2, 27.1/27.0, 25.8/25.7, 25.5/25.4, 24.3, 21.3. HPLC separation conditions : 
Chiralpak AD-H column, n-heptane/i-PrOH 99:1, flow rate 1 mL/min, 25°C, tR 10.6 min for 
(R)-enantiomer (major) and tR 11.9 min for (S)-enantiomer (minor). e.r. = 98.7:1.3. []D20 = 
+17.4° (c=1.05, CHCl3). HRMS (ESI) m/z: calcd. for C24H31NO3Na ([M + Na]+): 404.2196; 
found: 404.2198. IR (neat) v : 2979, 1692, 1375, 1058. 
(R)-(+)-3-((tert-Butyldimethylsilyl)oxy)-1-(p-tolyl)propyl 2,2,4,4-tetramethyloxazolidine-3-
carboxylate 2.5x: 
 
Following the general procedure C, 3-((tert-butyldimethylsilyl)oxy)propyl 2,2,4,4-
tetramethyloxazolidine-3-carboxylate (208 mg) was arylated with p-bromotoluene (51.8 µL). 
The crude residue was purified by column chromatography (pentane/Et2O 98:2 to 80:20) to 
give 156 mg (85%) of the racemic arylated product as an oil. 
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Following the general procedure D, 3-((tert-butyldimethylsilyl)oxy)propyl 2,2,4,4-
tetramethyloxazolidine-3-carboxylate (208 mg) was arylated with p-bromotoluene (51.8 µL). 
The crude residue was purified by column chromatography (pentane/Et2O 98:2 to 80:20) to 
give 125 mg (68%) of the enantioenriched arylated product as an oil. 
1H NMR (CDCl3, 400 MHz, rotamers) :7.24-7.21 (m, 2H), 7.15-7.13 (m, 2H), 5.82-5.78 
(m, 1H), 3.75-3.57 (m, 4H), 2.33 (s, 3H), 2.24-2.14 (m, 1H), 2.02-1.94 (m, 1H), 1.61-1.32 (m, 
12H), 0.89 (s, 9H), 0.05-0.00 (m, 6H).13C-{1H} NMR (CDCl3, 100 MHz, 
rotamers) :152.1/151.4, 138.4/138.3, 137.44/137.39, 129.3, 126.6, 96.1/94.9,76.5/76.2, 
73.7, 60.8/59.8, 40.0/39.9, 27.06/27.03, 26.1, 25.9/25.8, 25.6/25.4, 24.4/24.3, 21.3, 18.5, -
5.22/-5.23.HPLC separation conditions : Chiralpak AD-H column, n-heptane/i-PrOH 99:1, 
flow rate 1 mL/min, 25°C, tR 4.0 min for (R)-enantiomer (major) and tR 4.8 min for (S)-
enantiomer (minor). e.r. = 95:0.5.[]D20 = +5.5° (c=0.8, CHCl3).HRMS (ESI) m/z: calcd. for 
C24H41NO4SiNa ([M + Na]+):458.2697; found: 458.2703.IR (neat) v : 2929, 1697, 1375, 
1057, 833. 
(R)-(+)-1-(p-Tolyl)propane-1,3-diyl bis(2,2,4,4-tetramethyloxazolidine-3-carboxylate) 2.5y: 
 
Following the general procedure C, propane-1,3-diyl bis(2,2,4,4-tetramethyloxazolidine-3-
carboxylate) (232 mg) was arylated with p-bromotoluene (51.8 µL). The crude residue was 
purified by column chromatography (pentane/Et2O 98:2 to 80:20) to give 110 mg (55%) of 
the racemic arylated product as an oil. 
Following the general procedure D, propane-1,3-diyl bis(2,2,4,4-tetramethyloxazolidine-3-
carboxylate) (232 mg) was arylated with p-bromotoluene (51.8 µL). The crude residue was 
purified by column chromatography (pentane/Et2O 98:2 to 80:20) to give 176 mg (88%) of 
the enantioenriched arylated product as an oil. 
1H NMR (CDCl3, 400 MHz, rotamers) :7.22-7.20 (m, 2H), 7.14-7.12 (m, 2H), 5.79 (q, 
1H, J = 6.1 Hz) , 4.13-4.05 (m, 2H), 3.73-3.65 (m, 2H), 2.35-2.10 (m, 5H), 1.52-1.30 (m, 
24H). 13C-{1H} NMR (CDCl3, 100 MHz, rotamers) : 152.6/151.9, 151.8/151.1, 
137.8/137.7, 137.6, 129.4, 126.5, 96.1/95.0, 95.9/94.8, 76.4/76.1, 73.5, 61.1/59.79/59.76, 
164 
 
60.8/60.7, 36.2/.36.1, 27.0, 26.69/26.67, 25.8, 25.7, 25.48/25.45, 25.4/25.3, 24.23/24.19, 21.2. 
HPLC separation conditions : Chiralpak AD-H column, n-heptane/i-PrOH 99:1, flow rate 1 
mL/min, 25°C, tR 16.3 min for (R)-enantiomer (major) and tR 19.6 min for (S)-enantiomer 
(minor). e.r. = 97.9:2.1. []D20 = +3.8° (c=2.0, CHCl3). HRMS (ESI) m/z: calcd. for 
C26H40N2O6Na ([M + Na]+): 499.2779; found: 499.2777. IR (neat) v : 2978, 1698, 1345, 
1063. 
(R)-(+)-3-(Dibenzylamino)-1-(p-tolyl)propyl 2,2,4,4-tetramethyloxazolidine-3-
carboxylate2.5z : 
N
O
O ON
 
Arylation with TMEDA : 
In a tubular reactor (100 mm x 16 mm) set up with a rubber septum, a solution of 3-
(dibenzylamino)propyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate2.7i (247 mg, 0.6 mmol, 
1 eq) and TMEDA (181 µL, 1.2 mmol, 2 eq) in dry diethyl ether (2 mL) under argon was 
stirred and cooled down to -78°C (acetone bath, cryostat). s-Butyllithium (1.2 mmol, 2 eq, 
solution in hexane) was added dropwise, and the mixture was stirred for 4 h. A suspension of 
zinc acetate (232 mg, 1.26 mmol, 2.1 eq) in dry THF (2 mL) was sonicated for 30 min and 
added dropwise to the mixture. The resulting solution was stirred for 30 min at -78°C, and 
then allowed to heat to 20°C over 30 min. The solvents where evaporated over 30 min under 
high vacuum, and a solution of Pd2(dba)3 (9.62 mg, 10.5 µmol, 1.75 %mol) and Ruphos (9.85 
mg, 21 µmol, 3.5 %mol) in dry toluene (2 mL) was added to solve the residue, followed by p-
bromotoluene (51.8 µL, 0.42 mmol, 0.7 eq). The mixture was then vigorously stirred and 
heated to 80°C for 18h. After cooling down, the reaction was quenched with sat. aq. NH4Cl (2 
mL), and the organic phase was diluted with EtOAc (5mL) and separated. The aqueous phase 
was extracted with EtOAc (2 x 5 mL). The combined organic layers were dried over MgSO4, 
filtrated over a pad of celite, and evaporated under vacuum. The residue was purified by 
column chromatography (pentane/Et2O 98:2 to 50:50) to afford 128mg (61%) of the racemic 
arylated product. 
Enantioselective arylation with (-)-sparteine : 
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In a tubular reactor (100 mm x 16 mm) set up with a rubber septum, a solution of the 
protected alcohol2.7i  (247 mg, 0.6 mmol, 1 eq) and (-)-sparteine (276 µL, 1.2 mmol, 2 eq) in 
dry diethyl ether (2 mL) under argon was stirred and cooled down to -78°C (acetone bath, 
cryostat). s-Butyllithium (1.2 mmol, 2 eq, solution in hexane) was added dropwise, and the 
mixture was stirred for 5 h. A suspension of zinc acetate (232 mg, 1.26 mmol, 2.1 eq) in dry 
THF (2 mL) was sonicated for 30 min and added dropwise to the mixture. The resulting 
solution was stirred for 30 min at -78°C, and then allowed to heat to 20°C over 30 min. The 
solvents where evaporated over 30 min under high vacuum, and a solution of Pd2(dba)3 (9.62 
mg, 10.5 µmol, 1.75 %mol) and Ruphos (9.85 mg, 21 µmol, 3.5 %mol) in dry toluene (2 mL) 
was added to solve the residue, followed by the bromoaryl (0.42 mmol, 0.7 eq). The mixture 
was then vigorously stirred and heated to 80°C for 18h. After cooling down, the reaction was 
quenched with sat. aq. NH4Cl (2 mL), and the organic phase was diluted with EtOAc (5mL) 
and separated. The aqueous phase was extracted with EtOAc (2 x 5 mL). The combined 
organic layers were dried over MgSO4, filtrated over a pad of celite, and evaporated under 
vacuum. The residue was purified by column chromatography (pentane/Et2O 98:2 to 50:50) to 
afford 150mg (71%) of the enantioenriched arylated product. 
1H NMR (CDCl3, 400 MHz, rotamers) :7.34-7.19 (m, 10H), 7.13-7.08 (m, 4H), 5.71-
5.58 (m, 1H), 3.65-3.64 (m, 2H), 3.54 (s, 4H), 2.53-2.48 (m, 2H), 2.32 (s, 3H), 2.16-1.98 (m, 
2H), 1.52-1.13 (m, 12H).13C-{1H} NMR (CDCl3, 100 MHz, rotamers) :152.1/151.3, 
139.7, 138.7/138.5, 137.33/137.29, 129.3, 129.0, 128.4, 127.0, 126.4, 96.0/94.9, 76.4/76.2, 
74.9, 60.8/59.7, 58.6, 50.1, 34.8/34.7, 26.9/26.8, 25.7, 25.51/25.49, 24.4, 21.3.HPLC 
separation conditions : Chiralpak IC column, n-heptane/i-PrOH 99:1, flow rate 0.5 mL/min, 
25°C, tR 11.9 min for (R)-enantiomer (major) and tR 13.7 min for (S)-enantiomer (minor). e.r. 
= 97.2:2.8.[]D20= +1.5° (c=0.5, CHCl3).HRMS (ESI) m/z: calcd. for C32H40N2O3H1 ([M + 
H]+): 501.3112; found: 501.3116.IR (neat) v :3026, 2932, 1694, 1375, 1093, 1060. 
Arylation on a 3 mmol scale for ent-2.5a and 2.5v 
(S)-(-)-1-(4-Methoxyphenyl)ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate ent-2.5a : 
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In a oven-dried Schlenck tube (75 mm x 40 mm) set up with a rubber septum, a solution of 
2,2,4,4-tetramethyl-1,3-oxazolidine (604 mg, 3 mmol, 1 eq) and (+)-sparteine (896 µL, 3.9 
mmol, 1.3 eq) in dry diethyl ether (10 mL) under argon was stirred and cooled down to -78°C 
(acetone bath, cryostat). s-Butyllithium (3.9 mmol, 1.3 eq, solution in hexane) was added 
dropwise, and the mixture was stirred for 5 h. A suspension of zinc acetate (771 mg, 4.2 
mmol, 1.4 eq) in dry THF (10 mL) was sonicated for 30 min and added dropwise to the 
mixture. The resulting solution was stirred for 30 min at -78°C, and then allowed to heat to 
20°C over 30 min. The solvents where evaporated over 30 min under high vacuum, and a 
solution of Pd2(dba)3 (48.1 mg, 52.5 µmol, 1.75 %mol) and Ruphos (49 mg, 105 µmol, 3.5 
%mol) in dry toluene (10 mL) was added to solve the residue, followed by the 4-
bromoanisole (264 µL, 2.1 mmol, 0.7 eq). The mixture was then vigorously stirred and heated 
to 80°C for 18h. After cooling down, the reaction was quenched with sat. aq. NH4Cl (10 mL), 
and the organic phase was diluted with EtOAc (25 mL) and separated. The aqueous phase was 
extracted with EtOAc (2 x 25 mL). The combined organic layers were washed with water and 
dried over MgSO4, filtrated over a pad of celite, and evaporated under vacuum. The residue 
was purified by column chromatography (Et2O/pentane) to afford 542 mg (84%) of the 
enantioenriched benzylic alcohol ( (S), e.r. 1:99). 
[]D20 = -13° (c=0.6, CHCl3). 
(S)-(-)-1-Phenylbut-3-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate2.5v : 
 
Arylation with TMEDA : 
In a oven-dried Schlenck tube (75 mm x 40 mm) set up with a rubber septum, a solution of 
but-3-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate(684 mg, 3 mmol, 1 eq) and 
TMEDA (634 µL, 4.2 mmol, 1.4 eq) in dry diethyl ether (10 mL) under argon was stirredand 
cooled down to -78°C (acetone bath, cryostat). s-Butyllithium (4.2 mmol, 1.4 eq, solution in 
hexane) was added dropwise, and the mixture was stirred for 5 h. A suspension of zinc acetate 
(826 mg, 4.5 mmol, 1.5 eq) in dry THF (10 mL) was sonicated for 30 min and added 
dropwise to the mixture. The resulting solution was stirred for 30 min at -78°C, and then 
allowed to heat to 20°C over 30 min. The solvents where evaporated over 30 min under high 
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vacuum, and a solution of Pd2(dba)3 (48.1 mg, 52.5 µmol, 1.75 %mol) and Ruphos (49 mg, 
105 µmol, 3.5 %mol) in dry toluene (10 mL) was added to solve the residue, followed by 
thebromobenzene (224 µL, 2.1 mmol, 0.7 eq). The mixture was then vigorously stirred and 
heated to 80°C for 18h. After cooling down, the reaction was quenched with sat. aq. NH4Cl 
(10 mL), and the organic phase was diluted with EtOAc (25 mL) and separated. The aqueous 
phase was extracted with EtOAc (2 x 25 mL). The combined organic layers were washed with 
water and dried over MgSO4, filtrated over a pad of celite, and evaporated under vacuum. The 
residue was purified by column chromatography (Et2O/pentane) to afford 380 mg (60%) of 
the racemic benzylic alcohol. 
Enantioselective arylation with (+)-sparteine : 
In a oven-dried Schlenck tube (75 mm x 40 mm) set up with a rubber septum, a solution of 
but-3-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate (684 mg, 3 mmol, 1 eq) and (+)-
sparteine (965 µL, 4.2 mmol, 1.4 eq) in dry diethyl ether (10 mL) under argon was stirred and 
cooled down to -78°C (acetone bath, cryostat). s-Butyllithium (4.2 mmol, 1.4 eq, solution in 
hexane) was added dropwise, and the mixture was stirred for 5 h. A suspension of zinc acetate 
(826 mg, 4.5 mmol, 1.5 eq) in dry THF (10 mL) was sonicated for 30 min and added 
dropwise to the mixture. The resulting solution was stirred for 30 min at -78°C, and then 
allowed to heat to 20°C over 30 min. The solvents where evaporated over 30 min under high 
vacuum, and a solution of Pd2(dba)3 (48.1 mg, 52.5 µmol, 1.75 %mol) and Ruphos (49 mg, 
105 µmol, 3.5 %mol) in dry toluene (10 mL) was added to solve the residue, followed by the 
bromobenzene (224 µL, 2.1 mmol, 0.7 eq). The mixture was then vigorously stirred and 
heated to 80°C for 18h. After cooling down, the reaction was quenched with sat. aq. NH4Cl 
(10 mL), and the organic phase was diluted with EtOAc (25 mL) and separated. The aqueous 
phase was extracted with EtOAc (2 x 25 mL). The combined organic layers were washed with 
water and dried over MgSO4, filtrated over a pad of celite, and evaporated under vacuum. The 
residue was purified by column chromatography (Et2O/pentane) to afford 474 mg (74%) of 
the enantioenriched benzylic alcohol. 
1H NMR (CDCl3, 400 MHz, rotamers) : 7.37-7.25 (m, 5H), 5.80-5.68 (m, 2H), 5.10-5.03 
(m, 2H), 3.75-3.69 (m, 2H), 2.72-2.58 (m, 2H), 1.62-1.34 (m, 12H).13C-{1H} NMR (CDCl3, 
100 MHz, rotamers) : 152.1/151.4, 140.9/140.8, 133.82/133.75, 128.6, 127.8, 126.6, 
118.1, 96.1, 95.0,76.5/76.2, 76.1, 60.9/60.0, 41.5/41.4, 26.98/26.96, 25.73/27.70, 25.5/25.4, 
24.33/24.29.HPLC separation conditions : ChiralcelOJ column, n-heptane/i-PrOH 98:2, 
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flow rate 0.3 mL/min, 25°C, tR18.4min for (R)-enantiomer (minor) and tR 20.4 min for (S)-
enantiomer (major). e.r. = 1:99.[]D20 = -8° (c=0.3, CHCl3).HRMS (ESI) m/z: calcd. for 
C18H25NO3Na ([M + Na]+): 326.1727; found: 326.1725.IR (neat) v :3077, 2980, 1693, 1377, 
1060, 1027, 761, 651. 
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Synthesis of secondary and tertiary alcohols 2.12a-c via Aggarwal’s lithiation-
borylation method 
General procedure : 
To a stirred solution of 1-(4-methoxyphenyl)ethyl 2,2,4,4-tetramethyloxazolidine-3-
carboxylate (100 mg, 0.325 mmol, 1 eq) and TMEDA (54 µL, 0.358 mmol, 1.1 eq) in Et2O (2 
mL) at -78°C under argon was added s-BuLi (0.345 mmol, 1.06 eq) dropwise over 3 min. The 
mixture was stirred for 5 min at -78°C, and then a 1 M solution of boron reagent (1.1 to 3 eq) 
in Et2O was added dropwise under vigorous stirring. The solution was kept at -78°C for 20 
min, and then at ambient temperature for 2 h after cooling bath removal (unless otherwise 
stated). The mixture was diluted with THF (2 mL), cooled to ~0°C with an ice bath, and a 
mixture of 3 M NaOH (1.1 mL) and 30% aqueous H2O2  (0.8 mL) per 1 mmol of boron 
reagent employed was added. After removal of the ice bath, the reaction mixture was stirred at 
room temperature for 2 h, then diluted with water (3 mL) and extracted with Et2O (4 x 5 mL).  
The combined organic layer were washed with brine (20 mL), dried over MgSO4 and 
concentrated under reduced pressure. The crude product was purified by flash column 
chromatography (pentane/Et2O) to afford the pure secondary or tertiary alcohol. The 
analytical data of these latter were consistent with those reported in the literature153. 
1-(4-Methoxyphenyl)ethan-1-ol2.12a and ent-2.12a : 
 
Synthesis of (±)-2.12a: to a stirred solution of racemic 1-(4-methoxyphenyl)ethyl 2,2,4,4-
tetramethyloxazolidine-3-carboxylate (150 mg, 0.49 mmol, 1 eq) in Et2O (2 mL) at -78°C 
under argon was added s-BuLi (0.54 mmol, 1.1 eq) dropwise over 3 min. The mixture was 
stirred for 20 min at -78°C, and then a 1 M solution of BH3.THF (0.54 mL, 0.36 mmol, 1.1 
eq) was added dropwise under vigorous stirring. The solution was kept at -78°C for 20 min, 
and then at ambient temperature for 2 h after cooling bath removal. The work-up was 
performed according to the general procedure. The crude product was purified (pentane/Et2O 
80:20 to 50:50) to afford 52 mg (70%) of the racemic secondary alcohol as a colorless oil. 
Synthesis of (R)-(+)-2.12a: according to the general procedure, the (R)-(-)-carbamate (80 mg, 
0.26 mmol, 1 eq, e.r.99:1) was reacted with HB(pin) (113 µL, 0.78 mmol, 3 eq). The solution 
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was kept at -78°C for 2h, and then at -30°C for 3 h. The cooling bath was removed before the 
oxydation step in the sequence. The crude product was purified (pentane/Et2O 80:20 to 50:50) 
to afford 31 mg (78%) of the (R)-(+)-enantioenriched secondary alcohol2.12a as a colorless 
oil. 
Synthesis of (S)-(-)-2.12a: according to the general procedure, the (S)-(+)-carbamate (e.r. 
1:99) was reacted with HB(pin) (113 µL, 0.78 mmol, 3 eq). The solution was kept at -78°C 
for 2h, and then at -30°C for 3 h. The cooling bath was removed before the oxidation step in 
the sequence. The crude product was purified (pentane/Et2O 80:20 to 50:50) to afford 37.5 mg 
(76%) of the (S)-(-)-enantioenriched secondary alcohol ent-2.12a as a colorless oil. 
1H NMR (400 MHz, CDCl3) :7.31-7.28 (m, 2H), 6.90-6.87 (m, 2H), 4.85 (q, 1H, J = 6.4 
Hz), 3.80 (s, 3H), 1.85 (br. s, 1H), 1.48 (d, 3H, J = 6.4 Hz). 13C NMR (100 MHz, CDCl3) 
:153.2, 138.2, 126.8, 114.0, 70.2, 55.5, 25.2. HPLC separation conditions : Chiralcel 
OD-H column, n-heptane/i-PrOH 98:2, flow rate 1 mL/min, 25°C. For  2.12a: tR 20.9 min for 
(R)-enantiomer (major) and tR 24.5 min for (S)-enantiomer (minor). e.r. = 96:4. []D20 =  
+40.2° (c=1.5, CHCl3). For ent-2.12a :tR 21.5 min for (R)-enantiomer (minor) and tR 25.9 min 
for (S)-enantiomer (major). e.r. = 3:97. []D20 =  -41.6° (c=1.5, CHCl3). 
(R)-(+)-2-(4-Methoxyphenyl)butan-2-ol 2.12b: 
 
Synthesis of (±)-2.12b: according to the general procedure, the racemic carbamate was 
reacted with EtB(pin) (87 µL, 0.49 mmol, 1.5 eq). The crude product was purified 
(pentane/Et2O 80:20 to 50:50) to afford 50 mg (85%) of the racemic tertiary alcohol as a 
colorless oil. 
Synthesis of (R)-2.12b: according to the general procedure, the (S)-(+)-carbamate (e.r. 1:99) 
was reacted with EtB(pin) (87 µL, 0.49 mmol, 1.5 eq). The crude product was purified 
(pentane/Et2O 80:20 to 50:50) to afford 47 mg (80%) of the (R)-(+)-enantioenriched tertiary 
alcohol as a colorless oil. 
1H NMR (400 MHz, CDCl3) :7.36-7.34 (m, 2H), 6.88-6.86 (m, 2H), 3.80 (s, 3H), 1.86-
1.78 (m, 3H), 1.53 (s, 3H), 0.79 (t, 3H). 13C-{1H} NMR (100 MHz, CDCl3) :158.3, 
140.1, 126.2, 113.5, 74.8, 55.4, 36.9, 29.7, 8.5. HPLC separation conditions : Chiralcel OD-
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H column, n-heptane/i-PrOH 99:1, flow rate 0.8 mL/min, 25°C, tR 21.2 min for (R)-
enantiomer (major) and tR 25.3 min for (S)-enantiomer (minor). e.r. = 97:3. []D20 =  +22.2° 
(c=1.1, CHCl3). 
(R)-(+)-1-(4-Methoxyphenyl)-1-phenylethan-1-ol 2.12c: 
 
Synthesis of (±)-2.12c: according to the general procedure, the racemic carbamate was reacted 
with PhB(pin) (73 mg, 0.36 mmol, 1.1 eq,). The crude product was purified (pentane/Et2O 
80:20 to 50:50) to afford 58 mg (78%) of the racemic tertiary alcohol as a colorless oil. 
Synthesis of (R)-2.12c: according to the general procedure, the (S)-(+)-carbamate (e.r. 1:99) 
was reacted with PhB(pin) (87 µL, 0.49 mmol, 1.5 eq). The crude product was purified 
(pentane/Et2O 80:20 to 50:50) to afford 48 mg (65%) of the (R)-(+)-enantioenriched tertiary 
alcohol as a colorless oil. 
1H NMR (400 MHz, CDCl3) : 7.37-7.35 (m, 2H), 7.29-7.24 (m, 4H), 7.20-7.16 (m, 1H), 
6.81-6.77 (m, 2H), 3.73 (s, 1H), 2.16 (s, 1H), 1.88 (s, 3H). 13C NMR (100 MHz, CDCl3) : 
158.6, 148.5, 140.5, 128.3, 127.3, 127.0, 125.9, 113,6, 76.1, 55.4, 31.2. HPLC separation 
conditions : Chiralcel OJ column, n-heptane/i-PrOH 90:10, flow rate 1 mL/min, 25°C, tR 33.9 
min for (R)-enantiomer (major) and tR 41.6 min for (S)-enantiomer (minor). e.r. = 97:3. []D20 
=  +19.4° (c=0.9, CHCl3). 
 Toward the synthesis of fluoxetine 
3-oxo-1-phenylpropyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate2.17 : 
 
A solution of 1-phenylbut-3-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate2.5v (300 
mg, 1 mmol, 1 eq) in CH2Cl2 (20 mL) was cooled down to -78°C. A stream of ozone was 
bubbled through the solution. The ozone stream was stopped 5 minutes after the reaction 
mixture turned blue and then a stream of oxygen was bubbled through the solution to evacuate 
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the excess of ozone. Zn dust (647 mg, 9.9 mmol, 10 eq) and AcOH (0.6 mL, 9.9 mmol, 10 eq) 
were added to the reaction mixture before it was allowed to warm up to 23 °C over 30 
minutes. The reaction mixture was filtered through a pad of celite and sat. aq. NaHCO3 (15 
mL) was added to the filtrate. The aqueous phase was extracted with CH2Cl2 (3x30 mL) and 
the comined organic layer was washed with water (40 mL), and brine (40 mL), and then dried 
over MgSO4. The solvent was evaporated under vacuum to obtain the title compound (302 
mg, quant.) as a yellow oil, which is air sensitive. 
1H NMR (CDCl3, 400 MHz, rotamers) : 9.73 s, 1H), 7.34-7.23 (m, 5H), 6.19 (dd, J = 
8.5Hz, J = 4.8 Hz, 1H), 3.69-3.65 (m, 2H), 3.03-2.95 (m, 1H),  2.85-2.79 (m, 1H), 1.50-1.28 
(m, 12H).13C-{1H} NMR (CDCl3, 400 MHz, rotamers) :199.1, 139.7, 129.0, 128.4, 
126.4, 96.3/95.0, 76.5/76.1, 71.5, 61.1/60.0, 53.6, 50.7, 26.92/26.89, 25.7, 25.4, 24.2. HRMS 
(ESI) m/z: calcd. for C17H23NO4Na ([M + Na]+): 328.1519; found: 328.1520. IR (neat) v :not 
measured, compound not stable. 
3-(methylamino)-1-phenylpropyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate2.18 : 
 
To a solution of 3-oxo-1-phenylpropyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate (300 mg, 
1 mmol, 1 eq) in MeOH (15 mL) were added MeNH2.HCl (1.36 g, 19.6 mmol, 20 eq), 
NaHB(OAc)3 (520 mg, 2. 5 mmol, 2.5 eq), and acetic acid (0.1 mL,  2.5 mmol, 2.5 eq). The 
mixture was sitirred at 23°C for 3 days. The reaction mixture was quenched with aq. 1M 
NaOH (10 mL) and the aqueous phase was extracted with CH2Cl2 (3x30 mL). The combined 
organic layer was washed with sat. aq. NaHCO3 (25 mL) and brine (25 mL), dried over 
MgSO4, and concentrated under vacuum. The crude residue was purified by colomn 
chromatography (CH2Cl2 to CH2Cl2/(NH3 7M in MeOH) 95:5) followed by reversed phase 
preparative HPLC to obtain 31.5 mg (10%) of the title compound as a yellowish oil. 
1H NMR (CDCl3, 400 MHz, rotamers) : 7.35-7.27 (m, 5H), 5.81-5.78 (m, 1H), 3.75-
3.68 (m, 2H), 2.65-2.58 (m, 2H), 2.39 (s, 3H), 2.18-2.96 (m, 2H), 1.65-1.34 (m, 12H).13C-
{1H} NMR (CDCl3, 400 MHz, rotamers) :152.2/151.5, 141.1/140.0, 128.6, 127.9, 126.6, 
96.2/95.0, 76.5/76.2, 74.8, 60.9/59.9, 48.4, 37.2, 36.6, 27.0/26.9, 25.8/25.7, 25.44/25.38, 24.3. 
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HRMS (ESI) m/z: calcd. for C18H28N2O3H ([M + H]+): 321.2173; found: 321.2177. IR 
(neat) v :2935, 1689, 1394, 1092, 1058, 762, 698. 
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5.2. Attempts toward the -arylation of O-carbamates 
Preparation of 2,2,4,4-tetramethyloxazolidine-3-carboxylates 2.7j-n 
General procedure : 
A solution of the corresponding alcohol (1.0 eq) in THF (10 mL) was addeddropwise to a 
suspension of sodium hydride (95% in mineral oil, 1.1 eq) in THF (30 mL) and the mixture 
was stirred for 30 min at room temperature. A solution of 2,2,4,4-tetramethyloxazolidine-3-
carbonyl chloride (1.05 eq.) in THF (10 mL) was then added dropwise and the mixture was 
stirred for 12 h. After quenching with water, the solvent was removed under reduced pressure 
and Et2O (50 mL) was added to the crude mixture. The organic phase was washed with sat. 
aq. NaHCO3 (30 mL), water (30 mL) and brine (30 mL) and dried over MgSO4. After 
filtration, the solvent was evaporated and the residue was purified by silica gel column 
chromatography (Pent/Et2O 98:2 to 80:20). 
Pent-3-yn-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate2.7j: 
 
Following the general procedure, 3-pentyn-1-ol (550 µL, 5.9 mmol) gave 1.3 g (91%) of the 
corresponding carbamate as a colorless oil. 
1H NMR (CDCl3, 400 MHz, rotamers) :4.14-4.10 (m, 2H), 3.72 (s, 2H), 2.48-2.43 (m, 
2H), 1.74 (t, J5 = 2.5 Hz, 3H), 1.54 (s, 6H), (1.40) 1.38 (2 br. s, 6H).13C-{1H} NMR (CDCl3, 
100 MHz, rotamers) :, 
26.5/25.4, 25.3/24.2, 19.6, 3.5. HRMS (ESI) m/z:calcd. for C13H21NO3Na ([M + Na]+): 
262.1414; found: 262.1418. IR neat (𝛖/cm-1) : 2980, 2870, 2360, 1702, 1408, 1349, 1260, 
1099. 
2-(pyridin-2-yl)ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.7k: 
 
Following the general procedure, 2-(pyridin-2-yl)ethan-1-ol (0.85 mL, 7.5 mmol) gave 1.85 g 
(89%) of the title carbamate as a colorless oil. 
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1H NMR (CDCl3, 400 MHz, rotamers) :8.56-8.54 (m, 1H), 7.62-7.58 (m, 1H), 7.21-7.1 
(m, 2H), 4.52-4.48 (m, 2H), 3.67-3.66 (m, 2H), 3.17-3.12 (m, 2H), 1.53 (1.39) (2 br. s., 6H), 
(1.30) 1.16 (2 br. s., 6H).13C-{1H} NMR (CDCl3, 100 MHz, rotamers) :158.4, 152.2, 
151.8, 149.4, 136.3, 123.3, 121.5, 95.7/94.8, 76.3/76.0, 63.7, 60.5/59.6, 37.7, 26.2, 25.2, 249, 
24.1. HRMS (ESI) m/z : calcd. for C15H22N2O3H ([M + H]+): 279.1703; found: 279.1699.IR 
neat (𝛖/cm-1) :2980, 1697, 1582, 1407, 1343, 1260, 1097. 
4-(dibenzylamino)butyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate2.7l: 
 
Following the general procedure, 4-(dibenzylamino)butan-1-ol (1.08g, 3.64 mmol) gave 
850mg (50%) of the title carbamate as a colorless oil. 
1H NMR (CDCl3, 400 MHz, rotamers) : 7.37-7.29 (m, 8H), 7.25-7.21 (m, 2H), 4.05-
4.00 (m, 2H), 3.72 (s, 2H), 3.56 (s, 4H), 2.48-2.43 (m, 2H), 1.64-1.34 (m, 14H). 13C-{1H} 
NMR (CDCl3, 100 MHz, rotamers) : (C=O missing), 139.9, 128.88, 128. 85, 128.3, 
126.9, 95.9/94.9, 76.5/75.2, 64.6, 60.6/59.7, 58.4, 53.0, 27.0, 26.7, 26.4, 25.5, 24.3, 24.0, 
23.7. HRMS (ESI) m/z : calcd. for C26H36N2O3H ([M + H]+): 425.2799; found: 427.2807.IR 
neat (𝛖/cm-1) : 2940, 2798, 1697, 1453, 1408, 1363, 1259, 1067. 
3-(pyridin-2-yl)propyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate2.7m: 
 
Following the general procedure, 3-(pyridin-2-yl)propan-1-ol (500mg, 3.64 mmol) gave 1.00 
g (94%) of the title carbamate as a colorless oil. 
1H NMR (CDCl3, 400 MHz, rotamers) : 8.54-8.52 (m, 1H), 7.61-7.57 (m, 1H), 7.15-7.1 
(m, 2H), 4.17-4.13 (m, 2H), 3.73 (s, 2H), 2.91-2.85 (m, 2H), 2.17-2.08 (m, 2H), 156 (1.54 
(2br. s., 6H), (1.42) 1.38 (2br. s., 6H).13C-{1H} NMR (CDCl3, 100 MHz, rotamers) : 
161.0, 152.9, 152.2, 149.5, 136.5, 122.9, 121.3, 95.9/94.9, 76.4/76.2, 64.2, 60.6/59.8, 
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35.0, 28.9, 26.7/25.44, 25.38/24.2. HRMS (ESI) m/z : calcd. for C16H24N2O3H ([M + H]+): 
293.1860; found: 293.1859.IR neat (𝛖/cm-1) : 2980, 1693, 1409, 1364, 1260, 1098. 
Pent-4-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.7n: 
 
Following the general procedure, Pent-4-en-1-ol (600 µL, 5.8 mmol) gave 1.3 g (93%) of the 
corresponding carbamate as a colorless oil. 
1H NMR (CDCl3, 400 MHz, rotamers) :5.86-5.78 (m, 1H), 5.07-4.98 (m, 2 H), 4.12-
4.08 (m, 2H), 3.73 (s, 2H), 2.19-2.12 (m, 2H), 1.80-1.72 (m, 2H), 1.56 (1.53) (2 br. s, 6H), 
(1.42) 1.37 (2 br. s, 6H).13C-{1H} NMR (CDCl3, 100 MHz, rotamers) :153.0/152.2, 
137.7, 115.4, 95.9/94.9, 76.5/76.2, 64.0, 60.7/59.8, 30.5, 28.3, 26.7, 25.4, 24.3. HRMS (ESI) 
m/z:calcd. for C13H23NO3Na ([M + Na]+): 264.1570; found: 264.1570. IR neat (𝛖/cm-1) : 
2979, 2361, 1695, 1406, 1359, 1259, 1067, 914.  
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5.3. Ligand-controlled -arylation of O-carbamates 
Generalinformation 
All reactions were performed under an argon atmosphere (unless otherwise noted) in Pyrex 
glassware equipped with a magnetic stir bar. GC/MS analyses were run on a Shimadzu 
QP2010 apparatus using aRTx®-5ms column lined with a mass (EI 0.86 kV) detection 
system.1H, 13C and 19F NMR spectra were recorded on a BrukerAvance III (400 MHz) 
spectrometer at 298 K in CDCl3 (residual peaks 1H δ 7.26 ppm, 13C δ 77.16 ppm). Chemical 
shifts (δ) are reported in ppm relative totetramethylsilane (0.00 ppm). Data are reported as 
follows: chemical shift in parts per million (ppm), multiplicity (s = singlet, d = doublet, t = 
triplet, q = quartet, m = multiplet, and br. for broad), integration value, coupling constant in 
Hz if applicable. Analytical Thin Layer Chromatography (TLC) was performed using pre-
coated Merck silica gel 60 F254 plates (0.25 mm). Visualization of the developed 
chromatogram was performed by UV absorbance (254 nm) or TLC stains (Phosphomolybdic 
acid or KMnO4) Flash chromatographies were performed using SilicycleSiliaFlash P60 (230-
400 mesh) with the indicated solvents. High resolution mass spectrometry recorded by Dr. H. 
Nadig of the University of Basel on a BrukermaXis 4G QTOF ESI mass spectrometer. 
Infrared spectra were measured on aATR Varian Scimitar 800 FT-IR spectrometer and 
reported in cm–1. HPLC analyses were done using a Shimadzu Prominence system with SIL-
20A auto sample, CTO-20AC column oven, LC-20AD pump system, DGU-20A3 degasser 
and SPD-M20A Diode Array or UV/Vis detector. Chiralcel OD-H, OJ, or OJ-H and 
Chiralpak AD-H, IA or IC columns from Daicel Corporation were used for separation. 
Optical rotationwere measured on a Perkin Elmer 341Polarimeter in a 1 mL cuvette (cell 
length 100 mm) with NaD-Line ( = 589 nm) at 20°C. The concentration (c) is given in g/dL. 
 Commercially available reagents were used without further purification unless otherwise 
stated. Anhydrous solvents (Diethyl ether, THF, Toluene) were purchased form Sigma 
Aldrich and used as received.Tetramethylethylenediamine (TMEDA) was freshly distilled 
over CaH2 under argon atmosphere. (-)-Sparteine and (+)-sparteine were respectively 
purchased from Sigma Aldrich and Fluorochem, distillated over CaH2 under argon 
atmosphere, degassed under high vacuum via freeze-pumping process, and conserved at -
30°C. 2-Dicyclohexylphosphino-2’,6’-diisopropoxy-biphenyl (RuPhos) was purchased from 
Strem. Tris(dibenzylideneacetone)dipalladium(0) (Pd2(dba)3) was purchased from Strem and 
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ABCR. Zinc acetate (Zn(OAc)2)was purchased from Sigma Aldrich and thinly powdered. 
(RuPhos), (Pd2(dba)3), and (Zn(OAc)2) were conserved in a glove box. 
Additional optimization results 
First ligand screen : 
 
Structure Ligand X Y R1 R2 Alk 
Product ratio 
GCMS 
(//Z/E) 
19F NMR 
Yield % 
(//Z/E) 
N
Y
X P(Alk)2
R1R2
 
2.L11 CH CH H H nBu No prod. n.d. 
2.L10 CH CH H H iBu No prod. n.d. 
2.L9 CH CH H H iPr 9/44/16/31 Traces 
2.L28 CH CH H H Cy 12/37/17/33 0/13/0/11 
5.L83 CH CH H H tBu 100/0/0/0 n.d. 
5.L84 CH CH N(Me)2 H iPr 24/50/17/8 7.5/20/4/2 
2.L26 CH CH N(Me)2 H Cy 27/45/15/11 14/23/7/5 
5.L85 CH CH N(Me)2 H tBu 23/50/17/10 n.d 
2.L8 CH N N(Me)2 H Cy 18/36/25/21 7/16/10/8 
5.L86 CH N N(Me)2 H tBu 100/0/0/0 56/0/0/0 
2.L29 CH CH OMe H Cy 29/27/17/27 Traces 
5.L87 CH CH OMe H tBu 100/0/0/0 n.d. 
2.L30 CH N OiPr OiPr Cy 33/6/51/11 3/0/6/0 
5.L88 CH N OiPr OiPr tBu 100/0/0/0 60/0/0/0 
5.L89 N CH OiPr OiPr tBu 100/0/0/0 20/0/0/0 
2.L31 CH N N(Me)2 N(Me)2 Cy 88/1/9/3 67/0/0/0 
5.L890 CH N N(Me)2 N(Me)2 tBu 100/0/0/0 31/0/0/0 
2.L32 N CH N(Me)2 N(Me)2 Cy 48/15/30/8 20/6/16/3 
5.L91 N CH N(Me)2 N(Me)2 tBu 100/0/0/0 9/0/0/0 
5.L92 CH N OCy OCy tBu No prod. n.d 
5.L93 CH N OiPr OiPr Ad 100/0/0/0 38/0/0/0 
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5.L94 - - - - Cy 20/36/12/33 3/7/0/3 
5.L95 - - - - tBu 100/0/0/0 n.d. 
 
2.L27 - - - - Cy 18/25/40/48 11/15/21/12 
 
1.L2 
RuPhos 
 
- - - - - 100/0/0/0 54/0/0/0 
 
1.L4 
DavePhos 
- - - - - 93/7/0/0 n.d. 
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Second ligand screen : 
 
Structure Ligand X Y R1 R2 Alk 
Product ratio 
GCMS 
(//Z/E) 
19F NMR 
Yield % 
Z/E 
 
2.L27 - - - - Cy 9/6/64/21 49/12 
N
Y
X P(Alk)2
R1R2
 
2.L26 CH CH N(Me)2 H Cy 17/33/34/15 12/6 
2.L33 CH N N(Me)2 H iPr 9/19/46/26 16/6 
2.L34 CH N F H Cy 6/9/36/49 9/10 
2.L35 CH N CF3 H Cy 4/16/41/39 15/13 
2.L36 CH N iPr H Cy 8/5/52/35 20/14 
2.L37 CH N OMe H Cy 13/4/47/37 9/6 
2.L38 CH N N(Et)2 H Cy 7/12/57/24 7/4 
2.L39 CH N Me H Cy 7/14/46/33 9/6 
 
2.L40 - - - - - 12/14/51/23 14/9 
 
2.L41 - - - - - 13/10/57/20 31/10 
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Third ligand screen : 
Structure Ligand X Y R 
Product ratio 
GCMS 
(//Z/E) 
19F NMR 
Yield % 
Z/E 
 
2.L27 - - Cy 9/6/65/20 49/12 
2.L42 - - iPr 7/14/60/20 6/2 
 
2.L46 CH N Ph No traces n.d. 
2.L43 CH N Cy 16/0/76/8 21/2 
2.L44 CH N iPr 16/1/74/10 39/5 
2.L47 CH N nBu traces n.d. 
2.L48 CH N Et No traces n.d. 
2.L45 CH N tBu 100/0/0/0 n.d. 
2.L49 CH N iBu No traces n.d. 
2.L50 CH N Np No traces n.d. 
2.L51 N CH iPr 29/15/46/10 40/10 
 
2.L52 - - OEt 10/1/76/12 45/6 
2.L53 - - OiPr 9/0/79/12 42/6 
2.L54 - - Et 10/12/62/16 41/9 
2.L55 - - F 5/20/44/31 36/17 
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Temperature screen : 
 
Entry T°C 
Product ratio GCMS 
(//Z/E) 
19F NMR Yield% 
(Z/E) 
Isolated Yield -product 
1 100 18/8/51/22 32/14 31%, 68/32 Z/E 
2 80 11/7/59/22 44/16 33%, 71/29 Z/E 
3 60 9/6/64/21 49/12 48%, 75/25 Z/E 
4 40 4/6/70/19 40/11 31%, 77/23 Z/E 
5 20 traces <6/1 n.d. 
6 0 traces <2/1 n.d. 
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Solvent screen : 
 
Entry Solvent 
Product ratio 
GCMS 
(//Z/E) 
19F NMR 
Yield% 
(Z/E) 
Isolated Yield -
product 
1 toluene 9/6/64/21 49/12 48%, 75/25 Z/E 
2 THF 8/4/67/22 31/2 19%, 71/29 Z/E 
3 dimethylacetamide no conversion n.d. n.d. 
4 1,2-dichloroethane 13/0/75/13 <3/3 n.d. 
5 1,2-dimethoxyethane 0/0/86/14 7/<1 n.d. 
6 n-hexane 10/12/60/19 26/4 %, 73/27 Z/E 
7 1,4-dioxane no conversion n.d. n.d. 
8 cyclopentyl methyl 
ether 
10/6/65/19 <2/2 n.d. 
9 benzene 7/6/66/21 39/11 47%, 76/24 Z/E 
10 cyclohexane 10/6/65/19 <3/3 n.d. 
11 ,,-trifluorotoluene 8/0/65/27 n.d. 12%, 72/28 Z/E 
12 mesitylene 8/8/63/21 20/7 18%, 60/40 Z/E 
13 perfluorobenzene 13/8/59/19 20/5 n.d. 
  
OCby
OCby
i) s-BuLi/TMEDA 1.4 eq, Et2O, -78°C, 4 h
ii) Zn(OAc)2 1.5 eq, -78°C to 20°C, 1 h
iii) Pd2dba3 1.75 %mol, 2.L27 3.5 %mol,
2-F-PhBr 0.7 eq, Solvent, 60°C, 18 h 2.21a
F
OCby
2.21b
+
F
OCby
(E)-2.21g
FF OCby
(Z)-2.21g
+ +
(E)-2.21
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Additives/conditions deviations : 
 
Entry Additive / deviation 
Product ratio GCMS 
(//Z/E) 
19F NMR Yield% 
(Z/E) 
Isolated Yield -
product 
1 i) s-BuLi/TMEDA 2 eq 
ii) Zn(OAc) 2,1 eq  
6/7/68/16 29/8 31.5%, 74/26 Z/E 
2 i) s-BuLi/TMEDA 1.05 eq 
ii) Zn(OAc) 1.1eq 
11/5/70/14 42/13 43%, 75/25 Z/E 
3 ii) ZnCl2 i/o Zn(OAc)2 8/4/67/21 n.d. 35%, 71/29 Z/E 
4 iii) 0.5 eq ArBr 7/7/66/20 38/9 44%, 75/25 Z/E 
5 iii) 0.5 eq ArBr, 2.5 %mol 
cat. 
7/5/67/21 42/10 44%, 74/26 Z/E 
6 iii) 0.6 eq ArBr 6/6/67/20 32/9 n.d. 
7 iii) 1 eq ArBr 8/8/64/20 32/9.5 35%, 75/25 Z/E 
8 iii) 1 eq ArBr, 5 %mol cat. 7/6/67/20 33/9.5 35%, 75/25 Z/E 
9 iii) 1.5 eq ArBr 8/7/64/21 32/9.5 n.d. 
10 iii) 3.5 %mol Pd2dba3, 7 
%mol 2.L27 
8/7/67/19 46/14 53.5%, 75/25 Z/E 
11 iii) 7 %mol Pd2dba3, 14 
%mol 2.L27 
7/7/67/20 44/13 n.d. 
12 iii) 1.75 %mol Pd2dba3, 
5.25 %mol 2.L27 
8/5/67/20 43/13 42%, 75/25 Z/E 
13 iii) 1.75 %mol Pd2dba3, 7 
%mol 2.L27 
6/7/66/21 34/10 n.d. 
14 iii) reaction 40h 7/7/65/21 44/14 55%, 75/25 Z/E 
15 iii) + 12-Crown-4 1.5 eq 8/6/67/20 44/13 n.d. 
16 iii) + MgCl2 1.5 eq 8/7/67/18 41/12 n.d. 
17 iii) + ZnF2 1.5 eq 8/7/67/18 29/10 n.d. 
18 iii) + BF3.Et2O 1.5 eq no traces n.d. n.d. 
19 iii) + CO atmosphere No reaction, no insertion 
20 iii) + tBuNC Lower conversion, no insertion 
  
OCby
OCby
i) s-BuLi/TMEDA 1.4 eq, Et2O, -78°C, 4 h
ii) Zn(OAc)2 1.5 eq, -78°C to 20°C, 1 h
iii) Pd2dba3 1.75 %mol, 2.L27 3.5 %mol,
2-F-PhBr 0.7 eq, toluene, 60°C, 18 h 2.21a
F
OCby
2.21b
+
F
OCby
(E)-2.21g
FF OCby
(Z)-2.21g
+ +
(E)-2.21
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Palladium source screen : 
 
Entry Additive / deviation 
Product ratio GCMS 
(//Z/E) 
19F NMR Yield% 
(Z/E) 
Isolated Yield -
product 
1 3.5 %mol Pd(dba)2, 3.5 
%mol 2.L27 
6/6/66/21 14/4 n.d. 
2 L20 Pd G3 precatalyst 5 
%mol 
6/7/67/20 32/10 n.d. 
2 3.5 %mol PdCl2, 7 %mol 
2.L27 
6/6/66/21 24/8 n.d. 
4 3.5 %mol Pd(OAc)2, 7 
%mol 2.L27 
7/6/67/20 20/6 n.d. 
5 1.75 %mol 
[CinnamylPdCl]2 , 7 %mol 
2.L27 
7/7/66/20 35/11 n.d. 
6 3.5 %mol [PdCl2MeCN2], 
7 %mol 2.L27 
7/7/67/20 45/14 50%, 75/25 Z/E 
7 7 %mol [PdCl2MeCN2], 
14 %mol 2.L27 
7/5/67/21 43/15 44%, 74/26 Z/E 
8 7 %mol [PdCl2PhCN2], 14 
%mol 2.L27 
7/6/67/20 45/14 45%, 75/25 Z/E 
9 7 %mol [PdMe2TMEDA], 
14 %mol 2.L27 
7/6/67/20 43/13 n.d. 
10 7 %mol [PdCl2(SMe)2], 14 
%mol 2.L27 
7/5/67/20 44/14 n.d. 
11 7 %mol [Pd(CH2SiMe3)2 
COD], 14 %mol2.L27 
7/6/68/20 44/14 n.d. 
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Starting material synthesis 
 General procedure for the synthesis of homoallyl alcohols S2-S4 from 3-alkenoic 
acids 
 
 
A solution of the corresponding carboxylic acid (1 eq) in Et2O was added dropwise to a 
suspension of LiAlH4 (2.1 eq) in Et2O at 0°C over 30 min. The resulting mixture was stirred 
at 20°C for 12 h, quenched with 20% aq. NaOH, and then filtrated over celite. The aqueous 
layer was separated and extracted with Et2O. The combined organic layers were washed with 
water, dried over MgSO4, and concentrated under reduced pressure. The crude residue was 
purified by silica gel column chromatography (Pent/Et2O 95:5 to 50:50) to obtain the 
corresponding alcohol. 
(E)-Pent-3-en-1-ol S2: 
 
Following the general procedure, (E)-pent-3-enoic acid (1.5 mL, 14.7 mmol) in Et2O (10 mL) 
was reacted with LiAlH4 (1.2 g, 30.9 mmol) in Et2O (20 mL) to obtain 1.1 g (87%) of the title 
alcohol as a colorless oil. The spectral data are consistent with those reported in the 
literature.154 
1H NMR (CDCl3, 400 MHz) :5.62-5.53 (m, 1H), 5.44-5.36 (m, 1H), 3.62 (t, J3 = 6.3 Hz, 
2H), 2.28-2.23 (m, 2H), 1.70-1.67 (m, 3H), 1.49 (br. s, 1H).13C-{1H} NMR (CDCl3, 100 
MHz) :128.7, 127.2, 62.1, 36.1, 18.2. GCMS (EI) m/z (intensity %) :41 (100), 54 
(0.2).IR neat (𝛖/cm-1) : 3330, 3024, 2936, 2363, 1757, 1449, 1045, 966. 
(E)-Hex-3-en-1-ol S3: 
 
Following the general procedure, (E)-hex-3-enoic acid (1.5 g, 12.8 mmol) in Et2O (10 mL) 
was reacted with LiAlH4 (1.0 g, 26.9 mmol) in Et2O (20 mL) to obtain 1.0 g (78%) of the title 
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alcohol as a colorless oil.The spectral data are consistent with those reported in the 
literature.155 
1H NMR (CDCl3, 400 MHz) :5.64-5.57 (m, 1H), 5.41-5.33 (m, 1H), 3.63 (t, J3 = 6.3 Hz, 
2H), 2.29-2.23 (m, 2H), 2.08-2.00 (m, 2H), 1.48 (br. s, 1H), 0.98 (t, J3 = 7.4 Hz, 3H).13C-
{1H}NMR (CDCl3, 100 MHz) :135.9, 124.9, 62.2, 36.1, 25.8, 13.9. GCMS (EI) m/z 
(intensity %) :43 (100), 61 (34), 89 (27), 70 (25), 45 (20).IR neat (𝛖/cm-1) : 3342, 2963, 
2360, 1441, 1047, 967. 
(E)-Oct-3-en-1-ol S4: 
 
Following the general procedure, (E)-oct-3-enoic acid (570 mg, 4 mmol) in Et2O (10 mL) was 
reacted with LiAlH4 (320 mg, 8.4 mmol) in Et2O (20 mL) to obtain 460 mg (90%) of the title 
alcohol as a colorless oil. The spectral data are consistent with those reported in the 
literature.156 
1H NMR (CDCl3, 400 MHz) :5.59-5.52 (m, 1H), 5.41-5.33 (m, 1H), 3.62 (t, J3 = 6.3 Hz, 
2H), 2.29-2.23 (m, 2H), 2.04-1.99 (m, 2H), 1.48 (br. s, 1H), 1.35-1.29 (m, 4H), 0.89 (t, J3 = 
7.1 Hz, 3H).13C-{1H} NMR (CDCl3, 100 MHz) :134.5, 125.8, 62.2, 36.1, 32.5, 31.8, 
14.1. GCMS (EI) m/z (intensity %):55 (100) 41 (59), 68 (34), 81 (33), 95 (8), 110 (8).IR 
neat (𝛖/cm-1) : 3345, 2926, 2362, 1462, 1047, 968.  
 General procedure for the synthesis of homoallyl alcohols S5-S7 from 
homopropargylic alcohols 
 
 
The homopropargylic alcohol (1 eq) was added dropwise to a suspension of LiAlH4 (3 eq) in 
THF:Toluene (1:1 v:v) at 0°C. After the addition the mixture was stirred at 100°C for 15 h 
and then cooled down to room temperature. The reaction was quenched by a sequential 
addition of water (1µL/mg of LiAlH4), 15% aq. NaOH (1µL/mg of LiAlH4), and water 
(3µL/mg of LiAlH4). The precipitate was filtered off on celite with Et2O. The resulting 
organic phase was dried over MgSO4, filtered, and concentrated under vacuum. The oily 
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residue was purified by silica gel column chromatography (Pent/Et2O 95:5 to 50:50) the 
corresponding (E)-homoallyl alcohol as an oil. 
(E)-non-3-en-1-ol S5: 
 
Following the general procedure, non-3-yn-1-ol (2.2 g, 15.7 mmol) was reacted with LiAlH4 
(reagent grade 95%, 1.9 g, 47.1 mmol) in THF:Toluene (50 mL) to obtain 1.4 g (63%) of the 
title compound as a colorless oil. The spectral data are consistent with those reported in the 
literature.144 
1H NMR (CDCl3, 400 MHz) :5.59-5.52 (m, 1H), 5.41-5.33 (m, 1H), 3.62 (t, J = 6.3 Hz, 
2H), 2.28-2.23 (m, 2H), 2.03-1.98 (m, 2H), 1.48 (br. s., 1H), 1.36-1.25 (m, 6H), 0.88 (t, J = 
6.9 Hz, 2H).13C-{1H} NMR (CDCl3, 100 MHz) :134.6, 125.8, 62.1, 36.1, 32.8, 31.5, 
29.3, 22.7, 14.2. GCMS (EI) m/z (intensity %):41 (100), 55 (93), 69 (68), 81 (42), 95 (24), 
124 (5). IR neat (𝛖/cm-1) : 3333, 2924, 2856, 2361, 1461, 1335, 1048, 968.  
(E)-4-cyclohexylbut-3-en-1-ol S6: 
 
Following the general procedure, 4-cyclohexylbut-3-yn-1-ol (200 mg, 1.3 mmol) was reacted 
with LiAlH4 (reagent grade 95%, 157 mg, 3.9 mmol) in THF:Toluene (4 mL) to obtain 190 
mg (94%) of the title compound as a colorless oil.  
1H NMR (CDCl3, 400 MHz) :5.54-5.48 (m, 1H), 5.36-5.29 (m, 1H), 3.61 (t, J = 6.3 Hz, 
2H), 2.27-2.22 (m, 2H), 1.97-1.89 (m, 1H), 1.73-1.62 (m, 5H), 1.48 (s, 1H), 1.31-1.00 (m, 
5H).13C-{1H} NMR (CDCl3, 125 MHz) :140.6, 123.2, 62.2, 40.9, 36.2, 33.3, 26.3, 26.2. 
IR neat (𝛖/cm-1) : 3328, 2922, 2851, 2362, 1448, 1047, 968.  
(E)-5,5-dimethylhex-3-en-1-ol S7: 
 
Following the general procedure, (E)-5,5-dimethylhex-3-yn-1-ol (200 mg,  1.6 mmol) was 
reacted with LiAlH4 (reagent grade 95%, 189 mg, 4.7 mmol) in THF:Toluene (4 mL) to 
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obtain 145 mg (71%) of the title compound as a colorless oil. The spectral data are consistent 
with those reported in the literature.4 ref above 
1H NMR (CDCl3, 400 MHz) :5.59 (dt, J = 15.6 Hz, J = 1.3 Hz, 1H), 5.29 (dt, J = 15.6 
Hz, J = 7.0 Hz, 1H), 3.62 (t, J = 6.3 Hz, 2H), 2.29-2.23 (m, 2H), 1.42 (s, 1H), 1.00 (s, 
9H).13C-{1H} NMR (CDCl3, 125 MHz) :145.6, 120.3, 62.2, 36.2, 33.2, 29.9. IR neat 
(𝛖/cm-1) : 3727, 2956, 2362, 1748, 1634, 1460, 1046, 972.  
 General procedure for the synthesis of 2,2,4,4-tetramethyloxazolidine-3-carboxylates 
2.7e, 2.21, 2.23-31, 2.33-37, 2.39 
 
A solution of the corresponding alcohol (1.0 eq) in THF (10 mL) was added dropwise to a 
suspension of sodium hydride (95% in mineral oil, 1.1 eq) in THF (30 mL) and the mixture 
was stirred for 30 min at room temperature. A solution of 2,2,4,4-tetramethyloxazolidine-3-
carbonyl chloride (unless otherwise stated) (1.05 eq) in THF (10 mL) was then added 
dropwise and the mixture was stirred for 12 h. After quenching with water, the solvent was 
removed under reduced pressure and Et2O (50 mL) was added to the crude mixture. The 
organic phase was washed with sat. aq. NaHCO3 (30 mL), water (30 mL) and brine (30 mL) 
and dried over MgSO4. After filtration, the solvent was evaporated and the residue was 
purified by silica gel column chromatography (Pent/Et2O 98:2 to 80:20). 
But-3-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.7e: 
 
Following the general procedure, 3-buten-1-ol (652 µL, 7.5 mmol) gave 1.55 g (91 %) of the 
corresponding carbamate as a colorless oil. The analytical data were in accordance with the 
literature.157 
1H NMR (CDCl3, 400 MHz, rotamers) :5.85-5.76 (m, 1H), 5.14-5.05 (m, 2H), 4.16-4.12 
(m, 2H), 3.71 (s, 2H), 2.44-2.37 (m, 2H), 1.55 (1.50) (2 br. s, 6H), (1.41) 1.34 (2 br. s, 
6H).13C-{1H} NMR (CDCl3, 100 MHz, rotamers) :152.9/152.2, 134.8, 117.2, 95.9/95.0, 
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76.5/76.2, 63.8, 60.7/59.9, 33.6, 26.6/25.42, 25.39/24.3. HRMS (ESI) m/z:calcd. for 
C12H21NO3Na ([M + Na]+): 250.1414; found: 250.1416.IR neat (𝛖/cm-1) : 2980, 2361, 1695, 
1404, 1343, 1259, 1207, 1068, 991, 768, 652. 
(E)-Pent-3-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate (E)-2.21: 
 
Following the general procedure, (E)-pent-3-en-1-ol (1.2 g, 13.9 mmol) gave 3.2 g (95%) of 
the corresponding carbamate as a colorless oil. 
1H NMR (CDCl3, 400 MHz, rotamers) :5.57-5.49 (m, 1H), 5.45-5.39 (m, 1H), 4.11-4.07 
(m, 2H), 3.72 (s, 2H), 2.37-2.32 (m, 2H), 1.66 (dd, J3 = 6.2 Hz, J4 = 1.1 Hz, 3H), 1.56 (1.51) 
(2 br. s, 6H), (1.42) 1.35 (2 br. s, 6H).13C-{1H} NMR (CDCl3, 100 MHz, 
rotamers) :153.0/152.2, 127.9, 127.2, 95.9/95.0, 76.5/76.2, 64.3, 60.6/59.9, 35.5, 
26.5/25.4, 25.3/24.3, 18.1. HRMS (ESI) m/z:calcd. for C13H23NO3Na ([M + Na]+): 264.1570; 
found: 264.1572. IR neat (𝛖/cm-1) : 2972, 2573, 2361, 1696, 1406, 1343, 1258, 1067, 966. 
(E)-pent-3-en-1-yl 3,3-dimethyl-1-oxa-4-azaspiro[4.5]decane-4-carboxylate2.23: 
 
Following the general procedure, (E)-pent-3-en-1-ol (100 mg, 1.16 mmol) was reacted with 
3,3-dimethyl-1-oxa-4-azaspiro[4.5]decane-4-carbonyl chloride (271 mg, 1.17 mmol, 1.01 eq) 
to give 200 mg (61%) of the corresponding carbamate as a colorless oil. 
1H NMR (CDCl3, 400 MHz, rotamers) :5.57-5.49 (m, 1H), 5.45-5.38 (m, 1H), 4.08 (t, J 
= 6.5 Hz, 2H), 3.68 (s, 2H), 2.41-2.31 (m, 3H), 2.22-2.15 (m, 1H), 1.66-1.50 (m, 11H), (1.41) 
1.34 (br. s, 6H).13C-{1H} NMR (CDCl3, 100 MHz, rotamers) :153.1/152.5, 127.9, 127.5, 
127.2, 97.3/96.6, 76.4/76.0, 64.2, 60.4/59.8, 34.1, 32.9, 32.5, 25.5, 24.9, 24.7, 24.5, 23.6, 
23.4, 18.1. HRMS (ESI) m/z:calcd. for C16H27NO3Na ([M + Na]+): 304.1883; found: 
304.1885. IR neat (𝛖/cm-1) : 3300, 2929, 2856, 2361, 1697, 1407, 1346, 1269, 1226, 1099, 
965. 
(E)-pent-3-en-1-yl diisopropylcarbamate 2.24: 
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Following the general procedure, (E)-pent-3-en-1-ol (250 mg, 2.9 mmol) was reacted with 
N,N-diisopropylcarbamoyl chloride (522 mg, 3.2 mmol, 1.1 eq) to give 300 mg (48%) of the 
corresponding carbamate as a colorless oil. 
1H NMR (CDCl3, 400 MHz) :5.54-5.47 (m, 1H), 5.45-5.37 (m, 1H), 4.15-3.53 (m, 4H), 
2.34-2.29 (m, 2H), 1.65-1.63 (m, 2H), 1.18 (d, J = 6.8 Hz, 12H).13C-{1H} NMR (CDCl3, 100 
MHz) :156.0, 127.7, 127.3, 64.4, 45.6 (br. s), 32.7, 21.1 (br. s), 18.1. HRMS (ESI) 
m/z:calcd. for C12H23NO2Na ([M + Na]+): 236.1621; found: 236.1619. IR neat (𝛖/cm-1) : 
2969, 2360, 1695, 1437, 1370, 1311, 1219, 1157, 1066. 
(E)-Pent-2-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.26 : 
 
Following the general procedure, (E)-pent-2-en-1-ol (345 mg, 4 mmol) gave 850 mg (88%) of 
the corresponding carbamate as a colorless oil. 
1H NMR (CDCl3, 400 MHz, rotamers) :5.82-5.78 (m, 1H), 5.61-5.54 (m, 1H) 4.54-4.52 
(m, 2H), 3.73 (s, 2H), 2.11-2.04 (m, 2H), 1.56 (1.52) (2 br. s, 6H), (1.42) 1.36 (2 br. s, 6H), 
1.00 (t, J3 = 7.4 Hz, 3H).13C-{1H} NMR (CDCl3, 100 MHz, rotamers) :152.8/152.1, 
137.2/137.1, 123.6/123.6, 95.9/95.0, 76.5/76.26, 65.4, 60.7/59.8, 26.6, 25.4, 24.3, 13.4. 
HRMS (ESI) m/z:calcd. for C13H23NO3Na ([M + Na]+): 264.1570; found: 264.1575. IR neat 
(𝛖/cm-1) : 2968, 2871, 2361, 1701, 1405, 1348, 1261, 1065. 
Pentyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate2.27: 
 
Following the general procedure, pentanol (650 µL, 4 mmol) gave 820 mg (84%) of the 
corresponding carbamate as a colorless oil. 
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1H NMR (CDCl3, 400 MHz, rotamers) :4.09-4.05 (m, 2H), 3.73 (s, 2H), 1.68-1.63 (m, 
2H), 1.56 (1.52) (2 br. s., 6H), 1.44-1.31 (m, 10H), 0.93-0.89 (m, 3H).13C-{1H} NMR 
(CDCl3, 100 MHz, rotamers) :153.1/152.4, 95.9/94.9, 76.5/76.2, 64.7, 60.6/59.7, 28.7, 
28.5, 26.6/25.43, 25.39/24.3, 22.4, 14.1. HRMS (ESI) m/z:calcd. for C13H25NO3Na ([M + 
Na]+): 266.1727; found: 266.1729.IR neat (𝛖/cm-1) : 2961, 2867, 2360, 1700, 1408, 1348, 
1260, 1096. 
2-(2-methylcyclopropyl)ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate2.29 : 
 
To a solution of (E)-Pent-3-en-1-ol (300 mg, 3.5 mmol, 1 eq) in dichloromethane (25 mL) at -
20°C (acetone bath, cryostat) was carefully added diethylzinc (8.7 mL of a 1.5 M solution in 
toluene, 8.7 mmol, 2.5 eq) followed by addition of diiodomethane (0.56 mL, 7 mmol, 2 eq). 
The mixture was stirred for 5 min at this temperature, and was allowed to warm up to 20°C 
and stirred for 15h. Sat. aq. NH4Cl was added (15 mL) and the aqueous phase was extracted 
with Et2O (3x20 mL). The combined organic phase was washed with sat. aq. NaHCO3 (20 
mL), brine (20 mL), dried over MgSO4, filtrated, and then concentrated under vacuum. The 
residue was filtrated by silica gel column chromatography (Pent/Et2O 80:20) to obtain 200 mg 
(ca. 60%) of the intermediate 2-(2-methylcyclopropyl)ethan-1-olS8 (containing ~15% 
inseparable starting material) as a colorless oil. 
Following the general procedure, the intermediate 2-(2-methylcyclopropyl)ethan-1-ol S8 (200 
mg, ca.2 mmol, containing ~15% inseparable alkene) gave 250 mg (ca. 45%) of the 
corresponding carbamate (containing ~10% inseparable corresponding alkene) as a colorless 
oil. 
1H NMR (CDCl3, 400 MHz, rotamers) :4.11-4.07 (m, 2H), 3.70 (s, 2H), 1.54-1.48 (m, 
8H), (1.40) 1.34 (2 br. s, 6H), 0.99 (d, J = 5.9 Hz, 3H), 0.47-0.38 (m, 2H), 0.24-0.15 (m, 
2H).13C-{1H} NMR (CDCl3, 100 MHz, rotamers) :153.1/152.4, 95.9/94.9, 76.5/76.2, 
64.8, 60.6/59.7, 33.7, 26.6/25.6, 25.4/24.3, 19.0, 16.7, 19.9, 12.6. HRMS (ESI) m/z:calcd. for 
C14H25NO3Na ([M + Na]+): 278.1727; found: 278.1728. IR neat (𝛖/cm-1) : 2984, 2361, 1701, 
1408, 1352, 1261, 1098. 
(3E,5E)-hepta-3,5-dien-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate2.30 : 
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(E)-hept-5-en-3-yn-1-olS9 was synthesised using a modified procedure from the literature.158 
To a 3-neck 100 mL round-bottomed flask equipped with a dry ice condenser was added 
trimethylsilyldiazomethane (4 mL of a 2 M solution in hexane, 8 mmol, 1.1 eq) and THF (10 
mL). The solution was cooled to -78°C (acetone bath, cryostat) and n-BuLi (3.25 mL of a 
2.5M solution in hexanes, 8 mmol, 1.1 eq) was added slowly. The resulting orange solution 
was stirred for 10 min at this temperature, and then a solution of crotonaldehyde (0.59 mL, 
7.27 mmol, 1 eq) in THF (5 mL) was added. Stirring was continued at -78°C for 10 min, and 
then at 0°C (water, ice) for  10 min, before being cooled back to -78°C. n-BuLi (4.43 mL of a 
2.5M solution in hexanes, 10.9 mmol, 1.5 eq) was slowly added and the reaction was allowed 
to stir for 15 min. BF3.Et2O (2.88 mL of a 48% solution in Et2O, 10.9 mmol, 1.5 eq) was 
added and the solution was stirred for 15 min at this temperature before the addition of 
ethylene oxide (4.85 mL of a 3M solution in THF, 14.5 mmol, 2 eq). The solution was stirred 
for 1 h, quenched with MeOH (2 mL), stirred for an additional 5 min, and then allowed to 
warm up to room temperature. Water (20 mL) and Et2O (20 mL) were added to the mixture. 
The aqueous layer was separated and extracted with Et2O (2x20 mL). The organice layers 
were combined, washed with brine, dried over MgSO4, filtrated and concentrated under 
reduced pressure at 0°C. The oily residue was filtrated by silica gel column chromatography 
(Pent/Et2O 80:20) to obtain 400 mg of an oil containing the intermediate (E)-hept-5-en-3-yn-
1-olS9 along with inseparable unknown products. 
A solution of the intermediate (E)-hept-5-en-3-yn-1-olS9 (310 mg, ca. 2.8 mmol, ca. 1 eq) in 
THF (0.25 mL) was added to a suspension of LiAlH4 (135 mg, 3.8 mmol, 1.2 eq) in 
THF:Triglyme (7.25 mL:2.5 mL) at 0°C (water, ice) over 5 min. After addition, the mixture 
was stirred at 80°C for 15 h and then cooled down to room temperature. The reaction was 
quenched by a sequential addition of water (200µL), 15% aq. NaOH (200µL), and water (1 
mL). The precipitate was filtrated off on celite with Et2O. The resulting organic phase was 
dried over MgSO4, filtrated, and concentrated under vacuum. The oily residue was filtrated by 
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silica gel column chromatography (Pent/Et2O 80:20) to obtain 130 mg of an oil containing  
(3E,5E)-hepta-3,5-dien-1-olS10 along with inseparable unknown products. 
Following the general procedure, (3E,5E)-hepta-3,5-dien-1-olS10 (130 mg, ca. 1.2 mmol) 
gave 140 mg (9% on 3 steps) of the corresponding carbamate as a colorless oil. 
1H NMR (CDCl3, 400 MHz, rotamers) :6.11-5.98 (m, 2H), 5.65-5.49 (m, 2H), 4.14-4.10 
(m, 2H), 3.72 (s, 2H), 2.43-2.39 (m, 2H), 1.73 (d, J = 7.3Hz, 2H), 1.56 (1.50) (2 br. s, 6H), 
(1.42) 1.35 (2br. s, 6H).13C-{1H} NMR (CDCl3, 100 MHz, rotamers) :(C=O missing), 
133.0, 131.40/131.37, 128.21/128.15, 126.97/126.91, 95.9/95.1, 76.5/76.2, 64.1, 60.7/59.9, 
32.5/30.5, 26.6/25.5, 25.4/24.3, 18.2. HRMS (ESI) m/z:calcd. for C15H25NO3Na ([M + Na]+): 
290.1727; found: 290.1727. IR neat (𝛖/cm-1) : 2973, 2361, 1693, 1408, 1345, 1259, 1207, 
1067. 
(Z)-3-methylpent-3-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.31 : 
 
Following the general procedure, (Z)-3-methylpent-3-en-1-ol159 (300 mg, 3 mmol) gave 370 
mg (48%) of the corresponding carbamate as a colorless oil. 
1H NMR (CDCl3, 400 MHz, rotamers) :5.35-5.30 (m, 1H), 4.15-4.11 (m, 2H), 3.72 s, 
2H), 2.43-2.38 (m, 2H), 1.72-1.71 (m, 3H), 1.60-1.59 (m, 3H), 1.56 (1.50) (2 br. s., 6H), 
(1.42) 1.34 (2 br. s., 6H).13C-{1H} NMR (CDCl3, 100 MHz, rotamers) :153.0/152.3, 
131.8, 121.8, 95.9/95.0, 76.5/76.2, 62.4, 60.6/59.8, 31.0/30.9, 26.5, 25.4, 25.3, 24.3, 
23.2/23.1, 13.5. HRMS (ESI) m/z:calcd. for C14H25NO3Na ([M + Na]+): 278.1727; found: 
278.1722. IR neat (𝛖/cm-1) : 2976, 2361, 1699, 1454, 1407, 1348, 1260, 1069. 
(E)-hex-3-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.33: 
 
Following the general procedure, (E)-hex-3-en-1-ol (407 mg, 4.1 mmol) gave 930 mg (90%) 
of the corresponding carbamate as a colorless oil. 
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1H NMR (CDCl3, 400 MHz, rotamers) :5.58-5.51 (m, 1H), 5.41-5.33 (m, 1H), 4.10-4.06 
(m, 2H), 3.70 (s, 2H), 2.35-2.29 (m, 2H), 2.03-1.96 (m, 2H), 1.54 (1.49) (2 br. s, 6H), (1.40) 
1.33 (2 br. s, 6H), 0.94 (t, J = 7.5 Hz, 3H).13C-{1H} NMR (CDCl3, 100 MHz, 
rotamers) :153.0/152.2, 134.9, 125.0, 95.9/95.0, 76.5/76.2, 64.28/64.23, 60.6/59.8, 32.5, 
26.6/25.42, 25.7, 25.36/24.3, 13.8. HRMS (ESI) m/z:calcd. for C14H25NO3Na ([M + Na]+): 
278.1727; found: 278.1729. IR neat (𝛖/cm-1) : 2966, 2871, 2361, 1698, 1406, 1342, 1260, 
1097, 967. 
 (E)-non-3-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.34: 
 
Following the general procedure, (E)-non-3-en-1-ol (500 mg, 3.52 mmol) gave 940 mg (90%) 
of the corresponding carbamate as a colorless oil. 
1H NMR (CDCl3, 400 MHz, rotamers) :5.55-5.48 (m, 1H), 5.42-5.34 (m, 1H), 4.11-4.07 
(m, 2H), 3.72 (s, 2H), 2.37-2.30 (m, 2H), 2.00-1.95 (m, 2H), 1.55 (1.50) (2 br. s, 6H), 1.41-
1.23 (m, 12H), 0.87 (t, J = 6.9 Hz, 3H).13C-{1H} NMR (CDCl3, 100 MHz, 
rotamers) :153.0/152.3, 133.5, 125.8, 95.9/95.0, 76.5/76.2, 64.34/64.30, 60.6/59.9, 32.7, 
32.5, 31.5, 29.2, 26.6/25.5, 25.4/24.3, 22.7, 14.2. HRMS (ESI) m/z:calcd. for C17H31NO3Na 
([M + Na]+): 320.2196; found: 320.2199. IR neat (𝛖/cm-1) : 2930, 2361, 1701, 1407, 1344, 
1260, 1098. 
(E)-6-((tert-butyldimethylsilyl)oxy)hex-3-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-
carboxylate 2.35: 
 
Following the general procedure, (E)-6-((tert-butyldimethylsilyl)oxy)hex-3-en-1-ol(130 mg, 
0.56 mmol, E:Z 85:15) gave 120 mg (55%) of the corresponding carbamate as a colorless oil. 
1H NMR (CDCl3, 400 MHz, rotamers) :5.56-5.44 (m, 2H), 4.11-4.08 (m, 2H), 3.72 (s, 
2H), 3.61-3.59 (m, 2H), 2.38-2.32 (m, 2H), 2.24-2.20 (m, 2H), 1.55 (1.50) (2 br. s, 6H), (1.41) 
1.35 (2 br. s, 6H), 0.88 (s, 9H), -0.04 (s, 6H).13C-{1H} NMR (CDCl3, 125 MHz, 
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rotamers) :153.0/152.2, 129.5, 128.2, 95.9/95.0, 76.5/76.3, 64.22/64.17, 63.2, 60.7/59.9, 
36.5, 32.6, 26.6/25.5, 26.1, 25.4/24.3, 18.5, -5.11. HRMS (ESI) m/z:calcd. for 
C20H39NO4SiNa ([M + Na]+): 408.2541; found: 408.2546. IR neat (𝛖/cm-1) : 2956, 2361, 
1701, 1461, 1407, 1344, 1257, 1098. 
 
(E)-4-cyclohexylbut-3-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.36: 
 
Following the general procedure, (E)-4-cyclohexylbut-3-en-1-ol (150 mg, 0.97 mmol) gave 
230 mg (76%) of the corresponding carbamate as a colorless oil. 
1H NMR (CDCl3, 400 MHz, rotamers) :5.49-5.44 (m, 1H), 5.39-5.30 (m, 1H), 4.12-4.07 
(m, 2H), 3.72 (s, 2H), 2.36-2.29 (m, 2H), 1.94-1.86 (m, 1H), 1.69-1.65 (m, 5H), 1.55 (1.50) (2 
br. s, 6H), (1.41) 1.35 (2 br. s, 6H), 1.30-0.98 (m, 5H).13C-{1H} NMR (CDCl3, 125 MHz, 
rotamers) :153.0/152.3, 139.4, 123.44/123.40, 95.9/95.1, 76.5/76.3, 64.4/64.3, 60.6/59.9, 
40.9, 33.2, 32.6, 26.7, 26.3, 26.2,  25.5, 24.3. HRMS (ESI) m/z:calcd. for C18H31NO3Na ([M 
+ Na]+): 332.2196; found: 332.2197. IR neat (𝛖/cm-1) : 22925, 2853, 2361, 1697, 1450, 
1406, 1343, 1259, 1208, 1097, 969. 
(E)-5,5-dimethylhex-3-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.37: 
 
Following the general procedure, (E)-5,5-dimethylhex-3-en-1-ol(125 mg, 0.98 mmol) gave 
200 mg (72%) of the corresponding carbamate as a colorless oil. 
1H NMR (CDCl3, 400 MHz, rotamers) :5.56-5.52 (m, 1H), 5.35-5.26 (m, 1H), 4.12-4.08 
(m, 2H), 3.71 (s, 2H), 2.36-2.30 (m, 2H), 1.55 (1.50) (2 br. s, 6H), (1.41) 1.34 (2 br. s, 6H), 
0.97 (s, 9H).13C-{1H} NMR (CDCl3, 125 MHz, rotamers) :153.0/152.3, 144.3, 
120.78/120.74, 95.9/95.0, 765/76.3, 64.4/64.3, 60.6, 59.9, 33.1, 32.6, 29.8, 26.7, 25.5, 24.3. 
HRMS (ESI) m/z:calcd. for C16H29NO3Na ([M + Na]+): 306.2040; found: 306.2036. IR neat 
(𝛖/cm-1) : 2957, 2361, 1697, 1509, 1460, 1407, 1344, 1260, 1092, 972. 
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(E)-hex-3-ene-1,6-diyl bis(2,2,4,4-tetramethyloxazolidine-3-carboxylate)2.39: 
 
Following the general procedure, (E)-hex-3-ene-1,6-diol(290 mg, 2.5 mmol, E:Z 85:15) was 
reacted withsodium hydride (95% in mineral oil, 2.15 eq) and 2,2,4,4-tetramethyloxazolidine-
3-carbonyl chloride (2.1 eq) to give 311 mg (28%, E/Z) of the corresponding carbamate as a 
white solid. 
1H NMR (CDCl3, 400 MHz, rotamers) :5.53 (br. s, 1H), 4.12-4.07 (m, 2H), 3.71 (s, 2H), 
2.44-2.42 (m, 2H, mino.), 2.37-2.35 (m, 2H, majo.), 1.54 (1.49) (2 br. s, 6H), (1.41) 1.34 (2 
br. s, 6H).13C-{1H} NMR (CDCl3, 125 MHz, rotamers) :152.9/152.1, 128.9 (majo.), 
127.9 (mino.), 95.9/95.0, 76.5/76.2, 64.0, 60.7, 59.9, 32.6 (majo.), 27.4 (mino.), 26.6/25.43, 
25.41/24.3. HRMS (ESI) m/z:calcd. for C22H38N2O6Na ([M + Na]+): 449.2622; found: 
449.2626. IR neat (𝛖/cm-1) : 2980, 2361, 1685, 1405, 1333, 1260, 1205, 1067.M.p : 67°C 
 Synthesis of (E)-pent-3-en-1-yl 2,4,6-triisopropylbenzoate 2.25 
 
DIAD (0.68 mL, 3.5 mmol, 1.2 eq) was added dropwise over 10 min to a stirred solution of 
PPh3 (913 mg, 3.5 mmol, 1.2 eq), 2,4,6-triisopropyl benzoic acid (792mg, 3.2 mmol, 1.1 eq), 
and (E)-Pent-3-en-1-ol  (250 mg, 2.9 mmol, 1 eq) in THF (50 mL) at 0°C. The reaction 
mixture was stirred for 4 h at r.t., then the solvent was evaporated under vacuum, and the 
residue was dissolved in pentane (15mL) for 5 min. The white suspension was filtrated and 
the cake was washed with pentane (100 mL). The solvent was removed under vacuum, to 
obtain a yellow oil. The crude mixture was purified by column chromatography (Pent/Et2O 
100:0 to 90:10) to give 850mg (93%) of the ester as a colorless oil. 
1H NMR (CDCl3, 400 MHz) :7.00 (s, 2H), 5.60-5.53 (m, 1H), 5.48-5.41 (m, 1H), 4.32 (t, 
J = 6.7 Hz, 2H), 2.92-2.81 (m, 3H), 2.45-2.39 (m, 2H), 1.67-1.65 (m, 3H), 1.25-1.23 (m, 
18H).13C-{1H} NMR (CDCl3, 100 MHz) :171.1, 150.2, 144.9, 130.8, 128.1, 126.7, 121.0, 
64.8, 34.6, 32.1, 31.6, 24.3, 24.1, 18.2. HRMS (ESI) m/z:calcd. for C21H32O2Na ([M + Na]+): 
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339.2295; found: 339.2300. IR neat (𝛖/cm-1) : 2962, 2361, 1727, 1460, 1384, 1250, 1137, 
1075. 
 Synthesis of (Z)-Pent-3-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate (Z)-2.21 
 
A mixture of pent-3-yn-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate2.7j (800 mg, 3.3 
mmol, 1 eq), quinoline (200 µL, 1.7 mmol, 0.5 eq) and Lindlar’s catalyst (Pd 5% on CaCO3, 
poisoned with Pb, 50 mg) in ethyl acetate (10 mL) was stirred under hydrogen atmosphere 
(balloon) at 20°C for 2 h. The reaction mixture was then filtrated through a pad of celite, and 
washed with 1 M aq. HCl (2x10mL). The organic layer was dried over MgSO4, filtrated and 
then concentrated under vacuum. The oily residue was purified by silica gel column 
chromatography (Pent/Et2O 98:2 to 90:10) to obtain 750 mg (93%) of the title product as a 
colorless oil. 
1H NMR (CDCl3, 400 MHz, rotamers) :5.49-5.41 (m, 1H), 5.32-5.26 (m, 1H), 4.00-3.96 
(m, 2H), 3.60 (s, 3H), 2.31-2.28 (m, 2H), 1.52 (d, J = 6.7 Hz, 3H), 1.44 (1.39) (2 br. s, 6H), 
(1.30) 1.23 (2 br. s, 6H).13C-{1H} NMR (CDCl3, 100 MHz, rotamers) :152.9/152.2, 
126.5/126.4, 126.2, 95.9/95.0, 76.5/76.2, 64.1, 60.6/59.8, 26.9, 26.5/25.4, 25.3/24.2, 13.0. 
HRMS (ESI) m/z: calcd. for C13H23NO3Na ([M + Na]+): 264.1570; found: 264.1569. IR neat 
(𝛖/cm-1) : 2979, 2361, 1699, 1407, 1345, 1260, 1208, 1096.  
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General procedures for the -arylation 
General procedure A : arylation with TMEDA 
In a tubular reactor (100 mm x 16 mm)capped with a rubber septum, a solution of the 
carbamate(0.207 mmol, 1 eq) and TMEDA (44 µL, 0.29 mmol, 1.4 eq) in dry diethyl ether 
(1.5 mL) under argon was stirred and cooled down to -78°C (acetone bath, cryostat). s-
Butyllithium (0.29 mmol, 1.4 eq, solution in hexane) was added dropwise, and the mixture 
was stirred for 4 h. A suspension of zinc acetate (57 mg, 0.31 mmol, 1.5 eq) in dry THF (1.5 
mL) was sonicated for 30 min and added dropwise to the mixture. The resulting solution was 
stirred for 30 min at -78°C, and then allowed to warm up to 20°C over 30 min. The solvents 
were evaporated over 30 min under high vacuum, and a solution of Pd2(dba)3 (3.3 mg, 3.6 
µmol, 1.75 %mol) and 2.L27 (2.8 mg, 7.3 µmol, 3.5 %mol) in dry toluene (1.5 mL) was 
added, followed by the aryl bromide (0.15 mmol, 0.7 eq). The mixture was then vigorously 
stirred and heated to 60°C for 18h. After cooling down, the reaction was quenched with sat. 
aq. NH4Cl (2 mL), and the organic phase was diluted with EtOAc (3 mL) and separated. The 
aqueous phase was extracted with EtOAc (2 x 3 mL). The combined organic layers were dried 
over MgSO4, filtrated over a pad of celite, and evaporated under vacuum. The residue was 
purified by preparative reversed-phase HPLC (MeCN/H2O) to afford the -arylated products. 
General procedure B : enantioselective arylation with ()-sparteine 
In a tubular reactor (100 mm x 16 mm)capped with a rubber septum, a solution of the 
carbamate(0.207 mmol, 1 eq) and ()-sparteine (66 µL, 0.29 mmol, 1.4 eq) in dry diethyl 
ether (1.5 mL) under argon was stirred and cooled down to -78°C (acetone bath, cryostat). s-
Butyllithium (0.29 mmol, 1.4 eq, solution in hexane) was added dropwise, and the mixture 
was stirred for 4 h. A suspension of zinc acetate (57 mg, 0.31 mmol, 1.5 eq) in dry THF (1.5 
mL) was sonicated for 30 min and added dropwise to the mixture. The resulting solution was 
stirred for 30 min at -78°C, and then allowed to heat up to 20°C over 30 min. The solvents 
were evaporated over 30 min under high vacuum, and a solution of Pd2(dba)3 (3.3 mg, 3.6 
µmol, 1.75 %mol) and 2.L27 (2.8 mg, 7.3 µmol, 3.5 %mol) (unless otherwise stated) in dry 
toluene (1.5 mL) was added, followed by the aryl bromide (0.15 mmol, 0.7 eq). The mixture 
was then vigorously stirred and heated to 60°C for 18h. After cooling down, the reaction was 
quenched with sat. aq. NH4Cl (2 mL), and the organic phase was diluted with EtOAc (3 mL) 
and separated. The aqueous phase was extracted with EtOAc (2 x 3 mL). The combined 
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organic layers were dried over MgSO4, filtrated over a pad of celite, and evaporated under 
vacuum. The residue was purified by preparative reversed-phase HPLC (MeCN/H2O) to 
afford the -arylated products. 
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Arylation of carbamate (E)-2.21 : products 2.21g, 2.32a-i 
 Arylations with 1-bromo-2-fluorobenzene : products 2.21g and isomers 
3-(2-fluorophenyl)pent-1-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.21g : 
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Following the general procedure A, (E)-pent-3-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-
carboxylate (50 mg) was arylated with 1-bromo-2-fluorobenzene (15.8 µL) to give 29 mg 
(60%) of the title compound (75:25 Z:E ratio) as an oil. 
1H NMR (CDCl3, 400 MHz, rotamers) :7.24-7.06 (m, 4H, H1, HAr), 7.02-6.97 (m, 1H, 
HAr), 5.54-5.47 (m, 1H, H2E), 4.99-4.95 (m, 1H, H2Z), 4.07-3.96 (m, 1H, H3Z), 3.78-3.73 (m, 
2H, H6), 3.51-3.46 (m, 1H, H3E), 1.79-1.62 (m, 2H, H4), 1.64-1.32 (m, 12H, H7, H7’, H8, H8’), 
0.92-0.87 (m, 3H, H5). 13C-{1H} NMR (CDCl3, 125 MHz, rotamers) :162.0/161.9-
159.6/159.5 (d of rotamers, J = 245.4 Hz, C13), 150.0/149.1 (C11), 136.8/136.6 (C1E), 
134.8/134.7 (C1Z), 131.8/131.7 (C12Z), 131.4/131.3 (C12E), 128.8-128.5 (CAr), 127.9-127.6 
(CAr), 124.3-124.2 (CAr), 115.8/115.4 (CAr), 114.7/114.6 (C2E), 113.2/113.1 (C2Z), 
96.3/96.1/95.4 (C10), 76.6/76.4/76.2 (C6), 61.2/61.0/60.4/60.3 (C9), 39.6 (C3E), 36.63/36.56 
(C3Z), 29.4 (C4Z), 28.4 (C4E), 26.9-24.0 (C7, C7’, C8, C8’), 12.3 (C5E), 12.2 (C5Z)..F-{1H} 
NMR (CDCl3, 376 MHz, rotamers) :  -118.31/-118.32 (F13E), -118.35/-118.41 (F13Z). 
HRMS (ESI) m/z:calcd. for C19H26FNO3Na ([M + Na]+): 358.1789; found: 358.1794.IR 
neat (𝛖/cm-1) :2971, 2361, 1717, 1378, 1225, 1089. 
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References of the racemic products : 
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Observation and isolation of - and -products (E)-2.21a and (E)-2.21b : 
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After arylation following the general procedure A, 6 mg (12%) of amixture of - and -
arylated products (ratio 47:57) was isolated for analytical purpose. 
-product 2.21a : 
1H NMR (CDCl3, 400 MHz, rotamers), characteristic peaks :6.00-5.98 (m, 1H, H1), 
5.51-5.46 (m, 1H, H4), 5.39-5.33 (m, 1H, H3), 2.65-2.57 (m, 2H, H2), 1.62-1.60 (m, 3H, H5). 
13C-{1H} NMR (CDCl3, 125 MHz, rotamers), characteristic peaks :125.95/125.89 
(C3), 71.04/70.99 (C1), 31.11/39.05 (C2), 18.1 (C5).F-{1H} NMR (CDCl3, 376 MHz, 
rotamers) : -117.65/-117.68. 
-product 2.21b : 
1H NMR (CDCl3, 400 MHz, rotamers), characteristic peaks :5.65-5.56 (m, 2H, H3, 
H4), 4.40-4.35 (m, 1H, H1), 4.28-4.22 (m, 1H, H1), 4.04-3.97 (m, H2), 1.68-1.67 (m, 3H, 
H5).13C-{1H} NMR (CDCl3, 125 MHz, rotamers), characteristic peaks :66.7 (C1), 
42.03/41.98 (C2), 18.2 (C5).F-{1H} NMR (CDCl3, 376 MHz, rotamers) : -118.11/-
118.13. 
IR neat (𝛖/cm-1) of the mixture : 2978, 2361, 1696, 1398, 1341, 1258, 1064, 966. 
Selective-Arylation of (E)-2.21 : synthesis of enantiopure (E)-2.21a : 
()-(S,E)-1-(2-fluorophenyl)pent-3-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate : 
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Arylation with TMEDA : 
In a tubular reactor (100 mm x 16 mm)capped with a rubber septum, a solution of (E)-pent-3-
en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate (50 mg, 0.207 mmol, 1 eq) and TMEDA 
(44 µL, 0.29 mmol, 1.4 eq) in dry diethyl ether (1.5 mL) under argon was stirred and cooled 
down to -78°C (acetone bath, cryostat). s-Butyllithium (0.29 mmol, 1.4 eq, solution in 
hexane) was added dropwise, and the mixture was stirred for 4 h. A suspension of zinc acetate 
(57 mg, 0.31 mmol, 1.5 eq) in dry THF (1.5 mL) was sonicated for 30 min and added 
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dropwise to the mixture. The resulting solution was stirred for 30 min at -78°C, and then 
allowed to heat up to 20°C over 30 min. The solvents were evaporated over 30 min under 
high vacuum, and a solution of Pd2(dba)3 (3.3 mg, 3.6 µmol, 1.75 %mol) and RuPhos (3.4 
mg, 7.3 µmol, 3.5 %mol) in dry toluene (1.5 mL) was added, followed by 1-bromo-2-
fluorobenzene (15.8 µL, 0.15 mmol, 0.7 eq). The mixture was then vigorously stirred and 
heated to 60°C for 18h. After cooling down, the reaction was quenched with sat. aq. NH4Cl (2 
mL), and the organic phase was diluted with EtOAc (3 mL) and separated. The aqueous phase 
was extracted with EtOAc (2 x 3 mL). The combined organic layers were dried over MgSO4, 
filtrated over a pad of celite, and evaporated under vacuum. The residue was purified by 
preparative reversed-phase HPLC (MeCN/H2O) to afford 17 mg (35%) of the racemictitle 
compound as an oil. 
Arylation with (+)-sparteine : 
The same procedure as for the arylation with TMEDA was used, using ()-sparteine (88 µL, 
0.29 mmol, 1.4 eq) as the diamine, instead of TMEDA. The crude residue was purified by 
preparative reversed-phase HPLC (MeCN/H2O) to afford 20.5 mg (42%) of the 
enantioenrichedtitle compound as an oil. 
1H NMR (CDCl3, 400 MHz, rotamers) :7.34-7.23 (m, 2H, HAr), 7.13-7.10 (m, 1H, HAr), 
7.05-7.01 (m, 1H, HAr), 5.99 (t, J = 6.6 Hz, 1H, H1), 5.50-5.32 (m, 2H, H3, H4), 3.76-3.70 (m, 
2H, H6, 2.65-2.57 (m, 2H, H2), 1.62-1.34 (m, 15H, H5, H7, H7’, H8, H8’). 13C-{1H} NMR 
(CDCl3, 125 MHz, rotamers) :161.0-159.0 (d of rotamers, J = 247.6 Hz, C13), 
152.0/151.2 (C11), 129.24/129.17 (CAr), 128.9 (C4), 128.5-128.2 (C12), 128.1/128.0 (CAr), 
126.0/125.9 (C3), 124.12/124.09 (CAr), 115.8/115.7 (CAr), 96.2/95.1 (C10), 76.6/76.2 (C6), 71.0 
(C1), 60.9/60.0 (C9), 39.1/39.0 (C2), 26.8-24.3 (C7, C7’, C8, C8’), 18.1 (C5).F-{1H} NMR 
(CDCl3, 376 MHz, rotamers) : -117.62/-117.64 (F13). HPLC separation conditions : 
Chiralpak IC column, n-heptane/i-PrOH 99:1, flow rate 0.5 mL/min, 25°C, tR10.9 min for 
(R)-enantiomer (minor) and tR 12.7 min for (S)-enantiomer (major). e.r. = 1:99.[]D20 = +5.5° 
(c=0.8, CHCl3).HRMS (ESI) m/z:calcd. for C19H26NO3Na ([M + Na]+) : 358.1789; found: 
358.1784. IR neat (𝛖/cm-1) : 2960, 2361, 1701, 1397, 1258, 10630.[]D20 =  -3.1° (c=1, 
CHCl3). 
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 Scale-up of the arylation of 2.21 
In a oven-dried Schlenck tube (75 mm x 40 mm) set up with a rubber septum, a solution of 
(E)-2.21 (603 mg, 2.5 mmol, 1 eq) and TMEDA (530 µL, 3.5 mmol, 1.4 eq) in dry diethyl 
ether (10 mL) under argon was stirred and cooled down to -78°C (acetone bath, cryostat). s-
Butyllithium (3.5 mmol, 1.4 eq, solution in hexane) was added dropwise, and the mixture was 
stirred for 4 h. A suspension of zinc acetate (688 mg, 3.8 mmol, 1.5 eq) in dry THF (10 mL) 
was sonicated for 30 min and added dropwise to the mixture. The resulting solution was 
stirred for 30 min at -78°C, and then allowed to warm-up to 20°C over 30 min. The solvents 
where evaporated over 30 min under high vacuum, and a solution of Pd2(dba)3 (40.1 mg, 44 
µmol, 1.75 %mol) and 2.L27 (33.5 mg, 88 µmol, 3.5 %mol) in dry toluene (10 mL) was added 
to solve the residue, followed by 1-Br-2-F-benzene (191 µL, 1.75 mmol, 0.7 eq). The mixture 
was then vigorously stirred at60°C for 18h. After cooling down, the reaction was quenched 
with sat. aq. NH4Cl (10 mL), and the organic phase was diluted with EtOAc (25 mL) and 
separated. The aqueous phase was extracted with EtOAc (2 x 25 mL). The combined organic 
layers were washed with water and dried over MgSO4, filtrated over a pad of celite, and 
evaporated under vacuum. The residue was purified bypreparative reversed-phase HPLC 
(MeCN/H2O) to afford 397 mg (68%) of the -product 2.21g (74:26 Z:E ratio). 
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 Products 2.32a-h 
3-(2-(trifluoromethoxy)phenyl)pent-1-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-
carboxylate2.32a : 
   
Following the general procedure, (E)-pent-3-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-
carboxylate (50 mg) was arylated with 1-bromo-2-(trifluoromethoxy)benzene (21.6 µL) to 
give 37 mg (64%) of the title compound (61:39 Z:E ratio) as an oil. 
1H NMR (CDCl3, 400 MHz, rotamers) :7.34-7.21 (m, 4H, HAr), 7.10-7.07 (m, 1H, H1), 
5.48-5.40 (m, 1H, H2E), 4.93-4.88 (m, 1H, H2Z), 4.18-4.07 (m, 1H, H3Z), 3.77-3.74 (m, 2H, 
H6),  3.63-3.58 (m, 1H, H3E), 1.80-1.38 (m, 14H, H4, H7, H7’, H8, H8’), 0.92-0.85 (m, 3H, H5). 
13C-{1H} NMR (CDCl3, 125 MHz, rotamers) :150.2/150.0 (C11Z), 149.3/149.2 (C11E), 
149.2/147.1 (C13), 137.1-136.8 (C1E, CAr), 135.0/134.9 (C1Z), 128.7/128.5 (CAr), 127.5/127.4 
(CAr), 127.2-126.9 (CAr), 122.1/122.0-119.52/119.46 (q of rotamers, J = 257 Hz, C14), 
120.7/120.0 (CAr), 96.4-95.4 (C10), 76.6-76.2 (C6), 61.2-60.4 (C9), 38.7 (C3E), 36.3 (C3Z), 
30.0 (C4E), 29.8 (C4Z), 26.9-24.0 (C7, C7’, C8, C8’), 12.1 (C5).F-{1H} NMR (CDCl3, 376 
MHz, rotamers) :  -56.41/-56.43(F14Z), -56.74 (F13E).HRMS (ESI) m/z:calcd. for 
C20H26F3NO4Na ([M + Na]+): 424.1706; found: 424.1700. IR neat (𝛖/cm-1) :2972, 2876, 
2361, 1718, 1377, 1256, 1164, 1088. 
3-(2-(trifluoromethoxy)phenyl)pent-1-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-
carboxylate2.32b : 
  
Following the general procedure, (E)-pent-3-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-
carboxylate (50 mg) was arylated with 1-bromo-2-(trifluoromethyl)benzene(20.1 µL) to give 
23.6 mg (42%) of the title compound (48:52 Z:E ratio) as an oil. 
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1H NMR (CDCl3, 400 MHz, rotamers) :7.62-7.60 (m, 1H, HAr), 7.54-7.41 (m, 2H, HAr), 
7.30-7.27 (m, 1H, HAr), 7.09-7.06 (m, 1H, H1E), 7.03-7.01 (m, 1H, H1Z), 5.50-5.42 (m, 1H, 
H2E), 4.93-4.89 (m, 1H, H2Z), 4.23-4.13 (m, 1H, H3Z), 3.79-3.74 (m, 2H, H6), 3.66-3.62 (m, 
1H, H3E), 1.81-1.37 (m, 14H, H4, C7, C7’, C8, C8’), 0.89-0.84 (m, 3H, H5). 13C-{1H} NMR 
(CDCl3, 125 MHz, rotamers) :150.2-149.3 (C11), 144.0/143.9 (C12), 136.9/136.8 (C1E), 
134.8/134.7 (C1Z), 132.3/132.2 (CAr), 128.5/128.1 (CAr), 128.3 (q, J  = 29.6 Hz, C13), 126.2 
(CAr), 126.1-125.8 (CAr), 124.7 (q of rotamers, J  = 279.8 Hz, C14), 115.52/115.46 (C2E), 
114.64/114.59 (C2Z), 96.4-95.4 (C10), 76.6-76.1 (C6), 61.3-60.4 (C9), 40.9 (C3E), 38.7 (C3Z), 
31.2 (C4Z), 29.8 (C4E), 26.9-24.0 (C7, C7’, C8, C8’), 12.13/12.06 (C5).F-{1H} NMR (CDCl3, 
376 MHz, rotamers) :  -58.30/-58.33(F14).HRMS (ESI) m/z:calcd. for C20H26F3NO3Na 
([M + Na]+): 408.1757; found: 408.1753.  IR neat (𝛖/cm-1) : 2972, 2361, 1715, 1374, 1314, 
1122, 1071. 
3-(2-fluoro-4-methylphenyl)pent-1-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-
carboxylate2.32c : 
O
O
N O
F
   
Following the general procedure, (E)-pent-3-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-
carboxylate (50 mg) was arylated with 4-bromo-3-fluorotoluene (18.3 µL) to give 29.9 mg 
(59%) of the title compound (76:24 Z:E ratio) as an oil. 
1H NMR (CDCl3, 400 MHz, rotamers) :7.11-7.05 (m, 2H, H1, HAr), 6.90-6.88 (m, 1H, 
HAr), 6.84-6.80 (m, 1H, HAr), 5.53-5.45 (m, 1H, H2E), 4.98-4.93 (m, 1H, H2Z), 4.02-3.91 (m, 
1H, H3Z), 3.77-3.74 (m, 2H, H6), 3.46-3.41 (m, 1H, H3E), 2.31 (s, 3H, H14E), 2.30 (s, 3H, 
H14Z), 1.76-1.34 (m, 14H, H4, H7, H7’, H8, H8’), 0.91-0.86 (m, 3H, H5). 13C-{1H} NMR 
(CDCl3, 125 MHz, rotamers) :161.9/161.7-159.4/159.3 (d of rotamers, J = 244.3 Hz, 
C13), 150.0/149.2 (C11), 138.1-137.9 (CAr), 136.6/136.5 (C1E), 134.6/134.5 (C1Z), 128.6-128.2 
(C12, CAr), 125.0-124.9 (CAr), 116.3-116.0 (CAr), 115.0/114.9 (C2E), 113.5/113.3 (C2Z), 96.3-
95.4 (C10), 76.6-76.2 (C6), 61.1-60.3 (C9), 39.3 (C3E), 36.42/36.36 (C3Z), 29.4 (C4Z), 28.4 
(C4E), 26.9-24.0 (C7, C7’, C8, C8’), 21.01/21.99 (C14), 12.3 (C5E), 12.2 (C5Z).F-{1H} NMR 
(CDCl3, 376 MHz, rotamers) :  -119.3--119.4 (F13).HRMS (ESI) m/z:calcd. for 
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C20H28FNO3Na ([M + Na]+): 372.1945; found: 372.1953. IR neat (𝛖/cm-1) :2970, 2361, 
1718, 1377, 1258, 1089. 
3-(2-fluoro-4-methoxyphenyl)pent-1-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 
2.32d : 
   
Following the general procedure, (E)-pent-3-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-
carboxylate (50 mg) was arylated with 4-bromo-3-fluoroanisole (29.7 mg) to give 24.1 mg 
(46%) of the title compound (77:23 Z:E ratio) as an oil. 
1H NMR (CDCl3, 400 MHz, rotamers) :7.12-7.06 (m, 3H, H1, 2HAr), 6.66-6.63 (m, 1H, 
HAr), 6.60-6.56 (m, 1H, HAr), 5.52-5.44 (m, 1H, H2E), 4.96-4.91 (m, 1H, H2Z), 3.97-3.87 (m, 
1H, H3Z), 3.79-3.74 (m, 5H, H6, H14), 3.43-3.38 (m, 1H, H3E), 1.75-1.34 (m, 14H, H4, H7, 
H7’, H8, H8’), 0.91-0.95 (m, 3H, H5). 13C-{1H} NMR (CDCl3, 125 MHz, 
rotamers) :162.2/162.1-160.3/160.1 (d of rotamers, J = 244.2 Hz, C13), 159.3-159.1 
(C15), 150.2-149.2 (C11), 138.6/138.4 (C1E), 134.6-134.4 (C1Z), 129.1-128.8 (CAr), 123.7-
123.6 (C12Z), 123.2-123.1 (C12E), 115.11/115.06 (C2E), 113.6/113.5 (C2Z), 110.1-109.9 (CAr), 
101.9-101.7 (CAr), 93.3-95.4 (C10), 76.6-76.2 (C6), 61.2-60.3 (C9), 55.6 (C15), 40.0 (C3E), 
36.2/36.1 (C3Z), 29.5 (C4Z), 28.4 (C4E), 26.9-24.1 (C7, C7’, C8, C8’), 12.3 (C5E), 12.2 
(C5Z).F-{1H} NMR (CDCl3, 376 MHz, rotamers) :  -119.28--119.33 (F13).HRMS 
(ESI) m/z:calcd. for C20H28FNO4Na ([M + Na]+): 388.1895; found: 388.1897. IR neat (𝛖/cm-
1) : 2968, 2361, 1714, 1624, 1507, 1376, 1353, 1259, 1090. 
 Scale up of the arylation for the synthesis of 2.32d 
In a oven-dried Schlenck tube (75 mm x 40 mm) set up with a rubber septum, a solution of 
(E)-2.21 (302 mg, 1.25 mmol, 1 eq) and TMEDA (264 µL, 1.75 mmol, 1.4 eq) in dry diethyl 
ether (10 mL) under argon was stirred and cooled down to -78°C (acetone bath, cryostat). s-
Butyllithium (1.75 mmol, 1.4 eq, solution in hexane) was added dropwise, and the mixture 
was stirred for 4 h. A suspension of zinc acetate (344 mg, 3.8 mmol, 1.5 eq) in dry THF (10 
mL) was sonicated for 30 min and added dropwise to the mixture. The resulting solution was 
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stirred for 30 min at -78°C, and then allowed to warm-up to 20°C over 30 min. The solvents 
where evaporated over 30 min under high vacuum, and a solution of Pd2(dba)3 (20 mg, 22 
µmol, 1.75 %mol) and 2.L27 (16.7 mg, 88 µmol, 3.5 %mol) in dry toluene (10 mL) was added 
to solve the residue, followed by 4-Br-3-F-anisole (112 µL, 0.88 mmol, 0.7 eq). The mixture 
was then vigorously stirred at60°C for 18h. After cooling down, the reaction was quenched 
with sat. aq. NH4Cl (10 mL), and the organic phase was diluted with EtOAc (25 mL) and 
separated. The aqueous phase was extracted with EtOAc (2 x 25 mL). The combined organic 
layers were washed with water and dried over MgSO4, filtrated over a pad of celite, and 
evaporated under vacuum. The residue was purified bypreparative reversed-phase HPLC 
(MeCN/H2O) to afford 200 mg (44%) of the -product 2.32d (76:24Z:E ratio). 
3-(4-cyano-2-fluorophenyl)pent-1-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 
2.32e : 
   
Following the general procedure, (E)-pent-3-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-
carboxylate (50 mg) was arylated with 4-bromo-3-fluorobenzonitrile (29 mg) to give 22.5 mg 
(43%) of the title compound (67:33 Z:E ratio, contains ~10% - and -arylated products) as 
an oil. 
1H NMR (CDCl3, 400 MHz, rotamers) :7.42-7.40 (m, 1H, HAr), 7.37-7.29 (m, 2H, 
2HAr), 7.15-7.12 (m, 1H, H1), 5.47-5.39 (m, 1H, H2E), 4.93-4.88 (m, 1H, H2Z), 4.10-4.00 (m, 
H3Z), 3.78-3.73 (m, 2H, H6), 3.55-3.50 (m, 1H, H3E), 1.81-1.65 (m, 2H, H4), 1.61-1.38 (m, 
12H, H7, H7’, H8, H8’), 0.93-0.87 (m, 3H, H5). 13C-{1H} NMR (CDCl3, 125 MHz, 
rotamers) :161.2-159.1 (d of rotamers, J = 248.4 Hz, C13), 150.0-148.8 (C11), 138.2-
137.8 (C12), 137.6/137.5 (C1E), 136.0/135.8 (C1Z), 130.0-129.7 (C14, CAr), 128.48-128.45 
(CAr), 119.5-119.1 (CAr), 117.8 (C15), 113.04/112.99 (C2E), 111.6-111.4 (C2Z), 96.4-95.3 
(C10), 76.5-76.2 (C6), 61.3-60.3 (C9), 39.7 (C3E), 36.72/36.67 (C3Z), 29.2 (C4Z), 28.2 (C4E), 
26.9-23.8 (C7, C7’, C8, C8’), 12.12 (C5E), 12.05 (C5Z).F-{1H} NMR (CDCl3, 376 MHz, 
rotamers) :  [-113.73/-113.74 (F-prod), -114.4 (F-prod)], -114.84/-114.85 (F13E), -115.0/-
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115.1 (F13Z).HRMS (ESI) m/z:calcd. for C20H25FN2O3Na ([M + Na]+): 383.1741; found: 
383.1739. IR neat (𝛖/cm-1) :2970, 2874, 2361, 2234, 1713, 1376, 1257, 1088. 
3-(2-fluoro-4-(methoxycarbonyl)phenyl)pent-1-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-
carboxylate2.32f : 
O
O
N O
F
O O
   
Following the general procedure, (E)-pent-3-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-
carboxylate (50 mg) was arylated with methyl 4-bromo-3-fluorobenzoate (33.8 mg, in 0.5 mL 
of toluene) to give 31 mg (54%) of the title compound (68:32 Z:E ratio) as an oil. 
1H NMR (CDCl3, 400 MHz, rotamers) :7.78-7.75 (m, 1H, HAr), 7.68-7.64 (m, 1H, HAr), 
7.32-7.25 (m, 1H, HAr), 7.14-7.11 (m, 1H, H1), 5.52-5.43 (m, 1H, H2E), 4.98-4.92 (m, 1H, 
H2Z), 4.11-3.99 (m, 1H, H3Z), 3.90 (s, 3H, H15), 3.75-3.74 (m, 2H, H6), 3.55-3.48 (m, 1H, 
H3E), 1.78-1.66 (m, 2H, H4), 1.62-1.28 (m, 12H, H7, H7’, H8, H8’), 0.92-0.86 (m, 3H, H5). 13C-
{1H} NMR (CDCl3, 125 MHz, rotamers) :166.13/166.10 (C14), 161.6/161.5-159.2/159.0 
(d of rotamers, J = 245.3 Hz, C13), 150.0/149.8 (C11Z), 149.2/149.0 (C11E), 137.4-137.0 (CAr, 
C1E), 135.4/135.3 (C1Z), 130.2-130.0 (C12), 128.9-128.6 (CAr), 125.61-125.56 (CAr), 117.0-
116.6 (CAr), 113.74/113.69 (C2E), 112.2/112.1 (C2Z), 96.3-95.3 (C10), 76.5-76.1 (C6), 61.2-
60.3 (C9), 52.4 (C15), 39.7 (C3E), 36.8/36.7 (C3Z), 29.3 (C4Z), 28.7 (C4E), 26.7-24.0 (C7, C7’, 
C8, C8’), 12.2 (C5E), 12.1 (C5Z).F-{1H} NMR (CDCl3, 376 MHz, rotamers) :  -117.37--
117.38 (F13E), -117.47--117.52 (F13Z).HRMS (ESI) m/z:calcd. for C21H28FNO5Na ([M + 
Na]+): 416.1844; found: 416.1838. IR neat (𝛖/cm-1) :2969, 2874, 2361, 1720, 1353, 1290, 
1210, 1089. 
3-(2-fluoro-4-nitrophenyl)pent-1-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.32g : 
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Following the general procedure, (E)-pent-3-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-
carboxylate (50 mg) was arylated with 4-bromo-3-fluoronitrobenzene (32 mg) to give 17 mg 
(31%) of the title compound (65:35 Z:E ratio, contains ~5% - and -arylated products) as an 
orange oil. 
1H NMR (CDCl3, 400 MHz, rotamers) :8.00-7.98 (m, 1H, HAr), 7.91-7.88 (m, 1H, HAr), 
7.44-7.37 (m, 1H, HAr), 7.17-7.14 (m, 1H, H1), 5.49-5.41 (m, 1H, H2E), 4.96-4.91 (m, 1H, 
H2Z), 4.15-4.04 (m, 1H, H3Z), 3.78-3.74 (m, 2H, H6), 3.60-3.55 (m, 1H, H3E), 1.84-1.71 (m, 
2H, H4), 1.63-1.29 (m, 12H, H7, H7’, H8, H8’), 0.95-0.89 (m, 3H, H5). 13C-{1H} NMR (CDCl3, 
125 MHz, rotamers) :161.1-158.95 (d of rotamers, J = 248.5 Hz, C13), 149.9-148.8 (C11), 
147.3-147.1 (C14), 140.0-139.5 (C12), 137.8/137.6 (C1E), 136.1/136.0 (C1Z), 129.4-129.2 
(CAr), 119.62/119.59 (CAr), 112.90/112.86 (C2E), 111.8-111.2 (C2Z, CAr), 96.5-95.3 (C10), 
76.5-76.2 (C6), 61.4-60.3 (C9), 39.76/39.74 (C3E), 36.8-36.7 (C3Z), 29.3 (C4Z), 28.2 (C4E), 
26.8-24.0 (C7, C7’, C8, C8’), 12.14 (C5E), 12.07 (C5Z).F-{1H} NMR (CDCl3, 376 MHz, 
rotamers) :  [-112.52/-112.53 (F-prod), -113.2 (F-prod)], -113.67/-113.68 (F13E), -113.86/-
113.91 (F13Z).HRMS (ESI) m/z: calcd. for C19H25FN2O5Na ([M + Na]+): 403.1640; found: 
403.1633. IR neat (𝛖/cm-1) : 2971, 2874, 2361, 1714, 1528, 1351, 1258, 1088. 
3-(2-fluoropyridin-3-yl)pent-1-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.32h : 
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Following the general procedure, (E)-pent-3-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-
carboxylate (50 mg) was arylated with 3-bromo-2-fluoropyridine (14.7 µL) to give 25.6 mg 
(52.5%) of the title compound (75:25 Z:E ratio, contains ~10% of other isomers ) as an oil. 
1H NMR (CDCl3, 400 MHz, rotamers) :8.07-8.04 (m, 1H, HAr), 7.66-7.60 (m, 1H, HAr), 
7.15-7.12 (m, 2H, H1, HAr), 5.51-5.43 (m, 1H, H2E), 4.95-4.90 (m, 1H, H2Z), 4.00-3.89 (m, 
1H, H3Z), 3.77-3.73 (m, 2H, H6), 3.42-3.37 (m, 1H, H3E), 1.78-1.25 (m, 14H, H4, H7, H7’, H8, 
H8’), 0.94-0.88 (m, 3H, H5). 13C-{1H} NMR (CDCl3, 125 MHz, rotamers) :162.6-160.9 
(d of rotamers, J = 238.2 Hz, C13), 150.0-148.9 (C11), 145.5-145.2 (CAr), 139.4-139.0 (CAr), 
137.4/137.3 (C1E), 135.8-135.6 (C1Z), 126.9-126.6 (C12), 121.70/121.67 (CAr), 113.4-113.3 
(C2E), 111.8/111.7 (C2Z), 96.4-95.4 (C10), 76.5-76.2 (C6), 61.3-60.4 (C9), 40.0/39.9 (C3E), 
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36.57/36.55 (C3E), 29.1/29.0 (C4Z), 28.2 (C4E), 26.5-25.1 (C7, C7’, C8, C8’), 12.2-12.1 
(C5).F-{1H} NMR (CDCl3, 376 MHz, rotamers) :  [-69.53--70.2 (F other isomers)], -
71.7/-71.8 (F13E), -72.3 (F13Z).HRMS (ESI) m/z: calcd. for C18H25FN2O3Na ([M + Na]+): 
359.1741; found: 359.1740. IR neat (𝛖/cm-1) : 2970, 2874, 1361, 1713, 1435, 1377, 1257, 
1089. 
 Arylation of (E)-2.21 with 2-bromoanisole : products 2.32i and isomers 
 
Following the general procedure, (E)-pent-3-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-
carboxylate (50 mg) was arylated with 2-bromoanisole (18.1 µL) to give 15 mg (30%) of a 
mixture of isomeric arylated product (NMR ratio :  /E/Z 16/54/30). The calculated yield of 
combined -product 2.32i was ca. 24% (64:36 Z:E ratio). 
-isomer : 
1H NMR (CDCl3, 400 MHz, rotamers), characteristic peaks :6.16-6.13 (m, 1H, H1), 
5.45-5.39 (m, 2H, H3, H4), 2.57-2.49 (m, 2H, H2). 13C-{1H} NMR (CDCl3, 125 MHz, 
rotamers), characteristic peaks :71.4/71.3 (C1), 39.1/39.0 (C2). 
E-product (E)-2.32i : 
1H NMR (CDCl3, 400 MHz, rotamers), characteristic peaks :5.53-5.47 (m, 1H, H2), 
3.66-3.61 (m, 1H, H3). 13C-{1H} NMR (CDCl3, 125 MHz, rotamers), characteristic 
peaks :38.8 (C3). 
Z-product (Z)-2.32i: 
1H NMR (CDCl3, 400 MHz, rotamers), characteristic peaks :(m, 1H, H2), 
4.20-4.09 (m, 1H, H3), 1.75-1.67 (m, 2H, H4).13C-{1H} NMR (CDCl3, 125 MHz, rotamers), 
characteristic peaks :C2), 36.62/36.45 (C3), 29.3/29.2 (C4).  
HRMS (ESI) m/z: calcd. forC20H29NO4Na ([M + Na]+): 370.1989; found: 370.1989.IR neat 
(𝛖/cm-1) : 2969, 2361, 1711, 1596, 1377, 1350, 1241, 1091. 
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Arylation of carbamates 2.7e, 2.33-37 
 Arylation of 2.7e : products 2.20g and isomers 
3-(2-fluorophenyl)but-1-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.20g : 
   
Following the general procedure, but-3-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 
(47 mg) was arylated with 1-bromo-2-fluorobenzene (15.8 µL) to give 9.7 mg (21%) of the 
title compound (64:36 Z:E ratio) as an oil. 
1H NMR (CDCl3, 400 MHz, rotamers) :7.29-6.97 (m, 5H, H1, HAr), 5.59-5.51 (m, 1H, 
H2E), 5.01-4.97 (m, 1H, H2Z), 4.30-4.19 (m, 1H, H3Z), 3.95-3.79 (m, 1H, H3E), 3.76-3.75 (m, 
2H, H5), 1.62-1.28 (m, 15H, H4, H6, H6’, H7, H7’). 13C-{1H} NMR (CDCl3, 125 MHz, 
rotamers) :161.5/159.5 (d of rotamers, J = 246.4 Hz, C12), 150.2-149.1 (C10), 
136.4/136.3 (C1E), 133.8/133.7 (C1Z), 133.0-132.8 (C11Z), 132.5-132.4 (C11E), 128.3-127.7 
(2 CAr), 124.28/124.25 (CAr), 116.0/115.9 (C2E), 115.7-115.4 (CAr), 114.5/114.4 (C2Z), 96.3-
95.4 (C9), 76.5-76.1 (C5), 61.1-60.3 (C8), 31.7 (C3E), 29.6-24.0 (C3Z, C6, C6’, C7, C7’), 22.1 
(C4Z), 20.7 (C4E).F-{1H} NMR (CDCl3, 376 MHz, rotamers) :  -118.57/-118.62 (F12Z), 
-118.80/-118.81 (F12E). HRMS (ESI) m/z:calcd. for C18H24FNO3Na ([M + Na]+): 344.1632; 
found: 344.1638.IR neat (𝛖/cm-1) : 2974, 2921, 2361, 1717, 1374, 1241, 1069. 
Observation and isolation of - and -products 2.20a and 2.20b : 
 
After arylation, <10% yield of amixture of - and -arylated products (ratio 50:50) was 
isolated for analytical purpose. 
-product 2.20a : 
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1H NMR (CDCl3, 400 MHz, rotamers), characteristic peaks :6.07-6.04 (m, 1H, H1), 
5.79-5.69 (m, 1H, H3), 5.09-5.04 (m, 2H, H4), 2.75-2.63 (m, 2H, H2).13C-{1H} NMR (CDCl3, 
125 MHz, rotamers), characteristic peaks : (C3), 118.3 (C4), 70.74/70.69 
(C1), 40.2/40.1 (C2).F-{1H} NMR (CDCl3, 376 MHz, rotamers) : -117.93/-117.96. 
-product 2.20b : 
1H NMR (CDCl3, 400 MHz, rotamers), characteristic peaks :6.02-5.97 (m, 1H, H3), 
5.19-5.14 (m, 2H, H4), 4.48-4.43 (m, 1H, H1), 4.33-4.27 (m, 1H, H1), 4.10-4.04 (m, 1H, 
H2).13C-{1H} NMR (CDCl3, 125 MHz, rotamers), characteristic peaks :136.7-136.6 
(C3), 117.3 (C4),  66.3 (C1), 42.7/42.6 (C2).F-{1H} NMR (CDCl3, 376 MHz, rotamers) : 
-117.51/-117.55. 
IR neat (𝛖/cm-1) : 2980, 2361, 1699, 1399, 1347, 1259, 1066. 
 Arylation of carbamates 2.33-35 : products 2.38a-c 
3-(2-fluorophenyl)hex-1-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate2.38a : 
  
Following the general procedure, (E)-hex-3-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-
carboxylate (53 mg) was arylated with 1-bromo-2-fluorobenzene (15.8 µL) to give 27.2 mg 
(54%) of the title compound (76:24 Z:E ratio) as an oil. 
1H NMR (CDCl3, 400 MHz, rotamers) :7.24-7.06 (m, 4H, 3HAr, H1), 7.01-6.97 (m, 1H, 
HAr), 5.55-5.47 (m, 1H, H2E), 5.00-4.96 (m, 1H, H2Z), 4.17-4.07 (m, 1H, H3Z), 3.76-3.74 (m, 
2H, H7), 3.62-3.57 (m, 1H, H3E), 1.73-1.21 (m, 16H, H4, H5, H8, H8’, H9, H9’), 0.92-0.88 (m, 
3H, H6). 13C-{1H} NMR (CDCl3, 125 MHz, rotamers) :161.7/161.6-159.8/159.7 (d of 
rotamers, J = 245.1 Hz, C14), 150.2/150.0 (C12Z), 149.4/149.2 (C12E), 136.6/136.5 (C1E), 
134.6/134.5 (C1Z), 132.0-131.5 (C13), 128.8-128.5 (CAr), 127.8-127.6 (CAr), 124.29/124.27 
(CAr), 115.8-115.4 (CAr), 114.93/114.89 (C2E), 113.5/113.4 (C2Z), 96.3-95.4 (C11), 76.6-76.2 
(C7), 61.2-60.4 (C10), 38.7 (C4Z), 37.6 (C4E), 37.5 (C3E), 34.74-34.65 (C3Z), 26.9-24.0 (C8, 
C8’, C9, C9’), 20.80/20.76 (C5), 14.1/14.0 (C6).F-{1H} NMR (CDCl3, 376 MHz, rotamers) : 
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-118.31/-118.32 (F14E), -118.33/-118.39 (F14Z).HRMS (ESI) m/z:calcd. for 
C20H28FNO3Na ([M + Na]+): 372.1945; found: 372.1943.  IR neat (𝛖/cm-1) :2361, 1712, 
1345, 1240, 1225, 1089. 
3-(2-fluorophenyl)non-1-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.38b : 
   
Following the general procedure, (E)-oct-3-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-
carboxylate (50 mg) was arylated with 1-bromo-2-fluorobenzene (15.8 µL) to give 22.9 mg 
(45%) of the title compound (77:23 Z:E ratio) as an oil. 
1H NMR (CDCl3, 500 MHz, rotamers) :7.25-7.06 (m, 4H, H1, HAr), 7.02-6.97 (m, 1H, 
HAr), 5.54-5.47 (m, 1H, H2E), 5.00-4.95 (m, 1H, H2Z), 4.15-4.04 (m, 1H, H3Z), 3.76-3.74 (m, 
2H, H10), 3.59-3.54 (m, 1H, H3E), 1.73-1.23 (m, 22H, H4, H5, H6, H7, H8, H11, H11’, H12, H12’), 
0.87-0.84 (m, 3H, H9). 13C-{1H} NMR (CDCl3, 125 MHz, rotamers) :161.7/161.6-
159.8/159.7 (d of rotamers, J = 244.7 Hz, C17), 150.2/150.0 (C15Z), 149.4/149.2 (C15Z), 
136.6/136.5 (C1E), 134.6/134.5 (C1Z), 132.0/131.9 (C16Z), 31.6/131.5 (C16E), 128.8-128.5 
(CAr), 127.8-127.6 (CAr), 124.29/124.26 (CAr), 115.8-115.4 (CAr), 115.01/115.95 (C2E), 
113.6/113.5 (C2Z), 96.3-95.4 (C14), 76.6-76.2 (C10), 61.2-60.3 (C13), 37.80/37.78 (C3E), 36.5 
(C4Z), 35.4 (C4E), 35.0-34.9 (C3Z), 31.85/31.82 (C5), 29.3/29.2 (C6), 27.64/27.58 (C7), 26.7-
24.0 (C11, C11’, C12, C12’) 22.8 (C8), 14.2 (C9).F-{1H} NMR (CDCl3, 376 MHz, rotamers) : 
 -118.30/-118.31 (F17E), -118.34/-118.40 (F17Z).HRMS (ESI) m/z:calcd. for 
C23H34FNO3Na ([M + Na]+): 414.2415; found: 414.2414.  IR neat (𝛖/cm-1) :2929, 2361, 
1711, 1372, 1258, 1128, 1069. 
(Z)-6-((tert-butyldimethylsilyl)oxy)-3-(2-fluorophenyl)hex-1-en-1-yl 2,2,4,4-tetramethyloxa 
zolidine-3-carboxylate2.38c : 
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Following the general procedure, (E)-6-((tert-butyldimethylsilyl)oxy)hex-3-en-1-yl 2,2,4,4-
tetramethyloxazolidine-3-carboxylate (80 mg) was arylated with 1-bromo-2-fluorobenzene 
(15.8 µL) to give 11.5 mg (16.5%) of the title compound as an oil. 
1H NMR (CDCl3, 500 MHz, rotamers) :7.25-7.20 (m, 1H, HAr), 7.18-7.14 (m, 1H, HAr), 
7.09-7.06 (m, 2H, H1, HAr), 7.01-6.97 (m, 1H, HAr), 5.00-4.95 (m, 1H, H2), 4.15-4.04 (m, 1H, 
H3), 3.78-3.73 (m, 2H, H10), 3.60-3.57 (m, 2H, H6), 1.87-1.65 (m, 2H, H4), 1.64-1.32 (m, 
14H, H5, H11, H11’, H12, H12’), 0.87 (s, 9H, H9), 0.01 (m, 6H, H7). 13C-{1H} NMR (CDCl3, 125 
MHz, rotamers) :161.6-159.7 (d of rotamers, J = 244.2 Hz, C17), 150.0/149. (C15), 
134.7-134.6 (C1), 131.8/131.6 (C16), 128.6-128.5 (CAr), 127.8-127.7 (CAr), 124.4/124.3 (CAr), 
115.7/115.5 (CAr), 113.3/113.2 (C2), 96.3/95.4 (C14), 76.6/76.2 (C10), 63.07/63.05 (C6), 
61.2/60.3 (C13), 34.9/34.8 (C3), 32.7 (C4), 31.1 (C5), 26.8-24.0 (C11, C11’, C12, C12’), 26.1 (C9), 
18.5 (C8), -5.2 (C7).F-{1H} NMR (CDCl3, 376 MHz, rotamers) :  -118.21/-118.27 (F17). 
HRMS (ESI) m/z: calcd. for C26H42FNO4SiNa ([M + Na]+): 502.2759 ; found: 502.2766. IR 
neat (𝛖/cm-1) : 2935, 2863, 2361, 1719, 1400, 1349, 1256, 1091. 
 Arylation of carbamate 2.36 : products 2.38d and isomers 
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Following the general procedure A, (E)-4-cyclohexylbut-3-en-1-yl 2,2,4,4-
tetramethyloxazolidine-3-carboxylate (64.1 mg) was arylated with 1-bromo-2-fluorobenzene 
(15.8 µL) to give 30 mg (52%) of a mixture of isomeric arylated product (NMR ratio :  
/’/E/Z 13/2/11/74). The calculated yield of combined -product 2.38d was ca. 44% 
(87:13 Z:E ratio). 
-product : 
1H NMR (CDCl3, 400 MHz, rotamers), characteristic peaks :6.02-6.00 (m, 1H, H1), 
5.41-5.36 (m, 1H, H4), 5.31-5.24 (m, 1H, H3),2.66-2.52 (m, 2H, H2). 13C-{1H} NMR (CDCl3, 
125 MHz, rotamers), characteristic peaks :C4), 122.03/121.95 (C3), 71.1/71.0 
(C1), 39.1/39.0 (C2). ).F-{1H} NMR (CDCl3, 376 MHz, rotamers) :  -116.95. 
’-product : 
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1H NMR (CDCl3, 400 MHz, rotamers), characteristic peaks :6.41-6.39 (m, 1H, H1) 
5.75-5.63 (m, 2H, H2, H3). 13C-{1H} NMR (CDCl3, 125 MHz, rotamers), characteristic 
peaks :C1). F-{1H} NMR (CDCl3, 376 MHz, rotamers) :  -117.49/-117.53. 
E-product (E)-2.38d : 
1H NMR (CDCl3, 400 MHz, rotamers), characteristic peaks :5.52-5.45 (m, 1H, H2).  
13C-{1H} NMR (CDCl3, 125 MHz, rotamers), characteristic peaks :C2), 
34.6 (C3). F-{1H} NMR (CDCl3, 376 MHz, rotamers) :  -118.34/-118.35 
Z-product (Z)-2.38d : 
1H NMR (CDCl3, 400 MHz, rotamers), characteristic peaks :(m, 1H, H2), 
4.30-4.19 (m, 1H, H3). 13C-{1H} NMR (CDCl3, 125 MHz, rotamers), characteristic 
peaks :C2), 32.1-32.0 (C3). F-{1H} NMR (CDCl3, 376 MHz, rotamers) : 
 -118.6/-118.44. 
HRMS (ESI) m/z: calcd. forC24H34FNO3Na ([M + Na]+): 426.2415; found: 426.2412.IR 
neat (𝛖/cm-1) : 2923, 2852, 2361, 1714, 1349, 1258, 1091. 
 Arylation of carbamate 2.37 : products 2.38e and isomers 
  
Following the general procedure A, (E)-5,5-dimethylhex-3-en-1-yl 2,2,4,4-
tetramethyloxazolidine-3-carboxylate (58.7 mg) was arylated with 1-bromo-2-fluorobenzene 
(15.8 µL) to give 23 mg (42%) of a mixture of isomeric arylated product (NMR ratio :  
/’/E/Z 24/17/12/47). The calculated yield of combined -product was ca. 25% (80:20 Z:E 
ratio). 
-product : 
1H NMR (CDCl3, 400 MHz, rotamers), characteristic peaks :6.04-6.02 (m, 1H, H1), 
5.46-5.42 (m, 1H, H4), 5.29-5.21 (m, 1H, H3),2.66-2.51 (m, 2H, H2). 13C-{1H} NMR (CDCl3, 
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125 MHz, rotamers), characteristic peaks :C4), 119.4/119.3 (C3), 71.1/71.0 (C1), 
39.1/39.0 (C2). ).F-{1H} NMR (CDCl3, 376 MHz, rotamers) :  -117.52/-117.57. 
’-product : 
1H NMR (CDCl3, 400 MHz, rotamers), characteristic peaks :6.44-6.41 (m, 1H, H1) 
5.82-5.76 (m, 2H, H2), 5.70-5.65 ((m, 2H, H3), 1.92 (d, J = 7.5 Hz, 1H). 13C-{1H} NMR 
(CDCl3, 125 MHz, rotamers), characteristic peaks :C1), 132.2/132.1 (C2), 
129.7/129.6 (C3), 46.8 (C4). F-{1H} NMR (CDCl3, 376 MHz, rotamers) :  -116.97/-
116.99. 
E-product (E)-2.38e: 
1H NMR (CDCl3, 400 MHz, rotamers), characteristic peaks :5.57-5.49 (m, 1H, H2), 
1.80 (ddd, J = 13.9 Hz, J = 7.3 Hz, J = 2.4 Hz, 1H, H4).  13C-{1H} NMR (CDCl3, 125 MHz, 
rotamers), characteristic peaks :C2), 49.3 (C4), 34.68/34.66 (C3). F-{1H} 
NMR (CDCl3, 376 MHz, rotamers) :  -117.99/-118.0. 
Z-product (Z)-2.38e: 
1H NMR (CDCl3, 400 MHz, rotamers), characteristic peaks :5.07-5.02(m, 1H, H2), 
4.30-4.21 (m, 1H, H3). 13C-{1H} NMR (CDCl3, 125 MHz, rotamers), characteristic 
peaks :50.9  (C4).19F-{1H} NMR (CDCl3, 376 MHz, rotamers) :  -117.86/-117.95. 
HRMS (ESI) m/z:calcd. forC22H32FNO3Na ([M + Na]+): 400.2258; found: 400.2254.IR neat 
(𝛖/cm-1) :2958, 2361, 1712, 1397, 1259, 1066. 
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Deuterium labeling 
 Synthesis of the deuterated substrate 2.41 
OH
2H 2H
OH
2H 2H
LiAlH4 3eq
THF/Toluene 1:1, 100°C, 15h
NaH1.3 eq
CbyCl 1.3 eq
THF, 23°C, 15h
O
2H 2H
O
N O
S11
 
 [2,2-2H2]-non-3(E)-en-1-ol S11: 
 
LiAlH4 (211 mg, 5.3 mmol, 3 eq) was added portionwise to a solution of [2,2-2H2] non-3-yn-
1-ol160 (250 mg, 1.8 mmol, 1 eq) in THF/Toluene (5 mL, 1:1 v:v) at 0°C (water, ice) over 5 
min. The mixture was stirred at 100°C for 15 h and then cooled down to room temperature. 
The reaction was quenched by a sequential addition of water (250µL), 15% aq. NaOH 
(250µL), and water (750 µL). The precipitate was filtered off on celite with Et2O. The 
resulting organic phase was dried over MgSO4, filtered, and concentrated under vacuum. The 
oily residue was purified by silica gel column chromatography (Pent/Et2O 95:5 to 50:50) to 
obtain 180 mg (71 %, 100 % (E),  >98% 2H int.) of the desired deuterated alcohol as a 
colorless oil. 
1H NMR (CDCl3, 400 MHz) :5.55 (dt, J = 15.3 Hz, J = 6.7 Hz, 1H), 5.36 (br. d, J = 15.4 
Hz, 1H), 3.60 (s, 2H), 2.03-1.98 (m, 2H), 1.51 (s, 1H), 1.39-1.22 (m, 6H), 0.88 (t, J = 6.95 
Hz, 3H).13C-{1H} NMR (CDCl3, 100 MHz) :134.6, 125.7, 62.1, 35.6/35.4/35.2 (C2H2), 
32.8, 31.5, 29.3, 14.2. GCMS (EI) m/z (intensity %) : 70 (100), 41 (76), 57 (71), 83 (45), 97 
(27), 126 (7), 111 (2), 144 (0.2).IR neat (𝛖/cm-1) : 2927, 2361, 1394, 1249, 1054. 
[2,2-2H2]-non-3(E)-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.41 : 
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A solution of [2,2-2H2] non-3(E)-en-1-olS11 (150 mg, 1.0 mmol, 1 eq) in THF (1 mL) was 
added dropwise to a suspension of sodium hydride (34 mg, 1.4 mmol, 1.3 eq) in THF (4 mL) 
at 0°C (water, ice) over 5 min. The mixture was then stirred for 30 min at room temperature. 
A solution of 2,2,4,4-tetramethyloxazolidine-3-carbonyl chloride (259 mg, 1.4 eq, 1.3 eq) in 
THF (1 mL) was added dropwise and the mixture was stirred for 15 h at room temperature. 
After quenching with water, the solvent was removed under vacuum and the residue was 
diluted with Et2O (10 mL). The organic phase was washed with sat. aq. NaHCO3 (10 mL), 
water (10 mL), brine (10 mL) and then dried over MgSO4. After filtration, the solvent was 
removed under reduced pressure and the residue was purified by silica gel column 
chromatography (Pent/Et2O 95:5 to 80:20) to obtain 215 mg (70 %, 100 % (E),  >98% 2H int.) 
of the desired deuterated carbamate as colorless oil. 
1H NMR (CDCl3, 400 MHz, rotamers) :5.55-5.48 (m, 1H), 5.39-5.34 (m, 1H), 4.08-4.07 
(m, 2H), 3.71 (s, 2H), 2.00-1.95 (m, 2H), 1.55 (1.50) (2 br. s, 6H), 1.41-1.22 (m, 12H), 0.87 
(t, J = 6.9 Hz, 3H).13C-{1H} NMR (CDCl3, 100 MHz, rotamers) :153.0/152.3, 133.6, 
125.7, 95.9/95.0, 76.5/76.2, 64.2, 60.6/59.9, 32.7, 31.8/31.6/31.5 (C2H2 overlapped with 
CH2), 29.2, 26.6/25.44, 25.38/24.3, 22.7, 14.2. HRMS (ESI) m/z: calcd. for  C17H29D2NO3Na 
([M + Na]+): 322.2322; found: 322.2327 IR neat (𝛖/cm-1) : 2971, 1361, 1701, 1403, 1068. 
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 Arylation of 2.41 : products 2.41a and 2.41g 
 
GCMS report 
 
 (E)-1-(2-fluorophenyl)-[2,2-2H2]-non-3-en-1-yl 2,2,4,4-tetramethyl oxazolidine-3-
carboxylate 2.41a : 
   
1H NMR (CDCl3, 500 MHz, rotamers) :7.33-7.28 (m, 1H, HAr), 7.27-7.23 (m, 1H,HAr), 
7.13-7.10 (m, 1H, HAr), 7.05-7.01 (m,1H, HAr), 5.99 (s, 1H, H1), 5.47-5.42 (m, 1H, H3), 5.33-
5.28 (m, 1H, H4), 3.76-3.70 (m, 2H, H10), 1.94-1.91 (m, 2H, H5), 1.62-1.34 (m, 12H, H11, 
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H11’, H12, H12’), 1.29-1.23 (m, 4H, H6, H7), 1.20-1.17 (m, 2H, H8), 0.86 (t, J = 7.2 Hz, 3H, H9). 
2H NMR (CHCl3, 76 MHz, rotamers) :7.62-7.55 (m, 22H). 13C-{1H} NMR (CDCl3, 125 
MHz, rotamers) :(C17, C16,C15missing), 134.7 (C3), 129.24/129.16 (CAr), 128.2/128.1 
(CAr), 124.4/124.3 (CAr), 124.10/124.07 (C4), , 115.8/115.7 (CAr), 96.2/95.1 (C14), 76.6/76.2 
(C10), 71.1/71.0 (C1), 60.9/60.0 (C13), 32.7 (C5), 31.4 (C6), 29.9 (C2), 29.1 (C7), 26.9-24.3 
(C11, C11’, C12, C12’), 22.7 (C8), 14.2 (C9). F-{1H} NMR (CDCl3, 376 MHz, rotamers) : 
117.53/117.56 (F17). HRMS (ESI) m/z: calcd. for C23H32D2FNO3Na ([M + Na]+): 
416.2540; found: 416.2547 . IR neat (𝛖/cm-1) : 2969, 2361, 1702, 1395, 1260, 1063. 
 (Z)-3-(2-fluorophenyl)-[2,4-2H2]-non-1-en-1-yl 2,2,4,4-tetramethyl oxazolidine-3-
carboxylate (Z)-2.41g: 
   
1H NMR (CDCl3, 500 MHz, rotamers) :7.24-7.20 (m, 1H, HAr), 7.17-7.14 (m, 1H, HAr), 
7.08-7.06 (m, 2H, H1, HAr), 7.00-6.97 (m, 1H, HAr), 4.12-4.04 (m, 1H, H3), 3.78-3.72 (m, 2H, 
H10), 1.64-1.21 (m, 21H, H4, H5, H6, H7, H8, H11, H11’, H12, H12’), 0.86 (t, J = 7.0 Hz, 3H, H9). 
2H NMR (CHCl3, 76 MHz, rotamers) :5.02 (s, 12H, 2H2), 1.70 (s, 12H, 2H4). 13C-{1H} 
NMR (CDCl3, 100 MHz, rotamers) :161.8-159.4 (d, J = 245.7 Hz, C17), 150.0/149.2 
(C15), 134.6/134.4 (C1), 132.0/131.9 (C16), 128.60-128.51 (CAr), 127.7-127.6 (CAr), 
124.30/124.26 (CAr), 115.6/115.4 (CAr), 96.3/95.4 (C14), 76.6/76.2 (C10), 61.2/60.3 (C13), 36.3-
36.0 (C4), 34.84/34.77 (C3), 31.9 (C5), 29.2 (C6), 27.6 (C7), 26.7-24.0 (C11, C11’, C12, C12’), 
22.8 (C8), 14.2 (C9).F-{1H} NMR (CDCl3, 376 MHz, rotamers) : 40 (F17). 
HRMS (ESI) m/z:calcd. for C23H32D2FNO3Na ([M + Na]+): 416.2540; found: 416.2548 . IR 
neat (𝛖/cm-1) : 2926, 2361, 1716, 1375, 1258, 1141, 1087. 
 (E)-3-(2-fluorophenyl)-[2,4-2H2]-non-1-en-1-yl 2,2,4,4-tetramethyl oxazolidine-3-
carboxylate (Z)-2.41g: 
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1H NMR (CDCl3, 400 MHz, rotamers) :7.21-7.15 (m, 2H, HAr), 7.10-7.07 (m, 2H, H1, 
HAr), 7.02-6.99 (m, 1H, HAr), 3.76-3.74 (m, 2H, H10), 3.56-3.55 (m, 1H, H3), 1.70-1.68 (m, 
1H, H4), 1.57-1.21 (m, 20H, H5, H6, H7, H8, H11, H11’, H12, H12’) , 0.86 (t, J = 7.1 Hz, 3H, H9). 
2H NMR (CHCl3, 76 MHz, rotamers) :5.55 (s, 12H, 2H2), 1.71 (s, 12H, 2H4). 13C-{1H} 
NMR (CDCl3, 100 MHz, rotamers) :161.8-159.8 (d, J = 245.6 Hz, C17), 150.2 (C15), 
136.6/136.4 (C1), 131.7/131.5 (C16), 128.84/128.80 (CAr), 127.8/127.7 (CAr), 124.32/124.29 
(CAr), 115.8/115.6 (CAr), 96.2/95.4 (C14), 76.5/76.2 (C10), 61.0/60.4 (C13), 37.68/37.64 (C3), 
35.2-34.9 (C4), 31.8 (C5), 29.2 (C6), 27.5 (C7), 26.9-24.1 (C11, C11’, C12, C12’), 22.8 (C8), 14.2 
(C9). F-{1H} NMR (CDCl3, 376 MHz, rotamers) : 118.31/118.32 (F17). HRMS (ESI) 
m/z:calcd. for C23H32D2FNO3Na ([M + Na]+): 416.2540; found: 416.2548 . IR neat (𝛖/cm-1) 
: 2926, 2361, 1714, 1374, 1258, 1126, 1071. 
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Regio- and stereoconvergence in the arylation of 2.21 
 
Following the general procedure A, a mixture of (E)-pent-3-en-1-yl 2,2,4,4-
tetramethyloxazolidine-3-carboxylate and (Z)-pent-3-en-1-yl 2,2,4,4-tetramethyloxazolidine-
3-carboxylate (50 mg, ratio 50:50) was arylated with 1-bromo-2-fluorobenzene (15.8 µL) to 
give 25.1 mg (52%) of the title compound (73:27 Z:E ratio) as an oil. 
 
Following the general procedure A, (Z)-pent-3-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-
carboxylate (50 mg) was arylated with 1-bromo-2-fluorobenzene (15.8 µL) to give 24.6 mg 
(51%) of the title compound (73:27 Z:E ratio) as an oil. 
OCby
General Procedure B
F OCby F
OCby
+
2.21g
61%, 74:26 Z(98:2 er):E(98:2 er)
(E)-2.21g
Z:E 0:100
 
Following the general procedure B, (E)-pent-3-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-
carboxylate (50 mg) was arylated with 1-bromo-2-fluorobenzene (15.8 µL) to give 29.6 mg 
(61%) of the title compound (74:26 Z:E ratio) as an oil. The e.r. were, respectively, 98:2 for 
the Z-isomer and 98:2 for the E-isomer. 
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Following the general procedure B, a mixture of (E)-pent-3-en-1-yl 2,2,4,4-
tetramethyloxazolidine-3-carboxylate and (Z)-pent-3-en-1-yl 2,2,4,4-tetramethyloxazolidine-
3-carboxylate (50 mg, ratio 50:50) was arylated with 1-bromo-2-fluorobenzene (15.8 µL) to 
give 27.4 mg (56%) of the title compound (74:26 Z:E ratio) as an oil. The e.r. were, 
respectively, 98:2 for the Z-isomer and 98:2 for the E-isomer. 
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Following the general procedure B, (Z)-pent-3-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-
carboxylate (50 mg) was arylated with 1-bromo-2-fluorobenzene (15.8 µL) to give 25.3 mg 
(52%) of the title compound (74:26 Z:E ratio) as an oil. The e.r. were, respectively, 98:2 for 
the Z-isomer and 98:2 for the E-isomer. 
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Following the general procedure B, (E)-pent-3-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-
carboxylate (50 mg) was arylated with 1-bromo-2-fluorobenzene (15.8 µL) in presence of 
2.L44 to give 28 mg (58%) of the title compound (87:13 Z:E ratio) as an oil. The e.r. were, 
respectively, 98:2 for the Z-isomer and 98:2 for the E-isomer. 
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Cross over experiment 
 Preparation of the dieneS14 
 
The diene S14 was prepared following a procedure similar to the literature.161 
3-(trimethylsilyl)allyl 2,2,4,4-tetramethyloxazolidine-3-carboxylateS12 : 
 
Following the general procedure, (E)-3-(trimethylsilyl)prop-2-en-1-ol162(621 mg, 5 mmol, 
E:Z 85:15) was reacted with sodium hydride (95% in mineral oil, 3 eq)and 2,2,4,4-
tetramethyloxazolidine-3-carbonyl chloride (3 eq) to give 1.25 g (88%, E:Z 85:15) as a 
colorless oil. 
1H NMR (CDCl3, 400 MHz, rotamers) :6.43-6.36 (m, 1H, mino.), 6.12-6.05 (m, 1H, 
majo.), 5.95-5.90 (m, 1H, majo.), 5.81-5.79 (m, 1H, mino.), 4.66-4.60 (m, 2H), 3.76-3.73 (m, 
2H), 1.60-1.36 (m, 12H), 0.15-0.00 (m, 9H). 13C-{1H} NMR (CDCl3, 100 MHz, 
rotamers) :152.67/151.95, 142.0/141.9 (mino.), 140.3/140.2 (majo.), 134.4/134.3 
(mino.), 132.84/132.75 (mino.), 96.0/95.1, 76.6/76.2 (majo.), 75.3 (mino.), 67.1 (majo.), 
64.6/64.5 (mino), 60.8/59.9, 26.78/26.68, 25.5.48/25.46/25.42, 24.5, 24.3, 23.7/23.5, 0.12, -
1.3. HRMS (ESI) m/z:calcd. for C14H27NO3SiNa ([M + Na]+): 308.1652; found: 308.1658. 
IR neat (𝛖/cm-1) : 2957, 2361, 1700, 1400, 1338, 1250, 1097. 
(E)-4-hydroxy-3-(trimethylsilyl)pent-1-en-1-yl2,2,4,4-tetramethyloxazolidine-3-
carboxylateS13 : 
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To a solution of 3-(trimethylsilyl)allyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate (380 mg, 
1.3 mmol, 1 eq, 85:15 E:Z) and TMEDA (199 µL, 1.3 mmol, 1 eq) in dry diethyl ether (5 mL) 
at -78°C (cryostat, acetone bath) was added s-Butyllithium (1.46 mmol, 1.1 eq, solution in 
hexane) over 5 min. The orange mixture was stirred for 1 h, before the addition of 
diisobutylaluminium methanesulfonate163 (1.46 mmol, 1.1 eq, 0.5 M in Toluene:MTBE 1:1). 
The yellow mixture was then stirred for 1.5 h, before the addition of acetaldehyde (75 µL, 
1.33 mmol, 1 eq). After 1 h, the mixture was stirred for 15 min at 20°C before the addition of 
Seignette’s salt (10% in water, 20 mL) to quench the reaction. The aqueous layer was 
extracted with diethyl ether (3x 10 mL), and the combined organic layers were dried over 
MgSO4, filtrated, and concentrated under vacuum. The residue was purified by flash column 
chromatography (Pent/Et2O 80:20 to 30:70) to give 195 mg (45%) of the desired compound 
as a colorless oil. 
1H NMR (CDCl3, 500 MHz, rotamers) :6.97-6.94 (dd, J = 12.4 Hz, J = 2.4 Hz, 1H), 
5.32-5.24 (m, 1H), 4.01-3.96 (m, 1H), 3.76-3.75 (m, 2H), 1.58-1.56 (m, 6H), 1.48-1.41 (m, 
7H), 1.23-1.22 (m, 3H), 0.06 (m,9H). 13C-{1H} NMR (CDCl3, 125 MHz, 
rotamers) :150.3/149.5, 136.3/136.1, 109.5/109.4, 96.1/95.4, 76.5/76.2, 68.1, 61.0, 60.4, 
37.19/37.17, 26.9/26.8, 25.8/25.7, 25.3/25.2, 24.2/24.1, 23.8, 1.8. HRMS (ESI) m/z:calcd. 
for C16H31NO4SiNa ([M + Na]+): 352.1915; found: 352.1919. IR neat (𝛖/cm-1) : 2969, 2872, 
2361, 1695, 1373, 1255, 1118. 
(1E,3E)-penta-1,3-dien-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylateS14  : 
 
A solution of (E)-4-hydroxy-3-(trimethylsilyl)pent-1-en-1-yl 2,2,4,4-tetramethyloxazolidine-
3-carboxylate (190 mg, 0.58 mmol, 1 eq) in dichloromethane (1.9 mL) was cooled down to -
78°C (cryostat, acetone bath). BF3.Et2O (0.38 mL, 1.44 mmol, 2.5 eq) was slowly added and 
the resulting yellowish mixture was stirred at -78°C for 15 h. The reaction was quenched at -
78°C (total degradation of the product was observed when warmed up to 20°C before the 
quench) by addition of aq. sat. NaHCO3 (1.5 mL) and stirred for 5 min, and then was allowed 
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to warm up to room temperature over 30 min under vigourous stirring. The organic phase was 
separated and the aqueous layer was extracted with dichloromethane (3x1.5 mL). The 
combined organic layers were dried over MgSO4, filtrated and concentrated under vacuum. 
The oily residue was purified by flash column chromatography (Pent/Et2O 95:5 to 80:20) to 
give 107 mg (78%) of the desired compound as a colorless oil (the product appears also to be 
slightly volatile). 
1H NMR (CDCl3, 500 MHz, rotamers) :7.25-7.21 (m, 1H), 6.00-5.88 (m, 2H), 5.66-5.59 
(m, 1H), 3.75 (s, 1H), 1.75-1.74 (m, 3H), 1.57 (1.56) (2 br. s, 6H), (1.43) 1.41 (2 br. s, 6H). 
13C-{1H} NMR (CDCl3, 125 MHz, rotamers) :150.00/149.2, 137.3/137.2, 
128.13/128.10, 126.2/126.1, 113.72/113.66, 96.2/95.5, 76.4/76.2, 61.1/60.5, 26.9/25.7, 
25.2/24.1, 18.4. HRMS (ESI) m/z:calcd. for C13H21NO3Na ([M + Na]+): 262.1414; found: 
262.1419. IR neat (𝛖/cm-1) : 2980, 2361, 1716, 1372, 1258, 1133, 1068. 
 Procedure for the cross-over experiment : 
 
In a tubular reactor (100 mm x 16 mm)capped with a rubber septum, a solution of the 
carbamate(E)-2.21(50 mg, 0.207 mmol, 1 eq) and (+)-sparteine (67 µL, 0.29 mmol, 1.4 eq) in 
dry diethyl ether (1.5 mL) under argon was stirred and cooled down to -78°C (acetone bath, 
cryostat). s-Butyllithium (0.29 mmol, 1.4 eq, solution in hexane) was added dropwise, and the 
mixture was stirred for 4 h. A suspension of zinc acetate (57 mg, 0.31 mmol, 1.5 eq) in dry 
THF (1.5 mL) was sonicated for 30 min and added dropwise to the mixture. The resulting 
solution was stirred for 30 min at -78°C, and then allowed to heat up to 20°C over 30 min. 
The solvents were evaporated over 30 min under high vacuum, and a solution of Pd2(dba)3 
(3.3 mg, 3.6 µmol, 1.75 %mol) and CataCXium PICy2.L27 (2.8 mg, 7.3 µmol, 3.5 %mol) in 
dry toluene (1.0 mL) was added, followed by the aryl bromide (0.15 mmol, 0.7 eq) and the 
dieneS14(49.5 mg, 0.207 mmol, 1 eq,) in toluene (0.5 mL). The mixture was then vigorously 
stirred and heated to 60°C for 18h. After cooling down, the reaction was quenched with sat. 
aq. NH4Cl (2 mL), and the organic phase was diluted with EtOAc (3 mL) and separated. The 
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aqueous phase was extracted with EtOAc (2 x 3 mL). The combined organic layers were dried 
over MgSO4, filtrated over a pad of celite, and evaporated under vacuum. The residue was 
purified by preparative reversed-phase HPLC (MeCN/H2O) to afford 34 mg (70%) of 2.21g 
(74:26 Z:E ratio) as an oil. The e.r. were, respectively, 98:2 for the Z-isomer and 98:2 for the 
E-isomer. 
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Product derivatization 
 Hydrogenation product 2.22 
3-(2-fluorophenyl)pentyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate : 
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rac-3-(2-fluorophenyl)pent-1-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 
2.21g(75:25 Z:E) (206 mg, 0.6 mmol, 1 eq) was diluted with dry ethanol (6 mL) in a 10 mL 
glass vial. Pd/C 10%w/w (20 mg, 10% w/w) was added and the vial was loaded in an 
autoclave. The mixture was stirred at 50°C under H2 (50 bar) for 24h. After cooling down, the 
reaction mixture was filtered on celite and the filtrated solution was concentrated under 
vacuum. The crude residue was filtered over a pad of silica gel (Pent/Et2O 85:15) to afford 
192 mg (93%) of the desired rac-carbamate as an oil. 
Under the same conditions, an enantioenriched mixture of 3-(2-fluorophenyl)pent-1-en-1-yl 
2,2,4,4-tetramethyloxazolidine-3-carboxylate (75:25 Z:E, e.r. 98:2 respectively) (7 mg, 0.02 
mmol, 1 eq) was hydrogenated to give 7 mg (99 %) of the desired enantioenriched carbamate 
as an oil (e.r. 75:25) 
Under the same conditions, an enantioenriched mixture of 3-(2-fluorophenyl)pent-1-en-1-yl 
2,2,4,4-tetramethyloxazolidine-3-carboxylate (87:13 Z:E, e.r. 98:2 respectively) (20.2 mg, 
0.06 mmol, 1 eq) was hydrogenated to give 17 mg (84%) of the desired enantioenriched 
carbamate as an oil (e.r. 86.5:13.5) 
1H NMR (CDCl3, 400 MHz, rotamers) :7.17-7.13 (m, 2H, HAr), 7.09-7.06 (m, 1H, HAr), 
7.01-6.97 (m, 1H, HAr), 4.06-3.90 (m, 2H, H1), 3.71 (s, 2H, H6), 3.03-2.95 (m, 1H, H3), 2.08-
1.90 (m, 2H, H2), 1.77-1.62 (m, 2H, H4), 1.62-1.36 (m, 12H, H7, H7’, H8, H8’), 0.80 (t, J = 7.4 
Hz, 3H, H5). 13C-{1H} NMR (CDCl3, 125 MHz, rotamers) :162.36/160.42 (d of 
rotamers, J = 243.9 Hz, C13), 152.9/152.2 (C11), 131.2/131.1 (C12), 128.7/128.6 (CAr), 
127.72/127.66 (CAr), 124.32/124.29 (CAr), 115.7/115.5 (CAr), 95.9/94.9 (C10), 76.5/76.2 (C6), 
62.9 (C1), 60.7/59.7 (C9), 37.3 (C3), 34.6 (C2), 28.46/28.45 (C4), 26.6-24.3 (C7, C7’, C8, C8’), 
12.1 (C5).F-{1H} NMR (CDCl3, 376 MHz, rotamers) :  -118.30/-118.33 (F13). HPLC 
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separation conditions : Chiralpak IC column, n-heptane/i-PrOH 99.5:0.5, flow rate 0.5 
mL/min, 25°C, tR19.4 min for ()-enantiomer (major) and tR 21.3 min for ()-enantiomer 
(minor). e.r. = 86.5:13.5.HRMS (ESI) m/z:calcd. for C19H28FNO3Na ([M + Na]+) : 360.1945; 
found: 360.1946.IR neat (𝛖/cm-1) : 2970, 2361, 1699, 1408, 1364, 1258, 1068. 
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 Deprotection product 2.42 
3-(2-fluorophenyl)pentan-1-ol : 
   
rac-3-(2-fluorophenyl)pentyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate (50 mg, 0.15 
mmol, 1 eq) was diluted in methanol (1mL) and MeSO3H (38 µL, 0.59 mmol, 4 eq) was 
added. The mixture was refluxed for 3.5h, cooled down to 20°C, and Ba(OH)2.8H2O (304 mg, 
1.78 mmol, 12 eq) was added. The mixture was then refluxed for 18h. After cooling down, the 
solids were filtrated on a pad silica with Et2O (5 mL). After evaporation under vacuum, the 
residue was purified by silica gel column chromatography (Pent/Et2O 80:20) to give the 25.8 
mg (96%) of the racemic alcohol. 
H NMR (CDCl3, 400 MHz, rotamers) :7.20-7.15 (m, 2H, HAr), 7.11-7.08 (m, 1H, HAr), 
7.02-6.99 (m, 1H, HAr), 3.57-3.45 (m, 2H, H1), 3.03-2.97 (m, 1H, H3), 2.01-1.80 (m, 2H, H2), 
1.77-1.60 (m, 2H, H4), 0.81 (t, J = 7.4 Hz, 3H, H5). 13C-{1H} NMR (CDCl3, 125 MHz, 
rotamers) :162.47/160.53 (d, J = 244.8 Hz, C7), 131.6/131.4 (C6), 128.9/128.8 (CAr), 
127.63/127.56 (CAr), 124.34/124.31 (CAr), 115.6-115.4 (CAr), 61.3 (C1), 38.4 (C3), 
36.92/36.91 (C2), 28.67/28.66 (C4), 12.2 (C5).F-{1H} NMR (CDCl3, 376 MHz, rotamers) : 
 -118.54 (F7). HPLC separation conditions : ChiralcelOD-H column, n-heptane/i-PrOH 
99:1, flow rate 0.8 mL/min, 25°C, tR26.6 min for ()-enantiomer (major) and tR 32.4 min for ()-
enantiomer (minor). e.r. =.HRMS (ESI) m/z:calcd. for C11H15FO3Na ([M + Na]+) : 205.0999; 
found: 205.0998.IR neat (𝛖/cm-1) : 3352, 2963, 2361, 1224, 1052. 
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 Esterification product 2.43c 
3-(2-fluorophenyl)pentyl 4'-nitro-[1,1'-biphenyl]-4-carboxylate : 
   
To a solution of rac-3-(2-fluorophenyl)pentan-1-ol (25 mg, 0.14 mmol, 1 eq) in CH2Cl2 (0.2 
mL) were added 4'-nitro-[1,1'-biphenyl]-4-carbonyl chloride (39.4 mg, 0.15 mL, 1.1 eq), 
triethylamine (57 µL, 0.41 mmol, 3 eq), and DMAP (< 1mg, cat.). The mixture was stirred at 
23°C for 45 min.  After this time, the volatiles were evaporated under vacuum and the crude 
residue was purified by column chromatography (EtOAc:Cyclohexane 2.5:97.5) to give 30 
mg (54%) of the title compound as a white solid. 
H NMR (CDCl3, 400 MHz, rotamers) :8.34-8.32 (m, 2H, HAr), 8.08-8.07 (m, 2H, HAr), 
7.78-7.76 (m, 2H, HAr), 7.68-7.66 (m, 2H, HAr), 7.23-7.16 (m, 2H, 2HAr), 7.12-7.03 (m, 1H, 
HAr), 7.03-7.00 (m, 1H, HAr), 4.33-4.28 (m, 1H, H1), 4.21-4.16 (m, 1H, H1), .3.12-3.06 (m, 
1H, H3), 2.24-2.17 (m, 1H, H2), 2.13-2.06 (m, 1H, H2), 1.82-1.66 (m, 2H, H4), 0.84 (t, J = 7.4 
Hz, 1H).13C-{1H} NMR (CDCl3, 125 MHz, rotamers) :166.1 (C8), 162.5/160.5 (d, J = 
244.4 Hz, C7), 147.7 (CAr), 146.6 (CAr), 143.1 (CAr), 131.1/131.0 (C6), 130.8 (CAr), 130.5 
(CAr), 128.80/128.76 (CAr), 128.2 (CAr), 127.82/127.75 (CAr), 127.5 (CAr), 124.41/124.38 
(CAr), 124.35 (CAr), 115.8/115.6 (CAr), 63.9 (C1), 37.6 (C3), 34.2 (C2), 28.8 (C4), 12.2 (C5). 
F-{1H} NMR (CDCl3, 376 MHz, rotamers) :  -118.40 (F7). HPLC separation 
conditions :HPLC separation conditions :Chiralpak AD-H column, n-heptane/i-PrOH 98:2, 
flow rate 0.5 mL/min, 25°C, tR83.0 min for ()-enantiomer and tR 88.4 min for ()-enantiomer. 
e.r.HRMS (ESI) m/z: C24H22FO4Na ([M + Na]+) : 430.1425; found: 430.1419. IR neat 
(𝛖/cm-1) : 2963, 2361, 1716, 1598, 1519, 1343, 1275, 1109.M.p : 82°C 
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Preparation of ligands 2.L16 and 2.L42-55. 
 Synthesis of starting material heterocycles S15-S21 
1-(o-tolyl)-1H-imidazole S15 : 
 
A 20 mL reaction tube was loaded in a glovebox with imidazole (680 mg, 10 mmol, 1 eq), 
CuI (286 mg, 1.5 mmol, 0.15 eq), and Cs2CO3 (4.89 g, 15 mmol, 1.5 eq). Out of the glovebox, 
1-iodo-2-methylbenzene (1.56 mL, 12 mmol, 1.2 eq) and DMSO (10 mL) were added. The 
tube was sealed and placed in a microwave apparatus, stirred for 1 min at ambient 
temperature, and then stirred and heated at 150°C for 2 h under microwave irradiation. The 
reaction mixture was diluted with 100 mL of EtOAc:CyHex  (50:50) and 100 mL of 
Brine:Water (50:50) were added. The organic layer was separated and the aqueus layer was 
extracted 3 times with 100 mL of EtOAc:CyHex  (50:50). The combined organic layers were 
washed with 250 mL of Brine:Water (50:50), dried over MgSO4, filtrated and then 
concentrated under reduced pressure. The crude residue was purified by column 
chromatography (EtOAc) to afford 550 mg (35 %) of the desired product as a yellowish 
oil.The data were in accordance with the literature.164 
1H NMR (400 MHz, CDCl3) :7.56 (s, 1H), 7.38-7.27 (m, 3H), 7.23-7.21 (m, 2H), 7.06 (s, 
1H), 2.19 (s, 3H).13C-{1H} NMR (CDCl3, 100 MHz) :134.0, 131.4, 128.9, 127.0, 126.7, 
17.75. 
1-mesityl-1H-imidazoleS16 : 
 
Formaldehyde (2.2 mL (37% solution in H2O), 30 mmol, 1eq) and glyoxal (3.4 mL (40% 
solution in H2O), 30 mmol, 1 eq) were dissolved in a mixture of acetic acid and toluene (8 
mL, 1:1) and heated to 70°C for 15 min. A slurry of mesitylamine (4.2 mL, 30 mmol, 1 eq), 
ammonium acetate (2.3 g, 30 mmol, 1 eq), and acetic acid (4mL) was added to the reaction 
mixture. . The dark solution was stirred for 3 days, cooled down to room temperature, and 
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poured over a saturated solution of NaHCO3 (100 mL). Powdered KOH was added to raise 
the pH to 8. The mixture was then extracted with THF (3x75 mL), and the combined organic 
layers were washed with brine, dried over MgSO4, filtrated, and concentrated under reduced 
pressure. The brown residue was purified by column chromatography (EtOAc:CyHex 20:80 
to 100:0) to obtain a brown solid. Sublimation of this last under high vacuum afforded 2.62 g 
(47 %) of the title compound as a white solid. 
1H NMR (CDCl3, 400 MHz) :7.43-7.42 (m, 1H), 7.22 (m, 1H), 6.96 (m, 1H), 6.88 (m, 
1H), 2.33 (s, 3H), 1.98 (s, 6H).13C-{1H} NMR (CDCl3, 100 MHz) :139.0, 137.6, 135.6, 
133.5, 129.7, 129.1, 120.2, 21.2, 17.5.  
1-(2,6-diethylphenyl)-1H-imidazoleS17 : 
 
A 20 mL reaction tube was loaded in a glovebox with imidazole (251 mg, 3.7mmol, 1 eq), 
CuI (105 mg, 0.55mmol, 0.15 eq), and Cs2CO3 (1.80 g, 5.5mmol, 1.5 eq). Out of the 
glovebox, 1,3-diethyl-2-iodobenzene (960 mg, 3.7 mmol, 1 eq) and DMSO (10 mL) were 
added. The tube was sealed and placed in a microwave apparatus, stirred for 1 min at ambient 
temperature, and then stirred and heated at 170°C for 3 h under microwave irradiation. The 
reaction mixture was diluted with 100 mL of EtOAc:CyHex  (50:50) and 100 mL of 
Brine:Water (50:50) were added. The organic layer was separated and the aqueus layer was 
extracted 3 times with 100 mL of EtOAc:CyHex  (50:50). The combined organic layers were 
washed with 250 mL of Brine:Water (50:50), dried over MgSO4, filtrated and then 
concentrated under reduced pressure. The crude residue was purified by column 
chromatography (EtOAc) to afford 160 mg (22 %) of the desired product as a white solid. 
1H NMR (CDCl3, 500 MHz) :7.47 (b.s., 1H), 7.37-7.34 (m, 1H), 7.24 (b.s., 1H), 7.20-
7.18 (m, 2H), 6.94 (b.s., 1H), 2.28 (q, J = 7.6 Hz, 4H), 1.08 (t, J = 7.6 Hz, 6H).13C-{1H} 
NMR (CDCl3, 126 MHz) :142.0, 134.8, 129.6, 126.8, 24.3, 15.7. 
1-(2,6-dimethoxyphenyl)-1H-pyrroleS18 : 
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In a 25 mL round bottom flask was dissolved 2,6-dimethoxyaniline165(400 mg, 2.6 mmol, 1 
eq) in glacial acetic acid (10 mL). After the solution became clear (ca. 2 min), 
dimethoxytetrahydrofuran (0.34 mL, 2.6 mmol, 1 eq) was added, and the mixture was heated 
to 100°C for 3 h. After cooling, the dark solution was slowly poored to a solution of NaHCO3 
(14.7 g in 200 mL of H2O) to quench the acetic acid. Ethyl acetate (100 mL) was added and 
the aqueous layer was separated. The organic layer was rinced with water (100 mL), dried 
over MgSO4, and concentrated under reduced pressure. The brown solid residue was purified 
by silica gel chromatography (EtOAc:CyHex 10:80 to 50:50) to afford 220 mg (42 %) of the 
titled compound as a beige solid. 
1H NMR (CDCl3, 400 MHz) :7.29-7.25 (m, 1H), 6.76-6.75 (m, 2H), 6.67-6.65 (m, 2H), 
6.32-6.31 (m, 2H), 3.77 (s, 3H).13C-{1H} NMR (CDCl3, 100 MHz) :156.0, 128.5, 123.1, 
119.4, 108.0, 104.7, 56.2. 
1-(2,6-dimethoxyphenyl)-1H-imidazole S19 : 
 
A 20 mL reaction tube was loaded in a glovebox with imidazole (680 mg, 10 mmol, 1 eq), 
CuI (286 mg, 1.5 mmol, 0.15 eq), and Cs2CO3 (4.89 g, 15 mmol, 1.5 eq). Out of the glovebox, 
2-iodo-1,3-dimethoxybenzene (2.64 g, 10 mmol, 1 eq) and DMSO (10 mL) were added. The 
tube was sealed and placed in a microwave apparatus, stirred for 1 min at ambient 
temperature, and then stirred and heated at 160°C for 6 h under microwave irradiation. The 
reaction mixture was diluted with 100 mL of EtOAc:CyHex  (50:50) and 100 mL of 
Brine:Water (50:50) were added. The organic layer was separated and the aqueous layer was 
extracted 3 times with 100 mL of EtOAc:CyHex  (50:50). The combined organic layers were 
washed with 250 mL of Brine:Water (50:50), dried over MgSO4, filtrated and then 
concentrated under reduced pressure. The crude residue was purified by column 
chromatography (EtOAc:MeOH 100:0 to 95:5) to afford 480 mg (24%) of the desired product 
as anoff-white solid. 
1H NMR (CDCl3, 400 MHz) :7.56 (s, 1H), 7.34-7.30 (m, 1H), 7.17 (s, 1H), 7.02 (s, 1H), 
6.68-6.66 (m, 2H), 3.78 (s, 6H). 13C-{1H} NMR (CDCl3, 100 MHz) :155.5, 139.2, 139.1, 
129.6, 128.2, 121.3, 121.3, 104.6, 69.20. HRMS (ESI) m/z: calcd. for C11H12N2O2H ([M + 
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H]+): 205.0972; found: 205.0971. IR neat (𝛖/cm-1) : 2954, 2877, 2359, 1594, 1449, 1254, 
1110. M.p : 147°C 
1-(2,6-dimethoxyphenyl)-1H-pyrazoleS20 : 
 
A 20 mL reaction tube was loaded in a glovebox with pyrazole (258 mg, 3.8mmol, 1 eq), CuI 
(372 mg, 1.9mmol, 0.5eq), and Cs2CO3 (2.47 g, 7.6mmol, 2eq). Out of the glovebox, 2-iodo-
1,3-dimethoxybenzene (1.0 g, 3.8mmol, 1 eq), TMEDA (0.29 mL, 1.9 mmol, 0.5 eq) and 
DMF (10 mL) were added. The tube was sealed and vigorously stirred at 130°C for 36 h. The 
reaction mixture was diluted with 100 mL of EtOAc:CyHex  (50:50) and 100 mL of 
Brine:Water (50:50) were added. The organic layer was separated and the aqueous layer was 
extracted 3 times with 100 mL of EtOAc:CyHex  (50:50). The combined organic layers were 
washed with 250 mL of Brine:Water (50:50), dried over MgSO4, filtrated and then 
concentrated under reduced pressure. The crude residue was purified by column 
chromatography (EtOAc:CyHex 20:80 to 100:0) to afford 280 mg (36%) of the desired 
product as an off-white solid. 
1H NMR (CDCl3, 400 MHz) :7.78-7.77 (m, 1H), 7.51-7.50 (m, 1H), 7.38-7.31 (m, 1H), 
6.67-6.64 (m, 1H), 6.45-6.43 (m, 1H), 3.76 (s, 6H).13C-{1H} NMR (CDCl3, 100 
MHz) :156.7, 140.3, 132.6, 130.2, 118.9, 105.6, 104.4, 56.3.  
1-(2,6-diethoxyphenyl)-1H-imidazoleS21 : 
 
Formaldehyde (260µL (37% solution in H2O), 3.5mmol, 1eq) and glyoxal (400 µL (40% 
solution in H2O), 3.5mmol, 1 eq) were dissolved in a mixture of acetic acid and toluene (8 
mL, 1:1) and heated to 70°C for 15 min. A slurry of 2,6-diethoxyaniline2 (631 mg, 3.5mmol, 
1 eq), ammonium acetate (268 mg, 3.5mmol, 1 eq), and acetic acid (4mL) was added to the 
reaction mixture. . The dark solution was stirred for 24 h, cooled down to room temperature, 
and poured over a saturated solution of NaHCO3 (100 mL). Powdered KOH was added to 
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raise the pH to 8. The mixture was then extracted with THF (3x75 mL), and the combined 
organic layers were washed with brine, dried over MgSO4, filtrated, and concentrated under 
reduced pressure. The brown residue was purified by column chromatography (EtOAc:CyHex 
20:80 to 100:0) to obtain 420 mg (52%) of the title compound as a white solid. 
1H NMR (CDCl3, 400 MHz) :7.61-7.60 (m, 1H), 7.26-7.22 (m, 1H), 7.13 (m, 1H), 7.05-
7.04 (m, 1H), 6.63-6.61 (m, 2H), 4.00 (q, J = 7 Hz, 4H), 1.28 (t, J = 7 Hz, 6H).13C-{1H} 
NMR (CDCl3, 100 MHz) :154.6, 139.1, 129.2, 127.8, 121.3, 116.3, 105.7, 64.7, 14.8. 
1-(2,6-difluorophenyl)-1H-imidazole S22 : 
 
Formaldehyde (577 µL (37% solution in H2O), 7.75 mmol, 1 eq) and glyoxal (885 µL (40% 
solution in H2O), 7.75 mmol, 1 eq) were dissolved in a mixture of acetic acid and toluene (10 
mL, 1:1) and heated to 70°C for 15 min. A slurry of 2,6-difluoroaniline (1 g, 7.75 mmol, 1 
eq), ammonium acetate (600 mg, 7.75 mmol, 1 eq), and acetic acid (5 mL) was added to the 
reaction mixture. . The dark solution was stirred for 24 h, cooled down to room temperature, 
and poured over a saturated solution of NaHCO3 (100 mL). Powdered KOH was added to 
raise the pH to 8. The mixture was then extracted with THF (3x75 mL), and the combined 
organic layers were washed with brine, dried over MgSO4, filtrated, and concentrated under 
reduced pressure. The brown residue was purified by column chromatography (EtOAc:CyHex 
50:50 to 100:0) to obtain 880 mg (63%) of the title compound as a yellowish oil. 
1H NMR (CDCl3, 400 MHz) :7.73 (br. s, 1H), 7.38-7.31 (m, 1H), 7.22 (br. s, 1H), 7.17 
(m, 1H), 7.11-7.05 (m, 2H).13C-{1H} NMR (CDCl3, 100 MHz) :157.86, 157.82, 155.34, 
155.31, 138.1, 129.41, 129.39, 129.3, 129.2, 120.5, 115.4, 112.8, 112.74, 112.71, 112.57, 
112.55, 112.52.F-{1H} NMR (CDCl3, 376 MHz) :  -120.4.  
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 General procedure for the preparation of ligands 2.L16 and 2.L42-55 
The preparation steps must be carried out under argon atmosphere as much as possible via 
the use of argon filled balloons and/or a schlenk ramp. A solution of the N-arylated 
heterocycleS15-22 (1 eq)in THF (2 mL) was cooled down to -30°C (acetone, cryostat). s-
Butyllithium (1 eq, solution in hexane) was added dropwise and the mixture was stirred for 30 
min before addition of the chlorophosphine (1 to 1.05 eq) in THF (1 mL). The mixture was 
stirred for 30 min at -30°C and 30 min at 20°C. Then, the mixture was directly concentrated 
under reduced pressure (using an argon flushed rotavapor) and the residue was purified by 
column chromatography (Pent/Et2O 95:5 to 0:100) to afford the corresponding phosphine 
ligand. 
 Synthesis of ligands 2.L16 and 2.L42-55 
2-(dicyclohexylphosphanyl)-1-(o-tolyl)-1H-imidazole2.L16 : 
 
A solution of 1-(o-tolyl)-1H-imidazole (300 mg, 1.9 mmol, 1 eq) was reacted with 
chlorodicyclohexylphosphine (464 mg, 2 mmol, 1.05 eq) to afford 400 mg (59 %) of the title 
compound as a white solid. 
1H NMR (CDCl3, 400 MHz) :7.38 (m, 1H), 7.36-7.34 (m, 1H), 7.31-7.24 (m, 2H), 7.15 
(m, 1H), 7.04 (m, 1H), 2.30 (b.s., 1H), 2.04 (s, 3H), 1.88 (b.s., 1H), 1.88-1.56 (m, 10H), 1.38-
0.91 (m, 10H). 13C-{1H} NMR (CDCl3, 100 MHz) :147.5, 147.4, 137.8, 135.3, 130.9, 
129.2, 128.98, 128.96, 126.2, 123.1, 35.0 (b.s.), 33.5 (b.s.), 30.1 (b.s.), 29.9 (b.s.), 29.1 (b.s.), 
27.1 (b.s.), 26.5, 17.93, 17.89. P-{1H} NMR (CDCl3, 162 MHz) :-23.5. 
2-(diisopropylphosphanyl)-1-mesityl-1H-imidazole2.L42 : 
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A solution of 1-mesityl-1H-imidazole (100 mg, 0.54mmol, 1 eq) was reacted with 
chlorodiisopropylphosphine (86 mg, 0.56mmol, 1.05eq) to afford 97 mg (60 %) of the title 
compound as a colorless oil. 
1H NMR (CDCl3, 400 MHz) :7.40 (m, 1H), 6.96-6.95 (m, 3H), 2.33 (s, 3H), 2.28-2.21 
(m, 2H), 1.97 (s, 6H), 1.09-1.03(m, 12H). 13C-{1H} NMR (CDCl3, 100 MHz) :147.3, 
138.8, 135.2, 134.1, 131.0, 129.1, 122.9, 24.5, 24.4, 21.2, 20.4, 20.3, 19.8, 19.7, 18.4, 18.3. 
P-{1H} NMR (CDCl3, 162 MHz) :-12.5. 
2-(dicyclohexylphosphanyl)-1-(2,6-dimethoxyphenyl)-1H-imidazole 2.L43 : 
 
A solution of 1-(2,6-dimethoxyphenyl)-1H-imidazole (250 mg, 1.22 mmol, 1 eq) was reacted 
with chlorodicyclohexylphosphine (298 mg, 1.28 mmol, 1.05 eq) to afford 260 mg (53 %) of 
the title compound as a white solid. 
1H NMR (CDCl3, 400 MHz) :7.40 (m, 1H), 7.38-7.34 (m, 1H), 6.97 (m, 1H), 6.63-6.61 
(m, 2H), 3.73 (s, 3H), 2.08-2.03 (m, 2H), 1.69-1.61 (m, 10H), 1.28-1.14 (m, 10H). 13C-{1H} 
NMR (CDCl3, 100 MHz, rotamers) : 156.1, 148.3, 148.2, 130.4, 130.2, 123.3, 116.0, 
103.8, 55.6, 33.8, 33.7, 30.1, 29.9, 29.3, 29.2, 27.4, 27.3, 27.2, 27.1, 26.6. P-{1H} NMR 
(CDCl3, 162 MHz) :-22.9. 
2-(diisopropylphosphanyl)-1-(2,6-dimethoxyphenyl)-1H-imidazole 2.L44 : 
 
A solution of 1-(2,6-dimethoxyphenyl)-1H-imidazole (300 mg, 0.1.47 mmol, 1 eq) was 
reacted with chlorodiisopropylphosphine (236 mg, 0.1.54 mmol, 1.05 eq) to afford 310 mg 
(66 %) of the title compound as a white solid. 
1H NMR (CDCl3, 400 MHz) :7.39-7.34 (m, 2H), 6.99-6.98 (m, 1H), 6.64-6.62 (m, 2H), 
3.72 (s, 6H), 2.30-2.19 (m, 2H), 1.04-0.96 (m, 12H). 13C-{1H} NMR (CDCl3, 100 MHz) 
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:156.2, 130.4, 130.3, 123.5, 103.9, 55.7, 24.6, 24.50, 19.9, 19.7, 19.4, 19.3.. P-{1H} 
NMR (CDCl3, 162 MHz) :-14.3.HRMS (ESI) m/z: C17H25N2O2PH ([M + H]+): 
321.1726; found: 321.1725. IR neat (𝛖/cm-1) : 2959, 2841, 2359, 1593, 1477, 1257, 1103, 
986.M.p : 76°C 
2-(di-tert-butylphosphanyl)-1-(2,6-dimethoxyphenyl)-1H-imidazole2.L45 : 
 
A solution of 1-(2,6-dimethoxyphenyl)-1H-imidazole (50 mg, 0.24 mmol, 1 eq) was reacted 
with chlorodi-tert-butylphosphine (44 mg, 0.24 mmol, 1 eq) to afford 61 mg (70 %) of the 
title compound as a white solid. 
1H NMR (CDCl3, 400 MHz): 7.41-7.40 (m, 1H), 7.37-7.33 (m, 1H) 6.97-6.96 (m, 1H), 
6.62-6.60 (m, 2H), 3.70 (s, 6H), 1.20-1.17 (m, 18H). 13C-{1H} NMR (CDCl3, 100 
MHz) :156.2, 148.6, 148.4, 130.2, 129.8, 123.7, 103.8, 55.4, 33.3, 33.1, 30.4, 30.3.. P-
{1H} NMR (CDCl3, 162 MHz) :8.0. 
1-(2,6-dimethoxyphenyl)-2-(diphenylphosphanyl)-1H-imidazole2.L46 : 
 
A solution of 1-(2,6-dimethoxyphenyl)-1H-imidazole (150 mg, 0.74mmol, 1 eq) was reacted 
with chlorodiphenylphosphine (170 mg, 0.77mmol, 1.05 eq) to afford 150 mg (53 %) of the 
title compound as a white solid. 
1H NMR (CDCl3, 400 MHz) :7.46-7.62 (m, 5H), 7.37-7.26 (m, 7H), 7.07-7.06 (m, 1H), 
6.60-6.58 (m, 2H), 3.52 (s, 6H). 13C-{1H} NMR (CDCl3, 100 MHz):156.3, 147.79, 
147.78, 136.6, 136.5, 133.9, 133.7, 131.34, 131.32, 130.4, 128.6, 128.3, 128.2, 124.10, 
124.09, 104.1, 55.7. P-{1H} NMR (CDCl3, 162 MHz) :-30.5. 
2-(dibutylphosphanyl)-1-(2,6-dimethoxyphenyl)-1H-imidazole2.L47 : 
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A solution of 1-(2,6-dimethoxyphenyl)-1H-imidazole (70 mg, 0.34 mmol, 1 eq) was reacted 
with chlorodibutylphosphine (62 mg, 0.34 mmol, 1 eq) to afford 68 mg (57 %) of the title 
compound as a white solid. 
1H NMR (CDCl3, 400 MHz) :7.39-7.34 (m, 2H), 6.96-6.95 (m, 1H), 6.65-6.633 (m, 2H), 
3.74 (s, 6H), 1.95-1.87 (m, 2H), 1.63-1.56 (m, 2H), 1.33-1.22 (m, 8H), 0.83 (t, J = 7.05 Hz, 
6H). 13C-{1H} NMR (CDCl3, 100 MHz) :156.2, 150.7, 150.6, 130.3, 130.1, 123.2, 115,8, 
103.8, 55.7, 28.2, 28.1, 27.3, 27.3, 24.3, 24.2, 13.9. P-{1H} NMR (CDCl3, 162 MHz) :-
46.0. 
2-(diethylphosphanyl)-1-(2,6-dimethoxyphenyl)-1H-imidazole 2.L48 : 
 
A solution of 1-(2,6-dimethoxyphenyl)-1H-imidazole (50 mg, 0.24 mmol, 1 eq) was reacted 
with chlorodiethylphosphine (30 mg, 0.24 mmol, 1 eq) to afford 40 mg (56 %) of the title 
compound as a white solid. 
1H NMR (CDCl3, 400 MHz) :7.39-7.36 m, 2H), 6.98-6.97 (m, 1H), 6.66-6.64 (m, 2H), 
3.75 (s, 3H), 1.91-1.84 (m, 2H), 1.65-1.56 (m, 2H), 0.99-0.91 (m, 6H). 13C-{1H} NMR 
(CDCl3, 100 MHz) :156.4, 150.3, 130.4, 130.4, 123.6, 115.9, 104.1, 55.9, 19.9, 19.80, 
10.1, 9.9. P-{1H} NMR (CDCl3, 162 MHz) :-37.0. 
2-(diisobutyl)-1-(2,6-dimethoxyphenyl)-1H-imidazole 2.L49: 
 
A solution of 1-(2,6-dimethoxyphenyl)-1H-imidazole (50 mg, 0.24 mmol, 1 eq) was reacted 
with chlorodiisobutylphosphine (44.1 mg, 0.24 mmol, 1 eq) to afford 45 mg (53 %) of the title 
compound as a white solid. 
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1H NMR (CDCl3, 400 MHz) :7.39-7.34 (m, 2H), 6.95-6.94 (m, 1H), 6.65-6.63 (m, 2H), 
3.74 (s, 3H), 2.01-1.95 (m, 2H), 1.55-1.43 (m, 4H), 0.86-0.85 (m, 12H). 13C-{1H} NMR 
(CDCl3, 100 MHz) :156.3, 151.5, 151.4, 130.4, 130.3, 123.2, 115.8, 103.9, 55.8, 39.0, 
38.9, 26.4, 26.3, 24.5, 24.4, 24.0, 23.9. P-{1H} NMR (CDCl3, 162 MHz) :-55.3. 
2-(dineopentyl)-1-(2,6-dimethoxyphenyl)-1H-imidazole 2.L50 : 
 
A solution of 1-(2,6-dimethoxyphenyl)-1H-imidazole (50 mg, 0.24 mmol, 1 eq) was reacted 
with chlorodineopentylphosphine (56 mg, 0.24 mmol, 1 eq) to afford 46 mg (50 %) of the title 
compound as a white solid. 
1H NMR (CDCl3, 400 MHz) :7.38-7.34 (m, 1H), 7.32 (m, 1H), 6.93 (m, 1H), 6.64-6.62 
(m, 2H), 3.74 (s, 3H), 2.15-2.10 (m, 2H), 1.57-1.53 (m, 2H), 0.84 (s, 18H). 13C-{1H} NMR 
(CDCl3, 100 MHz) :156.4, 152.7, 152.6, 130.2, 130.1, 123.2, 115.8, 103.9, 55.8, 44.4, 
44.3, 31.4, 31.2, 30.7, 30.6. P-{1H} NMR (CDCl3, 162 MHz) :-64.0. 
5-(diisopropylphosphanyl)-1-(2,6-dimethoxyphenyl)-1H-pyrazole2.L51: 
 
A solution of 1-(2,6-dimethoxyphenyl)-1H-pyrazole (100 mg, 0.49mmol, 1 eq) was reacted 
with chlorodiisopropylphosphine (79 mg, 0.52mmol, 1.05 eq) to afford 45 mg (29 %) of the 
title compound as a white solid. 
1H NMR (CDCl3, 400 MHz) :7.83 (m, 1H), 7.40-7.35 (m, 1H), 6.63-6.61 (m, 2H), 6.54 
(m, 1H), 3.71 (s, 3H), 2.02-1.95 (m, 2H), 1.02-0.94 (m, 12H). 13C-{1H} NMR (CDCl3, 100 
MHz) :156.9, 141.6, 141.4, 140.37, 140.35, 130.7, 118.5, 111.41, 111.37, 103.8, 55.7, 
24.23, 24.15, 19.7, 19.5, 18.9, 18.8.P-{1H} NMR (CDCl3, 162 MHz) :-17.7. 
1-(2,6-diethoxyphenyl)-2-(diisopropylphosphanyl)-1H-imidazole2.L52 : 
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A solution of 1-(2,6-diethoxyphenyl)-1H-imidazole (200 mg, 0.86 mmol, 1 eq) was reacted 
with chlorodiisopropylphosphine (138 mg, 0.90 mmol, 1.05 eq) to afford 234 mg (78 %) of 
the title compound as a white solid. 
1H NMR (CDCl3, 400 MHz) :7.35 (m, 1H), 7.33-7.28 (m, 1H), 6.96-6.95 (m, 1H), 6.60-
6.58 (m, 2H), 4.00-3.93 (m, 4H), 2.28-2.21 (m, 2H), 1.22 (t, J = 7.0 Hz, 6H), 1.4-0.98 (m, 
12H). 13C-{1H} NMR (CDCl3, 100 MHz) :155.7, 148.4, 148.2, 130.04, 129.97, 123.7, 
116.3, 104.4, 64.0, 24.6, 24.5, 19.9, 19.8, 19.69, 19.68, 14.6. P-{1H} NMR (CDCl3, 162 
MHz) :-14.4. 
1-(2,6-diisopropoxyphenyl)-2-(diisopropylphosphanyl)-1H-imidazole2.L53: 
 
A solution of 1-(2,6-diisopropoxyphenyl)-1H-imidazole (100 mg, 0.38 mmol, 1 eq) was 
reacted with chlorodiisopropylphosphine (62 mg, 0.40mmol, 1.05 eq) to afford 93 mg (65 %) 
of the title compound as a white solid. 
1H NMR (CDCl3, 400 MHz) :7.25 (m, 1H), 7.22-7.18 (m, 1H), 6.81-6.80 (m, 1H), 6.52-
6.50 (m, 2H), 4.40 (sept, J = 5.9 Hz, 2H), 2.24-2.13 (m, 2H), 1.16 (d, J = 6.1 Hz, 6H), 1.06 
(d, J = 6.1 Hz, 6H), 1.00-0.93 (m, 12 H). 13C-{1H} NMR (CDCl3, 100 MHz) :155.0, 
148.7, 148.6, 129.8, 129.7, 123.6, 118.2, 105.9, 71.0, 24.7, 24.6, 22.13, 22.06, 20.2, 20.1, 
20.0, 19.9. P-{1H} NMR (CDCl3, 162 MHz) :-14.1.  
1-(2,6-diethylphenyl)-2-(diisopropylphosphanyl)-1H-imidazole2.L54 : 
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A solution of 1-(2,6-diethylphenyl)-1H-imidazole (100 mg, 0.5mmol, 1 eq) was reacted with 
chlorodiisopropylphosphine (80 mg, 0.52mmol, 1.05 eq) to afford 68 mg (43 %) of the title 
compound as a white solid. 
1H NMR (CDCl3, 400 MHz) :7.74-7.70 (m, 2H), 7.55-7.54 (m, 2H), 7.35-7.34 (m, 1H), 
2.72-2.44 (m, 6H), 1.46 (t, J = 7.5 Hz, 6H), 1.41-1.36 (m, 12H). 13C-{1H} NMR (CDCl3, 100 
MHz) :148,0 , 147.9, 141.4, 135.2, 130.7, 129.5, 126.3, 123.8, 24.49, 24.46, 24.4, 24.3, 
20.4, 20.3, 19.7, 19.6, 15.1. P-{1H} NMR (CDCl3, 162 MHz) :-13.1. 
1-(2,6-difluorophenyl)-2-(diisopropylphosphanyl)-1H-imidazole 2.L55 : 
 
A solution of 1-(2,6-difluorophenyl)-1H-imidazole (100 mg, 0.56 mmol, 1 eq) was reacted 
with chlorodiisopropylphosphine (89 mg, 0.58 mmol, 1.05 eq) to afford 90 mg (55 %) of the 
title compound as a white solid. 
1H NMR (CDCl3, 400 MHz) :7.46-7.39 (m, 2H), 7.09-7.03 (m, 3H), 2.32-2.22 (m, 2H), 
1.03-0.97 (m, 12H). 13C-{1H} NMR (CDCl3, 100 MHz) : 159.4, 156.9, 149.1, 148.9, 
131.4, 130.7, 130.6, 130.5, 123.2, 116.3, 112.2, 112.00, 111.97, 24.6, 24.4, 19.9, 19.7, 19.2, 
19.1. P-{1H} NMR (CDCl3, 162 MHz) :-13.9, -14, -14.1.F-{1H} NMR (CDCl3, 376 
MHz) :  -117.29, -117.35.  
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5.4. Atroposelective Csp2-H arylation 
Preparation of triazoles 3.1a-g 
General procedure : 
The alkyne (1 eq) and the azide (1 eq) were suspended in a 1:1 mixture of water and tBuOH 
(1 mol/L). Sodium ascorbate (10 %mol) was added, followed by CuSO4.5H2O (1 %mol). The 
heterogeneous mixture was vigorously stirred at 80°C for 15 h. The reaction mixture was 
cooled down and ice-cold water was added to dilute the mixture by 2. In the case that 
precipitation occurred, the product was collected by filtration, washed with cold water and 
dried under vacuum. Int the case that no precipitation occurred, the mixture was extracted 
with EtOAc (3x). The combined organic phase was dried over MgSO4. After filtration and 
evaporation of the volatile, the residue was purified by column chromatography 
(EtOAc/Cyclohexane) to afford the desired triazole. 
1-benzyl-4-phenyl-1H-1,2,3-triazole3.1a : 
 
Phenylacetylene (3.2 mL, 29.2 mmol) and benzylazide (3.6 mL, 29.2 mmol) were reacted. 
Filtration of the precipitate gave 5.8 g (84%) of the desired triazole as a white solid. The 
analytical data were consistent with those reported in the literature.166 
1H NMR (CDCl3, 400 MHz) :7.81-7.78 (m, 2H), 7.66 (s, 1H), 7.42-7.29 (m, 8H), 5.57 (s, 
2H). 13C-{1H} NMR (CDCl3, 100 MHz) :148.4, 134.8, 130.7, 129.3, 128.9, 128.3, 128.2, 
125.8, 119.6, 54.4. 
1-benzyl-4-(tert-butyl)-1H-1,2,3-triazole3.1b : 
 
3,3-dimethyl-1-butyne (0.6 mL, 5.0 mmol) and benzylazide (0.6 mL, 5 mmol) were reacted. 
Purification of the crude residue by column chromatography (EtOAc/Cyclohexane 10:90 to 
50:50) afforded 660 mg (61%) of the desired triazole as a white solid. The analytical data 
were consistent with those reported in the literature.167 
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1H NMR (CDCl3, 400 MHz) :7.30-7.28 (m, 3H), 7.20-7.13 (m, 3H), 5.40 (s, 1H), 1.25 (s, 
9H). 13C-{1H} NMR (CDCl3, 100 MHz) :135.2, 129.1, 128.7, 128.1, 54.1, 31.0, 30.4. 
1-benzyl-4-cyclohexyl-1H-1,2,3-triazole3.1c :  
 
Cyclohexaneacetylene (0.65 mL, 5.0 mmol) and benzylazide (0.6 mL, 5 mmol) were reacted. 
Purification of the crude residue by column chromatography (EtOAc/Cyclohexane 10:90 to 
50:50) afforded 1.03 g (86%) of the desired triazole as a white solid. The analytical data were 
consistent with those reported in the literature.168 
1H NMR (CDCl3, 400 MHz) :7.30-7.24 (m, 3H), 7.19-7.16 (m, 3H), 5.40 (s, 1H), 2.68 
(br. s., 1H), 1.97 (br. s., 2H), 1.70-1.61 (m, 3H), 1.30 (br. s., 1H), 1.16 (br. s., 1H). 13C-{1H} 
NMR (CDCl3, 100 MHz) :135.1, 129.1, 128.6, 128.1, 54.2, 35.4, 33.0, 26.2, 24.1. 
1-benzyl-4-pentyl-1H-1,2,3-triazole 3.1d :  
 
1-Heptyne (0.66 mL, 5.0 mmol) and benzylazide (0.6 mL, 5 mmol) were reacted. Purification 
of the crude residue by column chromatography (EtOAc/Cyclohexane 10:90 to 50:50) 
afforded 875 mg (75%) of the desired triazole as a white solid. The analytical data were 
consistent with those reported in the literature.169 
1H NMR (CDCl3, 400 MHz) :7.37-7.30 (m, 3H), 7.24-7.22 (m, 2H), 7.18 (m, 1H), 5.47 
(s, 2H), 2.68-2.64 (m, 2H), 1.66-1.59 (m, 2H), 1.34-1.27 (m, 4H), 0.88-0.84 (m, 3H). 13C-
{1H} NMR (CDCl3, 100 MHz) :149.0, 135.1, 129.1, 128.6, 128.0, 120.6, 54.0, 31.5, 29.2, 
25.8, 22.5, 14.1. 
4-([1,1'-biphenyl]-4-yl)-1-benzyl-1H-1,2,3-triazole 3.1e : 
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4-Ethynylbiphenyl (0.40 g, 2.25 mmol) and benzylazide (0.28 mL, 2.25 mmol) were reacted. 
Purification of the crude residue by column chromatography (EtOAc/Cyclohexane 10:90 to 
50:50) afforded 250 mg (36%) of the desired triazole as a white solid. The analytical data 
were consistent with those reported in the literature.170 
1H NMR (CDCl3/C6D610:1, 400 MHz) :8.12-8.10 (m, 2H), 7.87-7.82 (m, 4H), 7.77 (br. 
s., 1H), 7.66-7.63 (m, 2H), 7.57-7.54 (m, 4H), 7.47-7.45 (m, 2H), 5.66 (s, 1H). 13C-{1H} 
NMR (CDCl3/MeOH10:1, 100 MHz) :141.0, 140.2, 134.4, 128.9, 128.8, 128.6, 127.9, 
127.3, 126.7, 125.9, 120.1, 54.1. 
1-(cyclohexylmethyl)-4-phenyl-1H-1,2,3-triazole 3.1f : 
 
Phenylacetylene (0.8 mL, 7.2 mmol) and (azidomethyl)cyclohexane (1.0 g, 7.2 mmol) were 
reacted. Filtration of the precipitate gave 1.6 g (92%) of the desired triazole as a white solid.  
1H NMR (CDCl3, 400 MHz) :7.84-7.81 (m, 2H), 7.71 (s, 1H), 7.43-7.39 (m, 2H), 7.34-
7.29 (m, 1H), 4.20 (d, J = 7.2 Hz, 2H), 1.96-1.86 (m, 1H),  1.75-1.64 (m, 4H), 1.32-1.10 (m, 
4H), 1.05-0.96 (m, 2H). 13C-{1H} NMR (CDCl3, 100 MHz) :147.6, 130.8, 128.9, 128.1, 
125.8, 120.13, 56.6, 38.9, 30.6, 26.2, 25.6.HRMS (ESI) m/z : calcd. for C15H19N3H ([M + 
H]+): 242.1652; found: 242.1652.IR neat (𝛖/cm-1) : 3345,2923, 2361, 1447, 1222.M.p : 
111°C 
1,4-diphenyl-1H-1,2,3-triazole 3.1g: 
 
Phenylacetylene (0.28 mL, 2.5 mmol) and azidobenzene (~ 0.5 M in toluene, 5 mL, 2.5 
mmol) were reacted. Purification of the crude residue by column chromatography 
(EtOAc/Cyclohexane 10:90 to 50:50) afforded 150 mg (27%) of the desired triazole as a 
white solid. The analytical data were consistent with those reported in the literature.158 
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1H NMR (CDCl3, 400 MHz, rotamers) :8.12 (s, 1H), 7.85-7.82 (m, 2H), 7.73-7.70 (m, 
2H),  7.49-7.44 (m, 2H), 7.40-7.33 (m, 3H), 7.31-7.25 (m, 1H). 13C-{1H} NMR (CDCl3, 100 
MHz, rotamers) :148.6,137.2, 1300.3, 129.9, 129.1, 128.9, 128.6, 126.0, 120.7, 117.8. 
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Procedure for the arylation reactions 
A: Arylation in racemic fashion : 
A Pyrex glass tube equipped with a stir bar was charged with the triazole (0.15 mmol, 1 eq) 
and the aryl bromide (0.225 mmol, 1.5 eq). The tube was introduced in an argon filled glove-
box, and Pd2dba3 (3.43 mg, 3.75 µmol, 2.5 %mol), the ligand (10 %mol), PivOH (4.6 mg, 45 
µmol, 30 %mol), Cs2CO3 (73.3 mg, 0.225, 1.5 eq), and the molecular sieves 4Å (50 mg) were 
loaded in the tube. The tube was sealed with a septum and taken out of the glovebox. Under 
an argon atmosphere, mesitylene (0.3 mL, 0.5 M) was added. The mixture was stirred at 20 
°C for 1 min, and the septum was quickly removed and replaced with a phenolic screw cap 
before the tube was heated at 150°C for 18h in an aluminium block. After this time, the 
reaction mixture was diluted with ethyl acetate (1.5 mL), and was quenched with sat. aq. 
NH4Cl (1.5 mL). The organic layer was removed and the aqueous fraction was extracted with 
ethyl acetate (3x1.5 mL). The combined organic layer was dried under vacuum. The residue 
was diluted with CDCl3 (1.5 mL) and the NMR reference was added (75 µmol of 
trichloroethylene, equivalent to 50% of the possible maximum yield) in order to evaluate the 
NMR yield. After measurement, the crude fraction was recombined and dried under vacuum. 
The crude residue was purified by column chromatography (EtOAc/Cyclohexane 10:90 to 
50:50) to afford a racemic sample of the biaryl product for HPLC analysis. 
B : Enantioselective arylation with the (R)-MOP : 
A Pyrex glass tube equipped with a stir bar was charged with the triazole (0.15 mmol, 1 eq) 
and the aryl bromide (0.225 mmol, 1.5 eq). The tube was introduced in an argon filled glove-
box, and Pd2dba3 (3.43 mg, 3.75 µmol, 2.5 %mol), the MOP 3.L69 (7.0 mg, 15 µmol, 10 
%mol), PivOH, Cs2CO3 (73.3 mg, 0.225 mmol, 1.5 eq), and the molecular sieves 4Å (50 mg) 
were loaded in the tube. The tube was sealed with a septum and taken out of the glovebox. 
Under an argon atmosphere, xylenes (0.3 mL, 0.5 M) were added, followed by addition of 
hexanoic acid (5.6 µL, 45 µmol, 30 %mol. The mixture was stirred at 20 °C for 1 min, and the 
septum was quickly removed and replaced with a phenolic screw cap before the tube was 
heated at 140°C for 2h in an aluminium block. After this time, the reaction tube was rapidly 
cooled down by immersion in fresh water for 1 min. The reaction mixture was diluted with 
ethyl acetate (1.5 mL), and was quenched with sat. aq. NH4Cl (1.5 mL). The organic layer 
was removed and the aqueous fraction was extracted with ethyl acetate (3x1.5 mL). The 
combined organic layer was dried under vacuum. The residue was diluted with CDCl3 (1.5 
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mL) and the NMR reference was added (75 µmol of trichloroethylene, equivalent to 50% of 
the possible maximum yield) in order to evaluate the NMR yield. After measurement, the 
crude fraction was recombined and dried under vacuum. The crude residue was purified by 
column chromatography (EtOAc/Cyclohexane 10:90 to 50:50) to afford an enantioenriched 
sample of the biaryl product for HPLC analysis. 
C :Enantioselective arylation with the (R)-bifunctionnal ligand : 
A Pyrex glass tube equipped with a stir bar was charged with the triazole (0.15 mmol, 1 eq) 
and the aryl bromide (0.225 mmol, 1.5 eq). The tube was introduced in an argon filled glove-
box, and Pd2dba3 (3.43 mg, 3.75 µmol, 2.5 %mol), the bifunctionnal ligand (15 µmol, 10 
%mol), Cs2CO3 (73.3 mg, 0.225 mmol, 1.5 eq), and the molecular sieves 4Å (50 mg) were 
loaded in the tube. The tube was sealed with a septum and taken out of the glovebox. Under 
an argon atmosphere, xylenes (0.3 mL, 0.5 M) were added. The mixture was stirred at 20 °C 
for 1 min, and the septum was quickly removed and replaced with a phenolic screw cap 
before the tube was heated at 140°C for 2h in an aluminium block. After this time, the 
reaction tube was rapidly cooled down by immersion in fresh water for 1 min. The reaction 
mixture was diluted with ethyl acetate (1.5 mL), and was quenched with sat. aq. NH4Cl (1.5 
mL). The organic layer was removed and the aqueous fraction was extracted with ethyl 
acetate (3x1.5 mL). The combined organic layer was dried under vacuum. The residue was 
diluted with CDCl3 (1.5 mL) and the NMR reference was added (75 µmol of 
trichloroethylene, equivalent to 50% of the possible maximum yield) in order to evaluate the 
NMR yield. After measurement, the crude fraction was recombined and dried under vacuum. 
The crude residue was purified by column chromatography (EtOAc/Cyclohexane 10:90 to 
50:50) to afford an enantioenriched sample of the biaryl product for HPLC analysis. 
Arylation products 3.2a-c 
1-benzyl-5-(naphthalen-1-yl)-4-phenyl-1H-1,2,3-triazole3.2a: 
 
General procedure A : 1-benzyl-4-phenyl-1H-1,2,3-triazole (35.5 mg) was reacted with 1-Br-
naphtalene (31 µL) in presence of PCy3 (4.2 mg) in DME (instead of mesitylene) to afford 
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42% NMR yield of the title compound. The purification of the crude gave a fraction of the 
racemic product for HPLC analysis and configurational stability evaluation. The analytical 
data were consistent with those reported in the literature. 
1H NMR (CDCl3, 400 MHz) : 8.02-8.00 (m, 1H), 7.94-7.92 (m, 2H), 7.52-7.46 (m, 4H), 
7.30-7.28 (m, 1H), 7.22-7.19 (m, 2H), 7.16-7.05 (m, 6H) 6.81-6.79 (m, 2H), 5.38 (d, J = 14.9 
Hz, 1H), 5.09 (d, J = 14.9 Hz, 1H).. HPLC separation conditions : Chiralpak IC column, n-
heptane/i-PrOH 90:10, flow rate 1 mL/min, 25°C, tR24.3 min and tR 27.7 min.e.r. = 0:0 
(racemizes under 1 day at 25°C). 
1-benzyl-5-(2-methylnaphthalen-1-yl)-4-phenyl-1H-1,2,3-triazole3.2b : 
 
 
General procedure A : 1-benzyl-4-phenyl-1H-1,2,3-triazole (35.5 mg) was reacted with 1-Br-
2-Me-naphtalene (35 µL) in presence of PCy3 (4.2 mg) to afford 35% NMR yield of the title 
compound. The purification of the crude gave a fraction of the racemic product for HPLC 
analysis and configurational stability evaluation. 
General procedure B : 1-benzyl-4-phenyl-1H-1,2,3-triazole (35.5 mg) was reacted with 1-Br-
2-Me-naphtalene (35 µL) to afford 65% NMR yield of the title compound. The purification of 
the crude gave a fraction of the enantioenriched product that was 75:25 e.r.. 
General procedure C : 1-benzyl-4-phenyl-1H-1,2,3-triazole (35.5 mg) was reacted with 1-Br-
2-Me-naphtalene (35 µL) in presence of 3.L73to afford 63% NMR yield of the title compound. 
The purification of the crude gave a fraction of the enantioenriched product that was 77.5:22.5 
e.r.. 
1H NMR (CDCl3, 400 MHz) : 7.95-7.91 (m, 2H), 7.50-7.47 (m, 3H), 7.35-7.30 (m, 2H), 
7.16-7.05 (m, 7H), 6.76-6.74 (m, 2H), 5.40 (d, J = 14.6 Hz, 1H), 4.87 (d, J = 14.6 Hz, 1H), 
1.66 (s, 3H). HPLC separation conditions : Chiralpak IC column, n-heptane/i-PrOH 90:10, 
flow rate 1 mL/min, 25°C, tR16.3 min for the major enantiomer and tR 28.7 min for the minor 
enantiomer. 
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1-benzyl-5-(2-methoxynaphthalen-1-yl)-4-phenyl-1H-1,2,3-triazole3.2c :  
 
General procedure A : 1-benzyl-4-phenyl-1H-1,2,3-triazole (35.5 mg) was reacted with 1-Br-
2-OMe-naphtalene (53.3 mg) in presence of PCy3 (4.2 mg) to afford 40% NMR yield of the 
title compound. The purification of the crude gave a fraction of the racemic product for HPLC 
analysis. 
General procedure B : 1-benzyl-4-phenyl-1H-1,2,3-triazole (35.5 mg) was reacted with 1-Br-
2-OMe-naphtalene (53.3 mg) to afford >95% NMR yield of the title compound. The 
purification of the crude gave 50 mg (85%) of the enantioenriched product that was 70:30 e.r.. 
General procedure C : 1-benzyl-4-phenyl-1H-1,2,3-triazole (35.5 mg) was reacted with 1-Br-
2-OMe-naphtalene (53.3 mg) in presence of 3.L73to afford >95% NMR yield of the title 
compound. The purification of the crude gave a fraction of the enantioenriched product that 
was 73:27 e.r.. 
1H NMR (CDCl3, 400 MHz) : 8.18-8.16 (m, 1H), 8.00-7.98 (m, 1H), 7.71-7.69 (m, 2H), 
7.50-7.47 (m, 1H), 7.72-7.37 (m, 2H), 7.31-7.29 (m, 3H), 7.24-7.17 (m, 4H), 6.96-6.95 (m, 
1H),  5.48 (d, J = 14.9 Hz, 1H), 5.23 (d, J = 14.9 Hz, 1H), 3.69 (s, 3H).13C-{1H} NMR 
(CDCl3, 100 MHz) : 155.9, 146.0, 134.9, 133.1, 132.5, 131.5128.5, 128.3, 128.2, 128.1, 
128.0, 127.8, 127.5, 126.0, 124.3, 123.6, 112.8, 109.7, 56.0, 52.6. HPLC separation 
conditions : Chiralpak IA column, n-heptane/i-PrOH 90:10, flow rate 1 mL/min, 25°C, tR16.3 
min for the major enantiomer and tR 28.7 min for the minor enantiomer.HRMS (ESI) m/z : 
calcd. for C26H21N3OH ([M + H]+): 392.1757; found: 392.1753.IR neat (𝛖/cm-1) : 3324, 
2973, 1691, 2361, 1453, 1269, 1046.M.p : 175°C 
Arylation products 3.3b-e 
1-benzyl-4-cyclohexyl-5-(2-methoxynaphthalen-1-yl)-1H-1,2,3-triazole3.3b:  
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General procedure A : 1-benzyl-4-cyclohexyl-1H-1,2,3-triazole (36.2 mg) was reacted with 1-
Br-2-OMe-naphtalene (53.3 mg) in presence of PCy3 (4.2 mg) to afford 28% NMR yield of 
the title compound. The purification of the crude gave a fraction of the racemic product for 
HPLC analysis. 
General procedure C : 1-benzyl-4-cyclohexyl-1H-1,2,3-triazole (36.2 mg) was reacted with 1-
Br-2-OMe-naphtalene (53.3 mg) in presence of 3.L73to afford 22% NMR yield of the title 
compound. The purification of the crude gave a fraction of the enantioenriched product that 
was 44.5:55.5 e.r.. 
1H NMR (CDCl3, 400 MHz), characteristic peaks : 6.90-6.86 (m, 2H), 5.40 (d, J = 14.8 
Hz, 1H), 5.14 (d, J = 14.8 Hz, 1H), 3.70 (s, 3H).HPLC separation conditions : Chiralpak IA 
column, n-heptane/i-PrOH 90:10, flow rate 1 mL/min, 25°C, tR14.9 min for the minor 
enantiomer and tR 19.9 min for the major enantiomer. 
1-benzyl-5-(2-methoxynaphthalen-1-yl)-4-pentyl-1H-1,2,3-triazole3.3c:  
 
General procedure A : 1-benzyl-4-pentyl-1H-1,2,3-triazole (34.4 mg) was reacted with 1-Br-
2-OMe-naphtalene (53.3 mg) in presence of PCy3 (4.2 mg) to afford 76% NMR yield of the 
title compound. The purification of the crude gave a fraction of the racemic product for HPLC 
analysis. 
General procedure C : 1-benzyl-4-pentyl-1H-1,2,3-triazole (34.4 mg) was reacted with 1-Br-
2-OMe-naphtalene (53.3 mg) in presence of 3.L73to afford 95% NMR yield of the title 
compound. The purification of the crude gave a fraction of the enantioenriched product that 
was 46:54 e.r.. 
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1H NMR (CDCl3, 400 MHz), characteristic peaks : 6.93-6.1 (m, 2H), 5.42 (d, J = 14.9 
Hz, 1H), 5.26 (d, J = 14.9 Hz, 1H), 3.76 (s, 3H).HPLC separation conditions : Chiralpak IA 
column, n-heptane/i-PrOH 90:10, flow rate 1 mL/min, 25°C, tR14.1 min for the minor 
enantiomer and tR 15.5 min for the major enantiomer. 
4-([1,1'-biphenyl]-4-yl)-1-benzyl-5-(2-methoxynaphthalen-1-yl)-1H-1,2,3-triazole3.3d:  
 
General procedure A : 4-([1,1'-biphenyl]-4-yl)-1-benzyl-1H-1,2,3-triazole (46.7 mg) was 
reacted with 1-Br-2-OMe-naphtalene (53.3 mg) in presence of PCy3 (4.2 mg) to afford 37% 
NMR yield of the title compound. The purification of the crude gave a fraction of the racemic 
product for HPLC analysis. 
General procedure C : 4-([1,1'-biphenyl]-4-yl)-1-benzyl-1H-1,2,3-triazole (46.7 mg) was 
reacted with 1-Br-2-OMe-naphtalene (53.3 mg) in presence of 3.L73to afford 95% NMR yield 
of the title compound. The purification of the crude gave a fraction of the enantioenriched 
product that was 72:28 e.r.. 
1H NMR (CDCl3, 400 MHz), characteristic peaks : 6.79-6.77 (m, 2H), 5.29 (d, J = 14.9 
Hz, 1H), 5.05 (d, J = 14.9 Hz, 1H), 3.48 (s, 3H).HPLC separation conditions : Chiralpak IA 
column, n-heptane/i-PrOH 90:10, flow rate 1 mL/min, 25°C, tR71.9 min for the major 
enantiomer and tR 77.9 min for the minor enantiomer. 
1-(cyclohexylmethyl)-5-(2-methoxynaphthalen-1-yl)-4-phenyl-1H-1,2,3-triazole3.3e :  
 
General procedure A : 1-(cyclohexylmethyl)-4-phenyl-1H-1,2,3-triazole (36.2 mg) was 
reacted with 1-Br-2-OMe-naphtalene (53.3 mg) in presence of PCy3 (4.2 mg) to afford % 
NMR yield of the title compound. The purification of the crude gave a fraction of the racemic 
product for HPLC analysis. 
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General procedure C : 1-(cyclohexylmethyl)-4-phenyl-1H-1,2,3-triazole (36.2 mg) was 
reacted with 1-Br-2-OMe-naphtalene (53.3 mg) in presence of 3.L73to afford >70% NMR 
yield of the title compound. The purification of the crude gave a fraction of the 
enantioenriched product that was 75.5:24.5 e.r.. 
1H NMR (CDCl3, 400 MHz), characteristic peaks : 4.01 (dd, J = 13.6 Hz, J = 7.5 Hz, 
1H), 3.96-3.90 (m, 4H).HPLC separation conditions : Chiralpak IA column, n-heptane/i-
PrOH 90:10, flow rate 1 mL/min, 25°C, tR34.2 min for the major enantiomer and tR 36.9 min 
for the minor enantiomer. 
Arylation product 3.2d 
1-benzyl-5-(2-methoxy-6-methylphenyl)-4-phenyl-1H-1,2,3-triazole3.2d:  
 
General procedure A : 1-benzyl-4-phenyl-1H-1,2,3-triazole (35.5 mg) was reacted with 2-
bromo-1-methoxy-3-methylbenzene (45.2 mg) in presence of PCy3 (4.2 mg) to afford 21% 
NMR yield of the title compound. The purification of the crude gave a fraction of the racemic 
product for HPLC analysis. 
General procedure C : 1-benzyl-4-phenyl-1H-1,2,3-triazole (35.5 mg) was reacted with 2-
bromo-1-methoxy-3-methylbenzene (45.2 mg) in presence of 3.L73to afford 68% NMR yield 
of the title compound. The purification of the crude gave a fraction of the enantioenriched 
product that was 53.5:46.5 e.r.. 
1H NMR (CDCl3, 400 MHz), characteristic peaks : 5.58 (d, J = 14.7 Hz, 1H), 5.32 (d, J 
= 14.7 Hz, 1H), 3.76 (s, 3H), 1.71 (s, 3H).HPLC separation conditions : Chiralpak IA 
column, n-heptane/i-PrOH 90:10, flow rate 1 mL/min, 25°C, tR16.0 min for the major 
enantiomer and tR 18.4 min for the minor enantiomer. 
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7. NMR Spectra and HPLC chromatograms 
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2,2,4,4-tetramethyl-1,3-oxazolidine-3-carbonyl chloride S1 :
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Ethyl 2,2,4,4-tetramethyl-1,3-oxazolidine-3-carboxylate 2.5: 
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Ethyl 3,3-dimethyl-1-oxa-4-azaspiro[4.5]decane-4-carboxylate 2.6: 
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(R)-(+)-1-(4-methoxyphenyl)ethyl 2,4,6-triisopropylbenzoate 2.2a : 
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 (R)-(+)-1-(4-methoxyphenyl)ethyl N,N-diisopropylcarbamate2.4a: 
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 (R)-(+)-1-(4-methoxyphenyl)ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.5a : 
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(R)-(+)-1-(4-methoxyphenyl)ethyl 3,3-dimethyl-1-oxa-4-azaspiro[4.5]decane-4-
carboxylate 6a : 
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 (R)-(+)-1-phenylethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.5b: 
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(R)-(+)-1-(p-tolyl)ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.5c: 
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(R)-(-)-1-(4-(trifluoromethyl)phenyl)ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate2.5d: 
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(R)-1-(4-acetylphenyl)ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.5e :  
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(R)-(-)-1-(4-cyanophenyl)ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.5f : 
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(R)-(-)-1-(4-nitrophenyl)ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate2.5g : 
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(R)-(+)-1-(4-(methoxycarbonyl)phenyl)ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 
2.5h : 
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(R)-(+)-1-(m-tolyl)ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.5i : 
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(R)-(-)-1-(o-tolyl)ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.5j : 
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(R)-1-(2-fluorophenyl)ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate2.5k :
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(R)-(+)-1-(benzo[1,3]dioxol-5-yl)ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.5l : 
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(R)-(+)-1-(3,4,5-trimethoxyphenyl)ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate2.5m : 
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(R)-(-)-1-(naphthalen-1-yl)ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.5n : 
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324 
 
(S)-(-)-1-(pyridin-3-yl)ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate2.5o : 
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1-(pyridin-2-yl)ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.5p : 
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cyclohexylmethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.7c : 
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propane-1,3-diyl bis(2,2,4,4-tetramethyloxazolidine-3-carboxylate)  2.7h : 
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3-((tert-butyldimethylsilyl)oxy)propyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.7g : 
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3-(dibenzylamino)propyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.7i : 
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(R)-(+)-1-(p-tolyl)propyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.5q : 
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(R)-(+)-2-methyl-1-(p-tolyl)propyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.5r: 
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(R)-(+)-cyclohexyl(p-tolyl)methyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.5s : 
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(R)-(-)-2-phenyl-1-(p-tolyl)ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.5t : 
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(R)-(+)-1-(p-tolyl)but-3-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.5u : 
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(S)-(-)-1-phenylbut-3-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.5v : 
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(R)-(+)-3-phenyl-1-(p-tolyl)propyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate2.5w : 
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(R)-(+)-3-((tert-butyldimethylsilyl)oxy)-1-(p-tolyl)propyl 2,2,4,4-tetramethyloxazolidine-3-
carboxylate 2.5x : 
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(R)-(+)-1-(p-tolyl)propane-1,3-diyl bis(2,2,4,4-tetramethyloxazolidine-3-carboxylate) 2.5y : 
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(R)-(+)-3-(dibenzylamino)-1-(p-tolyl)propyl 2,2,4,4-tetramethyloxazolidine-3-
carboxylate 2.5z : 
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1-(4-methoxyphenyl)ethan-1-ol 2.12a and ent-2.12a: 
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 (R)-(+)-2-(4-methoxyphenyl)butan-2-ol2.12b : 
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 (R)-(+)-1-(4-methoxyphenyl)-1-phenylethan-1-ol 2.12c : 
(R)-(+)-1-(4-methoxyphenyl)-1-phenylethan-1-ol : 
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358 
 
3-oxo-1-phenylpropyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.17: 
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3-(methylamino)-1-phenylpropyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate2.18: 
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Pent-3-yn-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate2.7j : 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.5
f1 (ppm)
6.
26
6.
15
2.
94
2.
08
2.
05
1.
99
1.
38
1.
40
1.
54
1.
74
1.
74
1.
75
2.
43
2.
44
2.
45
2.
46
2.
46
2.
48
3.
72
4.
10
4.
11
4.
13
4.
14
0102030405060708090100110120130140150160170180190200
f1 (ppm)
3.
50
19
.6
4
24
.2
4
25
.2
6
25
.3
8
26
.4
6
59
.9
9
60
.6
6
63
.0
2
75
.5
9
76
.2
0
76
.4
9
77
.2
1
95
.1
9
95
.8
8
15
1.
85
15
2.
58
 
O
NO O
O
NO O
361 
 
2-(pyridin-2-yl)ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.7k: 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
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4-(dibenzylamino)butyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.7l: 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
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3-(pyridin-2-yl)propyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate2.7m: 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
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Pent-4-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.7n:
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(E)-Pent-3-en-1-ol S2 :
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.5
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(E)-Hex-3-en-1-ol S3 :
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(E)-Oct-3-en-1-ol S4 :
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(E)-Non-3-en-1-ol S5 :
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
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(E)-4-cyclohexylbut-3-en-1-ol S6 :
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
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(E)-5,5-dimethylhex-3-en-1-ol S7 :
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
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But-3-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.7e : 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
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(E)-Pent-3-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate (E)-2.21g :
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.5
f1 (ppm)
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(E)-pent-3-en-1-yl 3,3-dimethyl-1-oxa-4-azaspiro[4.5]decane-4-carboxylate 2.23 :
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
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(E)-pent-3-en-1-yl diisopropylcarbamate 2.24 : 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
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(E)-Pent-2-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.26 :
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Pentyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.27 :
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2-(2-methylcyclopropyl)ethyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.29 :
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
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(3E,5E)-hepta-3,5-dien-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.30 :
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
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(Z)-3-methylpent-3-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.31 :
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
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(E)-hex-3-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.33 : 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
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(E)-non-3-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.34 :
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
2.
85
12
.5
6
6.
30
1.
74
1.
75
2.
00
1.
97
0.
88
0.
85
0.
85
0.
87
0.
89
1.
27
1.
35
1.
41
1.
50
1.
55
1.
95
1.
97
1.
98
2.
30
2.
32
2.
33
2.
35
2.
37
3.
72
4.
07
4.
08
4.
09
4.
10
4.
11
5.
34
5.
35
5.
37
5.
39
5.
41
5.
42
5.
48
5.
50
5.
52
5.
54
5.
55
0102030405060708090100110120130140150160170180190200
f1 (ppm)
14
.1
9
22
.6
7
24
.3
0
25
.3
9
25
.4
5
26
.6
0
29
.2
1
31
.5
2
32
.5
2
32
.7
3
59
.8
6
60
.6
2
64
.3
0
64
.3
4
76
.2
3
76
.5
0
95
.0
4
95
.8
8
12
5.
84
13
3.
53
15
2.
27
15
2.
99
 
O
O
N O
O
O
N O
382 
 
(E)-6-((tert-butyldimethylsilyl)oxy)hex-3-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-
carboxylate 2.35 :
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
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(E)-4-cyclohexylbut-3-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.36 :
0102030405060708090100110120130140150160170180190200
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(E)-5,5-dimethylhex-3-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.37 :
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
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(E)-hex-3-ene-1,6-diyl bis(2,2,4,4-tetramethyloxazolidine-3-carboxylate) 2.39 :
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
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(E)-pent-3-en-1-yl 2,4,6-triisopropylbenzoate 2.25 :
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
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 (Z)-Pent-3-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate (Z)-2.21:
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
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3-(2-fluorophenyl)pent-1-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.21g :
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
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COSY and HMQC experiments :
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- and -products (E)-2.21a and (E)-2.21b :
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
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COSY and HMQC experiments :
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(E)-1-(2-fluorophenyl)pent-3-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate (E)-2.21a 
: 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
15
.9
0
1.
93
1.
99
1.
84
0.
86
0.
86
0.
91
2.
13
1.
34
1.
42
1.
42
1.
46
1.
47
1.
57
1.
60
1.
62
2.
57
2.
60
2.
61
2.
62
2.
64
2.
65
3.
70
3.
72
3.
72
3.
73
3.
74
3.
76
5.
32
5.
33
5.
35
5.
36
5.
38
5.
39
5.
46
5.
47
5.
49
5.
50
5.
98
5.
99
6.
01
7.
01
7.
01
7.
03
7.
03
7.
03
7.
04
7.
05
7.
05
7.
10
7.
12
7.
13
7.
23
7.
23
7.
24
7.
24
7.
24
7.
24
7.
25
7.
25
7.
26
7.
26
7.
27
7.
27
7.
28
7.
29
7.
31
7.
32
7.
34
0102030405060708090100110120130140150160170180190200
f1 (ppm)
18
.0
5
24
.2
9
25
.3
8
25
.4
7
25
.5
2
25
.5
5
26
.7
7
39
.0
4
39
.1
0
59
.9
7
60
.9
1
71
.0
0
76
.2
1
76
.5
8
95
.1
0
96
.1
7
11
5.
67
11
5.
84
12
4.
09
12
4.
12
12
5.
89
12
5.
95
12
8.
03
12
8.
07
12
8.
22
12
8.
34
12
8.
45
12
8.
90
12
9.
17
12
9.
24
15
1.
20
15
1.
97
15
9.
00
16
0.
96
 
396 
 
COSY and HMQC experiments :
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3-(2-(trifluoromethoxy)phenyl)pent-1-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 
2.32a :
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
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COSY and HMQC experiments :
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3-(2-(trifluoromethoxy)phenyl)pent-1-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-
carboxylate2.32b : 
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402 
 
COSY and HMQC experiments :
 
403 
 
 
404 
 
3-(2-fluoro-4-methylphenyl)pent-1-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-
carboxylate2.32c :
 
O
O
N O
F
O
O
N O
F
405 
 
COSY and HMQC experiments :
 
O
O
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F
406 
 
 
O
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407 
 
3-(2-fluoro-4-methoxyphenyl)pent-1-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-
carboxylate2.32d :
 
408 
 
COSY and HMQC experiments :
 
409 
 
 
410 
 
3-(4-cyano-2-fluorophenyl)pent-1-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 
2.32e :
 
411 
 
COSY and HMQC experiments :
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413 
 
3-(2-fluoro-4-(methoxycarbonyl)phenyl)pent-1-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-
carboxylate2.32f :
 
O
O
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F
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COSY and HMQC experiments :
 
  
O
O
N O
F
OO
415 
 
  
416 
 
3-(2-fluoro-4-nitrophenyl)pent-1-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.32g : 
 
417 
 
COSY and HMQC experiments :
 
418 
 
 
  
419 
 
3-(2-fluoropyridin-3-yl)pent-1-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.32h : 
 
420 
 
COSY and HMQC experiments :
 
421 
 
 
422 
 
Arylation of (E)-2.21 with 2-bromoanisole : product 2.32i and isomers 
 
423 
 
 
424 
 
 
  
425 
 
COSY and HMQC experiments :
 
426 
 
3-(2-fluorophenyl)pent-1-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.20g : 
 
427 
 
COSY and HMQC experiments :
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429 
 
- and -products (E)-2.20a and (E)-2.20b : 
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COSY and HMQC experiments :
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3-(2-fluorophenyl)hex-1-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.38a : 
 
434 
 
COSY and HMQC experiments :
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436 
 
3-(2-fluorophenyl)non-1-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.38b : 
 
437 
 
COSY and HMQC experiments :
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(Z)-6-((tert-butyldimethylsilyl)oxy)-3-(2-fluorophenyl)hex-1-en-1-yl2,2,4,4-
tetramethyloxazolidine-3-carboxylate2.38c : 
 
440 
 
COSY and HMQC experiments :
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Arylation of 2.36 : products 2.38d and isomers : 
: 
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COSY and HMQC experiments :
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Arylation of 2.37 : products 2.38e and isomers : 
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450 
 
COSY and HMQC experiments :
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[2,2-2H2]-non-3(E)-en-1-ol S11 : 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
3.
01
6.
91
0.
94
1.
88
1.
81
0.
95
0.
91
0.
86
0.
88
0.
89
1.
27
1.
27
1.
28
1.
28
1.
51
1.
98
1.
98
2.
00
2.
01
2.
02
2.
03
2.
03
3.
60
5.
34
5.
38
5.
52
5.
53
5.
55
5.
55
5.
57
5.
59
0102030405060708090100110120130140150160170180190200
f1 (ppm)
14
.1
8
22
.6
6
29
.2
7
31
.5
4
32
.7
9
35
.2
0
35
.3
9
35
.5
9
62
.0
5
12
5.
70
13
4.
58
 
OH
2H 2H
OH
2H 2H
453 
 
[2,2-2H2]-non-3(E)-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 2.41 :
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
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1H NMR of the -arylated product (rotamers) 2.41a:
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2H NMR of the -arylated product (rotamers) 2.41a:
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13C NMR of the -arylated product (rotamers) 2.41a: 
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19F NMR of the -arylated product (rotamers) 2.41a:
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1H NMR of the Z-arylated product (rotamers) (Z)-2.41g:
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2H NMR of the Z-arylated product (rotamers) (Z)-2.41g: 
0.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
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13C NMR of the -arylated product (rotamers) (Z)-2.41g: 
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19F NMR of the Z-arylated product (rotamers) (Z)-2.41g:
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1H NMR of the E-arylated product(E)-2.41g (rotamers, contains Z product): 
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2H NMR of the E-arylated product(E)-2.41g (rotamers, contains Zproduct ): 
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13C NMR of the -arylated product(E)-2.41g (rotamers, contains Z product): 
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19F NMR of the E-arylated product (E)-2.41g: 
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(E)-2.41g , 5%
>95% D int.
4
D D
F
OCby
(E)-2.41g , 5%
>95% D int.
4
D D
F
OCby
460 
 
3-(trimethylsilyl)allyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate S12 :
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(E)-4-hydroxy-3-(trimethylsilyl)pent-1-en-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate 
S13 : 
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(1E,3E)-penta-1,3-dien-1-yl 2,2,4,4-tetramethyloxazolidine-3-carboxylate S14 : 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
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3-(2-fluorophenyl)pentyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate2.22: 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
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COSY and HMQC experiments :
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3-(2-fluorophenyl)pentyl 2,2,4,4-tetramethyloxazolidine-3-carboxylate2.42:
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
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COSY and HMQC experiments :
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3-(2-fluorophenyl)pentyl 4'-nitro-[1,1'-biphenyl]-4-carboxylate2.43c :
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
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COSY and HMQC experiments :
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1-(o-tolyl)-1H-imidazole S15 : 
 
  
N
N
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1-mesityl-1H-imidazole S16 :
 
  
N N
N N
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1-(2,6-diethylphenyl)-1H-imidazole S17:
 
  
NN
NN
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1-(2,6-dimethoxyphenyl)-1H-pyrroleS18 : 
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1-(2,6-dimethoxyphenyl)-1H-imidazoleS19 : 
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1-(2,6-dimethoxyphenyl)-1H-pyrazoleS20 : 
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1-(2,6-difluorophenyl)-1H-imidazoleS22 :
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2-(dicyclohexylphosphanyl)-1-(o-tolyl)-1H-imidazole2.L16 : 
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2-(diisopropylphosphanyl)-1-mesityl-1H-imidazole 2.L42 :
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1-(2,6-dimethoxyphenyl)-2-(dicyclohexylphosphanyl)-1H-imidazole 2.L43 : 
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2-(diisopropylphosphanyl)-1-(2,6-dimethoxyphenyl)-1H-imidazole 2.L44 : 
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2-(di-tert-butylphosphanyl)-1-(2,6-dimethoxyphenyl)-1H-imidazole2.L45 : 
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1-(2,6-dimethoxyphenyl)-2-(diphenylphosphanyl)-1H-imidazole2.L46 : 
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2-(dibutylphosphanyl)-1-(2,6-dimethoxyphenyl)-1H-imidazole2.L47 : 
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2-(diethylphosphanyl)-1-(2,6-dimethoxyphenyl)-1H-imidazole2.L48 : 
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2-(diisobutyl)-1-(2,6-dimethoxyphenyl)-1H-imidazole2.L49 :
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2-(dineopentyl)-1-(2,6-dimethoxyphenyl)-1H-imidazole 2.L50 :  
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5-(diisopropylphosphanyl)-1-(2,6-dimethoxyphenyl)-1H-pyrazole 2.L51 : 
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1-(2,6-diethoxyphenyl)-2-(diisopropylphosphanyl)-1H-imidazole2.L52 :
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1-(2,6-diisopropoxyphenyl)-2-(diisopropylphosphanyl)-1H-imidazole 2.L53:
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1-(2,6-diethylphenyl)-2-(diisopropylphosphanyl)-1H-imidazole2.L54 :
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1-(2,6-difluorophenyl)-2-(diisopropylphosphanyl)-1H-imidazole2.L55 :
510 
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1-benzyl-4-phenyl-1H-1,2,3-triazole3.1a: 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
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1-benzyl-4-(tert-butyl)-1H-1,2,3-triazole 3.1b: 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
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1-benzyl-4-cyclohexyl-1H-1,2,3-triazole 3.1c: 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
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1-benzyl-4-pentyl-1H-1,2,3-triazole 3.1d :  
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
3.
00
4.
09
2.
01
2.
00
1.
96
0.
95
1.
81
2.
88
0.
84
0.
84
0.
86
0.
86
0.
86
0.
87
0.
88
1.
30
1.
31
1.
32
1.
61
1.
61
1.
62
1.
63
1.
63
1.
64
1.
65
1.
65
2.
64
2.
66
2.
68
5.
47
7.
18
7.
22
7.
22
7.
23
7.
23
7.
23
7.
24
7.
24
7.
30
7.
32
7.
32
7.
33
7.
33
7.
34
7.
35
7.
35
7.
36
7.
36
7.
36
7.
36
7.
37
7.
37
0102030405060708090100110120130140150160170180190200
f1 (ppm)
14
.0
6
22
.4
5
25
.7
7
29
.1
7
31
.5
2
54
.0
2
12
0.
57
12
8.
01
12
8.
64
12
9.
10
13
5.
13
14
9.
04
 
N N
N
N N
N
515 
 
4-([1,1'-biphenyl]-4-yl)-1-benzyl-1H-1,2,3-triazole 3.1e : 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
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1-(cyclohexylmethyl)-4-phenyl-1H-1,2,3-triazole 3.1f : 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
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1,4-diphenyl-1H-1,2,3-triazole 3.1g : 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
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1-benzyl-5-(naphthalen-1-yl)-4-phenyl-1H-1,2,3-triazole 3.2a: 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
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1-benzyl-5-(2-methylnaphthalen-1-yl)-4-phenyl-1H-1,2,3-triazole3.2b: 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
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0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.5
f1 (ppm)
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1-benzyl-5-(2-methoxynaphthalen-1-yl)-4-phenyl-1H-1,2,3-triazole3.2c:  
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
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0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
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1-benzyl-4-cyclohexyl-5-(2-methoxynaphthalen-1-yl)-1H-1,2,3-triazole3.3b :
0.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
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1-benzyl-5-(2-methoxynaphthalen-1-yl)-4-pentyl-1H-1,2,3-triazole3.3c:  
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
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4-([1,1'-biphenyl]-4-yl)-1-benzyl-5-(2-methoxynaphthalen-1-yl)-1H-1,2,3-triazole3.3d:  
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
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1-(cyclohexylmethyl)-5-(2-methoxynaphthalen-1-yl)-4-phenyl-1H-1,2,3-triazole3.3e:  
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
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1-benzyl-5-(2-methoxy-6-methylphenyl)-4-phenyl-1H-1,2,3-triazole3.2d: 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
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